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Abstract 
 
 
In this thesis, synthetic chemistry was used as a tool in the exploration of various aspects 
of natural products discovered by the natural products research group at the University of 
Canterbury.   
 
Work on the constituent amino acids and connectivity of the pteratides, a potently 
cytotoxic series of cyclodepsipeptides, had been completed before the beginning of this 
work (carried out by Miss C. Chen).  The elucidation of the stereochemistry of the 
constituent amino acids was undertaken in this present work.  The synthesis of all 
stereochemical entities of a number of unusual amino acids, which were either not 
available commercially or were expensive, was carried out, providing reference materials 
for comparison to the natural products.  The synthesis of the diastereoisomers of one of 
these amino acids, 4-methylproline, was carried out by modification of literature 
procedures, which led to the development of an improved, concise and stereoselective 
synthesis.  The hydrolysis of the natural products, derivatisation of the resultant 
hydrolysates, synthetic and commercial reference amino acids and HPLC analysis 
allowed the full stereochemical assignment of the pteratide series.     
 
The total synthesis of spiro-mamakone A, a cytotoxic polyketide isolated by Dr S. van 
der Sar, was undertaken.  The synthesis was not successfully completed due to 
difficulties in the late-stage formation of a crucial enedione motif.  However, very 
advanced intermediates were successfully synthesised.  These synthetic analogues of the 
natural product were analysed for biological activity, allowing valuable insight into the 
structure-activity relationship, for example, demonstrating the importance of the enedione 
moiety to biological activity.    
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1D  one dimensional 
2D  two dimensional 
9-BBN  9-Borabicyclo[3.3.1]nonane 
Ac2O  acetic anhydride 
AIBN  azobisisobutyronitrile 
Boc2O  t-butyl dicarbonate 
br s  broad singlet (in NMR) 
c  concentration (in optical rotation) 
C18  octadecyl phase (chromatography packing phase) 
calcd  calculated  
CBz  benzyloxycarbonyl 
CBzCl  benzyloxycarbonyl chloride 
CIGAR constant time inverse-detection gradient accordion rescaled (in NMR) 
CIMS  chemical ionisation mass spectrometry  
COSY  correlation spectroscopy (in NMR) 
d  doublet (in NMR) 
δ  chemical shift in parts per million 
DBU  1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCM  dichloromethane  
dd  doublet of doublets 
DDQ  dichlorodicyanoquinone   
DEAD  diethyl azodicarboxylate 
DHN  1,8-dihydroxynaphthalene 
DIBAL-H diisobutylaluminium hydride 
DMAP  dimethylaminopyridine 
DMF  dimethylformamide  
DMP  Dess-Martin periodinane / 3,5-dimethylpyrazole 
DMSO  dimethylsulfoxide 
dt  doublet of triplets 
DTS  diverted total synthesis 
EIMS  electron ionisation mass spectrometry  
ESIMS electrospray ionisation mass spectrometry 
ESI MS/MS electrospray ionisation tandem mass spectrometry 
eq  equivalent 
Fmoc  9-fluorenylmethoxycarbonyl 
FmocCl 9-fluorenylmethoxycarbonyl chloride 
HPLC  high pressure liquid chromatography 
HRCIMS high resolution chemical ionisation mass spectrometry 
HREIMS high resolution electron ionisation mass spectrometry 
HRESIMS high resolution electrospray ionisation mass spectrometry 
HRFABMS high resolution fast atom bombardment ionisation mass spectrometry 
HSQC  heteronuclear single quantum coherence (in NMR) 
IBX  o-iodoxybenzoic acid 
IC50  concentration of sample required to inhibit cell growth by 50% 
IR  infra-red 
KHMDS potassium hexamethyldisilazane 
LCMS  liquid chromatography mass spectrometry 
m  multiplet (in NMR) 
m/z  mass-to-charge ratio (in mass spectrometry) 
MDR  multi-drug resistance 
MeCN  acetonitrile 
MeOH  methanol 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MsCl  mesyl chloride 
NBS  N-bromosuccinimide 
NMO  N-methylmorpholine-N-oxide 
NMR  nuclear magnetic resonance 
NOESY nuclear Overhauser enhancement spectroscopy (in NMR) 
PCC  pyridinium chlorochromate 
PDC  pyridinium dichromate 
PMA  phosphomolybdic acid 
ppm  parts per million (in NMR and errors in mass spectrometry) 
pTSA  p-toluenesulfonic acid 
q  quartet (in NMR) 
Rf  retention factor 
Rt  retention time 
s  singlet (in NMR) 
t  triplet (in NMR) 
TBAF  tetra-n-butylammonium fluoride 
TBDMSCl t-butyldimethylsilyl chloride 
TCCA  trichloroisocyanuric acid 
TEA  triethylamine 
TEMPO 2,2,6,6-Tetramethylpiperidine-1-oxyl 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TLC  thin layer chromatography  
tRNA  transfer ribonucleic acid 
TsCl  tosyl chloride 
UV  ultra-violet 
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Chapter 1 
 
Introduction 
 
1.1 Natural products 
 
The wealth of biological molecules made by nature are commonly classified into two 
classes, the primary and secondary metabolites.  The basic metabolism and reproduction 
of an organism involves essential primary metabolites.  However, many organisms, and 
in particular microorganisms, are known to produce metabolites which are non-essential, 
but which are believed to improve the overall ‘fitness’ of the producing organism.  These 
are described as secondary metabolites, or alternatively, as natural products.   
 
Why secondary metabolites are produced has been the subject of a great deal of debate, 
which continues to this day.1,2  The role these natural products play in the producing 
organism is sometimes obvious, be it as a deterrent effect on would-be predators or 
resource competitors, or in communication, for example to attract potential mates.  
However, many organisms produce a vast array of secondary metabolites, many or all of 
which having no known role.  This may be explained simply by accepting that whilst the 
role is not obvious to the outside observer, a role for a given metabolite may still exist, or 
at least have existed in the past.  This view is being countered by a fascinating recent 
hypothesis put forward by Firn and Jones; the Screening Hypothesis.2  This theory is 
based on the premise that potent biological activity is a rare property for any one 
molecule to possess.  The authors therefore suggest that instead of carefully evolving a 
complex biosynthetic pathway to discreet potent metabolites, organisms endeavour to 
create natural product libraries, even if many of the metabolites eventually never play any 
role in the fitness of the organism.  In this way the producer has an array of ‘chemical 
weapons’ which will be screened during interactions with other organisms, one or more 
of which may confer an advantage to the producer.  This theory consciously draws 
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parallels with the high-throughput screening processes employed by man in the search for 
biologically useful compounds.  The economics of natural selection requires that the 
production of secondary metabolites must not ‘cost’ the organism more than the benefit 
derived.  That organisms would produce whole libraries of secondary metabolites on the 
off-chance one might be useful therefore runs counter to classical thinking.  The authors 
suggest that this expense is minimised by the use of both promiscuous enzymes with 
broad substrate specificity and by matrix pathways, where several promiscuous enzymes 
act upon each other’s products to generate an array of metabolites.  The promiscuity of 
enzymes involved in secondary metabolite production is becoming increasingly accepted.  
The Screening Hypothesis remains contentious, however.3,4
 
Whatever the precise advantage a natural product confers to its producing organism, its 
ultimate raison d’être is to interact with other biological molecules.  As such, man has 
long sought to harness nature’s treasure-trove to his own advantage, with natural products 
being selected both historically and currently to improve his own ‘fitness’.   
 
 
1.2 A historical perspective 
 
An ancient Indian legend tells of Jivaka, student of medicine with the learned guru 
Atreya, who, after many years of tutelage, was set the task of collecting plants which 
lacked any medicinal properties in the area around their ashram.  After combing the area, 
examining leaves and flowers, and tasting fruit, he returned to Atreya to sorrowfully 
report that he was not able to bring back a single plant which was without any sort of 
medicinal value.  Delighted, Atreya declared him ready to go out to help the people.5   
 
The medicinal value of the natural world has been examined and exploited by almost 
every society for thousands of years.  Some of the earliest records of ancient 
pharmacognosy include 660 clay tablets created around 1700 BC, documenting the 
medicines used in Mesopotamia.  They were found in the library of the last king of 
Assyria, and were unwittingly preserved, by baking, by invaders who set the palace on 
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fire.6  Many of these medicines were also included in the Ebers Papyrus, an Egyptian 
document dating from around 1550 BC.  The similarities in pharmacognosy between 
these two ancient civilisations are indicative of the extent of their trading, both in goods 
and ideas.  The medicinal knowledge of other contemporary civilisations was also 
documented, in the Charaka Samhita in India, and the Pen Ts’ao Ching in China, 
although the age of these documents is not as well defined.  These cultures frequently 
listed plant-based remedies, although fungi also featured.  The ancient Greeks are well 
known for their interest in medicine, with Hippocrates commonly called the ‘father of 
medicine’.  They used herbs and roots, and the herbal De Materia Medica by Dioscorides 
described over 600 plants for medicinal purposes.  Many of the herbs described in these 
ancient texts are still in use today to treat a range of ailments.7   
 
In Mesoamerica, the Aztecs and the Mayans both utilised plants and mushrooms for 
medicinal purposes.  The Aztecs used African day flower (Tagetes lucida) and 
wormwood (Artemisia mexicana) to cure a range of ills including fevers and digestive 
problems.8  They also used a concentrated sap of the maguey leaf (Agave spp.) to treat 
wounds due to its antibacterial properties.   The Mayans treated intestinal infections with 
a fungus grown on roasted green corn.9   
 
The advent of colonialism allowed the huge biodiversity of the new world to be exploited 
by the old world.  The ipecacuanha root (Cephalis ipecacuanha) was introduced in 
Europe from South America as a treatment for amoebic dysentery.6  Another example is 
cinchona bark, which was a traditional remedy amongst the indigenous peoples of Peru 
for fever, and which yielded one of the most celebrated natural product medicines ever 
discovered.  In a rather unfair swap, the Europeans brought malaria, caused by several 
species of the parasite Plasmodium, to South America and obtained in return an excellent 
treatment for the disease; quinine from cinchona bark.10  Quinine, 1.1,  was amongst the 
first drugs to be obtained in pure form by extraction from the natural source and was the 
first to be used therapeutically in its pure form.6   
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The massive demand for quinine caused by the prevalence of the disease, particularly in 
those areas being fought for by the colonising powers of the time, almost led to the 
extinction of the producing tree.  This led to a serious problem in the supply of the drug.  
The issue of supply is one of the most serious problems faced by natural products as 
drugs and is a theme that will be discussed further later.   
 
The utility of the bark of the willow tree (Salix spp.) was already known to the Greeks 
and the Romans for the relief of pain, and this traditional medicine lead to the 
development of one of the most popular analgesics and antipyretics, still widely used 
today, aspirin® (1.2).11   
O
O
O
OH
1.2
OH O
OH
O
OH
O
OH
OH
OH
HO
1.3 1.4  
The active constituent of willow tree bark is salicin (1.3) which is converted in vivo to 
salicylic acid, 1.4.  The semi-synthesis of aspirin® by acetylation of salicylic acid 
generated a drug which was both more palatable and less irritating to the gut than either 
1.3 or 1.4.  Aspirin® was the first semi-synthetic drug to be sold.    
 
Arguably the single most important development in modern medicine was the discovery 
of antibiotic agents from fungal sources.  In the early 1900’s many farmhouses in Europe 
kept a loaf of mouldy rye bread, pieces of which could be mixed with water into a paste 
that was used to treat cuts and burns.9  While the first report of bacterial inhibition by the 
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fungus Penicillium was in 1870 (John Burdon-Sanderson),9 it is Alexander Fleming who 
is credited with the discovery and initial scientific studies of this action.  He noted, in 
1928, that a rare strain of Penicillium notatum caused a zone of inhibition on agar plates 
of staphylococci bacteria.  He went on to show that the culture filtrate, named penicillin, 
showed activity against both Gram positive and negative bacteria and demonstrated some 
in vivo activity as a topical antibiotic.  However, the true utility of penicillin as a cure for 
systemic infections was not discovered until 1940 by Florey and others at the School of 
Pathology at Oxford.  With the war effort overwhelming most of the UK pharmaceutical 
industry, penicillin was not considered a sufficient priority to undertake the huge task of 
optimising large-scale production and carrying out clinical testing of penicillin.  Seeing 
its massive potential, however, Florey convinced several American pharmaceutical 
companies to work towards its production and after two years of intensive efforts 
sufficient penicillin could be produced to satisfy the Allies’ military efforts during the 
invasion of occupied France in 1944.   
 
As well as being a hugely important drug in itself, the success of penicillin led to the 
large-scale scientific examination of fungi and other organisms as a source of potential 
drugs; an effort which led to many further breakthroughs in medicine.  This was 
complementary to the rapid improvement in our understanding of disease and its causes.  
The development of increasingly specialised assay systems for a range of diseases 
allowed natural products, natural product derivatives and purely synthetic compounds to 
be screened for specific purposes, leading to more advanced drugs.  Some examples are 
given below.   
 
During investigations of fungal metabolites for antimicrobial activity, scientists at Sandoz 
in Basel discovered the peptide cyclosporin A, 1.5.6,9  This compound displayed only 
moderate anti-fungal activity; however, its true value was found when its potent  
immunosuppressant activity was discovered.  It rapidly revolutionised the field of organ 
transplant by radically reducing the organ rejection which was the main cause of 
mortality in organ replacement patients.   
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The most profitable drug class to come from natural product sources is undoubtedly the 
serum cholesterol-lowering statin drugs.6,9,11  High levels of cholesterol is a key risk 
factor in coronary heart disease and the discovery of a natural product, lovastatin, 1.6, 
which could inhibit the in vivo biosynthesis of cholesterol provided an excellent 
prophylaxis.  Lovastatin and many other natural and synthetic analogues now form a 
highly profitable class of drugs which has had a large impact on the treatment of heart 
disease. 
O
O
O
OHO
1.6  
This brief survey of the history of natural products as medicines is in no way intended to 
be exhaustive, with only a selection of examples of the way natural products have 
synergistically developed alongside medical understanding.  The modern pharmacopeia 
has extended the life expectancy of many populations massively.  However, it is worth 
noting that the World Health Organisation estimates that around 80% of the world’s 
inhabitants still rely largely on traditional medicines for their primary healthcare.7    
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1.3 The influence of natural products on drug discovery 
 
It should be clear from the above that the field of natural products research has played a 
critical role in the development of modern medicine.  Despite the rise of synthesis, and in 
particular combinatorial chemistry, in drug design, natural products continue to play an 
important role to this day.  It is impossible to quantify this impact, however some 
statistical analyses on the topic have appeared in the last ten years, covering the period 
from 1981 to today.7,12 ,13  These analyses show that of all the new small molecule 
chemical entities approved as drugs in this time period, 39% were either natural products, 
directly derived from natural products or synthetic compounds whose design was based 
on a natural product pharmacophore.13  In the areas of anti-infectives and anti-cancer 
drug discovery, natural product research has been particularly productive.  Amongst anti-
cancer drugs (approved between the 1940’s and today), 57%, and of anti-infectives 63% 
(approved between 1983 and 1994) were natural products, natural product-derived or 
synthetic analogues of natural product pharmacophores.   
 
The reasons for the success of natural products as drugs and in inspiring drug design has 
been the subject of much debate, particularly since the rise of their main competitor in the 
field - combinatorial chemistry.14,15  There are a number of features of natural products 
which make them good potential candidates as phamaceuticals.16  First, the very reason 
for the production of secondary metabolites by organisms is to interact in some way with 
other biological entities in order to confer an advantage to the producer.  Thus, natural 
products can be thought of as ‘drugs’ which have been fine-tuned over thousands or even 
millions of years by nature to interfere with biological processes.  This leads to massively 
diverse groups of highly ornate, stereodefined, rigid entities which only the most 
ambitious of combinatorial chemists could ever hope to mimic.  Secondly, natural 
products are generally produced to interact with other organisms and as such they must 
have a proven degree of environmental stability, bioavailability and overall 
‘pharmacoviability’ in nature.  Whilst the biological settings for a pharmaceutical may be 
very different from those in their original setting, this pharmacoviability may be a case of 
‘half the battle won’.   
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However, there are a number of clear disadvantages associated with natural products as a 
source of drug leads.  These relate mainly to identification of the active natural product, 
and issues of supply.  The use of large libraries of extracts from various natural sources 
against high-throughput assay systems often brings to light potential drug leads.  
However, once an extract has been selected, identification of the active component in 
what may be a very complex mixture of compounds can be difficult.  The complexity of 
natural products can make elucidation of the structure of the active component an 
arduous task.  Once the active component has been identified, reasonably significant 
quantities of this natural product are required for initial biological evaluation, and much 
more will be required for in vivo testing and clinical supply if the compound is successful.  
Most natural products are produced on a very small scale by their host organisms and 
isolation of the compound of interest directly from the natural source is often (although 
not always) uneconomical on large scales.  A number of approaches have been used to 
circumvent these supply issues: synthesis and, more recently, the use of natural product 
expression in heterologous hosts is being explored (discussed further later), however it is 
worth noting that these approaches are not without their own problems. 
 
In light of these disadvantages, combinatorial chemistry seemed an excellent alternative 
source of drug leads.  The huge libraries of purely synthetic compounds produced by 
combinatorial chemistry ensured that both the structure of any potential drug ‘hits’ was 
already known, and that a supply was readily available by already validated synthetic 
routes.  However, a number of problems have become evident when looking for ‘hits’ 
amongst these libraries.  First, these libraries were prone to false positives if any trace of 
reagents, side-products or other impurities were present in the samples.  Secondly, the 
number of new drug leads found from these libraries was significantly lower than had 
been anticipated.  Attempts to explain this phenomenon invoke the concept of the quality 
or pedigree of the compound library.  As discussed above, natural products libraries are 
typified by structurally highly diverse and complex groups of compounds, whereas 
combinatorial libraries tend to occupy a smaller area of what has been described as 
chemical space.14  Chemical space is an abstract concept which attempts to combine a 
variety of properties of a compound such as molecular weight, number of stereogenic 
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centres, rings, heteroatoms and solubility.  Since combinatorial libraries are generated by 
variance of substrates in a matrix of common reactions, the diversity in chemical space of 
the resultant library is limited.  It has been noted that drugs occupy a very large chemical 
space, as do natural products, which is why natural product libraries have a higher 
‘pedigree’ when searching for potential drugs.   
 
The intelligent marriage of these two approaches is likely to be the most useful approach 
for future drug discovery programs.  Few would claim that natural products no longer 
have a role to play in drug discovery.  The massive improvement in analytical techniques 
continues to simplify the elucidation of natural product drug leads.  In those cases where 
supply issues are critical to the success of the emerging pharmaceutical, total synthesis or 
the synthesis of more accessible natural product analogues will continue to facilitate the 
viability of natural products as lead compounds in drug discovery.          
 
 
1.4 The influence of natural products on organic synthesis  
 
In addition to the important role the field of natural products has had on drug design, it 
has also influenced other spheres of science, in particular the field of organic synthesis.  
These two fields have developed synergistically, with developments in one field pushing 
the boundaries of the other.16   
 
The aim of organic synthesis is to generate ‘organic’ compounds, or in other words, the 
compounds derived from living organisms, from simple building blocks.  The synthesis 
of urea, an organic compound, from inorganic ammonia and cyanic acid by Friedrich 
Wöhler in 1828 is often heralded as the demise of vitalism and the beginning of the field 
of organic synthesis.  In fact this is a popular myth and it has been argued that it is 
historically more appropriate to attribute the demise of vitalism to Kolbe’s synthesis of 
acetic acid.17,18  The early years involved the synthesis of very simple organic molecules, 
but the 20th century saw the interest in, and the sophistication of synthetic chemistry 
increase exponentially.  This occurred simultaneously with the improved analytical 
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techniques which allowed the structures of increasingly complex natural products to be 
elucidated.  The synthetic targets chosen were often driven by interest in the biological 
activity of a natural product whose supply was questionable.  An example is the total 
synthesis of a quinine precursor by Woodward and Doering in 1944.19  The supply issue 
of this strategic drug led to intense interest in a possible synthetic source.  When the 
successful synthesis was announced there was much fanfare amongst the public, although 
realistically the synthesis could not have provided a genuine alternative source, and the 
careful management of natural resources and discovery of synthetic analogues such as 
chloroquine, 1.7, made the synthesis of quinine, 1.1, a more academic pursuit.    
N
Cl
N
H
N
1.7  
Although the synthesis of quinine did not solve its supply issues, it did show that the 
synthesis of complex, biologically interesting natural products could be achieved.  Early 
synthetic conquests were largely achieved by clever exploitation of known reaction 
chemistry.16  The burgeoning field of natural products was, however, yielding ever more 
complex targets with interesting biological activities, on which the fresh faces of 
synthetic chemistry could test their mettle.20  In order to synthesise many of these new 
compounds, the methodology available to synthetic chemistry had to increase radically.  
The explosive growth in synthetic methodology in the last half century is attributable to 
the inventiveness of synthetic chemists, determined to reach their chosen natural product 
targets.  New methods involved both the classic elements with which organic chemists 
were well acquainted (eg C, H, N, O, the halogens and alkali earth metals), as well as 
exploitation of other elements (eg B, S, Se, Si, Sn, P) and in particular the transition 
metals, which opened up new synthetic opportunities.16  With the development of the 
new methodology, yet more ambitious natural products could be targeted, leading to 
further methodology development.  In this way, the field of organic synthesis became an 
increasingly sophisticated art, constantly being pushed by natural product discovery.  The 
complexity of the natural products which can now be successfully targeted (eg brevetoxin 
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B, 1.8;21 palytoxin, 1.9)22,23,24 would have astonished the early pioneers in this field (and 
frankly, astonish this author). 
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An early example of the advances in methodology which resulted directly from the 
synthesis of a natural product is the development of mild dehydrating agents by Sheehan, 
used in the synthesis of penicillin V (1.10).25,26  Although fermentation methods were 
able to generate significant amounts of penicillin for the war-effort (vide supra), the 
synthesis of penicillin was also actively pursued.  The synthesis of the penicillins had 
been hampered by an inability to form the highly labile β-lactam moiety which was so 
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critical to the activity of these natural products.  All the dehydrating agents for amide 
bond formation of the day involved harshly acidic conditions (eg thionyl chloride and 
phosphorous trichloride), and Sheehan appreciated that a more mild system would be 
required for the sensitive penicillin skeleton.  His development of 
dicyclohexylcarbodiimide (1.11) as a mild and efficient dehydrating agent allowed the 
synthesis of this challenging target to be completed.  In addition, the development of a 
mild dehydrating agent for amide bond formation had a huge effect on the field of 
peptide synthesis and aided important new developments such as solid-phase peptide 
synthesis.    
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The increased sophistication and scope of the new methodologies gleaned from natural 
product synthesis also impacted on other areas of chemistry.  From inorganic chemistry 
to biochemistry, materials science to nanotechnology; all have benefited from the large 
synthetic repertoire developed.  Ironically, it is on the back of the wealth of robust new 
methodology, increasingly well validated and understood, that combinatorial chemistry 
now rides.  The huge libraries of combinatorial chemical entities could not have been 
made without the hard work of countless synthetic chemists racing to be the first to 
publish the total synthesis of the latest natural product.   
 
Evidently, other branches of chemistry have played their roles in the development of 
synthetic chemistry, but only the field of natural products can claim to have challenged 
and forced the imagination of synthetic chemists; cajoled them even, into pushing the 
boundaries of their science ever further.    
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1.5 The influence of organic synthesis on natural products  
 
As mentioned earlier, the development of the field of natural products and organic 
synthesis was synergistic.  In Section 1.4 the importance of natural products to the 
development of organic synthesis was discussed.  Here, the importance of organic 
synthesis to natural product research will be examined.   
 
There are three main ways in which synthesis has aided natural product research; firstly 
in the validation of proposed structures for new metabolites, secondly by allowing 
improved supply for metabolites produced in insufficient quantities, and thirdly by 
generating analogues of the natural product pharmacophore which are, in some way, 
better than the original natural product.   
 
During the early years of natural product research, the structural elucidation of 
metabolites largely relied on extensive degradation and/or derivatisation studies, which 
allowed the researcher to piece together the structure.  This pain-staking process required 
a great deal of deductive skill and patience on the part of the researcher.  The 
unambiguous proposal of a single structure was often difficult or impossible.  The final 
validation therefore usually required the total synthesis of the proposed structure and 
comparison of physical data.  With the development of a number of analytical techniques, 
most notably X-ray crystallography, NMR spectroscopy and mass spectrometry over the 
last half century, the art of structure elucidation has been transformed.  It is now possible, 
and even routine, to elucidate the structure of very complex molecules, including their 
stereochemistry, present in milligram or even sub-milligram quantities.  These massive 
advances in technology would suggest that virtually any metabolite will succumb to 
elucidation without hitch, removing the need for any validation of the proposed structure.  
Whilst it is true that the vast majority of newly elucidated natural products are accurately 
proposed by the careful use of these techniques, a not insignificant number of structures 
are subsequently shown to have been misassigned.27  These misassignments are regularly 
only recognised on completion of a total synthesis.28,29  The misassignments are generally 
not the result of sloppy work on the part of the researcher, but the result of an unexpected 
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ambiguity in the data.27  This demonstrates the continued value total synthesis has in 
validating natural product structures.   
 
One of the chief complaints about natural products in drug discovery is the issue of 
supply.  The sustainable production of sufficient drug to supply demand in an economical 
fashion is a critical factor in the viability of any pharmaceutical candidate.  Many drugs 
derived from microorganisms can be successfully generated by fermentation eg 
daptomycin.30  However, total synthesis also plays an important role in alleviating the 
problem of supply.  Galantamine (Alzheimer’s) and mycophenolate sodium 
(immunosuppression), two natural product drugs which have recently reached the market, 
are both produced by total synthesis.31  Semi-synthesis is another approach to alleviating 
problems of supply, with paclitaxel or taxol (1.12) being a good example.  This clinically 
important anti-cancer drug is a natural product originally isolated from the bark of the 
Pacific yew tree (Taxus brevifolia) and its potential was recognised during research in the 
1960s and 70s.32  However, only 1 g of the metabolite could be extracted from 24 kg of 
dried bark.  Since a 125 year old tree was only capable of producing around 2 kg of bark 
and this species was relatively rare, the issue of supply was particularly acute in the case 
of this natural product and slowed its development as a drug.  The total synthesis of taxol 
was completed by Holton and Nicolaou independently.33,34,35  However, it was taxol’s 
semi-synthesis from a natural congener, 10-deacetyl baccatin III (1.13), more sustainably 
obtained from the needles of the Taxus baccata, which allowed for its large-scale 
manufacture and commercial supply.36
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Finally, synthetic studies can be used to improve the natural product pharmacophore in 
some way.  This may be by directly improving an aspect of a natural product’s biological 
activity, for example by reducing toxicity, increasing potency or selectivity or improving 
bioavailability.  Alternatively, synthesis may lead to an improvement in the economy of 
production.  A combination of these factors was achieved during the synthetic studies of 
epothilone B (1.14) by Danishefsky and co-workers, leading to several very promising 
lead compounds, which are currently at various stages of clinical testing.16,37   
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The highly cytotoxic epothilone B displays activity against multi-drug resistance (MDR) 
cancer cell lines, which sparked interest in its synthesis.  Having successfully synthesised 
the natural product, the group of Danishefsky then carried out diverted total synthesis 
(DTS) on the pharmacophore.  DTS can be defined as a process of optimisation of drug 
leads from natural products by using intermediates generated during the total synthesis of 
the natural product as a platform to generate a range of related analogues.  By examining 
these related analogues, any improvements in the pharmacophore will be discovered and 
a structure-activity relationship developed.  An understanding of medicinal chemistry 
 
Chapter 1: Introduction 16 
may allow the focussed design of this small library such that specific characteristics are 
added to, or removed from the pharmacophore.  In DTS studies on epothilone B, the 
removal of the epoxide of the natural product yielded an analogue (1.15) which is better 
tolerated in vivo due to the removal of the non-selective biological activity of this motif 
(currently in phase II testing, May 2006).  Whilst this product retained activity against 
MDR cell lines, its potency was less than that of 1.14.  The authors then carried out 
further DTS studies and found that 9,10-dehydro-dEpoB (1.16) and its trifluoromethyl 
analogue (1.17) retained selectivity, but showed potency analogous to that of the natural 
product.  Analogue 1.17 shows particular promise as an anti-cancer drug, with low 
toxicity and excellent pharmacokinetics, as well as high activity, and entered preclinical 
trials (May 2006).    
 
The synergistic development of synthetic chemistry and natural products research has 
therefore been to the great benefit of both fields, as well as many other fields of science.    
 
 
1.6 Future trends 
  
Investment in natural product programs by pharmaceutical companies was seriously 
reduced during the last twenty years as emerging technologies, in particular 
combinatorial chemistry, became popular.  Scientists have expressed surprise that such a 
time-honoured and successful approach had been abandoned so readily for far less 
validated drug discovery platforms.16  In more recent years, however, natural products 
have experienced a resurgence of interest from the pharmaceutical industry, and there is 
an increasing realisation that a combination of natural product libraries, more focussed 
combinatorial chemistry, and rational design will provide the best opportunities for drug 
discovery.15,38   
 
Synthesis is likely to continue to feature heavily in drug development programs.  The 
increased interest in and success of “green” chemistry is likely to improve the 
sustainability of using synthesis for commercial pharmaceutical supply.39   
 
Chapter 1: Introduction  17
The use of computational tools, such as virtual screening of in silico compound libraries 
for potential drug leads and for rational lead optimisation will, no doubt, continue to be 
important in drug design.40  Computing power continues to increase rapidly, and equally, 
scientist’s ability to design appropriate models and critically analyse results improves 
with experience, which is leading to more reliable predictive capabilities.   
 
As well as improvements in these traditional technologies, new technologies are also 
emerging which may aid pharmaceutical design and viability.41  In particular, the 
increased understanding of the enzymes involved in secondary metabolite production, 
and the genes which code for them, is opening up the opportunity of ‘combinatorial 
biosynthesis’.42,43  The polyketide and non-ribosomal peptides are the classes of natural 
products that are most amenable to this technology, and are two of the most productive 
biosynthetic pathways of viable pharmaceutical lead compounds.  Both classes are 
biosynthesised by either one or a small collection of large, modular synthetases 
(additional tailoring enzymes may also be involved).  These act as factory lines, with 
each well-defined module carrying out a catalytic reaction and passing the natural 
product precursor onto the next module for further manipulation, until the completed 
metabolite is released by the enzyme.  It has been found that these modular enzymes are 
highly promiscuous.  Not only can they be fed different precursors, leading to subtle 
changes in eventual metabolite structure, but the constituent modules can even be 
manipulated, deleted or exchanged, leading to radical variations in the structure of the 
final metabolite.  Not only can this approach lead to libraries of novel ‘natural’ 
products,44,45 but those which prove to be good drug leads can be produced on large 
scales since the genes coding for them can be introduced into heterologous hosts which 
are amenable to large-scale fermentation.   
 
In an alternative but related approach, ‘combinatorial biology’ offers the possibility of 
screening natural products produced by unculturable microorganisms, radically 
expanding the portion of biodiversity that can be exploited for pharmaceuticals.41  This is 
carried out by isolating and cloning the DNA from problematic microorganisms into 
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heterologous hosts.  The natural products produced by these organisms can then be 
expressed and examined for biological activity.     
  
The future of medicinal chemistry will therefore continue to be a very interdisciplinary 
venture.  The combination of talented chemists, biochemists, microbiologists, not to 
mention physicians will ensure that our understanding of the causes of disease will 
deepen and our ability to treat or prevent disease will improve.  The issue of 
sustainability will also be of increasingly critical importance, as competition for resources, 
particularly petrochemicals, becomes more intense.  The use of fermentation processes 
using renewable biomass may therefore become increasingly economical, and indeed 
ethical.  
 
 
1.7 Aims of this thesis 
 
The primary aim of the work presented in this thesis was to utilise synthesis as a tool in 
the study of natural products isolated by the natural products research group at the 
University of Canterbury.  In particular, the natural products chosen would be of 
biological interest, as determined in this group’s in-house biological assays.   
 
The synthetic studies undertaken covered two different stages in the development of 
natural products as potential lead compounds in drug discovery.  The first project utilised 
synthesis as a tool in the elucidation of the structure of natural products, namely the 
pteratides.46  The second project endeavoured to establish a total synthesis of a natural 
product whose structure had already been assigned, spiro-mamakone A.47  The latter 
would also serve as a platform for diverted total synthesis, allowing the generation of a 
library of natural product analogues and therefore, enabling the beginnings of a structure-
activity relationship to be established.   
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Chapter 2 
 
The Pteratides 
 
2.1 Introduction 
2.1.1 Depsipeptides 
 
Polypeptides are a central motif in biological systems, and constitute more than 50% of 
the dry weight of cells.  The overwhelming proportion of these are proteins, which play a 
crucial role in primary metabolism by catalysing the chemistry required for life.  Certain 
proteins can also provide essential structural components of cells, such as actin, whilst 
others, such as insulin and angiotensin II, regulate cellular processes.  They are 
unbranched polymers of the 20 common amino acids, linked by amide bonds and are 
formed by ribosomal peptide synthesis.    
 
In addition to these ‘ribosomal peptides’, peptides can also be produced by ‘non-
ribosomal peptide synthesis’, which involves dedicated biosynthetic pathways producing 
very diverse peptides for specific roles.  These fall into the category of secondary 
metabolites.  Amongst these, it is common to find amino acids incorporated which are 
either common amino acids which have been chemically modified, or even amino acids 
entirely distinct from the 20 common amino acids.  Biosynthetically distinct groups, such 
as polyketides, can also be incorporated into the peptide chain.  Backbone linkages other 
than amide bonds can be formed, in particular ester linkages to give a class of peptide 
called depsipeptides.  Cyclic peptides are also common,1 with cyclisation generally 
occurring via an amide linkage between termini of the peptide, or between one terminus 
and an appropriate amino acid side-chain functionality.  In those instances where 
cyclisation occurs with a side-chain hydroxyl or phenol group, forming an ester linkage, 
the name cyclodepsipeptide is used.    
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Many cyclodepsipeptides show promising biological activities.  Examples are didemnin 
B and FR901228 which have entered clinical trials as anti-cancer agents and the 
jaspamides which show a variety of biological activities including cytotoxicity, 
antimicrobial and antifungal properties.2
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2.1.2 Pteratides 
 
The pteratides are a new class of highly cytotoxic cyclodepsipeptides recently discovered 
by Miss C-H Chen of the Marine Group at the University of Canterbury.3  The family is 
comprised of three depsipeptides; two octadepsipeptides (pteratides I and II) and one 
hexadepsipeptide (pteratide III).  They were isolated from the fruiting bodies of a coral-
shaped Malaysian basidiomycete, identified as a Pterula species (Figure 2.1).  
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Figure 2.1 – Malaysian basidiomycete, Pterula species; the source of the pteratide series 
of natural products  
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Pteratides I and II display potent cytotoxicity against the P388 murine leukaemia cell line 
(IC50 values of 41 and 40 nM, respectively), whilst pteratide III shows more modest, but 
still notable, activity (2.9 μM).   
 
The structures of the pteratides I to III were elucidated by Miss Chen using extensive 
NMR and mass spectral analysis.  1H and 2D NMR data were used to establish the 
constituent amino acids and connectivity.  Methanolysis and ESI MS/MS of the resultant 
methyl esters were carried out on pteratides I and II, and the fragmentation pattern 
observed confirmed the proposed connectivity.    
 
The pteratides are structurally very interesting; incorporating many ‘unnatural’ or ‘non-
coded’ amino acids (those not amongst the 20 coded amino acids recognised by tRNA).  
Pteratides I and II each include five N-methylated amino acids, and pteratide III includes 
four.   
 
N-Methylation is a common chemical modification found in peptide secondary 
metabolites and is introduced by tailoring enzymes on the growing peptide chain during 
biosynthesis.4,5  As secondary amines, N-methylated amino acids introduce different 
structural features to the backbone of a peptide, in a manner similar to that of proline, the 
only secondary amine of the common amino acids.  Secondary amino acids confer 
structural rigidity to the peptide backbone as well as promoting the less favoured cis- 
conformation about the amide bond (discussed further in Section 2.2.2).  N-methylation 
of the backbone may alter intramolecular hydrogen bonding sites, which also alters the 
conformation of the peptide.  As such, N-methylation is an important biosynthetic tool in 
establishing the three-dimensional shape of peptidic natural products.   
 
N-Methylation of peptides also alters other physical properties important to biological 
activity.  For example increased membrane permeability may be observed, due to the 
reduction in hydrophobicity,6 and increased proteolytic stability, due to the blocking of 
enzyme cleavage sites.7    
 
 
Chapter 2: The Pteratides  25   
Another interesting structural feature of the pteratides is the incorporation of a benzoyl N-
terminus capping group.  This motif is relatively common, with examples including N-
benzoyl-S-phenylalaninol and related natural products such as anabellamide and 
hypothallin.8,9,10
 
Finally, pteratides I and II incorporate the very unusual amino acid 4-methylproline.  This 
amino acid was first isolated in young apples,11,12,13 and has also been found in 
bacteria,14,15 cyanobacteria,16,17,18 the sponge Theonella sp.19 and fungal sources.20,21,22  
This unusual feature is possibly the most interesting aspect of this series of natural 
products and elucidation of the importance of the methyl group to the biological activity 
observed in the natural products would be of critical value in a structure-activity 
relationship study.   
 
 
2.1.3 Stereochemistry in biology 
 
Chirality is important in biological systems as most of the building blocks of life contain 
stereogenic centres, and the correct spatial arrangement is important in interactions 
between biochemical entities.  For example, recognition of substrates by enzymes and 
receptors is critically dependant on the stereochemistry of the substrate.   
 
Many drugs are known in which one enantiomer is the active form, and the other is either 
inactive, or displays an entirely different activity.  The classic example of such a drug is 
thalidomide, which was marketed for the relief of morning sickness, amongst other 
indications, to pregnant women in late 1950’s.   
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The drug was given as a racemic mixture of its two enantiomers, but due to insufficient 
testing, the highly teratogenic properties of one of the enantiomers (levorotatory) was not 
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realised until after it had caused deformities in an estimated 10,000 children.  It was 
subsequently discovered that racemisation occurs in vivo, such that even prescribing the 
enantiomerically pure, non-teratogenic form may not have prevented the tragedy.23
 
 
2.1.4 Stereochemical elucidation 
 
With the nature of the amino acids present in the pteratides, and their connectivity already 
established, the remaining aspect of their structure to be elucidated was stereochemistry.  
Amino acids (with the exception of glycine) contain at least one chiral centre and all of 
the 20 common amino acids (except glycine) are found naturally in the L form in 
ribosomal polypeptides.  However, as noted above, peptides of non-ribosomal 
biosynthetic origin regularly include non-natural amino acids, including those of the D 
series.  It was therefore important to establish the stereochemistry of each of the amino 
acids to conclude the elucidation of the pteratide structures.   
 
There are a number of standard procedures for the elucidation of the stereochemistry of 
amino acids, which involve the use of chromatography to separate individual isomers.  
HPLC has proved to be a powerful tool for the separation of small quantities of 
compounds and is the method of choice in this case.  In order to study the stereochemistry 
of each amino acid, the peptides must first be broken down into their constituent amino 
acids, generally by hydrolysis of the amide (and ester, where present) bonds.  The 
constituent amino acids can then be compared to reference materials of each possible 
stereoisomer of each amino acid, to establish which is present in the natural product.    
 
Enantiomeric pairs cannot be separated on standard reverse phase columns since their 
physical properties are identical and therefore they will have identical affinities for the 
stationary phase.  Both direct and indirect methods have therefore been developed to 
allow the separation of amino acid enantiomeric pairs.  Direct methods involve the use of 
a chiral selector.  This can either be directly attached to the stationary phase, creating a 
chiral stationary phase such as the Phenomenex Nucleosil® Chiral 1 column, or the chiral 
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selector can be an additive in the mobile phase, eg L-histidine methyl ester/copper 
complex for separating dansyl amino acid derivatives.24  Indirect methods involve a pre-
column derivatisation step with a chiral reagent.  The diastereoisomeric products formed 
can then be separated on standard reverse phase columns.   
There are a number of advantages and disadvantages to the direct and indirect methods, 
some of which are summarised in Table 2.1.   
 
Table 2.1 – Comparison of direct and indirect methods of enantiomeric purity analysis 
 Direct enantiomeric purity 
analysis 
Indirect enantiomeric purity 
analysis 
1.  Simple sample preparation 1.  Resolution of enantiomers is   
     often superior 
2.  Enantiomers have same UV     
     adsorption so no detector bias 
2.  Elution order can be easier to    
     predict 
3.  Racemisation is less likely   
     during sample analysis 
3.  Can be used to enhance    
     sensitivity 
Advantages 
4.  Purity of chiral selector not as 
     critical  
4.  Achiral columns cheaper and  
     more rugged 
1.  Resolution may be poor 1.  Enantiomeric purity of chiral  
     selector important trying to    
     detect a trace enantiomer 
2.  Lengthy method development 
     time may be required  
2.  Diastereoisomers may not have  
     same UV adsorption leading to  
     detector bias 
3.  Expensive columns or mobile 
     phase additives required 
3.  Racemisation during  
     derivatisation may occur 
4.  Elution order often more  
     difficult to predict 
4.  Derivatisation steps may be  
     time-consuming 
Disadvantages 
 5.  Excess derivatisation reagent  
     may interfere in chromatogram 
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A very popular pre-column derivatisation procedure for indirect enantiomeric purity 
analysis is the reaction of the amino acids with 1-fluoro-2,4-dinitrophenyl-5-L-alanine 
amide, also known as Marfey’s reagent, 2.1.25,26  The amino acid in question, 2.2, either 
of unknown stereochemistry or a reference material, undergoes a nucleophilic aromatic 
substitution reaction with this chiral reagent, 2.1, to form diastereomeric Marfey’s 
derivatives, 2.3 (shown in Scheme 2.1).   
NO2
O2N
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H
N
NH2
O
NO2
O2N
R'N
H
N
NH2
O
R
OH
OR'HN
R
O
OH
+
2.1 2.2 2.3  
Scheme 2.1 – Derivatisation with Marfey’s reagent 
 
The Marfey’s derivatives of the amino acids can then be separated, often with very high 
selectivity factors, on C8 or C18 reverse phase columns.  It has been noted that amino 
acids of the L series elute with an earlier retention time than the corresponding D series, 
however some exceptions to this general rule have been encountered.  The derivatives 
have a distinctive UV chromophore (Figure 2.2), making identification simple.   
 
The popularity of this particular indirect method lies in both its simplicity and its 
effectiveness.  The derivatisation step is easy to carry out, and the yield of the reaction is 
usually in excess of 99% (around 2 equivalents of Marfey’s reagent are commonly 
employed).  No racemisation is observed during the derivatisation step and the 
hydrolysed reagent side-product does not generally coincide with the amino acid 
derivatives.  The introduction of a strong UV chromophore at 338 nm allows for very low 
detection limits.  This was the method chosen to study the stereochemical composition of 
the pteratides.   
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Figure 2.2 – UV chromophore of Marfey’s derivatives 
 
 
2.1.5 Reference materials 
 
In order to establish the stereochemistry of the amino acids of the pteratides, reference 
materials of all possible stereoisomers of the amino acids in question must be available.  
All stereoisomers of the 20 common amino acids are available commercially, and many 
of the less common amino acids are also available.  However, several of the amino acids 
found in the pteratides were either unavailable (in the case of 4-methylproline) or 
expensive.   
 
Most of the amino acids required were already available in house.  However, N-methyl-L-
valine, the four stereoisomers of N-methyl-threonine and the four stereoisomers of 4-
methylproline were not.  Initial work towards the elucidation of the stereochemistry of 
the pteratides therefore involved the synthesis of these amino acids.  These syntheses 
were carried out by directly following literature precedent, or modifications thereof, and 
are discussed in the following sections.   
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2.2 Synthesis of N-methyl amino acids 
 
2.2.1 Introduction 
 
N-Methylated amino acids have been highly sought-after synthetic targets whose 
preparation has been explored since Fischer’s first pioneering work.27  Their regular 
appearance in natural products and the interesting properties their presence imparts on the 
biological activity of peptides has ensured active research continues on their synthesis.  
Increasingly mild techniques have been sought as N-methylated amino acids which are 
protected or present in a peptide chain are more prone to racemisation under both basic 
and acidic conditions than their non-methylated counterparts.  This is postulated to be 
because in the absence of ionizable groups other than the α-centre, this centre is left 
exposed to racemisation.28,29  A number of varied approaches have been studied,30 a brief 
overview of which will be given here.   
 
Emil Fischer was the first chemist to prepare N-methylated amino acids using the direct 
methylation of tosyl derivatives of amino acids, with methyl iodide and base (Scheme 
2.2).27  Sulfonamide protection of amines greatly enhances the acidity of the sulfonamido 
nitrogen, due to the strongly electron withdrawing nature of this group, allowing 
deprotonation and subsequent attack on an alkyl electrophile.  The strongly basic 
conditions involved in the methylation can cause significant racemisation, however, and 
the vigorous conditions required for N-tosyl deprotection also detract from this first 
success.31  Milder conditions have been found, and of note is the methylation of N-nosyl 
amino acids with diazomethane under neutral conditions.32,33  The N-nosyl (p-
nitrobenzenesulfonamide) group is also a strongly electron withdrawing protecting group, 
but can be cleaved under milder conditions than the N-tosyl group.   
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Scheme 2.2 – Fischer’s route to N-methylated amino acids 
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The N-methylation of N-acyl and N-carbamoyl amino acids has been successfully 
achieved, notably using sodium hydride and methyl iodide, as developed by Benoiton et 
al. (Scheme 2.3).34  This method is a relatively mild procedure, although conditions must 
be carefully controlled to avoid racemisation.  Variations of both the base35 and methyl 
donor36 have also been published.    
R'
N
H
OH
O
R
O
NaH, MeI
R'
N
OH
O
R
O
R = OtBu, OBn, 
       Ph, Me
 
Scheme 2.3 – Benoiton’s route to N-methylated amino acids 
 
Reductive amination is an attractive route to N-methyl amino acids due to the mild 
conditions involved.  Whilst mono-alkylation of amino acids is possible using aldehydes 
larger than formaldehyde, 37 clean mono-methylation is not possible.  The secondary 
amine produced is more nucleophilic than the parent primary amino acid, and competes 
for the aldehyde, leading to a mixture of starting material, mono- and di-methylated 
products.  In the case of larger aldehyde homologues the additional steric bulk is 
sufficient to prevent the secondary amine from competing for the aldehyde.  Multi-step 
routes have been published which achieve mono-methylation via reductive amination,38 
however, and these will be discussed later (Section 2.2.3). 
 
The final major route for N-methylation involves the intermediacy of oxazolidinones.  
These were first prepared from N-CBz amino acids by Ben-Ishai by an acid catalysed 
dehydration with paraformaldehyde, followed by intramolecular ring closing.39  
Freidinger applied this to Fmoc protected amino acids and established that reduction of 
the oxazolidinone ring furnished N-methyl-Fmoc protected amino acids (Scheme 2.4).40  
This route is very mild and no racemisation is observed.  It was also found that these two 
steps (oxazolidinone formation/reduction) could be combined in one step.41      
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Scheme 2.4 – Freidinger’s route to N-methylated amino acids 
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2.2.2 Synthesis of N-methyl-L-valine 
 
In the synthesis of N-methyl-L-valine, it was decided to follow the method of Friedinger 
discussed above (Section 2.2.1) since it is a short, mild and high yielding synthesis.   
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N
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O
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2.4 2.5
2.62.7  
Scheme 2.5 – Synthesis of N-methyl-L-valine 
 
The synthesis (Scheme 2.5) begins with the Fmoc protection of L-valine under Schotten-
Baumann conditions.  This proceeded cleanly, to give 2.4 in a yield of 66%.  The next 
step involves the formation of the oxazolidinone.  The dehydration and cyclisation steps 
occur with paraformaldehyde and catalytic amounts of pTSA under standard Dean-Stark 
refluxing toluene conditions.  A good yield of 94% of oxazolidinone 2.5 was obtained 
and the product was characterised by NMR and IR spectroscopy.  The 1H NMR chemical 
shift data compared well to the literature data, however a broadening of all peaks except 
those of the Fmoc group was observed.  This broadening of the peaks can be explained by 
the slow interconversion of more than one ring conformation, and may be exacerbated by 
the presence of carbamate cis-trans isomerisation.  In the amide bonds of standard amino 
acids (except proline), the trans- isomer is preferred as it minimises the steric interactions 
of adjacent amino acids.  The energy barrier of conversion from trans- to cis- is also high, 
due to the significant double bond nature of the C-N bond, arising from the delocalisation 
of the nitrogen lone pair over the amide moiety.  In the case of proline and other 
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secondary amino acids, the trans- preference is less pronounced as the second group on 
the amine introduces other steric interactions.  The broadening of peaks was not, however, 
observed in the literature report.  This may be due to a difference in the temperature at 
which the spectrum was carried out (23ºC, in this work; temperature not stated in the 
literature report.  CDCl3 used as solvent in both cases).  Despite this ambiguity, the 
presence of the characteristic, strong oxazolidinone carbonyl IR absorption at 1801 cm-1 
provided confirmation that the ring had been formed.   
 
Reductive ring opening was carried out with triethylsilane, with chloroform and 
trifluoroacetic acid as the solvent.  The N-methyl product, 2.6, was obtained in 77% yield.  
NMR characterisation again showed minor variations on that reported in the literature.  A 
doubling of peaks with a ratio of around two to one was observed in both the 13C and 1H 
NMR spectra.  This can be readily explained by cis-trans isomerisation of the carbamate 
amide bond, as discussed above.  It is surprising, however, that the same phenomenon 
was not noted in the literature report.  High resolution mass spectral data confirmed the 
molecular formula of the product.   
 
Finally, cleavage of the Fmoc group was carried out using piperidine to give the free N-
methyl amino acid, 2.7, in quantitative yield.  NMR spectroscopic, high resolution mass 
spectral and optical rotation data were all in accordance with literature data.  To confirm 
optical purity, Marfey’s derivatives of the synthetic N-methyl-L-valine and commercial 
N-methyl-D/L-valine were carried out.  Results of HPLC analysis of the derivatives 
(Figure 2.3) show that the synthetic N-methyl-L-valine was free from any trace of its 
enantiomer.    
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Figure 2.3 – HPLC analysis of the Marfey’s derivatives of synthetic N-methyl-L-valine 
and commercial N-methyl-D/L-valine 
 
 
2.2.3 Synthesis of N-methyl-L- and D-threonine 
 
With N-methyl-L-valine in hand, attention was next given to the synthesis of all four 
diastereoisomers of N-methyl-threonine.   
 
The procedure of Freidinger utilised to synthesise N-Me-L-valine (Section 2.2.2), via the 
intermediacy of an oxazolidinone has one crucial drawback.  It works very well in the 
case of those amino acids with simple alkyl side-chains, however, certain side-chains are 
capable of intercepting the intermediate in oxazolidinone formation, creating alternative 
ring systems.42  In the case of threonine and serine, the oxazolidine was the predominant 
product, and in the case of cysteine a dimeric product was observed (Scheme 2.6).    
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Scheme 2.6 – Major side-products of oxazolidinone formation in amino acids with 
reactive side-chains 
 
Whilst this problem can be avoided with the use of side-chain protection, this adds two 
additional steps to the synthesis and makes it a less attractive route.43  There are a number 
of other routes (Section 2.2.1), and a method for efficiently N-methylating threonine was 
reported by Boger et al.38  This method involves the use of reductive amination to 
introduce the methyl group.  
 
As discussed previously (Section 2.2.1), reductive amination of amino acids with 
formaldehyde directly results in dimethylation of the amine since the additional steric 
hindrance provided by one methyl group is insufficient to prevent the second alkylation.  
However, other aldehydes do produce exclusively monoalkylated products, as steric 
hindrance becomes more important than electronic effects.  This allows for a multi-step 
route, where initially a reductive amination with benzaldehyde leads to an easily cleaved 
benzyl group on the amine.  The mono-methylation of this secondary amine by a further 
reductive amination now occurs cleanly and deprotection yields the final product.  This is 
a relatively short and very mild method which is free of epimerisation (Scheme 2.7).   
 
 
Chapter 2: The Pteratides 36 
OH
H2N
O
O
benzaldehyde
NaBH4
OH
N
H
O
O
Ph
formaldehyde
NaBH3CN
OH
N
O
O
Ph
OH
HN
O
O
Pd/C
H2(g)
LiOH(aq)
OH
HN
OLi
O
2.8
ent-2.8
2.9
ent-2.9
2.10
ent-2.10
2.11 (2S,3R)
ent-2.11 (2R,3S)
L-Thr (2S,3R)
D-Thr (2R,3S)
 
Scheme 2.7 – N-methylation of L-threonine and D-threonine 
 
This route was undertaken, initially with L- and D-threonine, from commercial L- and D-
threonine methyl ester.  Imine formation was carried out by stirring the amino acid with 
benzaldehyde for one hour, then reduction of the imine with sodium borohydride and 
acidic workup gave the secondary amines, 2.8 and ent-2.8, in good yields (93% and 78% 
respectively).  1H NMR data was in good agreement with the literature report, except that 
the reported broad singlets at δH 3.47 and δH 1.59 were not observed.  These are likely to 
be resonances from the exchangeable NH and OH protons and their absence can be 
explained by their exchange with trace amounts of water present in the solvent (CDCl3) 
over time.  High resolution mass spectral data confirmed the molecular formula of the 
product.   
 
The next step involved introduction of the methyl group by imine formation with 
formaldehyde, followed by reduction with sodium cyanoborohydride and acidic workup.  
Sodium cyanoborohydride, an alternative reducing agent which is milder than the more 
common sodium borohydride, is commonly used in reductive aminations as it will 
efficiently reduce an imine but reacts much more slowly with ketones and aldehydes.  As 
this methylation step is carried out without pre-formation of the imine (reductant and acid 
are added immediately after the aldehyde), this reagent was chosen in order to avoid 
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consumption of the aldehyde and reductant in the unproductive formation of methanol.  
The N-methylated threonine derivatives, 2.9 and ent-2.9, were obtained in good yields 
(80% and 77% respectively).  1H NMR data of the product were in good accordance with 
those reported, with high resolution mass spectral data confirming the molecular formula.  
The specific rotation of the product (-98º for 2.9 and +96º for ent-2.9) was slightly lower 
than that reported (-112º for 2.9), but the discrepancy may be due to experimental error 
rather than being indicative of racemisation.   
 
Cleavage of the benzyl group was carried out cleanly by catalytic hydrogenation using 
palladium on carbon as a catalyst.  The free secondary amines, 2.10 and ent-2.10, were 
obtained in moderate to excellent yield (55% and 97% respectively), with 1H NMR data 
in good agreement with those reported, except for the absence of the exchangeable 
protons reported.  High resolution mass spectral data confirmed the molecular formula of 
the product.  Specific rotation data (-19º for 2.10 and +17º for ent-2.10) was in good 
accordance with the reported specific rotation (-18º for 2.10).   
 
Finally, cleavage of the methyl ester under basic conditions was carried out.  Due to the 
possibility of epimerisation of amino acids under basic conditions, one equivalent of base 
was employed.  The final N-methyl amino acids, 2.11 and ent-2.11, were obtained as 
lithium salts, in approximately quantitative yield.  The 1H NMR data corresponded to 
those in the literature for the free amine,42 although some shifts in δH were observed.  A 
shift in δH is anticipated when comparing unprotected amino acids, as changes in 
ionization can make significant changes to the electronic environment of the nearby 
protons.44  The chemical shift of the protons closest to the ionizable centres are most 
significantly affected, as can be seen by comparison of the δH observed for the α, β and γ 
protons and those in the literature, given in Table 2.2.  
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Table 2.2 – Changes in chemical shift observed 
 Observed δH Literature δH ΔδH
α 2.72 3.22 0.5  
β 3.68 3.9 0.22 
γ 1.05 1.18 0.13 
NMe 2.15 2.59 0.44 
 
No optical rotation data are available for the lithium salt of the N-methyl-threonines, 
however the values obtained were moderately similar in value and opposite in sign (-2º 
for 2.11 and +10º for ent-2.11).  Marfey’s derivatisation and HPLC separation confirmed 
the optical purity of the product (Figure 2.4, Section 2.2.4).   
  
With N-methyl-L- and D-threonine in hand, attention was now turned to the synthesis of 
N-methyl-L- and D-allo-threonine.   
 
 
2.2.4 Attempts to invert the β stereochemistry of N-methyl-L- and D-threonine 
 
Of the coded amino acids, isoleucine and threonine are the only examples to contain two 
stereogenic centres.  As a result, they each have four possible diastereoisomers; those of 
threonine are shown below.   
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L-threonine is the coded amino acid, is available commercially and is inexpensive.  D-
threonine is also inexpensive.  L- and D-allo-threonine, whilst commercially available, are 
significantly more expensive, with L-allo- being around 450 times and D-allo- around 850 
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times as expensive as L-threonine.  This makes the synthesis of the N-methylated allo- 
stereoisomers significantly more expensive.  Whilst the procedure used in Section 2.2.3 
gave a good overall yield of 72%, the “student-induced isotope effect” described by 
Simpson suggests that this yield will be significantly lower when using more expensive 
starting materials.45  An additional esterification step would also be required to give the 
methyl ester starting material.   
 
This led to the consideration of attempting the inversion of the β position of the N-
methylated-L- and D-threonines that had been synthesized earlier.  This would allow 
access to the allo- diastereoisomers indirectly and at much lower cost.   
 
Inversion of the stereochemistry of alcohols is an important procedure which is used 
regularly in natural product synthesis46 and in particular in carbohydrate chemistry.47,48  
This is carried out by activation of the alcohol to form a good leaving group, followed by 
nucleophilic displacement.  The traditional means of alcohol activation involves 
conversion to a sulfonate, eg tosylate or mesylate, which are excellent leaving groups.  
The nucleophilic displacement can then be carried out either directly with hydroxide, or 
with alcohol precursors, such as acetate or benzoate which provide protected alcohols.  
An alternative to the sulfonate route is the widely-used, one-pot, activation-displacement 
method developed by Mitsunobu et al.49 which will be discussed in more detail later.   
 
Both the tosylate and the Mitsunobu activation routes were investigated as a means of 
inverting the stereochemistry of the β position.   
 
Initial attempts (Scheme 2.8) to invert the stereochemistry at the β position of protected 
N-methyl-L-threonine, 2.9, involved an attempt to form the tosylate of the alcohol.  The 
reaction was carried out with tosic anhydride in dry pyridine.  No desired product could 
be isolated from the reaction and no other product could be assigned.  In case 
decomposition of the desired product was occurring, the reaction was repeated but was 
quenched with sodium hydroxide after 5 minutes in the hope of hydrolyzing any tosylate 
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present.  However, only starting material and the product of elimination (discussed 
below) were recovered from this reaction.   
 
It seemed unlikely that the tertiary amine could be interfering with the formation of the 
tosylate, however to confirm this, the amine of 2.10 was CBz protected.  This was carried 
out using benzyl chloroformate under Schotten-Baumann conditions and gave 2.12 in a 
yield of 74%.  The tosylation of the carbamate protected N-methyl-L-threonine led to the 
formation of dehydro-N-methyl-threonine derivative, 2.13, and recovery of starting 
material, with no desired tosylate product isolated.  The assignment of the 
stereochemistry about the double bond of alkene 2.13 was not attempted.  
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Scheme 2.8 – Tosylation attempts on N-methyl-L-threonine derivatives 
 
Elimination can be observed when the proton adjacent to an activated alcohol is acidic; a 
requirement that is fulfilled by the α proton in an amino acid.  The isolation of a 
dehydration product suggests that the tosyl product was formed, but that it was 
sufficiently unstable under the basic tosylation conditions to eliminate.  A survey of the 
literature revealed that elimination had also been observed as the main product when 
tosylation of N-Fmoc-threonine benzyl ester had been attempted.  The authors noted that 
varying degrees of tosylation and elimination occurred with different amino and acid 
protecting groups.50  They also noted that in the presence of pyridine only (ie no 
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tosylating agent added) the amino acid derivatives were stable, confirming the 
intermediacy of an O-tosyl group in the elimination step.     
 
It was apparent that a route involving tosylate activation was going to require a great deal 
of optimisation.  It was therefore decided to investigate the Mitsunobu protocol as an 
alternative method.   
 
As a means of stereochemical inversion of alcohols, the Mitsunobu reaction is 
undoubtedly one of the most widely-used and studied.51  It involves the activation of the 
alcohol as an alkoxyphosphonium salt which is formed by reaction with the betaine, 2.14, 
derived from a phosphine (most commonly triphenyl phosphine) and a dialkyl 
azodicarboxylate (usually diethyl azodicarboxylate).  It has been established as a reliably 
stereoselective reaction, giving inversion of alcohols, and as such, has become popular 
amongst synthetic chemists for inverting the configuration of optically active alcohols.52  
The mechanism proposed by Mitsunobu is shown in Scheme 2.9.      
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Scheme 2.9 – Reaction mechanism for the Mitsunobu reaction 
 
The Mitsunobu reaction is a redox reaction since during the course of the reaction, the 
diethyl azodicarboxylate is reduced to a hydrazine, and triphenylphosphine is oxidized to 
triphenylphosphine oxide.  It is the stability of the latter that drives the final nucleophilic 
displacement of the activated alcohol by the conjugate base X-.  In this scheme the 
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nucleophile (which must be acidic with pKa<13)53 has been represented as an ionic acid, 
and are most commonly carboxylic acids or phenols, however many other acids, both 
ionic and neutral,54 can also be used successfully, for example, phthalimide,55,53 which 
can then be converted to an amine by hydrazinolysis.  The broad range of nucleophiles 
which can be used to displace the activated alcohol has allowed the Mitsunobu protocol 
to find application in the introduction of an array of functional groups, and it is a very 
powerful tool in synthetic chemistry.49  This brief description of the mechanism of the 
Mitsunobu reaction will be expanded upon later.      
 
Initial attempts (Scheme 2.10) to invert the stereochemistry at the β position of an N-
methyl-threonine derivative involved the reaction of protected N-methylthreonine 2.9 
with one equivalent of acetic acid, in the presence of an excess of both 
triphenylphosphine and diethyl azodicarboxylate.  Acetic acid was chosen as the acetate 
derivative formed could potentially be hydrolysed under the same conditions as the 
methyl ester.  The only product which could be isolated from the reaction was a dehydro-
N-methyl-threonine derivative (characterized by 1H NMR spectroscopy), formed by 
elimination of the activated alcohol similar to that observed with tosyl activation.  As the 
most basic species present, the betaine is most likely the vehicle for this elimination 
reaction.   
 
The reaction was repeated but with a large excess (100 equivalents) of acetic acid, in an 
attempt to quench the alkyloxyphosphonium salt before elimination occurred, and ensure 
that the betaine deprotonated the nucleophile instead of the activated alcohol.  This 
reaction gave some of the desired acetate, 2.15, (8%) but largely starting material was 
recovered (84%).  It is postulated that the increased acidity of the reaction mixture under 
these conditions may be preventing the formation of the alkyloxyphosphonium salt, so 
therefore the reaction was repeated with fewer equivalents (20) of acetic acid.  Under 
these conditions a respectable yield of 51% was obtained, accompanied by good recovery 
of starting material (48%).   
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Scheme 2.10 – Mitsunobu inversion and deprotection attempts 
 
With the inverted acetate, 2.15, in-hand, deprotection was attempted to give the N-
methyl-allo-L-threonine.  The same hydrogenation conditions were employed as those 
used to deprotect 2.9 and ent-2.9 (Section 2.2.3).  The crude product of the reaction 
appeared to be the correct product, 2.16, however the product was quite impure.  
Purification by successive phase separations did not significantly improve the purity.  The 
crude product was therefore hydrolysed using lithium hydroxide, but the 1H NMR 
spectrum of the product was complicated and appeared still to contain signals indicative 
of an acetate group.  By inverting the two deprotection steps it was hoped that these 
problems might be circumvented.  Therefore the hydrolysis of acetate 2.15 was attempted 
using lithium hydroxide.  One clean product was obtained with 3 equivalents of base, 
however the product clearly still contained an acetate group.  It was clear that cleavage of 
the acetate group would require more forcing basic conditions, which could cause 
epimerisation of the α proton.  Acidic conditions can also be used to cleave ester groups, 
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however, high temperatures are commonly required; conditions which can cause 
elimination of the alcohol in threonine derivatives.   
 
The use of an alternative nucleophilic acid in the Mitsunobu reaction, was considered as a 
possible solution to the deprotection problems discussed above.  Benzoic acid is a very 
commonly used nucleophile in Mitsunobu reactions, and whilst a benzoate would be 
expected to be slightly more difficult to hydrolyse than an acetate, it was chosen as an 
alternative nucleophile.     
 
The Mitsunobu reaction was therefore attempted on the protected N-methyl-D-threonine, 
ent-2.9, (the D derivative was used as more was available) using 20 equivalents of 
benzoic acid (Scheme 2.11).  This, pleasingly, gave an excellent yield of 95% of ent-2.18 
if the reaction was allowed to proceed for three days.  The deprotection of ent-2.18 began 
with a catalytic hydrogenation, which on this occasion proceeded smoothly to give the 
clean product, amine ent-2.19, in 76% yield.  The final hydrolysis step was carried out, 
on this occasion, using sodium hydroxide.  This led to the complete hydrolysis of both the 
benzoate and the methyl ester, giving a quantitative yield of the allo-N-methyl-amino 
acid ent-2.20 as a sodium salt.  The hydrolysis was also attempted using lithium 
hydroxide, as had been used for deprotection of the acetate derivative, 2.15, discussed 
earlier.  The product obtained under these conditions displayed a complicated mixture by 
1H NMR spectroscopy, suggesting that the problems in deprotection encountered may 
have been due to the use of the inappropriate base.  The deprotection of acetate 2.15 was 
not revisited, however. 
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Scheme 2.11 – Mitsunobu reaction and successful deprotection 
 
Since this route had proved successful, it was repeated with 2.9 to give 2.20, in similar 
yields.  With N-methyl-threonine of both L-allo and D-allo configuration in hand, the 
synthesis of all four stereoisomers of N-methyl-threonine was deemed complete.  
Examination of the optical purity of the four stereoisomers was carried out by 
derivatisation of the amino acids with Marfey’s reagent and separation by HPLC 
chromatography.   The results are shown in Figure 2.4. 
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Figure 2.4 – Marfey’s derivatives of the stereoisomers of N-methyl-threonine 
 
These results were surprising, in that no separation of L (2.11) from L-allo (2.20) was 
observed, and likewise with D (ent-2.11) from D-allo (ent-2.20).  It would be expected 
that there is a sufficiently significant difference in the physical properties of the allo- 
series from the natural series to allow separation by HPLC.  A series of HPLC methods 
were attempted in an effort to achieve separation.  In each method, different parameters 
were explored; both methanol and acetonitrile were used as eluents, the column 
temperature was altered, and isocratic and gradient methods were employed.  A method 
described in the literature for separating the four stereoisomers of N-methyl-thronine was 
also attempted.56  However, under all of these varied conditions, the L and L-allo pair 
invariably had the same retention time, and likewise for the D and D-allo pair. 
 
It became clear that the problem was not a separation issue, but rather that the Mitsunobu 
reaction had not occurred with the anticipated inversion of stereochemistry and had 
instead occurred with complete retention.  Therefore 2.20 was actually 2.11 and ent-2.20 
was ent-2.11.  This is very surprising in light of this reaction’s position as the “industry 
standard” for inversion of alcohols and its well-documented reliability.  A study of recent 
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literature, however, showed that retention in the Mitsunobu reaction has been 
documented, albeit rarely. A number of independent studies reported the isolation of 
retention products from sterically hindered chiral secondary alcohols when using 
carboxylic acids as the nucleophile.  As a result, the accepted mechanism of the 
Mitsunobu reaction has come under close scrutiny.52  Some fascinating new insights have 
been made in the last few years which have begun to uncover subtle but important 
mechanistic details, unrecognised by Mitsunobu.   These are still under investigation, but 
some of these mechanistic modifications are described below (Section 2.2.5).   
 
 
2.2.5 The mechanism of the Mitsunobu reaction 
 
The most important factor which alters the stereochemical outcome of the Mitsunobu 
reaction is the use of sterically hindered substrates.57,58  The electronic nature of the 
phosphine used,59 the presence of a base,60 conformational constraints61 and substrate-
specific rearrangements of reaction intermediates62 have also been implicated.  These 
have been rationalised largely through the inclusion of an important intermediate during 
the course of the Mitsunobu reaction which had not been postulated previously.  This is 
the acyloxyphosphonium salt, 2.22, and the anhydride, 2.23, which can be formed from 
2.22 with a second equivalent of carboxylic acid.  A revised mechanism is portrayed in 
Scheme 2.12.   
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Scheme 2.12 – Revised Mitsunobu mechanism 
 
In the originally proposed mechanism, after protonation of the betaine by the carboxylic 
acid, the alcohol attacks the phosphorus centre of 2.21 giving an alkyloxyphosphonium 
salt, 2.24, directly.  This intermediate is then attacked by the nucleophilic carboxylate 
anion with inversion to give the ester product.  The major difference in the newly 
proposed mechanism is that it is the more nucleophilic carboxylate anion which attacks 
the betaine, generating an acyloxyphosphonium salt, 2.22, and a hydrazide anion.  This 
initially formed intermediate then undergoes a base-mediated cross-over reaction to the 
alkyloxyphosphonium salt, 2.24, via an acyloxyalkoxyphosphorane, 2.25 (Scheme 
2.13).60  The base would usually be the hydrazide anion.  Under normal Mitsunobu 
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conditions and with relatively unhindered substrates, this equilibrium lies towards 2.24, 
and attack by the carboxylate anion generates the ester with inversion of stereochemistry.    
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Scheme 2.13 – Base-mediated “cross-over” reaction 
 
A number of factors can shift this equilibrium in favour of 2.22, however, and the most 
important of these is steric hindrance in the alcohol.  This inhibits the formation of 2.25 
and therefore prevents the “cross-over” to 2.24.  The long lifetime of 2.22 allows 
alternative pathways to compete effectively.  Acyloxyphosphonium salt 2.22 is an 
activated acid, and as such can undergo esterification by attack of an alcohol at the 
carbonyl centre with displacement of triphenylphosphine oxide.  This reaction does not 
involve inversion at the alcohol and therefore generates an ester with retention of 
stereochemistry at this centre.  Under some conditions, 2.22 may react with a further 
carboxylate anion to form an anhydride, 2.23.63  The anhydride is also an activated acid 
and may also form an ester with retention of stereochemistry. 
 
Indirect evidence for the involvement of an acyloxyphosphonium salt was described by 
McNulty et al. by generating the salt by an alternative method, and reacting it with L-
menthol.60  The ester formed was present in 97% as the product of retention (3% 
inversion).  In this fascinating paper, they also investigated the role of base in the “cross-
over” step.  By including an amine base in the reaction they found that the stereochemical 
outcome could be reversed, with up to 99% of the inversion ester produced instead. 
 
Taking into account this new mechanism, it is possible to postulate why the ester 
obtained from Mitsunobu reaction with N-methyl-N-benzyl-threonine methyl ester, was 
the product of retention of stereochemistry and not the intended inversion product 2.18.  
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In order to suppress competing elimination reactions, the number of equivalents of 
benzoic acid used in the reaction was greater than that usually employed.  It is probable 
that this excessively acidic medium quenched any basic species, such as the betaine or 
hydrazide anion, before the base-mediated conversion of acyloxyphosphonium salt, 2.22, 
to alkoxyphosphonium salt, 2.24, could occur.  The activated acid was then available for 
attack by the alcohol of the precursor, 2.9, giving the ester with retention of 
stereochemistry. 
 
Despite the new information available on the mechanism of the Mitsunobu reaction, one 
question remains unanswered.  In the majority of cases where the inversion reaction is 
disfavoured, a low yield or no reaction is observed.  However, in this small number of 
examples moderate to good yields with complete retention are observed.  In many of 
these cases sterically hindered alcohols are involved; seemingly disfavouring the 
nucleophilic attack of the alcohol on the carbonyl of the acyloxyphosphonium salt.  It is 
interesting to speculate why retention is observed in certain cases.  One common theme 
amongst several reports58,61,62 observing retention products (although not exclusively)57 is 
that they are using the Mitsunobu reaction to achieve intramolecular lactonisation.  It may 
be that by having the acyloxyphosphonium salt in the same molecule as an alcohol 
promotes the esterification sufficiently to observe the retention product.  There appears to 
be an active research field currently investigating aspects of the mechanism of the 
Mitsunobu reaction and hopefully this will, in the future, uncover further details. 
 
A number of amendments were made to the conditions used to carry out the Mitsunobu 
reaction on N-methyl-N-benzyl-L-threonine methyl ester in an attempt to promote the 
inversion reaction. 
 
As mentioned earlier, the addition of base has been shown to efficiently promote the 
“cross-over” step which leads to inversion.  Mitsunobu reactions with the addition of an 
excess of tbutylamine, pyridine and triethylamine were therefore all attempted, but in 
each case only starting material was recovered.  Base, therefore, is able to prevent the 
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retention pathway from occurring, but does not promote the inversion reaction, in this 
case. 
 
The use of a salt of benzoate instead of the acid was considered as a means of avoiding 
the acidic conditions.  It has been reported that the choice of nucleophile counter-ion in 
Mitsunobu reactions is of significant importance, with tight ion-pairing preventing 
reaction.64,65  Zinc salts of nucleophiles are reported to react efficiently under Mitsunobu 
reaction conditions, so the zinc salt of benzoic acid was formed by following literature 
procedure for the similar zinc p-chlorobenzoate salt.66  The Mitsunobu reaction, again, 
did not take place, and only starting materials were recovered. 
 
A reaction was carried out with a large excess of triphenylphosphine and diethyl 
azodicarboxylate (11 equivalents each and 10 equivalents of benzoic acid), in the hope 
that sufficient betaine would remain after reaction with benzoic acid to act as a base.  
Starting materials were, again, the only product isolated from this reaction. 
 
Whilst benzoic acid has been the most popular choice of carboxyl nucleophile in 
Mitsunobu esterification reactions, it has recently been shown that it is not necessarily the 
most appropriate.  The pKa of the carboxylic acid used as the nucleophile is known to 
have a profound influence on the product yield of Mitsunobu reactions when sterically 
hindered alcohols are employed.67  The use of p-nitrobenzoic acid (pKa 3.41)68 and 
chloroacetic acid (pKa 2.85)69 were reported to give improved yields compared to benzoic 
acid (pKa 4.15).    It has been shown that this is due to a shift in the equilibrium between 
the acyloxy- and alkoxy-phosphonium salt.70,63 A lower limit is placed on the pKa of the 
nucleophile, however, as the acid must still be sufficiently nucleophilic to attack the 
alkoxyphosphonium salt.  Attempts were made to couple the threonine precursor to both 
p-nitrobenzoic acid and chloroacetic acid.  The major product of the Mitsunobu reaction 
using p-nitrobenzoic acid was the dehydration product, with small amounts of starting 
material recovered, but no desired product was formed.  In the case of chloroacetic acid 
only starting material was recovered. 
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It became clear that the inversion of the β centre of N-methyl-threonine derivatives gave 
rise to significantly more complex results than anticipated and it was decided to cease 
attempts to access the allo- series in this way.  A large number of variables had been 
explored in the Mitsunobu reaction, but to no avail.  This project gave some interesting 
results which could only be accounted for by achieving a deeper understanding of the 
subtleties of the Mitsunobu reaction mechanism. 
 
 
2.2.6 Synthesis of N-methyl-L-allo- and D-allo-threonine 
 
As inversion of the β centre of N-methyl-threonine derivatives had not been achieved, the 
synthesis of the allo- series was carried out using the original method discussed above 
(Section 2.2.3), using the expensive, commercially available L-allo- and D-allo-threonine 
as starting materials (Scheme 2.14).  An additional step was required, to form the methyl 
ester from the free amino acids.  This was carried out by the classical method of refluxing 
the amino acid in methanol with thionyl chloride and the methyl esters 2.26 and ent-2.26 
were obtained in quantitative yield (characterized by 1H NMR spectroscopy). 
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Scheme 2.14 – Synthesis of L- and D-allo-N-methyl-threonine 
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The first reductive amination, to introduce the benzyl protecting group, proceeded 
smoothly as before to give the secondary amines 2.27 and ent-2.27 in 60 and 62% yield 
respectively.  The 1H NMR data of the allo- products displayed some differences to the 
natural series, as anticipated.  The largest chemical shift differences were at the α and β 
centres (ΔδH of both centres was 0.38).  Optical rotation data are not available in the 
literature for these compounds, however they were of similar value, but opposite sign (-
56º for 2.27 and +50º for ent-2.27), as expected.   
 
The second reductive amination to introduce the methyl group also proceeded cleanly 
giving protected N-methylthreonines 2.28 and ent-2.28 in yields of 88 and 95% 
respectively.  The 1H NMR data were, again, in good agreement with the natural series, 
with minor changes in chemical shift.  In this case the β (ΔδH of 0.19) and γ (ΔδH of 0.13) 
centres displayed the greatest variation.  Again, optical rotation data are not available in 
the literature, but they were of similar value and opposite in sign (-128º for 2.28 and 
+129º for ent-2.28).   
 
Deprotection of the benzyl group by catalytic hydrogenation proceeded in moderate 
yields of 80 (2.29) and 56% (ent-2.29).  The 1H NMR data were in good agreement with 
the natural series, although again, changes in chemical shifts were observed.  The main 
differences were at the α (ΔδH of 0.35) and β centre (ΔδH of 0.38).  Optical rotation data 
(also not available from the literature) for each were of similar value and opposite in sign 
(-4º for 2.29 and +4º for ent-2.29).   
 
Finally, deprotection of the methyl ester by acidic hydrolysis proceeded cleanly in 
quantitative yield to give the N-methylated amino acids 2.30 and ent-2.30 as 
hydrochloride salts.  The 1H NMR data compared well to the natural series, but with 
some large changes in chemical shifts (eg ΔδH of 1.14 for α and ΔδH of 0.62 for the β).  
Throughout the synthesis of the allo- series, the coupling constants of the α proton were 
found to be somewhat different (> 5 Hz) from those observed in the natural series.  An 
optical rotation of +6º was obtained for 2.30, however insufficient material was obtained 
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to obtain a reliable optical rotation value for ent-2.30.  Marfey’s derivatisation and HPLC 
analysis (below) allowed the purity of the isomers to be confirmed, however. 
 
With the allo- series now in hand, Marfey’s derivatisation and HPLC separation of the 
four stereoisomers was repeated (Figure 2.5).  All four stereoisomers were readily 
separable on C18.  In both the L- and D-pair (2.11 and ent-2.11), and the L-allo- and D-
allo- pair (2.30 and ent-2.30), the L- isomer eluted before the D-; following the reported 
trend for Marfey’s derivatives.   
 
 
Figure 2.5 – HPLC of the Marfey’s derivatives of the four stereoisomers of N-methyl-
threonine 
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2.3  Synthesis of 4-methylproline 
 
2.3.1 Introduction 
 
One of the most interesting residues contained in the pteratide series is 4-methylproline, 
found in pteratides I and II.  This is a rarely encountered amino acid, however it has been 
found from a number of different sources, as discussed in Section 2.1.2.  A number of 
other alkyl-proline derivatives are also known; from natural sources71,72,73 and synthetic 
analogues.71  In recent years they have been successfully utilised in the drug development 
of novel angiotensin converting enzyme inhibitors such as Fosinopril (trade name 
Monopril).74    
 
The inclusion of such a small and inert group on an otherwise very common amino acid 
might suggest that the methyl group of 4-methylproline has little role to play in the 
bioactivity of the pteratides.  However, an organism has to invest a great deal of 
evolutionary energy in developing the biosynthetic pathways to unusual amino acids, so 
that it is unlikely that the change plays no role.  Since a methyl group cannot be involved 
directly in bonding (covalent, hydrogen, electrostatic or π-stacking) it is most likely to be 
involved in altering the conformation adopted by the depsipeptide, promoting the 
adoption of a bioactive conformer.  Proline residues are commonly found in peptides and 
proteins due to their ability to induce twists in the amide backbone with subsequent 
effects on secondary structure.  It may be that the introduction of a methyl group on the 
proline induces further conformational changes to the backbone; by altering the 
conformation of the proline itself, or by steric interactions with other residues within the 
depsipeptide.   
 
In order to further investigate the effects of this unusual amino acid in the bioactivity of 
the pteratides, it is important to know its stereochemistry in the natural products.  This 
would allow more informed prediction of the conformational effects this residue may be 
inducing in the backbone of the depsipeptide.  It was therefore important to obtain all 
four stereoisomers of 4-methylproline for comparison to the natural product hydrolysate 
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to establish which was present.  The synthesis of 4-methylproline has been carried out 
previously by a number of different routes, by several authors.  These are briefly 
reviewed here.   
 
The synthetic routes to 4-methylproline almost all involve manipulation of common 
amino acid derivatives, as these are commercially available and can be obtained in 
optically pure form at the α carbon.  As a result, only one new stereogenic centre must be 
generated during the reaction sequence, if epimerisation at the α centre is avoided.  The 
different methods offer varying degrees of stereoselectivity during the introduction of the 
second stereogenic centre at the γ position.  
 
The earliest literature synthesis of 4-methylproline, published in 1962 by Dalby et al., is 
the only example which begins with the eventual γ position stereogenic centre defined.75  
It uses the industrial by-product, 2.31, as a starting point and involves cyclisation by 
displacement of a bromine α to the carboxylic acid by an amine to generate the amino 
acid moiety (Scheme 2.15).  After ring-closing, the diastereoisomers could be separated 
by crystallisation or by enzymatic processes, however these separations were poor 
yielding and difficult.    
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Scheme 2.15 – Dalby’s synthesis of 4-methylproline 
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A radical cyclisation (Hofmann-Loeffler-Freytag reaction) of N-chloro-L-leucine was 
reported to give a diastereomeric mixture of cis- and trans-4-methyl-L-proline (Scheme 
2.16).76  Separation of the stereoisomers was achieved in a similar manner to Dalby et al.   
H2N
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OEt
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1) hv, H+
2) -OH
HN
O
OH
 
Scheme 2.16 – Titouani’s route to 4-methylproline 
 
To avoid the tedious separation issues associated with these routes, stereoselective 
syntheses began to emerge.  These relied on asymmetric induction methods, whereby the 
chirality of the centre to be formed is influenced by other stereogenic centres already 
present in the precursor.  As mentioned earlier, generally the optically pure amino acid 
precursors provided the template for this chiral induction.  The most popular precursors 
were pyroglutamic acid and 4-hydroxyproline, both of which are commercially available.   
 
Krapcho’s synthesis of cis-4-phenylproline and cis-4-cyclohexylproline from 4-
hydroxyproline,74 Moody’s synthesis of cis-4-methylproline from pyroglutamic acid77,78 
and Chirgadze’s synthesis79 of cis-4-methylproline from 4-hydroxyproline all utilised a 
facially-selective catalytic hydrogenation to induce cis- stereoselectivity at the γ position 
(Scheme 2.17 and Scheme 2.18).  This idea was extended by Del Valle (Scheme 2.22, 
vide infra).    
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Scheme 2.17 – Moody’s cis-4-methylproline synthesis 
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Scheme 2.18– Chirgadze’s cis-4-methylproline synthesis 
 
The condensation of formaldehyde with pyroglutamic acid and subsequent manipulations 
reported by Xie et al. gave protected 4-methylproline with a small preference (1.7:1) for 
the trans- diastereoisomer (Scheme 2.19).80  The two diastereoisomers of 2.32 were 
readily separable using chromatographic methods.   
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Scheme 2.19 – Xie’s synthetic route to protected 4-methylproline 
 
Belokon et al. described the use of a chiral Nickel complex template to induce limited 
diastereoselectivity at the γ position during the condensation of α-methylacrylaldehyde 
with glycine, giving 4-methylproline.81     
 
Wang and co-workers reported a very long, but stereoselective synthesis of trans-4-
methylproline via the chiral synthon 2.33.82   
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The alkylation of a protected glutamic acid derivative was used by Koskinen and 
Rapoport to make a number of 4-alkylprolines and displayed a slight stereoselectivity 
towards forming the cis- diastereoisomer (ratio of 2:1 observed for the synthesis of 4-
methylproline). 83  Separation of the isomers could be achieved using chromatographic 
methods (Scheme 2.20).   
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Scheme 2.20 – Koskinen’s route to 4-methylproline 
 
These routes all have significant drawbacks, with most displaying poor or no 
stereoselectivity, resulting in the need to separate isomers.  Those routes which do display 
good stereoselectivity result in the synthesis of only one diastereoisomer.  There was 
clearly a need for routes which would allow reliable stereospecific access to each 
diastereoisomer of 4-methylproline from a common starting material, and two interesting 
methods appeared in 2003.   
 
The first of these is Heindl and co-workers’ report of the stereoselective synthesis of 
protected 4-methylproline derivatives from 4-hydroxyproline.84,85  In this route (Scheme 
2.21) the alcohol of a protected 4-hydroxyproline is activated by formation of a tosylate 
group which is subsequently displaced using a methyl nucleophile.  The Gilman cuprate 
reagent was used as methyl nucleophile as it is a mild nucleophile which helps to 
minimise competing methylation at the carbonyl group of the protected acid.    
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Scheme 2.21 – Heindl’s stereospecific synthesis of 4-methylproline 
 
This route allows access to all four diastereoisomers of 4-methylproline from a single, 
commercially available diastereoisomer of 4-hydroxyproline.  As such, it is a powerful 
new method.  However, it does suffer a very low yield during methylation to generate the 
cis- series (11%; 70% was observed in the trans- series).  This can be attributed to 
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additional steric hindrance slowing nucleophilic displacement, allowing side-reactions to 
dominate.     
 
The other stereoselective method to 4-alkyl-prolines was reported by Del Valle and 
Goodman,86 who used asymmetric hydrogenation procedures to induce stereoselectivity 
(Scheme 2.22).  They extended the scope of the previous examples discussed (vide 
supra).  In those cases, steric bulk induces facial selectivity during hydrogenation of 
either an exocyclic78 or endocyclic74 double bond, giving good stereoselectivity for the 
cis- diastereoisomer.  Del Valle and Goodman took advantage of the development of 
Crabtree’s homogeneous hydrogenation catalyst,87 which can give excellent 
stereoselective control when a group capable of coordinating to a metal (eg hydroxyl) 
which can direct the hydrogenation is present.88  In this way they were able to access, 
stereoselectively, the trans- diastereoisomer.  
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Scheme 2.22 – Del Valle’s stereoselective route to 4-methylproline 
 
Chapter 2: The Pteratides  63   
This method is also very powerful, allowing late stage stereochemical divergence from a 
common precursor. It does suffer some drawbacks however.  Whilst the stereoselectivity 
observed with Crabtree’s directed hydrogenation was very high (> 40:1 of the trans- 
isomer to cis-), the facial selectivity observed with heterogeneous catalytic hydrogenation 
was significantly lower (3:1 of the cis- isomer to trans-) than that reported by Moody and 
Krapcho (stereospecific).  This is most likely as a result of lower steric hindrance being 
exerted by the alcohol compared to carboxyl derivatives.  In addition, this route is 
relatively lengthy, requiring redox manipulation and functional group protection.   
 
Of the routes reviewed above, the last two85,86 were the most appropriate for the purpose 
of obtaining reference samples of all four diastereoisomers of 4-methylproline.  The route 
of Heindl was chosen initially, as it offered a relatively short synthesis and involved 
readily available and inexpensive reagents (Section 2.3.2).  In the present work, this route 
proved challenging, with low and irreproducible results obtained at the crucial γ 
methylation reaction.  As a result, a modified version of the route of Del Valle was 
successfully utilised to obtain the four diastereoisomers of 4-methylproline (Section 
2.3.3).     
 
 
2.3.2 Attempted synthesis of 4-methylproline via Heindl’s method   
 
The synthesis of 4-methylproline by the route of Heindl et al. begins with protection of 
both the acid and the amine functional groups of trans-4-hydroxy-proline.  The route was 
initially undertaken with trans-4-hydroxy-L-proline to establish the route as this is 
commercially available and the most inexpensive stereoisomer.  The first step was to 
protect the carboxylic acid moiety as an ethyl ester (Scheme 2.23).  This was readily 
achieved by addition of thionyl chloride to an ethanolic suspension of the amino acid.89  
Subsequent N-benzylation by a nucleophilic substitution reaction of the amine on benzyl 
chloride gave the protected amino acid 2.34.  Good yields were obtained at each 
protection step and 1H NMR data of 2.34 were in excellent agreement with those reported 
by Heindl et al.   
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Scheme 2.23 – Variation on Heindl and co-workers synthesis of protected 4-
methylproline 
 
It is at this point that the stereochemical divergence in the route begins.  The eventual 
stereochemistry of the γ-methyl group on 4-methylproline is determined by the 
stereochemistry of the activated alcohol generated from 2.34, as the alkylation of the 
activated alcohol should proceed reliably with inversion.  Therefore this method relies on 
two divergent methods to generate the trans- and cis- diastereoisomers, 2.35 and 2.36.  A 
simple direct tosylation gives access to the tosyl derivative 2.35.  This reaction proceeded 
in a similarly moderate yield (57%) to that reported by Heindl et al. (67%) with tosyl 
chloride.  In an attempt to improve the yield, the reaction was repeated with the 
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alternative tosylating reagent tosic anhydride, however, this did not offer any 
improvement on the yield (48%).  The 1H NMR data of the product were in good 
agreement with those reported and the molecular formula was confirmed by high 
resolution mass spectrometry.  
 
For generation of the diastereoisomer of 2.36, Heindl et al. relied on a three step 
conversion of 2.35.  This involved first the displacement of the tosylate group with the 
tetrabutylammonium salt of acetate which proceeds with inversion.  The acetate group 
generated is hydrolysed under basic conditions to generate the protected cis-4-
hydroxyproline and the alcohol is tosylated as before to give protected O-tosyl-cis-4-
hydroxyproline, 2.36.  Whilst this four-step route from alcohol 2.34 to inverted tosylate 
2.36 is effective and relatively high yielding, it adds several steps to the overall synthesis 
and is therefore not very efficient.   
 
A one-step procedure to introduce tosylate groups with inversion of stereochemistry 
relative to the starting alcohol was first described by Galynker and Still,90 and has 
subsequently been used extensively for bond formation with net retention of 
stereochemistry (literature examples given by Anderson et al.).91  This procedure is a 
variant of the Mitusnobu reaction, in which a nucleophile displaces an alcohol which is 
activated as an alkyloxyphosphonium salt (see Section 2.2.4 for further discussion of the 
mechanism).  Galynker and Still demonstrated that the tosylate anion could be used as a 
nucleophile under Mitsunobu conditions, although the counter-ion used proved to be of 
importance, with zinc tosylate being the reagent of choice.  The reaction is high yielding 
and reliably occurs with inversion of stereochemistry.    
 
The use of this procedure would allow the four-step tosylation route used by Heindl and 
co-workers to be abbreviated to a single step, clearly offering a significant improvement 
on the original synthesis.  The Mitsunobu tosylation procedure was therefore attempted 
on alcohol 2.34.  Pleasingly, the reaction proceeded smoothly to afford the tosylation 
product, 2.36, with inversion of stereochemistry (as judged by comparison of 1H NMR 
data – which were in excellent agreement with the literature data for the cis- 
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diastereoisomer 2.36) in a moderate 52% yield.   Whilst the yield was not high, it is 
comparable with that observed during the standard (retentive) tosylation (to give 2.35), is 
similar to the combined yield over the reported four-step route (49%) and offers the clear 
advantage of a reduced number of synthetic manipulations.   
 
With both diastereoisomers of the activated hydroxyproline derivative in hand (2.35 and 
2.36) the methylation reaction could be undertaken.  With two potential electrophilic sites 
available on these proline derivatives, an ester and an activated alcohol, careful choice of 
the nucleophile is necessary.  For example a Grignard reagent would be inappropriate as 
such a reactive nucleophile would be expected to react very readily at the carbonyl of the 
ester function at the same time or even in preference to the tosylate sp3 carbon.  Heindl’s 
method takes advantage of a mild methyl nucleophile, the Gilman reagent, to improve 
regioselectivity.   
 
The Gilman reagent is an example of an organocuprate reagent; reagents which have 
found a great deal of utility in a range of different synthetic manipulations due to their 
differing reactivity patterns to traditional organometallics such as organolithium or 
Grignard reagents.92  They are considered to be soft nucleophiles, with the copper-carbon 
bond displaying relatively low ionic character and are considerably less basic than their 
organoalkali counterparts.  As a result they display a more controlled reactivity with 
fewer competing side-reactions such as elimination reactions.  They are formed from the 
corresponding organoalkali compound by reaction with a copper(I) salt.  
 
The first example of an organocopper reagent was described by Kharasch and Tawney.  
They investigated the reaction of a Grignard with a conjugated ketone and observed a 
change in reaction outcome on addition of catalytic quantities of various metal salts, in 
particular copper.93  They found that the usual tendency to form 1,2-addition products 
observed with Grignard reagents became a Michael-type 1,4-addition on inclusion of 
catalytic copper.  The 1,4-alkylation of unconjugated ketones has become one of the 
principal synthetic applications of organocuprates.94  The other major application of 
organocuprates is in substitution reactions of halides and activated alcohols where they 
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behave as efficient nucleophiles and display fewer competing side-reactions. The 
application of organocuprate 1,2-addition on carbonyls is rare,94 although it is known.  In 
particular it has been used in asymmetric addition to chiral aldehydes, where copper’s 
ability to coordinate multiple ligands allows chelation controlled addition and steric bulk 
allows non-chelation controlled addition.95      
 
Whilst the first reports of organocopper reagents used catalytic quantities of copper salt, 
the use of stoichiometric quantities has been found to give more reliable results.92  There 
are a number of different forms of organocopper reagents which differ in the ratio of 
organoalkali to copper(I).  The addition of one equivalent of methyl lithium to copper 
iodide forms an insoluble monoorganocopper reagent of type 2.39 (Scheme 2.24) which 
generally has no synthetic utility.  The addition of a second equivalent of methyl lithium, 
however, leads to the organic soluble organocuprate of type 2.40, which is highly reactive 
and is the most commonly used form of organocopper reagent.96   
 
CuI
RLi
RCu + LiI
RLi
R2CuLi + LiI
2.39 2.40  
Scheme 2.24 – Generation of organocopper reagents 
 
The above brief review of organocuprate chemistry demonstrates their utility in 
substitution reactions and benefits they offer over organoalkali reagents.  In addition, 
their limited reactivity in 1,2-addition to carbonyl groups explains Heindl and co-
worker’s choice of the Gilman reagent for the substitution of the activated alcohol in their 
synthesis of 4-methylproline derivatives.85   
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Scheme 2.25 – Methylation results reported by Heindl et al. 
 
They reported a respectable yield of 70% during methylation of the cis- tosyl 2.36 to 
generate the protected trans-4-methylproline 2.38 (Scheme 2.25).  However, the 
methylation of the protected trans- tosyl 2.35 to generate the cis- diastereoisomer 2.37 
proceeded in only 11% yield.  The major product isolated from this reaction was reported 
as the alcohol 2.41, the product of a 1,2-carbonyl double addition.  This latter result is 
best explained by steric hindrance due to the ester functional group slowing attack at the 
activated alcohol carbon sufficiently to allow the slower 1,2-carbonyl addition reaction to 
compete effectively for the Gilman reagent.  It is therefore evident that a 1,2-carbonyl 
addition to an ester is also possible in this system.     
 
The methylations of 2.35 and 2.36 were carried out under the same conditions used by 
Heindl and co-workers.  Since organocuprates are relatively unstable, the reactions are 
carried out at low temperatures, with the cuprate initially formed at -20ºC and then the 
reaction performed at 0ºC.  The instability of the organocuprates also requires a large 
excess to be used, and Heindl reported that the use of 7 equivalents gave the best results.  
The reaction products were analysed by LCMS or NMR spectroscopy.  In the case of 
methylation of 2.35, LCMS of the crude reaction product showed mainly the product of 
carbonyl dimethylation, 2.41, with no desired substitution product observed.  In the 
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reaction of 2.36 to give the trans- diastereoisomer, 2.38, the 1H NMR spectrum of the 
crude material showed that no starting material remained and purification of the crude 
residue gave the desired product in 8% yield.  These were disappointing results, since one 
diastereoisomer (the cis-) was not formed at all and the other was formed in only 8% 
compared to the literature report of 70%.   
 
In order to improve these results, some adjustments were made to the reaction conditions. 
These were largely attempted using 2.35 to make the cis- diastereoisomer, as this had not 
been formed at all under the literature conditions.  The main parameter examined was 
temperature.  Organocuprates are known to be active at temperatures as low as –78ºC,97 
so lower temperatures were explored in the hope that the 1,2-carbonyl dimethylation 
could be slowed sufficiently to allow the desired substitution to compete.  The reaction 
was carried out as Heindl reported except the temperature was varied between –40 and 
0ºC (the temperature during organocuprate pre-formation was the same as that employed 
for the reaction) and the reaction times were extended to around 6 hours.  It was found 
that at temperatures below -12ºC only starting material was recovered.  At 0ºC the 
desired product 2.37 was isolated in 5% yield on one occasion, however this result 
proved not to be reproducible, with carbonyl addition the only reaction on most occasions.  
The methylation of 2.36 was also repeated at different temperatures, and gave a 
respectable yield of 75% of 2.38 on one occasion (-8ºC) but this result could not be 
repeated.   
 
The irreproducibility of the methylation reactions in our hands, and particularly the low 
yield achieved when forming the cis- diastereoisomer detracts significantly from the 
utility of this route to 4-methylproline.  Whilst further efforts could have been made to 
optimise reaction conditions, it was decided to attempt the route of Del Valle as an 
alternative route.   
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2.3.3 Synthesis of 4-methylproline based on Del Valle’s method 
 
The method of Del Valle and Goodman provides access to all four diastereoisomers of 4-
methylproline via a stereoselective route, with reasonably late-stage stereochemical 
divergence.86  This divergence relies on two different stereoselective, catalytic 
hydrogenations of an exomethylene double bond to create the γ methyl group (Scheme 
2.26).  The exomethylene group is introduced via modification of 4-hydroxyproline.  A 
number of redox and protection reactions are utilised in the route, whose roles are 
explained later.   
BocN
OTBS
Raney-Ni
H2(g) BocN
OTBS
BocN
OH
1) TBAF
2) Crabtree's cat.
    H2(g)  
Scheme 2.26 – Stereochemical divergence in the synthesis of 4-methylproline by Del 
Valle and Goodman 
 
Traditional heterogeneous catalytic hydrogenation using Raney nickel was employed to 
obtain the cis- diastereisomer with a modest stereoselectivity of 3:1.  This 
stereoselectivity is a result of differential steric environments on either face of the 
molecule as a result of a -CH2OTBS group whose stereochemistry is defined by that of 
the optically pure starting 4-hydroxyproline.  The sterically encumbered face will not be 
able to approach the surface of the heterogeneous catalyst as easily and will therefore not 
be hydrogenated as easily.  This modest selectivity was the result of optimisation, with 
three heterogeneous catalysts examined (Pd/C, Rh/C and Raney nickel).  As mentioned 
earlier, the degree of stereoselectivity observed is not as great as the stereospecific 
catalytic (Pd/C) hydrogenation of an exomethylene derivative of pyroglutamic acid 
(Scheme 2.17) reported by Moody et al.  This may be partly due to the greater ring 
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tension induced by the sp2 lactam locking the five-membered ring into such a 
conformation that hydrogenation from the same side as the α ester group is impossible.  It 
is also likely that the ester offers greater steric bulk than a -CH2OTBS functional group, 
which, whilst bulky, may be able to adopt a position which does not effectively hinder the 
approach of the catalyst to this face.   
 
Crabtree’s homogeneous hydrogenation catalyst is employed to obtain the trans- 
diastereoisomer by a directed hydrogenation.  Directed homogeneous hydrogenation is 
arguably one of the most important tools in the arsenal of asymmetric synthesis.98  Its 
importance was acknowledged by the award of the 2001 Nobel Prize to Knowles and 
Noyori for the development of chiral homogeneous catalysts (rhodium or ruthenium 
metal complexes) capable of directing hydrogenation selectively to one face of a pro-
chiral alkene.  These catalysts require the presence of a functional group near to the 
alkene which is also capable of coordinating to the metal.  The chiral ligand spatially 
arranges the alkene and hydrogen selectively around the metal, so that hydrogenation 
occurs on the desired face of the alkene when the appropriate ligand is chosen.  
Surprisingly, mechanistic studies showed that it is actually the less stable 
diastereoisomeric metal-substrate complex which defines the eventual product.99  This 
occurs because the less stable complex reacts with a molecule of hydrogen more readily 
than the more stable complex, and as hydrogen addition is the rate-limiting-step, this step 
determines the eventual reaction pathway.   
 
When hydrogenating chiral alkenes with a coordinating functional group, a chiral catalyst 
may no longer be required as advantage can be taken of the stereochemistry inherent in 
the substrate (substrate directed hydrogenation). Since both the alkene and the additional 
coordinating group (vide infra) are bound to the metal centre, cis- delivery of hydrogen is 
enforced.  Evidently only one diastereoisomer is accessible by this approach.  This 
concept was first proved by Thompson and McPherson using Wilkinson’s homogeneous 
rhodium catalyst, 2.42.100  However, as commented by the authors, the potential of this 
approach was limited by the low activity of this catalyst since those instances where it 
might be applied usually involve alkenes whose degree of substitution is significant.  
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Therefore the popularisation of this approach had to wait until the advent of more active 
homogeneous hydrogenation catalysts such as the iridium catalyst [Ir(cod)pyr(PCy3)]PF6, 
2.43, known as Crabtree’s catalyst.  This catalyst was developed by Crabtree, Felkin and 
Morris,101 with initial interest stemming from the observation that it was highly active; 
capable of catalysing the hydrogenation of very hindered, tri- and tetra- substituted 
alkenes not hydrogenated by other catalysts.87  The catalyst’s application in directed 
hydrogenation was subsequently discovered and independently reported by Crabtree and 
Davis,102 and Stork and Kahne.88  The rhodium complex 2.44 has also been demonstrated 
to be capable of catalysing directed hydrogenation, however it displays significantly 
lower activity.  The stability and ease of use of Crabtree’s catalyst, its high activity, 
commercial availability and the reliably high enantiomeric excesses observed with it have 
led to its popularity in directed homogeneous hydrogenations of chiral alkenes.       
 
Rh+
BF4-
Ir+
Cy3P
PF6-
2.43 2.44
Ph3P
Rh
ClPh3P
PPh3
2.42
N
P
P
Ph2
Ph2
 
 
Many functional groups are known to be capable of directing hydrogenation with 
Crabtree’s catalyst.  The initial studies employed alkenes with a hydroxyl group in close 
proximity, and the hydrogenations generally proceeded with excellent 
diastereoselectivity.88,102  However, other polar functionalities capable of donating a lone 
pair to a metal are also able to direct hydrogenation with Crabtree’s catalyst.  Proximal 
esters and amides in particular are known to be capable of inducing high 
stereoselectivity.103,104  It was demonstrated by Schultz and McCloskey that amides are 
the better directing group, with higher diastereoisomeric excess observed (Scheme 2.27), 
however esters still display a good degree of stereoselectivity.   
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Scheme 2.27 – Comparison of amide and ester directing groups in Crabtree’s catalysed 
hydrogenation103
 
Del Valle and Goodman report high diastereoisomeric excess when using Crabtree’s 
catalyst (> 40:1) to form derivatives of trans-4-methylproline.  In their work, the 
principal aim was to generate 4-substituted prolinols for use in peptidomimetic research 
programs, rather than the 4-substituted proline required in this present work.  As a result, 
the synthetic route chosen by the authors involved reduction of the carboxylic acid 
moiety of protected 4-hydroxyproline to generate an alcohol, which is the classic 
directing group used in directing asymmetric hydrogenation.  Details of the synthetic 
steps in Del Valle and Goodman’s route are shown in Scheme 2.28.   
 
After protection of the amine of trans-4-hydroxyproline with a Boc group, the carboxylic 
acid is reduced to an alcohol in a two-step process via the intermediacy of a mixed 
anhydride.  The authors found that the reduction of the anhydride was easier when 
working on a large-scale, proceeding with less solvent and offered a less complicated 
workup than the more traditional reduction of an ester route.  The requirement for 
oxidation of the γ hydroxyl group required protection of this newly formed alcohol, and 
was therefore protected as a silyl ether under standard conditions.  Oxidation of the γ 
alcohol was carried out using trichloroisocyanuric acid as the stoichiometric oxidant in 
the presence of catalytic quantities of TEMPO to give ketone 2.45.105  Olefination of the 
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ketone was then achieved using classic Wittig conditions.  This sequence provided the 
crucial exomethylene precursor, 2.46, for the divergent hydrogenations.    
 
BocN
O
OTBS
BocN
OTBS
Raney-Ni
H2(g)
BocN
OTBS
BocN
OH
BocN
OH
BocN
OH
O
1) TBAF
2) Crabtree's cat.
    H2(g)
HN
OH
O
OH
BocN
OH
OTBS
1) Boc2O, Na2CO3
2) ibutyl chloroformate, NMM;
    NaBH4
3) TBDMSCl, TEA, DMAP
TCCA, 
TEMPO (cat.)
-Br+PPh3Me
NaClO2, 
NaClO (cat.), 
TEMPO
2.46 2.45
2.47 2.48
TBAF
base
 
Scheme 2.28 – Details of the synthetic route to 4-methylproline by Del Valle and 
Goodman 
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Exomethylene 2.46 was hydrogenated under heterogeneous conditions to generate the 
protected cis-4-methylprolinol, 2.47.  As discussed earlier, the use of Raney nickel gave 
the best stereoselectivity of the heterogeneous catalysts examined, giving a 3:1 mixture of 
cis- and trans- diastereoisomers.  The hydrogenation was carried out before cleavage of 
the silyl ether presumably due to the increased steric bulk of this group compared to an 
unprotected alcohol, thus optimising facial selectivity in the delivery of hydrogen at the 
catalyst surface.   Cleavage of the silyl ether was then carried out after the hydrogenation 
using standard, basic fluorinating conditions (TBAF).   
 
The Crabtree’s hydrogenation to give the trans- diastereoisomer must be carried out after 
removal of the silyl ether protecting group, since the alcohol must be able to coordinate to 
the iridium catalyst to direct the hydrogenation.  The hydrogenation of the alcohol then 
proceeded in good yield to give 2.48 and with excellent stereoselectivity of >40:1 trans- 
to cis- diastereoisomer.   
 
Whilst the authors had successfully obtained the 4-substituted prolinols, which was their 
aim, they also undertook the oxidation of one of the alcohols, 2.48, to obtain the trans-4-
substituted proline amino acid.  They carried out the oxidation using a buffered solution 
of sodium chlorite and sodium hypochlorite with catalytic TEMPO.  The authors did not 
cleave the amine protecting Boc group, but this has been readily achieved in related 
compounds using standard acid treatment.78   
 
 As discussed earlier, this route is a powerful method to generate 4-methylprolines with 
moderate to excellent stereoselectivities. It does suffer some drawbacks, in that it is a 
relatively long route, involving a number of changes of oxidation state and protection 
steps.  In addition, the stereoselectivity observed for the cis- series is not as high as might 
be hoped.  Consideration was therefore given to amending one crucial aspect of the 
synthesis in the hope that it would improve both of these problems.  Del Valle and 
Goodman’s use of an alcohol as the directing group in the Crabtree’s hydrogenation 
requires the inclusion of a reductive and subsequently a reoxidative step in the synthetic 
route.  Whilst very successful in directing the trans- hydrogenation, it is likely that the 
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more flexible -CH2OTBS functional group results in the diminished stereoselectivity 
during the formation of the cis- diastereoisomer.  If an ester functional group were 
employed as the directing group, it was speculated that the stereoselectivity observed in 
the heterogeneous hydrogenation might be improved to a level similar to that observed by 
Moody et al. (vide supra, Scheme 2.17).78  In addition, this would remove the need to 
reduce and reoxidise the carboxylic acid moiety, and would thus abbreviate the synthesis.  
It has been shown that esters can be excellent directing groups in asymmetric 
hydrogenations,104 although their ability to direct is slightly less than equivalent alcohols.  
Nonetheless, it would not be anticipated that there would be a significant change in the 
level of stereoselectivity during the formation of the trans- series.  With this change in 
mind, the amended synthetic strategy shown in Scheme 2.29 (only one enantiomeric 
series, L-, is shown) was developed.       
 
In this amended strategy, after esterification and amine protection, oxidation would be 
carried out to give the ketone.  PCC (generated in situ) was chosen as oxidant since it was 
readily available in-house, although it has many drawbacks, such as high stoichiometry 
requirements and environmental toxicity.  As in Del Valle and Goodman’s synthesis, a 
Wittig or Petasis (vide infra) reaction would be used to install the exomethylene function.  
Stereodivergent hydrogenations would then be carried out on the exomethylene 2.52, by 
the methods employed by Del Valle and Goodman.  Finally simultaneous deprotection of 
both amine and carboxylate groups would be carried out under acidic conditions.   
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Scheme 2.29 - Alternative route to 4-methylprolines 
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This route was carried out using both trans-4-hydroxy-L-proline and cis-4-hydroxy-D-
proline; the least expensive of the four diastereoisomers of 4-hydroxyproline.  Since the 
stereochemistry of the γ position in these starting materials is lost during oxidation to 
form a ketone, the initial stereochemistry is unimportant.  After esterification (as 
discussed earlier), protection of the amine using CBz chloride under basic conditions 
afforded the protected 4-hydroxyprolines, 2.49 and 2.50, in approximately quantitative 
yields, which were characterised by NMR spectroscopy and high resolution mass 
spectrometry.  The specific optical rotation of the alcohols 2.49 and 2.50 were -55 and 
+20º respectively (no literature values available).     
 
The oxidation of the alcohols to give ketones 2.51 and ent-2.51 proceeded in good yields 
(85% and 87% respectively) using 13 equivalents of PCC (generated in situ) 
(characterised by NMR spectroscopy and high resolution mass spectrometry).  The 
measured specific optical rotations of 2.51 and ent-2.51 were of equal value and opposite 
sign (-4 and +4º respectively, no literature values available).  In an attempt to use a more 
environmentally benign oxidative conditions, oxidation of 2.49 using IBX in DMSO was 
examined.  The oxidation proceeded, but gave only a 36% yield.   
 
The olefination of 2.51 and ent-2.51 was undertaken using the Wittig reaction under the 
same conditions as those described by Chirgadze.79  This involved formation of the 
methylenetriphenylphosphorane ylide from the methylenephosphonium iodide (itself 
made by reaction of triphenylphosphine with methyl iodide) using potassium tbutoxide as 
base.  The product was obtained in a disappointing 26% yield for 2.52 and 30% for ent-
2.52.  This result was also found to be quite variable, frequently giving lower yields.  The 
product was characterised by NMR spectroscopy and high resolution mass spectrometry.  
No NMR data were given for 2.52 by Chirgadze et al., precluding direct comparison, 
however 2D NMR experiments confirmed the assignment of the product.  The optical 
rotations observed for the L and D forms (2.52 and ent-2.52, observed at 589 nm) were 
very small, to the extent that no accurate value could be assigned.  This result boded ill 
for the optical purity of the product, since the Wittig reagent is mildly basic and could 
therefore theoretically epimerise the α carbon of the proline derivative.  This seems 
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unlikely, however, given the common use of the Wittig reaction on amino acids with no 
observed α epimerisation.  In the absence of literature values (none given by Chirgadze et 
al.) for direct comparison, the optical purity of the product was assumed to have been 
conserved during the olefination.   
 
Stereodivergent hydrogenations were undertaken on exomethylenes 2.52 and ent-2.52 to 
form 2.53, 2.54 and their enantiomers.  Heterogeneous catalytic hydrogenation was 
carried out on 2.52 and ent-2.52 using palladium on carbon as the catalyst at atmospheric 
pressure.  This proceeded cleanly to give protected cis-4-methylprolines 2.54 and ent-
2.54 in good yields of 80% and 71% respectively.  After passing the crude reaction 
mixture through a pad of Celite, a 1H NMR spectrum of the product showed trace 
impurities were present, however no further purification was attempted at this stage.  2D 
NMR data and high resolution mass spectrometry confirmed the identity of the product.  
Due to limitations of scale, no optical rotation data was obtained at this stage.  The 
presence of small amounts of a related compound were in evidence from the 1H NMR 
spectrum, which was assumed to be the diastereoisomeric side-product and is discussed 
further later.   
 
The homogeneous Crabtree’s catalysed hydrogenation of exomethylenes 2.52 and ent-
2.52 were carried out under standard conditions (DCM as solvent and atmospheric 
pressure).  This gave the protected trans-4-methylprolines 2.53 and ent-2.53 in good 
yields (84% and 80% respectively) after several days.  The structure of the product was 
confirmed by NMR data (discussed further later) and high resolution mass spectral data.  
Both the 1H and 13C NMR spectra displayed isomerisation around the carbamate, with 
doubling of peaks observed.  Only trace impurities were observed in the 1H NMR 
spectrum, which were tentatively assigned as the product diastereoisomer, suggesting that 
the reaction had proceeded with good stereoselectivity.  Again, due to limitations of scale, 
no optical rotation data were obtained at this stage.   
 
Close monitoring of the hydrogenation reaction showed that after one day, no starting 
exomethylene 2.52 remained, but only small amounts of product 2.53 had been formed.  
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The major compound present was the product of a double bond migration from 
exomethylene to an endocyclic position, 2.58 (also observed in ent- series).  High 
resolution mass spectrometry showed the mass of the pseudomolecular ion of 2.58 was 
isobaric with the starting material, 2.52, suggestive of an isomerisation product. 1H NMR 
data (Figure 2.6, 1:1 mixture of isomers around the carbamate observed) established the 
presence of broadened singlet olefinic protons (δ 6.40 and 6.32) and broadened singlet 
methyl groups (δ 1.70 and 1.68). COSY NMR spectroscopy supported the proposed 
structure, with correlations between the H-2 (δ 4.70 and 4.64) and H-3 (δ 2.99 and 2.53) 
protons, as well as an allylic coupling between the H-5 proton and H-6 protons.  
 
CBzN
O
OEt
2.58
ent-2.58  
Figure 2.6 – 1H NMR spectrum of Crabtree’s catalyst induced double bond isomerisation 
product 
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Double bond isomerisation has been observed under Crabtree’s hydrogenation conditions, 
first by Krel et al. and subsequently by Solé and co-workers and by Fehr and Farris 
(Scheme 2.30).106,107,108   
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Scheme 2.30 – Crabtree’s catalyst (2.43) induced double bond isomerisation 
 
In the first two examples, an exocyclic methylene migrates to the more stable endocyclic 
isomers.  In the final example the exomethylene migrates onto an alkyl side chain, 
generating an aldehyde, which is subsequently attacked intramolecularly by a tertiary 
alcohol to yield a lactol.  The first group to describe the phenomenon, Krel et al., 
postulated a mechanism for this isomerisation after brief mechanistic studies, as shown in 
Scheme 2.31.     
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Scheme 2.31 – Krel’s proposed mechanism for Crabtree’s catalysed double bond 
migration 
 
The authors suggest that the bulky substrate or a third substrate-metal bond (via the 
second methoxyl group) prevents the oxidative addition of hydrogen to the metal centre 
and therefore prevents the hydrogenation pathway.  CH insertion and η3 allyl formation 
can then occur, and on reductive elimination of the substrate, the more 
thermodynamically stable double bond is formed.  Given that hydrogen oxidative 
addition to asymmetric metal hydrogenation catalysts (vide supra) is known to be the 
rate-determining step, this mechanism seems very plausible.  A longer-lived substrate-
metal complex has time to undergo rearrangements to more stable isomers, and this 
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mechanism seems appropriate, both for the other literature examples and for the 
isomerisation of exomethylene 2.52.    
 
It is interesting to note that in all the literature cases discussed above, the isomerisation 
product was stable to the hydrogenation conditions, with no hydrogenated products of the 
newly formed double bond obtained.  In this present work, if the hydrogenation reaction 
was left for extended periods (or when the isolated endocyclic olefin 2.58 was 
resubmitted to Crabtree’s hydrogenation conditions), hydrogenation to give the protected 
trans-4-methylproline product, 2.53, eventually went to completion.    
 
Whilst cleavage of the CBz and the ester was later found to be achievable in one step by 
acid hydrolysis, initially a two step procedure was adopted.  A heterogeneous 
hydrogenation over palladium on carbon was carried out to give the diastereoisomers of 
2.55 and ent-2.55. With all four diastereoisomers of 4-methylproline ethyl ester in hand, 
hydrolysis of the esters was achieved using basic hydrolysis (KOH(aq) in ethanol).  Care 
was taken to use only a small excess of base, in order to avoid epimerisation at the α 
carbon.   
 
With the four diastereoisomers of 4-methylproline now available, Marfey’s derivatisation 
was carried out on each.  The derivatives were examined by HPLC and the results are 
shown in Figure 2.7.   
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Figure 2.7 – HPLC chromatograms for the Marfey’s derivative of the four 
diastereoisomers of 4-methylproline 
 
Disappointingly, the results of the HPLC analysis of the four derivatives of 4-
methylproline reveal that epimerisation of the α carbon had occurred.  The two trans- 
diastereoisomers contain two Marfey’s peaks of equal area with equal retention times, as 
do the two cis- diastereomers.  This result means that at least one step in the synthesis has 
caused epimerisation.  There are two steps during the synthesis that have the possibility 
of epimerising the α carbon (ie basic conditions); the Wittig reaction and the basic 
hydrolysis of the ester.  The nature of the mixtures of diastereoisomers observed in the 
products allows the exclusion of the latter.  If a base-induced epimerisation of the α 
carbon had occurred on an optically pure protected 4-methylproline, the 
diastereoisomeric pairs would be anticipated.  For example, if the ester hydrolysis of L-
cis-4-methylproline ethyl ester, 2.54 caused epimerisation of the α centre, a mixture of L-
cis and D-trans-4-methylproline would be expected (Scheme 2.32).   
 
 
Chapter 2: The Pteratides  85   
HN
O
OEt
HN
O
OH
HN
O
OH
+
L-cis L-cis D-trans
-OH
2.54
 
Scheme 2.32 – Expected products of base induced α-epimerisation of cis-4-methylproline 
ethyl ester 
 
Examination of the HPLC chromatograms of the Marfey’s derivatives also revealed that 
small quantities of diastereomeric pairs were also present, but this will be discussed in 
more detail later.   
 
Since the observed mixtures of products were enantiomeric pairs (eg L-trans and D-trans), 
the epimerisation must have occurred prior to the stereoselective hydrogenations.  This 
makes the Wittig reaction the most likely suspect.  Further incriminating evidence was 
the lack of observable optical activity of the product of the Wittig reaction; exomethylene 
2.52.  This step was a reproduction of that described by Chirgadze et al., but since the 
authors gave no optical activity data, it is impossible to say if they also observed 
racemisation during their reaction.  Del Valle and Goodman did not observe any 
epimerisation of the α carbon during the Wittig reaction of ketone 2.45.  However the 
divergence of these results from theirs is readily explained by the fact that their ketone 
precursor was a 1,2-amino alcohol rather than an amino acid, making the α carbon 
considerably less acidic.   
 
The epimerisation of an amino acid under Wittig conditions had not been anticipated, 
since this reaction has been commonly used for synthetic manipulation of amino acid 
containing substrates.109,110  Indeed, during Mori and co-workers’ synthesis of the 
alkaloid prothracarcin, 2.60, the Wittig reaction was successfully employed to generate 
an olefin from a derivative of 4-ketoproline, 2.59, with a good correspondence between 
the specific optical rotation of the final synthetic and natural product (Scheme 2.33).109   
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Scheme 2.33 - Wittig reaction utilised during synthesis of Prothracarcin 
 
The Wittig reaction was carried out as per Chirgadze et al. ie using solid potassium 
tbutoxide.  The potassium tbutoxide employed was technical grade; however it had been 
open for an unknown time prior to use.  This reagent is highly reactive with water and 
interaction with atmospheric water may lead to decomposition to give potassium 
hydroxide and butanol.  This opened up the possibility that potassium hydroxide was 
responsible for the racemisation observed, since it would not be basic enough to 
deprotonate the phosphonium salt and would therefore remain present after the initial 
ylide formation step of the Wittig reaction.  This explanation may also account for the 
low yields of reaction observed, since less ylide would be present than anticipated.  The 
Wittig reaction was therefore reattempted employing fresh, commercial potassium 
tbutoxide THF solution on ketone 2.51.  Again a low yield of 11% was obtained.  
Hydrogenation over palladium on carbon and hydrolysis of the ester (on this occasion, 
under acidic conditions), Marfey’s derivatisation and HPLC analysis of the product were 
carried out.  The results of this are shown in Figure 2.8, with the results of the original 
Wittig procedure (L-cis, Figure 2.7) also shown for comparison. 
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Figure 2.8 – HPLC analysis of Marfey’s derivatives of 4-methylproline arising from 
different Wittig conditions 
 
It can be seen that the same mixture of enantiomers was obtained under both Wittig 
conditions, whether solid or fresh, commercial solutions of potassium tbutoxide were 
employed.  This indicates that the Wittig reagent itself is sufficiently basic to promote the 
racemisation of the α carbon of either ketone 2.51 or exomethylene 2.52 or both.   
 
It was clear that a different method of methylenation was required.  The olefination of 
carbonyl groups is most traditionally undertaken employing the classic Wittig reaction.  
However, a number of other olefination reactions have also been developed in response 
to the drawbacks inherent in the Wittig reaction.111  The chief drawbacks are the low 
yields observed with sterically hindered and cyclic ketones, and the basicity of the ylide 
which makes it an inappropriate reagent when enolisable ketones are to be olefinated or 
when other functionalities in the substrate preclude mildly basic conditions.   
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The various methods of carbonyl olefination all incorporate an element which is highly 
oxophilic.  The Wittig reaction uses a phosphorus based system, however silicon, sulfur, 
titanium and zinc systems are also used.  In general an intermediate 4-membered ring (eg 
the cyclophosphetane in the Wittig reaction) is involved from which the oxidised 
oxophilic element is subsequently eliminated to yield the olefin.  In several cases a stable 
carbonyl addition product is initially obtained, from which the elimination must be 
carried out.  A brief review of methylenation reactions will be given here.   
 
The Peterson olefination is based on silicon chemistry and involves addition of a 
silylcarbanion onto the carbonyl (Scheme 2.34).112  The magnesium alkoxides initially 
formed are too stable to eliminate but exchange of the counter-ion for sodium or 
potassium leads to smooth elimination.  Acidic conditions can also be employed to 
achieve elimination.  The Peterson reaction often gives improved yields compared to the 
Wittig reaction. 
O
Me3SiCH2MgCl
ClMg+O-
SiMe3
O
Me3
Si -
Na+
NaH
+ O=SiMe3  
Scheme 2.34 – Example of Peterson olefination 
 
The use of sulfur chemistry in carbonyl olefination was demonstrated by Corey and Durst 
using sulfinamides.113  The addition of N-methanesulfinyl-p-toluidine to a carbonyl yields 
a β-hydroxy sulfinamide, which eliminates thermally to give an olefin (Scheme 2.35).  
The high basicity of the N-methanesulfinyl-p-toluidine dianion makes this method 
inappropriate with enolizable ketones and base sensitive substrates.    
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Scheme 2.35 – Sulfinamide olefination 
 
The Julia olefination is another sulfur based system, involving addition of a metallated 
sulfone followed by activation of the resultant alcohol as a mesylate, and reductive 
elimination using sodium/mercury amalgams to give the olefin.  This method is, however, 
rarely used for methylenation due to the existence of simpler procedures.   
 
Transition metal based systems have been developed, using zinc and titanium.  Nysted’s 
zinc based methylenation reagent, 2.61, is an example (Scheme 2.36).114  This reagent is 
particularly useful for enolizable ketones since it requires Lewis acid activation.   
 
BrZn
Zn
ZnBr
OO
O
RR
BF3.OEt2
RR+
2.61  
Scheme 2.36 – Nysted’s methylenation reagent 
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The most important advance in methylenation chemistry came with the discovery of 
titanium based reagents, combining mild conditions with high yields.  The first of these 
was the Tebbe reagent, 2.62, prepared from titanocene(IV) dichloride with 
trimethylaluminium.115  Treatment of the reagent with a mild Lewis base such as pyridine 
produces the Schrock carbene, 2.63, which is the active reagent (Scheme 2.37).  
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Scheme 2.37 – Generation of the Tebbe reagent and Schrock carbene 
 
In Schrock carbenes, the carbon centre is nucleophilic and the metal centre is 
electrophilic.  Thus this system mirrors that of the phosphorus ylide in the Wittig reaction 
and the same reactivity is observed, with a strong titanium-oxygen bond eventually 
formed.  Thus, the carbene undergoes a [2+2] cycloaddition with the carbonyl forming an 
oxatitanocyclobutane which spontaneously decomposes to give the olefin (Scheme 2.38). 
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Scheme 2.38 – Reaction of Schrock carbene with carbonyl 
 
Whilst the Tebbe reagent is a very useful reagent, its significant sensitivity to air and 
moisture makes it a difficult reagent to handle and it has now been largely displaced by 
the milder and more stable Petasis reagent, 2.64 (Scheme 2.39).116  This reagent, which is 
also prepared from titanocene(IV) dichloride, allows access to the same Schrock carbene, 
2.63.  It is generated by reaction of titanocene(IV) dichloride with two equivalents of 
methyl lithium.  Upon heating, this complex decomposes to the active Schrock carbene, 
without releasing a Lewis acidic by-product, as is the case with the Tebbe reagent.  As 
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such, this reagent is particularly mild, methylenating under neutral conditions.  Relatively 
high reaction temperatures are required however, with decomposition to the carbene 
occurring at around 60-70ºC, and the reagent is sensitive to light.    
 
Ti
Cl
Cl 2 MeLi
Ti Ti CH2
2.632.64  
Scheme 2.39– Generation of the Petasis reagent and subsequent Schrock carbene 
formation 
 
One interesting property of the titanium based reagents is an ability to olefinate 
carboxylic acid derivatives such as esters and amides, although these reactions are slower 
than reaction at a ketone or aldehyde.   
 
The preceding review suggests that the Petasis reagent is the reagent of choice for 
methylenating base or acid sensitive substrates.  The starting material is inexpensive, the 
reagent relatively easy to make and handle, and yields are often high.   
 
It was decided to apply this chemistry to the 4-methylproline synthesis in the hope that 
methylenation could be achieved without racemisation of the α carbon.  The 
methylenation of 2.51 and ent-2.51 was therefore undertaken.  Synthesis of the Petasis 
reagent was carried out by the method described by Ndakala et al., in which titanocene 
dichloride in toluene is reacted with methyl lithium in diethyl ether at 0ºC.117  The reagent 
is then purified by extraction with cold ammonium chloride.  The solvent is partially 
removed until a concentrated toluene solution of the reagent is obtained.  This is 
necessary because it is unstable in the solid form.  Care is also taken to limit exposure to 
light throughout the preparation and use of the reagent.  The solution of the reagent is 
then added to the substrate ketone and the reaction heated.   
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Reaction conditions, and in particular, work-up conditions were optimised such that this 
reaction achieved a 56% yield on one occasion.  This result was not reproducible, 
however, with yields normally ranging from 30 to 45%.  Heating of the ketone with 
Petasis reagent in toluene at 90ºC for 3 hours were found to be the optimal conditions for 
reaction.  After cooling it was important to add the toluene reaction solution dropwise to 
a large excess of petroleum ether.  In this way, most of the titanium residues could be 
precipitated, allowing a relatively clean reaction product to be obtained after filtration 
through Celite.  1H NMR spectroscopy of the crude reaction mixture after 3 hours showed 
that no starting material remained, however, after work-up and purification of the crude 
residue by chromatography on silica, the yields were invariably disappointing (values 
above).   
 
The products obtained from methylenation with the Petasis reagent had identical NMR 
spectral properties to those obtained from the Wittig reaction.  Pleasingly, the two 
enantiomers now displayed strong optical activity (-26º for 2.52 and +25º for ent-2.52), 
suggesting that the integrity at the α carbon had been maintained.   
 
The exomethylene was stereodivergently hydrogenated under the same conditions as 
discussed earlier and gave the anticipated products, 2.53, 2.54 and their enantiomers.  
Both hydrogenation products showed significant optical activity as expected (-43º for 
2.53 and +41º for ent-2.53; -36º for 2.54 and +39º for ent-2.54).  These results do not 
necessarily indicate optical purity, however.  It was evident from the 1H NMR spectra of 
2.54 and its enantiomer that small amounts of diastereoisomeric products were present, in 
a ratio of approximately 7 to 1, however broadening of the peaks made accurate 
integration difficult (Figure 2.9).  As previously discussed, trace impurities were present 
in the 1H NMR spectrum of 2.53 and its enantiomer (Figure 2.10), which were 
tentatively assigned as the diastereoisomeric product.  Carbamate isomerisation of the 
CBz group accounts for the doubling of peaks observed in the 1H NMR spectrum of 2.53.  
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Figure 2.9 – 1H NMR spectrum of cis-4-methylproline ethyl ester, 2.54 
 
Figure 2.10 – 1H NMR spectrum of CBz-trans-4-methylproline ethyl ester, 2.53 
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These results suggested that the two hydrogenation procedures had occurred with a 
reasonable stereoselectivity, but not in a totally stereospecific manner.  This postulate 
was examined more closely once HPLC of the Marfey’s derivatives of the final products 
was carried out (vide infra). 
 
The mode of cleavage of the remaining protecting groups on the 4-methylproline 
derivatives (CBz and ester in the case of 2.53 and ester in the case of 2.54) was adapted 
in order to abbreviate the route.  Acid hydrolysis would be capable of removing both the 
CBz and the ester of 2.53 where previously hydrogenation to remove the CBz was 
followed by a basic hydrolysis to cleave the ester.  In addition, the use of HCl(aq) would 
allow accurate measurement of the optical rotation of the HCl salt to be carried out, since 
any excess could be readily removed under vacuum.  Finally, the use of acidic conditions 
for protecting group cleavage would be expected to occur without racemisation, since 
amino acids are generally only sensitive to basic conditions.   
   
Acid hydrolysis was carried out by heating the amino acid derivatives, 2.53, 2.54 and 
their enantiomers, in aqueous HCl (6 M) at 110ºC overnight.  This successfully cleaved 
all protecting groups, although 1H NMR spectroscopy (Figure 2.11) of the 4-
methylproline products suggested that diastereoisomeric mixtures had been formed.  The 
presence of a reasonably significant proportion of the undesired diastereoisomer appeared 
to be present, of the order of around 3 to 1 in both cases.  1H NMR spectroscopy of 2.53 
and 2.54 (Figures 2.10 and 2.9 respectively) had suggested a greater stereoselectivity in 
both hydrogenations, so this result was puzzling.   
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Figure 2.11 – 1H NMR spectra of 4-methylproline diastereoisomers, 2.56 and 2.57 
 
The four diastereoisomeric mixtures were derivatised with Marfey’s reagent and analysed 
by HPLC (Figure 2.12).   
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Figure 2.12 – HPLC of Marfey’s derivatives of 4-methylproline synthesised by Petasis 
methylenation route  
 
These HPLC results indicated that epimerisation of the α carbon might have been the 
cause of the disappointing diastereoisomeric mixtures observed by 1H NMR spectroscopy.  
This conclusion was drawn due principally to the evidence given by the HPLC 
chromatogram of cis-4-methyl-L-proline.  Three Marfey’s derivative peaks are in 
evidence, the major peak being that of the L-cis diastereoisomer.  Due to the lack of 
stereospecificity during the hydrogenation step, a peak for the L-trans diastereomer was 
also expected, and was present in a ratio of around 1:7 to the major peak.  However, the 
final peak corresponds to the D-trans diastereoisomer and was present in around a 1:3 
ratio with the major peak.  This represents epimerisation at the α carbon of the L-cis 
major diastereoisomer.  It is possible that the product of racemisation of the minor L-trans 
product (D-cis) was also present, however the resolution obtained between D-cis and L-
trans isomers was not sufficient to confirm this.  Optimisation of HPLC conditions was 
attempted to improve the resolution of these residues, however no significant 
improvement could be made.   
 
Chapter 2: The Pteratides  97   
The HPLC chromatogram of cis-4-methyl-L-proline could not be fully analysed, again 
due to a lack of resolution between D-cis and L-trans under these conditions.  Analysis of 
the HPLC chromatograms of the two trans- diastereoisomers was somewhat confusing, 
however.  Only two peaks were present in each, and the minor peak (present in a ratio of 
around 1:15) in each case, was the expected cis- diastereoisomer, formed due to lack of 
stereospecificity during the hydrogenation stage.  This was precisely the result hoped for, 
however it was not the result anticipated from analysis of the 1H NMR spectrum (Figure 
2.11).   
 
In order to examine whether acid hydrolysis was leading to the racemisation of the α 
carbon, Marfey’s derivatisation was carried out on 2.54, the compound immediately prior 
to the acid hydrolysis.  The cis-4-methyl-L-proline ethyl ester, 2.54, was chosen as it 
would allow direct comparison to the HPLC results above which clearly indicated α 
carbon racemisation.  The HPLC results are shown in Figure 2.13.  It can be seen that 
only two diastereoisomers are present, compared with the three observed after acid 
hydrolysis.  This lent further credence to the postulate that acid hydrolysis was causing α 
carbon racemisation.   
 
The harsh conditions of acid hydrolysis were therefore optimised.  It was found that 
complete cleavage of both protecting groups could be achieved at 70ºC in 6 hours.  The 
1H NMR of the hydrolysis products were significantly cleaner, containing only trace 
amounts of diastereoisomeric impurities (Figure 2.14).   
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Figure 2.13 – HPLC analysis of the Marfey’s derivative of cis-4-methyl-L-proline ethyl 
ester  
 
Figure 2.14 – 1H NMR spectra of 4-methylproline synthesised by Petasis methylenation 
route employing milder deprotection method 
 
Chapter 2: The Pteratides  99   
Marfey’s derivatisation of the 4-methylproline residues and analysis by HPLC (Figure 
2.15) showed that the levels of racemisation had been significantly reduced, although not 
entirely eliminated.  Thus, examination of the chromatogram of the Marfey’s derivative 
of the L-cis diastereoisomer revealed a ratio of 15:1 of the major peak to the product of 
racemisation at the α carbon (D-trans).  The diastereoisomeric impurity derived from the 
lack of stereospecificity of the hydrogenation (L-trans) was present in a ratio of 1:7 of the 
major peak.    
 
Figure 2.15 - HPLC of Marfey’s derivatives of 4-methylproline synthesised by Petasis 
methylenation route employing milder deprotection method  
 
Examination of the chromatograms of the other three diastereoisomers of 4-methylproline 
also revealed relatively good diastereoisomeric purity.  Exact diastereoisomeric ratios 
could not be calculated for cis-4-Methyl-D-proline due to an overlap of the major peak 
with the minor D-trans diastereoisomer, however visual analysis suggested similar levels 
to those seen for L-cis.  The trans- series showed a ratio of around 15:1 of the major 
isomer to the minor.     
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The stereoselectivity of the stereodivergent hydrogenations could now be analysed.  The 
stereoselectivity observed in the heterogeneous hydrogenation using palladium on carbon 
was 7 to 1.  This is not as high as that reported by Moody et al., however it is 
significantly higher than that observed by Del Valle and Goodman.  This latter result may 
be rationalised by considering the steric bulk imposed by the ester functional group, 
hindering approach of the substrate to the catalyst on that face.  Whilst bulky, the 
protected alcohol group which fulfills the same role in Del Valle’s synthesis would be 
expected to be more flexible, since the C1 carbon (sp3) is a primary alcohol.  With free 
rotation between C1, C2 and the protected alcohol, the bulky silyl group can adopt a 
position which does not significantly hinder the substrate’s approach to a surface.  In the 
case of the ester, C1 (sp2) is surrounded by two bulky oxygen atoms, steric bulk which 
rotation about the C1 to C2 bond does not alleviate.  The protected alcohol therefore 
permits approach on the same face more readily than the ester. 
 
The stereoselectivity observed with Crabtree’s homogeneous hydrogenation was 15 to 1.  
This is significantly lower than the stereoselectivity observed by Del Valle and Goodman, 
who obtained ratios of greater than 40 to 1.  This lower stereoselectivity can be 
rationalised by comparing the efficiency of the directing groups used to steer the 
hydrogenation onto one face.  Alcohols are excellent directing groups, due to the ready 
availability of their lone pair to coordinate to the metal centre and their minimal steric 
bulk.  On the other hand, whilst esters have been shown to be good directing groups, they 
are known to be less efficient in this role than alcohols.104  This is because their lone pair 
is less available to the metal both due to resonance within the ester, and to a lesser degree, 
due to the bulkiness of the ester impeding approach of the metal to the lone pair.  With 
the directing effect slightly diminished, competing, non-directed hydrogenations take 
place, leading to a lowering of the observed stereoselectivity.   
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2.3.4 Epimerisation of 4-hydroxyproline 
 
In order to extend the utility of this synthetic route to 4-methylproline, the reported 
epimerisation of trans-4-hydroxy-L-proline to give cis-4-hydroxy-D-proline was 
examined.  If the D- series could be readily accessed from the inexpensive trans-4-
hydroxy-L-proline, this route would allow all four diastereoisomers to be generated from 
a single, readily available starting material.   
 
The epimerisation of trans-4-hydroxy-L-proline was first reported by Baker et al. and, 
according to the authors, leads to complete inversion of the α carbon stereochemistry.118  
This method has subsequently been employed by other groups,119,120 and most notably by 
Heindl and co-workers during their synthesis of 4-substituted prolines, discussed 
earlier.84   
 
Therefore the epimerisation of trans-4-hydroxy-L-proline following the method of Baker 
et al was attempted.  It is a simple two-step protocol, which does not require purification 
of the intermediate.  The starting material was first refluxed in acetic anhydride and 
glacial acetic acid, then after removal of these reagents in vacuo, the residue was taken up 
in 2M HCl(aq) and further refluxed.  After filtration, the product was obtained by simple 
removal of all solvents and reagents to give the product as a crystalline solid.  This 
protocol gave the product as a slightly off-white solid.  1H NMR spectroscopy of the 
product revealed, however, that epimerisation of the α carbon had not been complete 
(Figure 2.16).  Small changes in chemical shift were observed.  This was due to the fact 
that the product of the epimerisation reaction yields the HCl salt, whereas the commercial 
amino acids were present as the free amino acid.   
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Figure 2.16 – 1H NMR spectra of the product of epimerisation and commercial L-trans 
and D-cis hydroxyproline 
 
In order to confirm the stereochemical outcome of the reaction, a comparison of the 
Marfey’s derivatives of the four commercial diastereoisomers of 4-hydroxyproline and 
the reaction product was made.  The results of HPLC analysis of the derivatives is shown 
in Figure 2.17.    
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Figure 2.17 – HPLC analysis of the Marfey’s derivative of the product of epimerisation 
and the four commercial diastereoisomers of hydroxyproline 
 
Figure 2.18 – HPLC of the resolved Marfey’s derivatives of the product of epimerisation  
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HPLC analysis clearly shows that whilst D-cis is the major diastereoisomeric product of 
the epimerisation method, a small amount of the starting L-trans diastereoisomer remains.  
To ascertain the exact ratio of product to starting material, optimisation of the HPLC 
conditions was undertaken, since the two peaks were not resolved.  The use of an 
optimised HPLC method are shown in Figure 2.18, and allowed the ratio of major to 
minor peak to be estimated at 4 to 1.   
 
No attempts to optimise the reaction conditions of this epimerisation to improve the 
stereoselectivity were undertaken.  It is evident that this literature procedure does allow 
ready access to the D- series of hydroxyproline, and therefore allows the synthesis of all 
four diastereoisomer of 4-methylproline from one starting material.  However, it is does 
not occur in an entirely stereospecific manner (as reported) and therefore should only be 
used where high levels of optical purity in the final products are not required.  In the case 
of those undertaking the assignment of a naturally occurring 4-methylproline in a 
secondary metabolite, less vigorous levels of optical purity are probably acceptable.   
 
 
2.3.5 Conclusions 
 
By this route all four diastereoisomers of 4-methylproline have been successfully 
synthesised, with a good level of stereoselectivity, in just six steps from two inexpensive 
starting materials.  The yields at most steps were high, in the range of 80 to 100%, 
however the yields obtained during the formation of the exomethylene were consistently 
low, with a maximum isolated yield of 56%.  This detracted from the maximum 
cumulative yields, which were 46% for the cis- series and 34% for the trans- series.  The 
stereoselectivities observed were of the order of 7 to 1 for the cis- series and 15 to 1 for 
the trans- series.  It has also been shown that the inclusion of one (two-part) additional 
step into the synthesis would allow all four diastereoisomers to be obtained from just one 
starting material, although this would be accompanied by a small decrease in product 
optical purity.  
 
 
Chapter 2: The Pteratides  105   
This route compares favourably to the route reported by Del Valle and Goodman.  Whilst 
their route may be more applicable when synthesising 4-substituted prolinols, this method 
provides more succinct access to 4-methylproline itself.  The route of Del Valle and 
Goodman is 8 steps, although the authors did not remove the Boc protecting group, so 
that it becomes 9 steps if the fully deprotected amino acid is required.  The route 
developed here compares favourably, with only 6 steps to final deprotected 4-
methylproline.   The cumulative yield of this route is better than that obtained by Del 
Valle and Goodman, although direct comparison is difficult as they did not fully 
deprotect the product and only carried out the penultimate oxidation on the trans- methyl 
derivative.  They reported a 26% cumulative yield for the Boc-trans-4-methylproline and 
28% for the Boc-cis-4-methylprolinol.  In addition, this route offers more consistent 
stereoselectivity to the cis- and trans- series.  Del Valle and Goodman observed a ratio of 
greater than 40 to 1 for the trans- series (compared to 15 to 1), however they obtained a 
maximum of 3 to 1 for the cis- series (compared to 7 to 1).   
 
The route also compares favourably to the other principal stereosepecific route to 
protected 4-methylproline derivatives, reported by Heindl et al.  Whilst Heindl’s route is 
stereospecific, it suffers from low cumulative yields (44% for N-benzyl-trans-4-methyl-
D-proline and 9% for N-benzyl-cis-4-methyl-L-proline ethyl ester) and does not report the 
potentially difficult deprotection of the N-benzyl group.  Also it includes the use of 
cuprate reagents which proved to be unreliable in the present work.    
 
Therefore overall this route offers an improvement on the literature procedures for 
synthesising 4-methylproline, a naturally-occurring and pharmaceutically relevant amino 
acid.     
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2.4  Stereochemical assignment of the pteratides 
 
With all of the reference amino acids in hand, it was possible to undertake the full 
stereochemical elucidation of the pteratides.  Hydrolysis of each of the depsipeptides was 
carried out under acidic conditions to give the free amino acid mixture.  Marfey’s 
derivatisation of all reference amino acids and each of the pteratide hydrolysates was then 
carried out.  Finally, HPLC analysis was carried out to examine which amino acids were 
present in the hydrolysates.  Good resolution of the stereoisomers of each amino acid was 
important for the accurate assignment of the amino acids present in the natural product 
hydrolysate.  In addition, good resolution of the constituent amino acids in the natural 
product hydrolysate mixture was taken into account when optimising HPLC elution 
conditions.  Two different methods were therefore used for the HPLC analyses, in order 
to obtain good resolution of the each of the amino acids.  In the case of pteratide I, 
several of the amino acids (phenylalanine, N-methylvaline and N-methylleucine) were 
analysed on a different HPLC instrument (Shimadzu, indicated on appropriate figures), 
using a similar column and method to that employed on all other occasions.  These 
stereochemical elucidation studies were carried out with the help of Drs Maya Mitova 
and Gerhard Lang (in particular, the derivatisation of the hydrolysates of pteratides II and 
III and some of the reference amino acids).  The derivatisation of pteratide I and all other 
reference amino acids was carried out as part of this thesis work.     
 
Examples of the HPLC results for Marfey’s derivatives of the commercial reference 
amino acid residues are given in Figures 2.19 and 2.20.   
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Figure 2.19 – HPLC chromatograms for the Marfey’s derivatives of phenylalanine and 
valine reference amino acids 
Figure 2.20 - HPLC chromatograms for the Marfey’s derivatives of N-methylvaline and 
N-methylleucine reference amino acids 
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The HPLC chromatograms of the Marfey’s derivatised hydrolysate products of the 
pteratides are shown in Figures 2.21 to 2.25 with the assigned amino acids labelled.   
 
Figure 2.21 – HPLC analysis of the Marfey’s derivative of Pteratide I (Shimadzu) 
 
 
Figure 2.22 - HPLC analysis of the Marfey’s derivative of Pteratide I 
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Figure 2.23- HPLC analysis of the Marfey’s derivative of Pteratide II 
 
 
Figure 2.24 – HPLC analysis of the Marfey’s derivative of Pteratide II 
 
Chapter 2: The Pteratides 110 
Figure 2.25 – HPLC analysis of the Marfey’s derivatives of Pteratide III 
 
 
Since the Marfey’s derivatives of the reference amino acids and pteratide hydrolysates 
were not run simultaneously on HPLC, a slight drift of the retention time of the 
hydrolysed Marfey’s reagent was observed.  The retention times for the amino acids were 
therefore standardised using the hydrolysed Marfey’s reagent as an internal standard.  
Table 2.3 shows the standardised retention times for the amino acid standards used to 
assign the stereochemistry of the pteratides.  It also indicates the amino acid which was 
found to be present in the natural products, by comparison of HPLC retention times.   
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Table 2.3 – Retention times of amino acid standards and natural product hydrolysates 
 Rt of standards (min) pteratide 
Amino acid Eluent A† Eluent B† Shimadzu† I II III 
L-valine 10.3     * 
D-valine 15.0      
L-threonine  8.9  * *  
D-threonine  12.9     
L-allo-threonine  10.2     
D-allo-threonine  10.9     
L-phenylalanine 15.7  30.3 * *  
D-phenylalanine 20.9  34.1    
N-methyl- L-alanine  15.4  * *  
N-methyl- D-alanine  15.0     
N-methyl- L-valine 14.3  28.9 * * * 
N-methyl- D-valine 17.8  31.6    
N-methyl- L-leucine 18.4  32.4 * * * 
N-methyl- D-leucine 21.3  34.1    
N-methyl- L-isoleucine 19.4    *  
N-methyl- D-isoleucine 24.2      
N-methyl- L-allo-isoleucine 19.9      
N-methyl- D-allo-isoleucine 22.6      
N-methyl- L-threonine  9.9    * 
N-methyl- D-threonine  10.6     
N-methyl- L-allo-threonine  15.4     
N-methyl- D-allo-threonine  16.0     
N-methyl- L-phenylalanine 16.0     * 
N-methyl- D-phenylalanine 16.7      
trans-4-methyl- L-proline  18.3  * *  
cis-4-methyl- L-proline  16.6     
trans-4-methyl- D-proline  19.3     
cis-4-methyl- D-proline  18.5     
 
† Elution conditions, including column type, temperature and solvent systems are given on p258-9 (Chapter 5) 
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The amino acids were all found to belong to the L- series (S) and threonine and isoleucine 
derived residues were all of the natural stereochemistry at the β position (R for threonine, 
S for isoleucine).  The 4-methylproline residue was found to have L-trans- 
stereochemistry (2S,4R).   
 
The structures of the pteratides including their newly assigned stereochemistry are shown 
below. 
 
This full structural characterisation of the pteratide structures has been published in the 
Journal of Organic Chemistry (included in Appendix).3
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2.5 Final concluding remarks 
 
The syntheses of all possible diastereoisomers of a number of unusual amino acids were 
successfully completed, using either literature methods or new synthetic routes.  These 
were synthesised with high levels of optical purity.  The classical method for 
stereochemical determination of amino acids was then employed to elucidate the 
stereochemistry of three naturally occurring depsipeptides.25  This involved derivatisation 
of both synthetic and commercially available amino acid standards, and hydrolysates of 
the natural products, followed by HPLC analysis of the derivatives.  The stereochemistry 
of the natural products were successfully determined, allowing the publication of the full 
structures of these novel and highly cytotoxic secondary metabolites in a peer-reviewed 
publication.3   
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Chapter 3 
 
The spiro-Mamakones 
 
3.1 Introduction 
3.1.1 spiro-Mamakones – new spirobisnaphthalene natural products 
 
A new series of polyketide derived natural products, the spiro-mamakones, 3.1 to 3.5, 
were recently discovered in the University of Canterbury natural products group, by Dr S. 
van der Sar.  Of these, spiro-mamakone A, 3.1, has been disclosed in the peer-reviewed 
literature.1  These natural products were isolated from the extract of a cultured non-
sporulating fungal endophyte derived from the New Zealand native tree Knightia excelsa 
(rewarewa).     
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The spiro-mamakone series represents a new category in the diverse spirobisnaphthalene 
class of natural products.  Spirobisnaphthalenes are a relatively new class of compounds, 
with the first example, antibiotic MK3018, appearing in a Japanese patent in 1989 and 
preussomerin A (3.7) appearing in the wider literature in 1990.2,3  Since then, however, a 
large number have been found, principally from fungi.  Reports have been made of their 
isolation from plant sources, however the possibility that these plant derived 
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spirobisnaphthalenes are actually produced by an endophytic fungal source is the subject 
of some debate.4,5      
 
Spirobisnaphthalenes are biosynthesised by the oxidative coupling of two oxygenated 
naphthalene units.  The natural products isolated fall into three general structural types; 
those with two oxygen bridges between the two naphthalene units, such as palmarumycin 
CP1 (3.6);6 those with three oxygen bridges, such as preussomerin A (3.7);3 and those 
with two oxygen and one carbon bridge, such as spiroxin A (3.8).7   
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Considering its simple monomeric napthol building blocks, this class of natural products 
shows a huge diversity.  Extensive reduction or oxidation (including epoxidation in the 
diepoxins) of the naphthalene cores is common, and other chemical modifications such as 
methylation and halogenation have also been observed.  They are examples of how 
proficient nature is in exploring chemical space with simple starting materials.  In his 
2003 review of the spirobisnaphthalenes, Krohn summarised more than 60 naturally-
occurring analogues, all found since 1990, some examples of which are shown in Figure 
3.1.8  This demonstrates the rapid growth of this important class of natural products.   
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Figure 3.1 – Further examples of the spirobisnaphthalene class of natural  
products2,6,7,9,10,11,12,13,14    
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There are a number of related bisnaphthalene natural products with alternative 
naphthalene bridging motifs.  Stemphytriol (3.9) and the phytotoxin alteichin (3.10) are 
fungal metabolites.15,16   Sphaerolone (3.11) was produced when the normal 
spirobisnaphthalene biosynthetic pathway of the Sphaeropsidales sp. fungus was 
disrupted by inhibiting an enzyme involved in dihydroxynaphthalene biosynthesis (vide 
infra).17  These compounds will not be discussed further, however, as they have a 
fundamentally different skeleton to the spirobisnaphthalenes.   
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In addition to their interesting structures, the spirobisnaphthalene class also display 
diverse biological activities.  Antibacterial and antifungal properties are common, for 
example, amongst the palmarumycins, the diepoxins and the preussomerins.  Herbicidal 
activity has been noted in cladospirone bisepoxide18 and some spirobisnaphthalenes have 
demonstrated antitumour poperties, such as the spiroxins.  The preussomerins have been 
shown to selectively inhibit farnesyl-protein transferase,13 an enzyme involved in post-
translational modification of many proteins involved in intracellular signalling.  The 
oncologically mutated form of one of these proteins is found in over 30% of human 
cancers.  Selective inhibitors of this enzyme are therefore being developed as potential 
antitumour agents.     
 
The biosynthetic origin of the spirobisnaphthalenes has been speculated upon and studied 
by a number of groups.  Krohn et al. postulated the intermediacy of 1,8-
dihydroxynaphthalene, DHN, a fungal metabolite derived from a penta- or hexaketide 
(Scheme 3.1).9  DHN is one of the precursors used by fungi to produce melanins, which 
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are highly coloured polymers.19  Melanins are found in several animal kingdoms, and 
whilst not essential for survival, they have a range of functions which increase organism 
fitness.  For example, melanin’s ability to absorb UV radiation reduces environmental 
cell damage, and is useful in camouflage.  The ink secreted by squid, as a defence 
mechanism, is a fine suspension of melanin granules.  Melanin also increases resistance 
to hydrolytic enzymes in fungi, and melanin precursors or derivatives (including DHN) 
often have antibiotic activity or phytotoxic activity (eg alteichin, 3.10). 
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Scheme 3.1 – Krohn and co-workers’ proposed biosynthetic origin for Palmarumycin 
CP1
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Krohn et al. proposed that fungi also use DHN as a precursor in the elaborate and 
specialised biosynthesis of the spirobisnaphthalene class.  Phenol oxidation and coupling 
provides the core skeleton, which on further enzymatic processing, allows biosynthesis of 
this vast array of natural products.  The same group studied the plausibility of the key 
oxidative spiroketal formation by forming palmarumycin CP1 by oxidation of a naturally 
occurring biosynthetic precursor (discussed further in Section 3.1.2, Scheme 3.3).20   
 
Several experimental studies on the biosynthesis of spirobisnaphthalene natural products 
were carried out by Bode et al..  The polyketide nature of these natural products was 
confirmed using labelling studies.21  In addition, the intermediacy of 1,8-
dihydroxynaphthalene (DHN) was confirmed by simultaneous inhibition of cladospirone 
bisepoxide and DHN melanin biosynthesis using a small molecule inhibitor.17  Interesting 
new natural products were produced by the organism during the course of this experiment 
(including sphaerolone, 3.11), derived from oxidative coupling of DHN precursors.  
Finally, variation of culture conditions also yielded insight into the regulation of 
biosynthetic pathways.14  For example, oxygen levels during fermentation of a 
spirobisnaphthalene producing fungus affected the production of various oxygenated or 
reduced spirobisnaphthalenes.      
 
The spiro-mamakone series, whilst clearly structurally and biosynthetically related, have 
a markedly different carbon skeleton to the rest of the spirobisnaphthalene class.   One of 
the naphthalene units has one carbon extracted, and an interesting nine-membered, spiro-
bicyclic unit results.  This represents an interesting tangent on the biosynthetic pathway 
of spirobisnaphthalene natural products, and is a further example of the fascinating ways 
nature explores diverse chemical space using modification of simple precursors.  It has 
been shown by Drs van der Sar and Mitova in the University of Canterbury natural 
products group that the biosynthetic origin of this skeletal modification involves the 
oxidation and rearrangement of an epoxide intermediate, with loss of CO2 (Scheme 
3.2).22  Interestingly, spiro-mamakone A, 3.1, is a rare example of a racemic natural 
product, which can be accounted for by the proposed biosynthetic pathway, which was 
formulated on the basis of unnatural isotope incorporation studies.  The spiro-bicyclic 
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moiety of the spiro-mamakones is characterised by extensive oxidation, and the degree of 
oxidation varies across the series.   
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Scheme 3.2 – Proposed biosynthesis of spiro-mamakone A 
 
The spiro-mamakones display some potent bioactivities.  spiro-Mamakone A (3.1) 
displayed potent cytotoxicity (IC50 of 0.33 μM in the murine leukaemia cell line P388 
assay) and showed potent antimicrobial activity against Bacillus subtilis, Trichophyton 
mentagrophytes and Cladosporium resinae.  spiro-Mamakone B (3.2) and C (3.3) 
showed cytotoxicity in the P388 assay (1.39 μM and 0.95 μM respectively) and moderate 
antimicrobial activity against B. subtilis and T. mentagrophytes.  spiro-Mamakone D 
(3.4) showed a cytotoxicity of 3.76 μM, but was not antimicrobial.  No biological data for 
spiro-mamakone E (3.5) were obtained.   
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During studies of the spiro-mamakones, a semi-synthetic analogue was prepared by Dr 
van der Sar, spiro-mamakone F, 3.12.  This was prepared by oxidation of the racemic 
alcohol of spiro-mamakone A and also displayed cytotoxicity (1.13 μM) and moderate 
antimicrobial activity (B.subtilis, T. mentagrophytes, and C. resinae).   
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The compact but highly functionalised nature of the spiro-mamakones and their 
biological activities make them attractive and challenging synthetic targets.   
 
 
3.1.2 Spirobisnaphthalene synthesis – a literature review 
 
Whilst the isolation of the spirobisnaphthalene class of natural products began in the early 
1990s and a massive array of natural compounds rapidly amassed in the literature, it was 
not until 1997 that the first tentative studies of their synthesis appeared in the literature.  
In that year, a model study for the synthesis of diepoxin σ was reported by Wipf and 
Jung,23 and a semi-synthetic preparation of a palmarumycin analogue (3.14) from a 
naturally occurring, “open-chain” analogue, 3.13, was described by Krohn et al. (Scheme 
3.3).20  The latter study supports the proposed biosynthetic route to the 
spirobisnaphthalenes, involving oxidative cyclisation of phenolic bisnaphthyl ethers.   
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Scheme 3.3 – Semi-synthesis of a palmarumycin analogue 
 
After these two initial reports, the floodgates were opened, however, and in the last ten 
years, several groups have reported significant progress in the synthesis of the 
spirobisnaphthalene class, with many natural products having succumbed to total 
synthesis.  These synthetic efforts have covered several different subsets of the 
spirobisnaphthalenes including the palmarumycins, preussomerins, diepoxins and the 
spiroxins.  Stereoselective syntheses of chiral spirobisnaphthalenes have recently been 
reported.  This burgeoning field has also helped shed light on biosynthetic aspects of the 
spirobisnaphthalenes.  A number of different strategies have been developed to access the 
crucial bisnaphthyl spiroketal moiety, using both “biomimetic” and non-biomimetic 
methods.  
 
In early 1998, the three main contenders in this field, Wipf, Taylor and Barrett, and co-
workers, all published their first syntheses of spirobisnaphthalene natural products.  Wipf 
and Jung reported the synthesis of palmarumycin CP1 and (±)-deoxypreussomerin.24  This 
involved a “biomimetic” strategy for spiroketal formation, by formation of a phenolic 
bisnaphthyl ether employing the Ullman coupling of a phenol and an iodo- derivative.  
The ether then underwent an oxidative spirocyclisation with a proximal phenol to form 
the spiroketal (Scheme 3.4).  This work was extended in a later publication, to include an 
array of analogues where Mitsunobu conditions were used to form ethers from the 
palmarumycin phenol.25   
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Barrett and Taylor, and co-workers, published very similar strategies to palmarumycin 
CP1, CP2 and CJ-12,371 (Scheme 3.5).26,27  The precise reagents used were different, 
however, the overall strategy was identical.  Barrett’s synthesis included an asymmetric 
reduction to give CJ-12,371 (S) in good enantiomeric excess by use of chiral reducing 
agent (+)-B-chlorodiisopinocamphenylborane.     
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Scheme 3.4 – Wipf and Jung’s synthesis of spirobisnaphthalene natural products 
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Scheme 3.5 – Barrett and Taylor’s synthetic route to spirobisnaphthalene natural 
products 
 
In 1999, Wipf and Taylor both extended their strategies to new spirobisnaphthalene 
natural products.  Wipf and Jung successfully synthesised (±)-diepoxin σ, with good 
levels of diastereoisomeric excess during the double epoxide formation (Scheme 3.6).28  
Taylor et al. synthesised deoxypreussomerin A by epoxidation of palmarumycin CP1, and 
subsequent reduction of deoxypreussomerin A yielded palmarumycin CP11 (Scheme 
3.7).29   
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Scheme 3.6 – Wipf and Jung’s synthesis of (±)-diepoxin σ 
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Scheme 3.7 – Further spirobisnaphthalenes from the group of Taylor 
 
Also in 1999, Chi and Heathcock reported the first synthesis of members of the 
preussomerin group (G and I), where the naphthalene units are joined by three oxygen 
bridges.30  The formation of the key bis-spiroketal moiety was carried out by a “ring-
chain tautomerisation” in what is believed to be a biomimetic mechanism (Scheme 3.8).  
The resonance energy gained during the formation of two isolated aromatic systems of 
3.16 from one naphthalene in 3.15 drives this reaction.  Further synthetic manipulation of 
3.16 afforded preussomerins G and I.    
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Scheme 3.8 – Biomimetic bis-spiroketal formation demonstrated by Chi and Heathcock 
 
Taylor and Wipf reported further progress in this field in 2000, with Wipf and Jung 
reporting the formal asymmetric synthesis of (+)-diepoxin σ and Taylor et al. describing 
a new, non-biomimetic approach to the bis-spironaphthyl core.  Wipf’s asymmetric 
synthesis of (+)-diepoxin σ relied on the asymmetric introduction (using a chiral boron 
complex) of a cyclopentadiene Diels-Alder derived protected double bond.31  This bulky 
protecting group served as a stereochemical anchor which could be removed at 250-
260ºC (refluxing phenyl ether), conditions under which the compound is stable.   
 
Taylor et al. synthesised a preussomerin analogue using an unusual aryl acetal anion 
strategy (Scheme 3.9). 32  They synthesised the bis-spiroketal core by dimerisation of 
salicyl aldehydes.  They then showed that these moieties could be successively 
deprotonated and alkylated, and after oxidation and a Freidel-Crafts cyclisation afforded 
the preussomerin skeleton.  This group would later go on to demonstrate the utility of this 
approach to preussomerins by synthesising (±)-preussomerins F, K and L.33,34   
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Scheme 3.9 – Novel approach to the preussomerin skeleton 
  
In 2000, Coutts et al. published a novel approach to the palmarumycin skeleton in a 
manner similar to the biomimetic method, employed by Wipf and Jung.35  The crucial 
difference was the replacement of the Ullman coupling with a nucleophilic aromatic 
substitution on an activated aryl fluoride by a phenol under basic conditions.  They used 
this route to make a number of palmarumycin analogues.   
 
In 2002, Barrett et al. described a unified route to the palmarumycin and preussomerin 
core structures, employing a strategy similar to Chi and Heathcock.36  The authors also 
described the stereoselective synthesis of (-)-preussomerin G, with stereoselectivity 
induced by use of a chiral phase transfer reagent during epoxidation.       
 
2003 saw the first synthesis of the spiroxin subset of the spirobisnaphthalene class, with 
the synthesis of (±)-spiroxin by Miyashita and co-workers.37  In these natural products, 
the two naphthalene groups are bridged by both a spiroketal, and a carbon-carbon bond.  
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The authors first tackled the carbon-carbon bond, via a Suzuki-Miyaura cross-coupling 
reaction (Scheme 3.10).  Deprotection of a phenol formed a protected hemiacetal, 3.17, 
which, after deprotection, formed the spiroketal, 3.18, by intramolecular addition to a 
double bond in the presence of a brominating reagent.  Subsequent synthetic 
manipulation yielded (±)-spiroxin C (3.19).  
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Scheme 3.10 – Miyashita and co-workers’ synthesis of (±)-spiroxin C (3.19) 
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The report of Inoue and co-workers presented a novel approach to the spiroketal moiety, 
which was employed in these authors’ synthesis of CJ-12,372 (Scheme 3.11).  They 
generated thiocarbonate, 3.20, which underwent nucleophilic addition and was trapped as 
the monothioorthoester, 3.21.  A Suzuki-Miyaura coupling yielded the precursor, 3.22, 
for cationic cyclisation which provided the basic spirobisnaphthalene skeleton.  After 
further synthetic manipulation, (±)-CJ-12,372 (3.23) was successfully synthesised.  This 
unusual approach to the spirobisnaphthalene skeleton has not been employed by any 
other groups to date. 
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Scheme 3.11 – Alternative approach to spiroketal moiety and synthesis of (±)-CJ-12,372, 
3.23  
 
The most recent report of a spirobisnaphthalene synthesis was the application of a new 
benzylic oxidation rhodium catalyst in the conversion of a late stage intermediate to 
palmarumycin CP2 (3.24, Scheme 3.12) described by Catino and co-workers.38     
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Scheme 3.12 – Palmarumycin CP2, 3.24, synthesis using new rhodium benzylic oxidation 
catalyst 
 
With such a structurally diverse class of natural products as the spirobisnaphthalenes, 
generalisation of their synthesis is not trivial.  However, a common thread through most 
synthetic routes to spirobisnaphthalenes is the early introduction of the crucial spiroketal 
(or bis-spiroketal) moiety, followed by varying degrees of subsequent manipulation.  A 
wide variety of reaction conditions have been employed on the spiroketal bisnaphthyl 
cores, with oxidative and reductive processes among the most heavily utilised.  The 
ability to introduce the spiroketal function so early in these syntheses relies on the 
stability that it displays to a wide range of conditions.  Even under acidic conditions, the 
ketal has been shown to be surprisingly stable; surviving refluxing methanol and aqueous 
HCl mixtures, and boiling in acetic acid.9    
 
 
3.1.3 Synthetic strategies to spiro-mamakone A 
 
Due to both the interesting structural features of the spiro-mamakones and their 
biological activity, their synthesis is of interest.  The successful synthesis of related 
spirobisnaphthalenes suggests that they are a realistic, albeit challenging synthetic target.  
spiro-Mamakone A, 3.1, was the principal synthetic target, however, the structural 
features of the other spiro-mamakones were borne in mind throughout these synthetic 
explorations in the hope of generating a unified route to the series.   
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When designing a synthetic route to spiro-mamakone A, the main structural difference to 
the other spirobisnapthalenes is the nine carbon spiro-bicyclic moiety which replaces the 
ten carbon naphthalenoid moiety.  This would require a different strategy to this half of 
the molecule, however, the overall nature of spiro-mamakone A is otherwise very similar 
to the other spirobisnaphthalenes.  It was therefore assumed that the synthetic 
considerations appearing in the literature for the spirobisnaphthalenes (discussed above, 
Section 3.1.2) could be broadly applied to spiro-mamakone A.  For example, it seemed 
reasonable to expect the spiroketal functionality to be of a similar stability in both classes, 
allowing its formation at an early stage of the synthesis from an appropriate pair of nine 
and ten-membered bicyclic structures.  With a basic spiro-mamakone skeleton thus in 
place, it was anticipated that manipulation of the oxidation state of the heavily 
functionalised northern hemisphere would be possible.   
 
Three basic methods for generating the key spirobisnaphthalene spiroketal have been 
published, as discussed previously (Section 3.1.2).  First, the “biomimetic” Ullman 
coupling method, as employed by Wipf et al. (Scheme 3.4), where an ether is first 
formed between two aryl systems (an aryl iodide and phenol) using copper mediated 
nucleophilic aromatic substitution.  A proximal phenol is then involved in an oxidative 
ring-closing ketalisation reaction.  Coutts et al. described a similar approach using an aryl 
fluoride.  This approach is, however, not easily applicable to spiro-mamakone A.  The 
reaction is applicable to those spirobisnapthalenes where the final product is, or an 
intermediate can be derived from, two aromatic systems.  This can be envisioned for all 
spirobisnaphthalenes with the exception of the spiro-mamakones, since the northern 
hemisphere involves two 5-membered rings connected by a spiro- centre.  Whilst five-
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membered aromatic systems such as cylcopentadiene anions can react in Ullman type 
reactions39 a spiro-disubstituted cyclopentadiene could not be deprotonated and therefore 
can not be aromatised.   
 
The second method is the non-biomimetic approach of Inoue et al. (Scheme 3.11).  Here 
DHN is functionalised to generate an activated ‘ketal’ with an electrophilic centre which 
can then undergo nucleophilic addition.  After further functionalisation, ring-closing 
yields the final spirobisnaphthalene skeleton.  This sort of approach is more amenable to 
the synthesis of spiro-mamakone A and one route to spiro-mamakone A which was 
briefly examined (retrosynthesis described in Scheme 3.13) is related to this one, and is 
described further later (Section 3.2.1).   
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Scheme 3.13 – Retrosynthetic analysis of spiro-mamakone A, 3.1, using an approach 
related to that of Inoue and co-workers 
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The final, non-biomimetic method for spiroketal formation used by Taylor and Barrett 
(eg Scheme 3.5) involves classic ketal formation using an acid catalysed dehydration 
reaction between a diol and a ketone.  This approach would be expected to be appropriate 
for the synthesis of spiro-mamakone A (retrosynthetic analysis shown in Scheme 3.14).  
The use of DHN as diol that would be required for synthesis of spiro-mamakone A was 
successfully employed for spirobisnaphthalene synthesis by these authors.  It is fair to 
assume that an appropriate nine-membered ketone might react similarly to the tetralone 
employed by the authors, to form the spiro-mamakone skeleton.   This approach therefore 
requires the design of an appropriate ketone for ketalisation with DHN.   
OO
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OH OH
+
O
3.25
 
Scheme 3.14 – Gross retrosynthetic analysis of spiro-mamakone A related to approach of 
Taylor and Barrett and co-workers 
 
Since there should be an opportunity to functionalise the northern hemisphere after 
construction of the spiroketal, the exact nature of ketone 3.25 can be varied for ease of 
access.  Certain restrictions on ketone 3.25 do exist, however.  For example, heavily 
conjugated ketones tend to form ketals only reluctantly, so an unconjugated ketone would 
be preferred.  The presence of appropriate functionality in both rings of ketone 3.25 is 
required to allow manipulation of the spiro-mamakone skeleton to give the final target 
compound.   
 
A number of different ketones were considered for this purpose, however, a search of the 
literature brought to light a very promising ketone, 3.27, whose two step synthesis was 
reported in high yields (Scheme 3.15).40,41  This nine-carbon bicyclic ketone appeared to 
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be an excellent starting point for an attempt to synthesise the spiro-mamakone carbon-
skeleton and offered differential functionalities in each ring for further functionalisation.  
 
O
O
OAc
+
O
O
3.26
O
O
3.27
Pd(PPh3)4
Grubbs I
catalyst
 
Scheme 3.15 – Kotha and co-workers synthesis of spirobicyclic 3.27 
 
Ketone 3.27 contains two non-conjugated ketones which would be expected to form a 
spiroketal readily.  The possibility of forming two ketals from 3.27 must be considered, 
however steric hindrance may impede a second ketal forming.  Differential functionality 
on each half of the spirobicyclic 3.27 should allow selective manipulation of the northern 
hemisphere after spiroketalisation.  This would be of benefit since spiro-mamakone A is 
asymmetrically oxidised and differentiation of these two rings would be necessary.   
Finally, the synthesis of ketone 3.27 is already known, is succinct and proceeds in good 
yields.  It does require the use of the moderately expensive Grubbs’ catalyst, however, as 
an efficient and reliable catalyst, this does not detract significantly from the approach.   
 
The high degree of functionality in so small a molecule as spiro-mamakone A gives the 
synthetic chemist a wide range of possibilities in the design of a synthetic strategy.  
Whilst other approaches were considered, the examples given above represent those 
approaches which seemed most promising.  The first of these methods was not pursued 
extensively after falling at an early hurdle.  Though further investigation may have 
allowed this hurdle to be cleared, it became clear that the other route (the ketalisation of 
ketone 3.27) showed more promise.  The “unsuccessful” route will be discussed initially 
(Section 3.2.1) with a more extensive discussion of the ultimately more successful route 
following (Sections 3.2.2 to 3.2.10).   
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3.2 Synthetic investigations 
3.2.1 Investigation of Inoue-based approach 
 
The first synthetic approach to spiro-mamakone A examined was that which was broadly 
based on the method of Inoue et al. (vide supra, Scheme 3.13).  This synthetic method 
was kindly proposed by Professor Martin Banwell of the Australian National University, 
Canberra.  A more detailed description of the synthetic route envisioned is given in 
Scheme 3.16.     
 
In this route, after formation of DHN using literature methods, equilibration with ethyl-
3,3-ethoxyacrylate (3.28) would be expected to generate ketal 3.29.  Reduction of the 
ester to an alcohol and generation of a leaving group would generate an electrophilic 
centre which upon reaction with 4-cyclopentene-1,3-dione under basic conditions would 
rearrange to give terminal alkene 3.30.  After metathesis of the alkene with acrolein, 
aldehyde 3.31 would be anticipated to undergo a Knoevenagel isomerisation to give 
spiro-mamakone A.  This final step can be considered to be biomimetic as it resembles 
the final intermediate proposed in the biosynthetic pathway to this natural product 
(Scheme 3.2). 
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Scheme 3.16 – Proposed synthetic route to spiro-mamakone A using an approach similar 
to Inoue and co-workers 
 
The synthesis begins with the generation of 1,8-dihydroxynaphthalene.  The method 
which has been reported to be most effective29 is that by Erdmann, which involves fusion 
of 1,8-naphthosultone with potassium hydroxide.42  This reaction was successfully 
repeated on scales of up to 6 g, with yields of around 70%.    
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The next step is an acetal exchange process between ketene acetal 3.28 and DHN.  This 
reaction is an equilibration process, which would be expected to entropically favour the 
formation of desired 3.29, as two molecules of ethanol would be generated.  Acid is 
required to catalyse this process.  Attempts were made to carry out this reaction, initially 
using DCM as solvent with catalytic quantities of pTSA.  Carrying out the reaction 
overnight at either room temperature or reflux led only to recovery of starting materials.  
Carrying out the reaction in the absence of solvent at 45ºC did not improve the situation, 
although an impurity was observed.  This impurity was the sole product of reaction at 
85ºC, and could be purified and characterised as 3.32, as described below, using 1H 
(Figure 3.2), 2D and 13C NMR spectroscopy and mass spectrometry.   
OH O
O
OEt
3.32  
Figure 3.2 – 1H NMR spectrum of 3.32 
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The aromatic region of the 1H NMR spectrum of the product did not show the typical 
pattern of the 1,2,3-trisubstituted rings of DHN.  Instead one of the rings showed a 
1,2,3,4-tetrasubstituted ring pattern. This suggested that substitution on the ring had 
occurred.  The presence of only one up-field aromatic doublet suggested that the 
substituted proton was in the ortho-position relative to a phenol.  The presence of one 
ethyl group suggested that only monosubstitution of the diethoxyacetal had occurred.  
Low resolution mass spectrometry (electron impact ionisation) showed that the 
pseudomolecular ion had a mass of 256 Dalton, corresponding to a molecular formula of 
C15H12O4.  This evidence allowed assignment of the product as 3.32.  One of the protons 
(δH 7.76) on the 1,2,3,4-tetrasubstituted ring showed a correlation in an HMBC NMR 
experiment to a carbonyl carbon at δC 167.  The structure 3.32 makes this correlation a 
five-bond correlation, which is unusual, but in this heavily conjugated system, not 
impossible.   
 
This is a surprising result and demonstrates that the phenolic oxygens are not efficient 
nucleophiles.  The formation of 3.32 can be rationalised by an acid-catalysed attack on 
the electrophilic ketene acetal by the electron-rich phenol ortho-position, in a Friedel-
Crafts alkylation-type reaction.  After displacement of ethanol, the ester is ideally placed 
for an intramolecular lactonisation to form a six-membered ring.  An alternative 
mechanism can be proposed which reverses these two steps.  Thus, if the electrophilicity 
of the carbonyl were greater than that of the ketene acetal, initial attack by the phenol 
could occur at the ester.  The electron-rich ortho-position would then be well placed to 
generate the six-membered ring of 3.32.  The latter of these two mechanisms is much less 
plausible, however, as the electrophilicity of the ketene acetal should be very high.  
Enones are good Michael acceptors and the additional electron withdrawing effects of the 
ethoxy substituents should make this a very electrophilic centre.  Further evidence for the 
former mechanism was also found during the course of later experimentation (discussed 
further later, Section 3.2.3).  
 
Whilst acetal exchange is generally catalysed by acid, the possibility of a base catalysed 
route was considered.  The phenolic oxygen had been shown to be insufficiently 
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nucleophilic to initiate an acetal exchange, however a phenoxide would be significantly 
more nucleophilic.  The use of catalytic sodium ethoxide would allow an equilibrium to 
set up which should favour the desired product.   This reaction was attempted, however, 
no reaction was observed.  Both starting materials were stable under the conditions (as 
observed by monitoring by 1H NMR spectroscopy) except on refluxing the reaction 
(ethanol as solvent) when the ketene acetal decomposed.    
 
With extensive experimentation, the problematic side-reactions and lack of reactivity may 
have been circumvented and the desired acetal exchange promoted, however, efforts were 
instead concentrated on other more promising approaches (Section 3.2.2).   
 
 
3.2.2 Synthetic studies towards spiro-mamakone A via nonadione 3.27  
 
The most promising approach towards the synthesis of spiro-mamakone A was deemed 
to involve spiroketalisation of the known nonadione 3.27 with DHN and subsequent 
synthetic manipulation.   
O
O
3.27  
 A detailed retrosynthetic analysis is shown in Scheme 3.17.  The key spiroketalisation 
was envisioned to be carried out using methods described by Taylor et al. in their 
synthesis of spirobisnaphthalenes (vide supra).  With the spiro-mamakone skeleton thus 
generated, the manipulation of the oxidation state of the northern hemisphere would have 
to be achieved.  A variety of conditions are known which can achieve dehydrogenation of 
a ketone to yield an enone.  Successful application of such a reaction to 3.35 would 
generate 3.34.  Selective 1,2-reduction of the enone 3.33 would introduce the allylic 
alcohol moiety required by the target spiro-mamakone A.  The racemic nature of the 
natural product precludes the necessity to use asymmetric conditions for introduction of 
this moiety.  Protection of this alcohol would be judicious before undertaking further 
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oxidative manipulations.  Several methods have been reported to achieve allylic oxidation 
of alkenes first to enones and then to enediones.  Successful double allylic oxidation of 
3.33 to an enedione and cleavage of the allylic alcohol protecting group would then yield 
the final target spiro-mamakone A.    
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Scheme 3.17 – Retrosynthetic analysis of spiro-mamakone A via ketone 3.27 
 
The retrosynthetic scheme shown in Scheme 3.17 does not represent the only way in 
which these final oxidative steps may be envisioned, and during the course of a synthetic 
route it may prove necessary or desirable to invert them.  To this end, a number of related 
tangents to this scheme were examined during the course of this synthetic study, which 
will each be discussed further.  The method shown in Scheme 3.17 does offer the 
possibility of introducing the allylic alcohol moiety before other ketones are present, 
however, which is a considerable advantage.   
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Having previously achieved the synthesis of DHN (vide supra), synthetic efforts towards 
spiro-mamakone A using this strategy therefore began with the preparation by literature 
methods of 3.27.  The procedure described by Kotha et al. was shown in Scheme 
3.15.40,41  Their synthesis of 3.26 is based on that described by Schwartz and Curran and 
calls for palladium-catalysed allylation of cyclopenta-1,3-dione using allyl acetate as the 
allyl source.43  Cyclopenta-1,3-dione was available in-house, however allyl acetate was 
not available.  A straightforward synthesis was therefore undertaken by following 
literature precedent and a moderate yield of 41% achieved.44  The allylation reaction was 
then successfully carried out, however very low yields were encountered.  This was found 
to be at least partly due to product volatility.   
 
An alternative procedure for allylation of cyclopenta-1,3-dione to give 3.26 also exists in 
the literature.45  This involved an alternative palladium(0) catalyst and allyl alcohol as the 
allyl source.  The direct use of allyl alcohol would circumvent the need to synthesise allyl 
acetate (although it is also commercially available) and this procedure was also attempted.  
Improved yields were obtained by this method and it was the method employed 
throughout these synthetic studies.  The volatility of 3.26 was found to diminish yields 
somewhat (around 85% isolated yield), however, this problem could be circumvented to 
give quantitative yields over this and the subsequent ring-closing step (vide infra).  1H 
and 13C NMR spectra of the product were in good agreement with literature values.   
 
Kotha et al. employed ring-closing metathesis of 3.26 using Grubbs’ first generation 
catalyst to yield ketone 3.27.  Due to the in-house availability of Grubbs’ second 
generation, its known higher activity and improved air stability prompted the use of this 
catalyst as a substitute for the first generation version.  The ring-closed product, 3.27, was 
successfully generated in near quantitative yield using 4 mole% of catalyst.  1H and 13C 
NMR data and the melting point of the product were all in good agreement with literature 
values.  The volatility and diminished yields obtained after chromatographic purification 
of 3.26 prompted the examination of carrying out the ring-closing metathesis on the crude 
3.26, obtained without chromatography.  Pleasingly, it was found that the metathesis step 
was unaffected by palladium and other impurities contained in crude 3.26.  When crude 
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3.26 was used, all impurities could be removed after metathesis to yield pure 3.27 in 
almost quantitative yields over the two steps.  This represents an improvement on the 
overall yield observed by Kotha et al. of 78%.   
 
Whilst the product was pure by 1H NMR spectroscopy, the colour of various batches of 
3.27 varied from dark to light grey.  This was likely due to trace amounts of ruthenium 
complexes remaining after purification from the Grubbs’ catalysed ring-closing 
metathesis.  It was found that 3.27 could be obtained as a pure white crystalline solid by 
recrystallisation (some batches required multiple recrystallisation steps) from diethyl 
ether.  Sublimation of 3.27 was often observed on leaving the product over several weeks 
at room temperature.  Large scale sublimation was therefore attempted in order to obtain 
high purity 3.27.  Whilst trace amounts of pure 3.27 could be obtained by sublimation at 
around 50ºC (either under reduced or atmospheric pressure), this was found not to be a 
good method for large scale purification.  If higher temperatures were employed (around 
80ºC) the process was somewhat faster, however 1H NMR data (Figure 3.3) showed that 
significant quantities of a thermal degradation product were also collected.   
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Figure 3.3 – 1H NMR spectrum of the crude product of the sublimation of 3.27 at 80ºC 
(peaks arising from starting material, 3.27, are labelled; all others correspond to 
degradation product 3.36) 
 
The separation of 3.27 from the degradation product could not be achieved using 
chromatography on silica.  The degradation product is less symmetric than ketone 3.27 as 
judged by examination of the 1H NMR spectrum and was tentatively assigned as the 
olefin rearrangement product 3.36 on the basis of 1D and 2D (COSY and HSQC) NMR 
data.  The olefinic protons (δH 6.12 and 5.38) display allylic coupling to the allylic 
methylene protons (δH 2.61), which then couple to protons (δH 2.18) on a further 
methylene carbon.  The protons (δH 2.95-2.76) adjacent to the ketones are also non-
symmetric.  In the absence of a pure sample of 3.36, the proposed structure could not be 
supported by mass spectral analysis, but compounds with similar features were obtained 
in later work (3.37, 3.53 and 3.83) which support this assignment.  The sensitivity of 
ketone 3.27 to sublimation conditions meant that recrystallisation remained the method of 
choice in obtaining pure crystalline 3.27.    
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O
O
3.36  
With an appropriate ketone, 3.27, now in hand, the key spiroketalisation step could be 
undertaken.  Ragot et al. discussed, in their synthesis of spirobisnaphthalenes, the 
surprising difficulty they encountered on forming a spiroketal with DHN.29  The authors 
carried out a survey of different acids for the reaction, under classic Dean-Stark refluxing 
conditions to remove water, and reported best yields when using triflic acid.  Dean-Stark 
conditions with trace quantities of triflic acid were unsuccessfully attempted to form 3.35 
from DHN and 3.27.  This reaction was hampered by the formation of large amounts of 
an intractable black tar and simultaneous consumption of DHN, which is assumed to be 
due to oxidative polymerisation of DHN to give melanin type polymers.  Even under very 
rigorously de-oxygenated conditions and with exclusion of light, this side-reaction 
persisted.  In these reactions, 3.27 which was pure by 1H NMR spectroscopy but still 
slightly grey in colour was used.  At a later point (vide infra) it became evident that a 
correlation between the “visual purity” of 3.27 and the degree of tar formation existed.  
Despite the presence of this black tar, 3.27 and some DHN could be recovered after 
several days of reflux under Dean-Stark conditions, with no desired spiroketal formed.  It 
was found that use of forcing refluxing conditions (125ºC) led to the formation of the 
correct product, 3.35 (discussed further below), however, it was contaminated with an 
impurity (Figure 3.4 - 1H NMR spectrum of the mixture).  The ratio of 3.35 to impurity 
was around 1:1 in a combined yield of around 20% (assuming the impurity is 3.37, see 
below).  Separation of the two products on silica or diol solid phases was unsuccessful.  
1H NMR data showed that the impurity was similar to the olefin rearrangement product, 
3.36, observed earlier during the sublimation of nonadione 3.27.  The olefin protons 
displayed a similar coupling pattern and COSY and HSQC data were also similar.  
Comparison of the integrals of the olefinic protons of both products to the naphthalene 
protons suggested that both products were spiro-ketals with DHN.  The impurity was 
therefore tentatively assigned as olefin rearrangement product 3.37.  Since the impurity 
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was not obtained in pure form, further data to confirm this assignment (eg mass spectral 
analysis) could not be obtained.      
OO
O
3.37  
Figure 3.4 – 1H NMR spectrum of the products of spiroketalisation under Dean-Stark 
conditions (125ºC) 
 
The use of activated molecular sieves as an alternative means of water removal was 
briefly examined, however no 3.35 was formed and only starting materials were 
recovered.  Alternative, milder methods to form spiroketal 3.35 were found, utilising an 
acetal exchange method as described below.   
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It was suspected that the difficulties in forming 3.35 were largely due to inefficient 
removal of water, which is required to push the reaction equilibrium towards 3.35.  An 
acetal exchange reaction was therefore considered, allowing the crucial removal of water 
to be carried out during formation of a ketal from lower-value intermediates.  If “simple 
acetals” of either 3.27 or DHN could be made (Scheme 3.18), it might then be possible to 
carry out an acetal exchange process to generate 3.35 cleanly.   
O
O
O OOH OH
O
OMeMeO
3.27 3.38
3.39  
Scheme 3.18 – Proposed “simple ketals” of 3.27 and DHN, for the purposes of acetal 
exchange 
 
In order to examine the plausibility of such an approach, a model system was initially 
examined and cyclopentanone was chosen as a simple model for ketone 3.27.  Formation 
of 3.40 (Scheme 3.19) was attempted using pTSA catalyst in methanol with anhydrous 
MgSO4 added as dehydrating agent but resulted in no reaction.  The use of an acetal 
exchange to form 3.40 was then examined, using the commercially available, inexpensive 
dimethoxy-ketal of acetone.  By refluxing cyclopentanone in 2,2-dimethoxypropane with 
pTSA as acid catalyst, the formation of 3.40 proceeded cleanly.  Purification of 3.40 was 
attempted on both deacidified silica and by distillation, however the product proved to be 
too unstable for purification by these methods.  Therefore, after washing to remove pTSA, 
and removal of most of the 2,2-dimethoxypropane in vacuo, the acetal exchange of crude 
3.40 was undertaken.  Using triflic acid as a catalyst, the acetal exchange of an excess of 
3.40 with DHN proceeded smoothly to give 3.41 (~ 28% yield).  Variable amounts of 
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acetonide 3.39 (see below) were also formed, due to the presence of 2,2-
dimethoxypropane as an impurity in 3.40, and the separation of 3.39 from 3.41 was not 
possible.   
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Scheme 3.19 – Cyclopentanone model system for acetal exchange 
 
This model system demonstrated both the plausibility of using acetal exchange to 
generate spiroketals of DHN, and the utility of acetal exchange with 2,2-
dimethoxypropane to avoid the need to efficiently remove water.   
 
This model system was extended to form 3.38, using refluxing 2,2-dimethoxypropane 
and pTSA as catalyst.  In the case of 3.27, two ketones are present and therefore the 
possibility of both ketones forming ketals giving 3.42, could not be ignored (Scheme 
3.20).  This result would be problematic because acetal exchange of 3.42 with DHN 
could potentially lead to two DHN spiroketals forming.  Pleasingly, however, 1H and 13C 
NMR data suggested that the correct product, 3.38, had been formed, and no evidence for 
the formation of 3.42 was observed.  As with cyclopentanone, after washing the crude 
product, 3.38, and the removal of almost all 2,2-dimethoxypropane in vacuo, the acetal 
exchange reaction was attempted without further purification.    
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Scheme 3.20 – Possible products of acetal exchange with 2,2-dimethoxypropane 
 
The acetal exchange reaction of 3.38 with DHN successfully gave 3.35 on heating (45ºC) 
in toluene with triflic acid catalyst (Scheme 3.21).  The product was fully characterised 
by 1H (Figure 3.5), 2D and 13C NMR spectroscopy and high resolution mass 
spectrometry.   
Figure 3.5 –  1H NMR spectrum of spiroketal 3.35 
 
Yields of up to 24% were obtained.  This yield is disappointing considering the high 
yields obtained by Ragot et al. (up to 74%).  The consumption of DHN was again 
observed, with black tar formation.  The amount of acid catalyst added proved to be 
important to the reaction outcome, with more than trace quantities required for successful 
reaction (usually around 0.2 to 0.4 equivalents employed).  This result may be due to 
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proton complexing by DHN reducing the effective quantities of acid catalyst in solution.  
The sudden darkening of the reaction mixture on addition of acid supports this theory, 
since the resultant charged DHN delocalised complex would be expected to interact 
strongly with light.    
OMeMeO
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Scheme 3.21 – Formation of 3.35 by acetal exchange 
 
Whilst this route provided the desired spiroketal 3.35, it involved using an excess of 3.38 
which was not generally recovered in good yield.  This is derived from a moderately 
advanced intermediate, 3.27, whose two-step synthesis involves use of the expensive 
Grubbs’ II catalyst and is therefore a “high-value” intermediate.  An alternative acetal 
exchange approach, involving formation of a ketal of DHN such as 3.39, was therefore 
investigated.  DHN can be made in one straightforward step from cheap starting materials 
making it a lower-value intermediate.  The formation of the acetonide of DHN, 3.39, was 
found to proceed in good yields of 74% using an acetal exchange reaction with 2,2-
dimethoxypropane with pTSA as catalyst.  Acetonide 3.39 could be obtained in very pure 
form by chromatographic purification, first using deacidified silica to remove polar 
impurities, and then elution through a short reverse phase (C18) pad to remove non-polar 
impurities.  The white crystalline solid produced is stable for several months at room 
temperature.  Increased stability, ease of purification and cheap starting materials make 
acetonide 3.39 more attractive as an acetal exchange partner than dimethoxy-ketal 3.38.   
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Scheme 3.22 – Alternative acetal exchange approach to 3.35 
 
Acetal exchange of acetonide 3.39 with 3.27 was successfully achieved on heating (45ºC) 
in chloroform using triflic acid as catalyst to give 3.35 (Scheme 3.22).  Disappointing 
yields of around 15% were obtained.  Toluene, benzene, DCM and THF were also 
examined for this reaction.  DCM successfully yielded the correct product, although 
chloroform allowed higher temperatures to be accessed.  From all other solvents only 
starting materials were recovered.  The use of pTSA instead of triflic acid as catalyst was 
also examined, but no reaction was observed and starting materials were recovered.   
 
Despite disappointing yields from this reaction, this route offered access to the crucial 
intermediate, spiroketal 3.35.  Since most of the precursor ketone 3.27 and variable 
quantities of the acetonide 3.39 could be recovered, this reaction was used to obtain 
sufficient 3.35 to continue synthetic efforts towards spiro-mamakone A.  As this reaction 
was repeated on a number of occasions, it became clear that the quantities of black tar 
produced during the reaction varied with the “visual” purity of ketone 3.27.  As 
mentioned earlier, whilst 3.27 was pure by 1H NMR spectroscopy, different batches 
ranged in colour from dark to light grey after chromatographic purification.  Upon 
rigorous recrystallisation of 3.27 to a white crystalline solid, acetal exchange reactions 
were found to occur with almost no black tar formation.  This suggests that traces of 
ruthenium may be responsible for catalysing the oxidative polymerisation of DHN to 
melanin tar.  No further experiments were carried out to confirm this, however.  It is 
interesting to note that no significant improvement of the yield of 3.35 was observed on 
elimination of melanin production, but acetonide 3.39 was recovered in improved yields.  
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This suggests that this side-reaction does not compete significantly with the acetal 
exchange process (an excess of acetonide was employed).     
 
The analytical methods employed during the synthetic efforts towards spiro-mamakone A 
described in this work, deserve brief discussion at this juncture.  The spiro-mamakone 
natural products all display a very distinctive UV chromophore, as a result of the 
dihydroxynaphthalene moiety, as do all of the spiro-mamakone synthetic analogues 
which are described in this thesis.  The UV spectra of spiro-mamakone A and synthetic 
analogue 3.35, shown in Figure 3.6, demonstrate the similarity of the UV chromophores 
of natural and synthetic spiro-mamakone analogues.   
 
Figure 3.6 – UV spectrum of spiro-mamakone A and spiro-mamakone synthetic 
analogue, 3.35 
 
Monitoring reactions was greatly aided by this distinctive UV chromophore.  Reactions 
could be monitored by classic TLC techniques, using UV (254 nm) and PMA 
(phosphomolybdic acid) for visualisation.  However, HPLC was very useful in 
monitoring the progress of synthetic reactions, since it allowed ready identification of any 
new spiro-mamakone analogues generated during the course of the reaction.    
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3.2.3 Synthetic investigations of nonadione 3.27   
 
With a method developed to generate a ketal of ketone 3.27 with DHN, two routes 
towards spiro-mamakone A were at this point considered.  The first involved taking the 
intermediate 3.35 through a series of steps to adjust the oxidation pattern of the northern 
hemisphere.  Key steps, as discussed earlier, would include dehydrogenation to give an 
enone, reduction to an allylic alcohol, and allylic oxidation of the olefin.  Investigation of 
this route is described further below (Section 3.2.4).  However, an alternative route 
(Scheme 3.23) which was also briefly examined involved synthesis of a more advanced 
nine-carbon bicyclic system, to which it was hoped the same ketal-formation 
methodology developed in the synthesis of 3.35 might be applied.  This approach has a 
number of advantages and drawbacks.  It allows the crucial spiroketal formation to be 
carried out later in the synthesis and therefore reduces the number of synthetic 
manipulations required after the low-yielding spiroketalisation.  This minimises the 
number of small-scale manipulations required.  Whilst this ketal has been shown to be 
remarkably stable under a variety of even acidic conditions in the spirobisnaphthalenes, it 
is, nonetheless, likely to be the most sensitive functional group in the target molecule, 
also making late introduction an attractive approach.    A possible drawback is the fact 
that 3.43 is a conjugated ketone, which are known to be more reluctant to form ketals 
than unconjugated ketones.  This may affect the yield or even prevent entirely the 
spiroketalisation step.   
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Scheme 3.23 – Alternative retrosynthetic analysis involving dehydrogenation prior to 
spiroketalisation 
 
The description in the literature of the dehydrogenation of a substrate very similar to 3.27 
(Scheme 3.24) prompted the investigation of this route.  Kreiser et al. described the 
dehydrogenation of 2,2-dimethylcyclopenta-1,3-dione in excellent yields (96%) using 
copper(II) bromide as oxidant.46   
 
O
O
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O
O  
Scheme 3.24 – Literature description of dehydrogenation of a cyclopenta-1,3-dione 
 
The oxidation of 3.27 was undertaken using identical conditions (Scheme 3.25).  
Pleasingly, the reaction took place in equally good yields (96%) under the same reaction 
conditions, giving enedione 3.44.  The product was characterised by 1H, 2D and 13C 
NMR spectroscopy as well as high resolution mass spectrometry.   
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Scheme 3.25 – Examining the reactivity of 3.27 
 
Reduction of 3.44 was carried out using sodium borohydride in methanol at -78ºC.  
Unproductive double-reduction could be avoided by use of an excess of enedione relative 
to reducing agent, and recovery of starting material.  Mixtures of 3.45 (1,2-hydride 
addition) and 3.46 (1,4-hydride addition followed by 1,2-hydride addition) were obtained 
in a ratio of around 1.4:1 respectively.  Selective reductions to improve this ratio (such as 
the Luche reduction) were not attempted, however.   
 
Protection of 3.45 (Scheme 3.26) was undertaken initially using the tbutyldimethylsilyl 
protecting group under the classic conditions introduced by Corey and Venkateswarlu.47  
The product was found to be volatile, however, and a yield of only 5% of 3.47 could be 
achieved.  The use of an acetyl protecting group, introduced under standard conditions 
(acetic anhydride, pyridine) was more successful, yielding 3.48 in 94%.  Compounds 3.45, 
3.47 and 3.48 were all fully characterised by NMR spectroscopy and high resolution mass 
spectrometry.   
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Scheme 3.26 – Protection of 3.45 
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The formation of a spiroketal of 3.48 via trans-ketalisation with acetonide 3.39 was 
attempted.   
 
The same conditions were employed as those successfully used in the formation of 3.35 
(chloroform as solvent and triflic acid catalyst at 45ºC). After one day, 1H NMR 
spectroscopy of the crude mixture showed that none of the protected allyl alcohol, 3.48, 
remained, but significant amounts of the acetonide of DHN were present, suggesting that 
3.48 was unstable to the conditions.  Trace amounts of a promising compound were 
present, however, and this product was isolated.  The product could only be obtained in 
good purity after two rounds of chromatography on deacidified silica, which may have 
been partly responsible for the low overall isolated yield of only around 2%.  
Characterisation of the product was carried out using 1H (Figure 3.7) and 2D NMR 
spectroscopy (insufficient material obtained for 13C NMR spectroscopy).      
Figure 3.7 – 1H NMR spectrum of 3.49 
 
Whilst the 1H NMR spectrum showed that aromatic protons as well as protons expected 
from the nine-carbon bicyclic unit were both present, it was evident that the anticipated 
spiroketalisation product, acetate protected 3.33 had not been formed.  Only five protons 
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were present in the aromatic region, with the missing naphthalene proton being one of 
those ortho- to a phenol (usually in the region δH 6.8 to 7.0).  This suggested that 
substitution at this position had occurred.  In addition, only two olefinic protons were 
present (δH 5.65 and 5.55).  A COSY NMR experiment showed that the acetate proton 
(δH 5.80) had a correlation to a proton at δH 3.79, which itself had correlations to two 
protons at δH 2.99 and 2.64.  Three methyl groups were present at δH 1.92, 1.68 and 1.67.  
These data all pointed to the generation product 3.49, an assignment which HSQC data 
supported.  The molecular formula of 3.49 could not be confirmed by mass spectral 
analysis, as the anticipated ion was not formed using ESIMS and the sample had 
decomposed before other ionisation techniques could be attempted.  The product is, 
therefore, only tentatively assigned as 3.49.   
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Scheme 3.27 – Unexpected product of spiroketalisation attempt with 3.39 and 3.48 
 
The formation of 3.49 (Scheme 3.27) can be explained by the tendency for enones to 
undergo 1,4-addition with a suitable nucleophile.  In this case, the electron-rich ortho-
position of the protected naphthalene diol has behaved as the nucleophile.  This 
represents a Friedel-Crafts alkylation reaction, and involves the activation of the enone by 
protonation by the strong Bronsted acid (triflic acid). 
 
This unanticipated secondary reactivity of enone 3.48 to act as a Michael acceptor in a 
Friedel-Crafts reaction efficiently competes with the desired trans-ketalisation.  Whilst 
optimisation of this step could have been undertaken, the known reluctance of enones to 
form ketals led to the abandonment of this alternative strategy to spiro-mamakone A.     
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3.2.4 Synthetic manipulation of spiro-mamakone intermediate 3.35 
 
With spiroketal 3.35 in hand, manipulation of the oxidation state of the northern 
hemisphere could be undertaken.  In accordance with the approach shown in Scheme 
3.17 (shown again below), the dehydrogenation of 3.35 was the first synthetic 
manipulation to be attempted.   
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Scheme 3.17 – Retrosynthetic analysis of spiro-mamakone A via ketone 3.27 
 
There are a wide range of methods known for dehydrogenating a ketone to generate an 
enone (Scheme 3.28).48   
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Scheme 3.28 – General methods for dehydrogenation of ketones  
 
The classical methods involve a two-step halogenation-dehydrohalogenation process, 
whereby a halide is first introduced α to a carbonyl via its enol or enolate.  A base is then 
employed to promote a dehydrohalogenation reaction to yield an enone.  This approach 
has largely been replaced by an equivalent procedure involving elimination of α-
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selenoxides of carbonyls.49  The use of toxic and expensive selenium reagents detracts 
from this approach, however.  Quinones bearing strong electon-withdrawing substituents 
such as DDQ can be used to carry out a dehydrogenation directly, in a single step.  This is 
thought to involve an ionic mechanism where hydride abstraction on the substrate enol by 
the quinone is followed by rapid loss of a proton.  The quinone is reduced to a 
dihydroquinone.  Catalytic palladium (II) salts in the presence of cooxidants can also be 
used to dehydrogenate ketones.  This involves the insertion of the Pd into an enol or silyl 
enol ether, yielding an α-palladium ketone, which eliminates as palladium hydride.  
 
These methods constitute the most common and traditional methods employed for the 
purpose of dehydrogenating ketones, however other oxidants such as MnO2 and NiO2 
have been also used successfully.  A more recent method devised by Nicolaou et al. 
involves the use of IBX, with or without additives such as N-methylmorpholine-N-oxide 
to dehydrogenate ketones or silyl enol ethers and this method will be discussed further 
below.50,51,52  
 
Whilst dehydrogenation via selenium derivative of ketones is a classic method, the use of 
toxic and unpleasant selenium compounds led to the investigation of some of the other 
methods mentioned above in the attempt to dehydrogenate 3.35.  DDQ was first 
examined as oxidant.  Ketone 3.35 was mixed with an excess of DDQ (~2 equivalents) 
under standard refluxing dioxane or benzene conditions.53  After 24 hours, 1H NMR 
spectra of the crude reaction mixtures showed that no reaction was taking place.   
 
Next, the very recent dehydrogenation method reported by Nicolaou and co-workers was 
examined, as this involves readily available IBX, which demonstrates low-toxicity.50  
IBX (o-iodoxybenzoic acid, 3.50) is a hypervalent iodine compound which, despite being 
known for over a century,54 has experienced a resurgence of interest very recently.  This 
is attributable to its complete lack of solubility in almost all solvents.  A more soluble 
derivative of IBX, the Dess-Martin periodinane (DMP), 3.51, became a hugely popular 
oxidant in natural product synthesis due to its ability to efficiently oxidise alcohols under 
mild conditions.55,56  
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Scheme 3.29 – Preparation of hypervalent iodine oxidants 
 
The discovery that IBX is soluble in DMSO by Frigerio and Santagostino allowed them 
to study its chemical reactivity.57  They found that, like DMP, IBX could act as a mild, 
efficient and selective oxidant of alcohols to generate aldehydes or ketones and it has 
since become a popular tool in total synthesis.56  The reactivity of IBX was extended by 
Nicolaou et al. when they discovered its ability to further oxidise the ketone generated 
from an alcohol to an enone or even a dienone at elevated temperatures.50  The proposed 
mechanism for this process is shown in Scheme 3.30.  After nucleophilic attack of the 
enol on the electrophilic hypervalent iodine, a single electron transfer occurs and 
rearrangement of the resultant radical cation generates IBA, 3.52, and the enone.       
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Scheme 3.30 – Proposed mechanism for IBX dehydrogenation of ketones 
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Further studies on this reaction demonstrated that the active oxidant was a complex of 
IBX with DMSO which formed at the higher temperatures (> 50ºC) employed during the 
reaction.51  A survey of other heteroatom oxides revealed other useful IBX.oxide 
complexes, in particular IBX.N-methylmorpholine-N-oxide, which were capable of 
carrying out the dehydrogenation at room temperature.  This methodology has since been 
applied to the synthesis of natural products, including spirobisnaphthalenes.58,33     
 
IBX was generated by oxidation of o-iodobenzoic acid using oxone,59 a method 
developed by Frigerio et al. which involves less toxic and more environmentally benign 
conditions than earlier methods.55  The dehydrogenation of 3.35 was attempted using IBX 
and N-methylmorpholine-N-oxide (NMO), initially at room temperature.  IBX and NMO 
were first dissolved in DMSO, then 3.35 was added.  Ketone 3.35 was not soluble at 
room temperature in DMSO, so it was added in minimal amounts of DCM (as 
recommended by Nicolaou et al.).  After 24 hours, 1H NMR spectroscopy of the crude 
reaction showed that no reaction was occurring.  If the reaction was heated to around 
50ºC the desired enone 3.34 (see below) was formed in low yields.  The product was 
contaminated with an impurity which could only be partially separated using 
chromatography on reverse phase on HPLC.  The impurity was assigned as 3.53 by 
examination of 1H (Figure 3.8) and 2D NMR data, high resolution mass spectrometry 
and by comparison with earlier thermal degradation products, 3.36 and 3.37 (vide supra).  
1H NMR data showed that the product was related to the product 3.34, however 
desymmetrisation of the northern right-hand ring was evident, suggesting that olefin 
migration had occurred, as seen before.  The coupling pattern of the olefinic protons (δH 
6.01 and 5.63) was very similar to that observed in 3.36 and 3.37, with correlations to the 
allylic protons at δH 2.58-2.48 and 2.24-2.13.  Overlapping with the allylic methylene 
protons were the non-allylic methylene protons, as evidenced by two distinct methylene 
carbon signals arising at these 1H chemical shifts in an HSQC NMR experiment.  The 
naphthalene moiety also showed a subtle lack of symmetry with the protons from each 
aromatic ring appearing at distinct chemical shifts.  Mass spectrometry (HRESIMS) 
indicated that the pseudomolecular ion [M+H]+ had a mass of 291.1022 Dalton, 
corresponding to a molecular formula of C19H14O3, however trace quantities of 3.34 
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present in the sample of 3.53 mean that this result is not completely reliable.  The 
impurity, 3.53, was present in an approximately 1:1.4 ratio with the product, 3.34 in the 
crude material.    
OO
3.53
O
 
Figure 3.8 – 1H NMR spectrum of impurity 3.53, formed during dehydrogenation at 
50ºC using IBX 
 
If the reaction was carried out at higher temperature (70ºC), ketone 3.35 was found to be 
soluble in DMSO and was therefore added in the solid state.  The reaction was monitored 
by 1H NMR spectroscopy, and after around 24 hours, a white precipitate was seen to form 
(IBA, 3.52).  No further reaction was observed with longer reaction time and the reaction 
was quenched.  At this elevated temperature, no impurity was formed and 1H NMR 
spectroscopy suggested a conversion of around 60 - 70% was achieved.  The isolated 
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yield of 3.34 was usually somewhat lower than this, at around 40%.  This may be due to 
decomposition during chromatographic purification on deacidified silica.  The use of diol 
solid phase did not improve the isolated yield and no further solid phases were 
investigated.  The product 3.34 was fully characterised by 1H (Figure 3.9), 2D and 13C 
NMR spectroscopy and high resolution mass spectrometry.   
 
Figure 3.9 – 1H NMR spectrum of enone 3.34 
 
The reduction of the enone to generate allylic alcohol 3.54 was the next step in the 
synthetic strategy to spiro-mamakone A.  Initially, simple sodium borohydride and 
lithium aluminium hydride reductions were attempted, however without success, due to 
preferential 1,4-addition of hydride to the enone.  One equivalent of sodium borohydride 
gave exclusively 3.55 and 3.35 in a ratio of around 3:2.  The alcohol 3.55 is generated by 
carbonyl reduction of the initially formed 3.35.  Alcohol 3.55 could also be generated by 
NaBH4 reduction of 3.35.   
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The use of 0.3 equivalents of lithium aluminium hydride also resulted in mixtures, but 
this time, of the desired compound 3.54, and 3.55.  A ratio of around 1:1 was formed, and 
these two alcohols proved to be inseparable on deacidified silica.   
 
Examination of the literature revealed that cyclopentenones are known to be particularly 
prone to undergo 1,4-hydride addition in preference to 1,2-hydride addition.60  More 
selective reduction conditions were therefore required to obtain pure 3.54 in good yields.  
A number of reducing conditions have been reported to be capable of selectively reducing 
enones to their allylic alcohol,61 for example 9-BBN, 62 aluminium hydride63 and 
DIBAL.64  However, one of the most popular and commonly used is the Luche 
reduction.65  This involves premixing sodium borohydride with non-toxic, lanthanide salt 
cerium (III) chloride in methanol.  The reaction can tolerate significant proportions of 
water, such that the inexpensive, commercially-available cerium (III) chloride 
heptahydrate can be employed.  This reaction has found extensive utility in natural 
products synthesis due to its high selectivity and the mild conditions employed.66,67,68  
The mechanism for this reaction is thought to involve the generation of various sodium 
methoxyborohydrides.69  These are formed after activation of the solvent methanol by the 
Lewis acid cerium (III) chloride (Scheme 3.31).  Since methoxyborohydrides are 
“harder” reducing agents, they selectively attack the “harder” electrophilic position, 
which is the carbonyl of the enone.   
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Scheme 3.31 – Mechanism of the Luche enone reduction 
 
The Luche reduction was therefore applied to the reduction of 3.34 and successfully gave 
3.54 in quantitative yield and without contamination with the 1,4-hydride addition 
products 3.35 or 3.55.  The product was fully characterised by 1H (Figure 3.10), 2D and 
13C NMR spectroscopy and high resolution mass spectrometry.      
 
Figure 3.10 – 1H NMR spectrum of allyl alcohol 3.54 
 
The protection of the allylic alcohol of 3.54 was undertaken before attempting to carry 
out allylic oxidation to introduce the enedione required by the target spiro-mamakone A.  
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An appropriate protecting group must be removed under conditions to which the final 
target molecule is expected to be stable.  Whilst the spiroketal moiety is known to be 
relatively stable to acid conditions, the use of a protecting group which could be removed 
under basic conditions was considered judicious.  Both an ester such as the classic acetyl 
protecting group or a silyl protecting group (which can be cleaved by fluoride sources 
such as TBAF) would fulfil these criteria.  Minimisation of the steric environment around 
the double bond to be oxidised would maximise the chance of successfully carrying out 
this crucial, final key step.  Therefore the acetyl group was chosen for the protection of 
the allyl alcohol of 3.54.   
 
The esterification of 3.54 was carried out under classic conditions, using acetic anhydride 
in pyridine.  This reaction proceeded cleanly to give 3.56 in quantitative yield.  The 
product was fully characterised by 1H (Figure 3.11), 2D and 13C NMR spectroscopy and 
high resolution mass spectrometry.   
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Figure 3.11 –  1H NMR spectrum of 3.56 
 
With protected 3.56 in hand, the final key functional group conversion required was the 
double allylic oxidation of the cyclopentene ring to generate the required enedione of 
spiro-mamakone A.  There are a large number of different procedures reported for allylic 
oxidation, and a brief review of some of these is given here.   
 
Allylic oxidations fall into two broad categories; those which generate allylic alcohols 
and those which give α,β-unsaturated carbonyls directly.  In practice, however, many 
methods straddle both of these categories, giving mixtures of oxidation products or 
different products under different conditions.  Some may also involve double bond 
migration, or oxidation of the double bond itself.  However, whilst a lack of 
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regiochemical control can plague allylic oxidations, several very reliable procedures are 
known and the reaction remains of considerable value to organic synthesis.70     
 
The classic and still popular reagent for allylic oxidation is selenium dioxide, despite 
issues of toxicity.71  It can be used in stoichiometric quantities, or catalytically in the 
presence of co-oxidants.  The most common co-oxidant is tbutyl hydroperoxide, although 
other oxidants such as sodium periodate and N-methylmorpholine-N-oxide have been 
used.  This reagent is known to be able to give both allylic alcohols and α,β-unsaturated 
carbonyls, with a dependence on solvent noted.  The generally accepted mechanisms for 
the reaction are shown in Scheme 3.32 (allylic oxidation to allylic alcohol is shown in 
scheme a, and further oxidation to α,β-unsaturated carbonyl in scheme b).72,73   
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Scheme 3.32 – Mechanisms of SeO2 allylic oxidation  
 
A once popular allylic oxidation protocol which gives allylic esters is the Kharasch-
Sosnovsky reaction.74  This involves copper-catalysed, radical coupling of an alkene and 
a carboxyl group, introduced as a peroxyester.  Alkene migration can be observed during 
this reaction. Allylic oxidation using singlet oxygen is also known, and involves 
migration of the double bond.75     
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The reaction of certain metal acetates, in particular mercury (II) acetate can generate 
allylic acetates.76  Mixtures of products including double bond migration are often 
observed.77  The use of manganese (III) acetate has very recently been shown to catalyse 
allylic oxidation to give enones and even enediones in the presence of tbutyl 
hydroperoxide.78  This reaction is believed to proceed by a different mechanism to that of 
mercury (II) acetate, however.      
 
Chromium based oxidants have been the most popular for allylic oxidation to α,β-
unsaturated carbonyls.  Early work involved common oxidants such as chromic acid, 
sodium dichromate and pyridinium dichromate.  However, the development by Salmond 
and co-workers of a chromium reagent specifically designed for allylic oxidations made 
the reaction far more reliable.79  The authors found that a complex of chromium trioxide 
with 3,5-dimethylpyrazole (DMP) offered a massive rate increase for allylic oxidation of 
steroids in comparison with other chromium based oxidants.  They attributed this increase 
to the ability of the DMP ligand to hasten the removal of the allylic proton and aid attack 
of the chromium on the alkene (Scheme 3.33).  This system has found widespread use in 
the synthetic literature.80,81    
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Scheme 3.33 – Mechanism for allylic oxidation using CrO3-DMP oxidant system 
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Palladium-catalysed processes are known to achieve allylic oxidation, however they are 
often accompanied by varying degrees of isomerisation of the double bond.82,83  A 
selective method to oxidise enones to enediones was reported by Yu and Corey, however, 
using Pearlman’s catalyst (Pd(OH)2/C),84 base and tbutyl hydroperoxide.85  This is 
believed to proceed via a palladium-catalysed radical process involving a tbutyl 
hydroperoxide radical and base-catalysed decomposition of the resulting peroxy ether to 
generate the carbonyl (Scheme 3.34).   
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Scheme 3.34 – Proposed mechanism for palladium-catalysed enedione synthesis 
 
Oxo-vanadium complexes (VO(OR)Cl2, where R is OEt or OiPr) have been used to carry 
out allylic oxidations of cyclic enones, to generate enediones.86  This method has not 
been adopted by the wider synthetic community, however, possibly due to the 
requirement of stoichiometric amounts of the vanadium complex.   
 
 
 
 
176   Chapter 3: The spiro-Mamakones 
More recently, Catino et al. demonstrated that dirhodium(II) caprolactamate can catalyse 
allylic oxidation, giving enones and enediones using tbutyl hydroperoxide as 
stoichiometric oxidant.87  High catalytic turnover numbers and frequencies, plus mild 
reaction conditions make this a promising oxidation system.      
 
In the synthesis of spiro-mamakone A, the final, key step required is the allylic oxidation 
of the alkene of 3.33 (or 3.56) to an enedione moiety (Scheme 3.17).  Strongly acidic 
allylic oxidation conditions are precluded by the presence of a spiroketal in 3.33, 
although the observed acid stability of the spiroketals of spirobisnaphthalenes suggests 
that mildly acidic conditions may be tolerated.   
 
Initially, several of the reagent systems described above were screened against the earlier 
intermediates 3.34 and 3.35, which were more readily available than the advanced 
intermediate 3.56.  The oxidants were partially chosen on the basis of ease of availability 
or preparation (DMP and Pearlman’s catalyst were prepared following literature 
precedures).88,84  Chromium trioxide and DMP, Pearlman’s catalyst and tbutyl 
hydroperoxide and Catino’s dirhodium(II) tetrakis(caprolactam), tbutyl hydroperoxide 
system were screened against 3.35.  While all three systems gave the same product, they 
did not all proceed as cleanly.  Both the chromium based system and the Pearlman’s 
catalysed oxidation required around 5 days to proceed to a satisfactory conversion 
(around 60% in both cases, as judged by HPLC analysis).  Catino’s rhodium based 
system proved to be the superior method, giving 100% conversion (as judged by HPLC 
analysis) to the product in around 16 hours.  The isolated yields of the product were 
around 40% using the rhodium system, and around 60% using Pearlman’s catalyst.  The 
product from the chromium system was not isolated.  The product obtained was fully 
characterised by 1H (Figure 3.12), 2D and 13C NMR spectroscopy and high resolution 
mass spectrometry.  The structure of the product was assigned as the mono-oxidised 
product 3.57.  It was evident from NMR spectroscopy that an enone had been generated 
rather than the desired enedione.  The position of the enone in the product was assumed 
to be that shown in 3.57 on the basis that all three oxidation methods are known largely to 
proceed without migration of the double bond.  Whilst no COSY correlation was 
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observed between the methylene protons at δH 2.94 and 2.50 and the down-field enone 
proton at δH 7.55, only very weak correlations were observed between the methylene and 
the alkene protons in the precursors 3.34 and 3.35.  All other 2D NMR data supported the 
structure 3.57.    
OO
O O
3.57  
Figure 3.12 – 1H NMR spectrum of the mono-allylic oxidation product of 3.35 
 
A catalytic chromium system (pyridinium dichromate catalyst and tbutyl hydroperoxide 
oxidant),89 and a bismuth catalysed system (bismuth(III) nitrate pentahydrate catalyst and 
tbutyl hydroperoxide oxidant) were also screened using 3.34 as the precursor.90  Catino’s 
rhodium catalyst system was also applied to the oxidation of 3.34.  Again, all three 
systems yielded the same product.  The bismuth system proceeded only slowly, reaching 
around 70% conversion (as judged by HPLC analysis) after 2 days.  The chromium 
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system was more rapid, proceeding to 60% in 1 day and completion after 2 days (as 
judged by HPLC analysis).  The rhodium system again proved to be the best, however, 
proceeding to around 95% in 1 day.  An isolated yield of 32% was obtained from the 
rhodium system, but no attempts were made to isolate the product from the other two 
systems (very small scales employed).  The product was fully characterised by 1H 
(Figure 3.13), 2D and 13C NMR spectroscopy and high resolution mass spectrometry and 
the mono-allylic oxidation product 3.58 was assigned.  Again, no COSY correlation was 
observed between the methylene protons at δH 3.09 and 2.62 and the down-field enone 
proton at δH 7.56, but all other 2D data indicated structure 3.58 had been formed.   
OO
O O
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Figure 3.13 – 1H NMR spectrum of the mono-allylic oxidation product of 3.34 
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It was evident from these studies that the mono-oxidation of these types of alkenes was 
relatively facile, with all oxidative systems attempted capable of achieving the oxidation 
to a greater or lesser degree.  The rhodium oxidation system appeared to offer the most 
complete conversion and shortest reaction times.  However, the further oxidation of the 
enone formed, to generate an enedione required by the final natural product, was 
unsuccessful.  All reactions were monitored for several days after mono-oxidation, with 
further oxidant (tbutyl hydroperoxide, or chromium trioxide/DMP) added but no further 
oxidation was observed.    
 
Despite this, the rhodium oxidation system was applied to 3.54 and 3.56 in order to 
examine the oxidation of these more advanced intermediates.  Whilst it may be 
anticipated that the oxidative conditions employed may be capable of reoxidising the 
allylic alcohol of 3.54, its oxidation was still examined.  If the allylic alcohol remained 
unoxidised, the synthetic scheme would be abbreviated by removing the need for 
protection and deprotection steps, making this route worth examining.  However, on 
oxidation of 3.54 under Catino’s conditions complete conversion to the oxidation 
products 3.34 and 3.58 was obtained (ratio of 2:1, 3.58: 3.34) with a 12% isolated yield of 
3.58.  This corresponds to complete reoxidation of the allylic alcohol to an enone as well 
as partial mono-allylic oxidation to generate a second enone.  This experiment 
demonstrates the need for protection of the allylic alcohol before oxidation can be 
undertaken.   
 
The oxidation of protected allylic alcohol 3.56 was therefore examined next.  The 
rhodium oxidation system was again employed and two products were obtained.  These 
were two mono-allylic oxidation products, with different stereochemistry.  This 
asymmetry arises from oxidation of the alkene on the same side, product assigned as 3.60, 
or opposite side, assigned as 3.59, relative to the protected alcohol.  The allylic alcohol, 
3.56, is generated in an asymmetric reduction, such that it is a racemic mixture of two 
enantiomers.  The two diastereomeric enone products generated on mono-allylic 
oxidation are therefore each a pair of enantiomers.  The ratio of the two diastereoisomers 
was around 4:3 of 3.59 to 3.60.  The oxidation therefore demonstrates a small preference 
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to add oxygen on the opposite side to the protected allylic alcohol; a preference readily 
explained by long-range steric hindrance.  An isolated yield of 25% of 3.59 and 9% of 
3.60 was obtained, as well as a further 25% of a mixture of the two products.  Both 
products were fully characterised by 1H (Figures 3.14 and 3.15) and 2D NMR 
spectroscopy and high resolution mass spectrometry.  Again, no COSY correlation was 
observed in either product between the methylene protons and the enone, but all other 
data were consistent with the structures 3.59 and 3.60.   
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Figures 3.14 - 1H NMR spectrum of major mono-allylic oxidation product, 3.59 
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Figures 3.15 - 1H NMR spectrum of minor mono-allylic oxidation product, 3.60 
 
Products 3.59 and 3.60 are clearly very closely related to the final natural product, spiro-
mamakone A, and the final key step which remained was the allylic oxidation of an 
enone to an enedione.  Unfortunately, all those reagents which were readily available had 
been examined and proved incapable of carrying out this conversion.  An alternative 
scheme was examined to try to circumvent this problem (Scheme 3.35).  As a result of 
this work, a clue came to light which pointed to an error in the assignment of the 
structures of all of the products of mono-allylic oxidation, and thereby an explanation for 
the difficulty encountered when attempting to form an enedione, as discussed below 
(Section 3.2.5). 
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3.2.5 Investigation of synthetic strategies involving early allylic oxidation  
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Scheme 3.35 – Alternative route to spiro-mamakone A involving late-stage Grubbs’ 
catalysed ring-closing metathesis of two enones. 
 
The difficulties encountered in further oxidising the enone generated by mono-allylic 
oxidation to an enedione was assumed to be due to electronic differences between an 
alkene and an enone as an allylic oxidation precursor.  Re-examination of the literature 
showed that the oxidative systems employed had varying degrees of precedence in the 
allylic oxidation of cyclic enones.  Catino et al. had shown that their rhodium catalysed 
system could efficiently oxidise cyclic enones to enediones in a number of examples, and 
Yu and Corey had demonstrated the allylic oxidation of enones exclusively (they did not 
report oxidation of alkenes).  Both the bismuth oxidant system and the pyridinium 
dichromate system had no precedence for the oxidation of enones, but the chromium 
trioxide/DMP had been successfully used to oxidise an enone to an enedione.81  Despite 
literature precedence for enone to enedione conversions with a number of the oxidant 
systems employed, an alternative strategy was developed which would allow the 
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formation of two acyclic enones which could be cyclised to an enedione by late-stage 
Grubbs’ catalysed ring-closing metathesis.  This strategy would take advantage of the 
precursor, 3.26, of nonadione 3.27, which contains two allyl groups.  The Grubb’s 
catalysed metathesis of enones has been demonstrated by Choi et al.91  The key steps in 
such an approach to spiro-mamakone A would be spiroketal formation, double allylic 
oxidation and ring-closing metathesis, as well as introduction of the allyl alcohol in the 
central ring.  A number of different routes can be envisioned whereby the order these 
steps are carried out in differ, with two of the most promising shown in Scheme 3.35.  In 
the first route, a ketal, 3.61, is formed from 3.26, which is then manipulated to generate a 
protected allylic alcohol followed by allylic oxidation.  Alternatively the allylic oxidation 
of 3.26 is first undertaken and the enones cyclised to generate the tetraketone 3.62, which 
could then form a ketal, followed by manipulation of the central ring to generate the allyl 
alcohol.  Selective reduction of the ketone on the central ring in the presence of the 
enedione may prove troublesome, making this the less attractive route.   
The first of these two routes was therefore examined.  The trans-acetalisation of the 3.39 
and 3.26 was attempted under the same conditions to those employed for the generation 
of 3.35 (CHCl3, 40ºC, 2 days).  The precursor, 3.26, appeared to be relatively unstable to 
the conditions and had degraded (as judged by 1H NMR spectroscopy) after 1 day.  As 
well as starting material DHN acetonide, small amounts of a product clearly related to 
3.61 was observed, in the 1H NMR spectrum of the crude sample, but no olefinic proton 
signals were observed.  The product was isolated and fully characterised by 1H (Figure 
3.16), 2D and 13C NMR spectroscopy, and high resolution mass spectrometry.   
High resolution mass spectrometry showed the mass of the pseudomolecular ion 
([M+H]+) to be 321.1489 Dalton, indicating a molecular formula of C21H20O3, which 
corresponds to the molecular weight of the desired compound 3.61.  However, the 
absence of any olefinic proton signals in the 1H NMR spectrum indicated that 3.61 had 
not been formed, and therefore that the product was an isomer of 3.61.  The 1H NMR 
spectrum most closely resembled that of 3.35, but with an additional singlet 
corresponding to 6 protons at δH 1.66, and the slightly up-field shifted methylene protons 
(δH 2.97 and 2.48) were more broad than in the case of 3.35.  This information allowed 
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the structure to be tentatively assigned as 3.63, which was confirmed by examination of 
2D and 13C NMR data.   
OO
O
3.63
Figure 3.16 – 1H NMR spectrum of 3.63 
 
This product is clearly derived from the cycloisomerisation of the 1,6-diene, although 
whether this reaction occurs before or after ketal formation is unknown. 
Cycloisomerisation of dienes is known to occur under the catalysis of a number of 
different transition metals.92  In particular the rearrangement of 1,6-dienes have been 
shown to undergo cycloisomerisation to give five-membered rings, generally yielding 
structures of type 3.64 and 3.65, although occasionally structures of type 3.66 have been 
encountered (Scheme 3.36).93,94,95  Many transition metals have been shown to promote 
this type of isomerisation, including palladium.      
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Scheme 3.36 – Cycloisomerisation of 1,6-dienes to yield five-membered rings 
 
This type of reaction has not been observed in the absence of transition metal catalysts.  
The presence of trace quantities of a transition metal is therefore likely in the trans-
acetalisation of 3.26 and acetonide 3.39.  The most likely source is the starting material 
3.26, which is produced via a palladium catalysed dehydration (see Section 3.2.2).  The 
diene 3.26 had been purified by chromatography prior to its use in this reaction, however 
it is possible that trace quantities of palladium impurities remained which were not 
evident by 1H NMR spectroscopy.  As 3.26 is an oil, recrystallisation is not available as 
an alternative method of purification, and distillation was not considered due to the likely 
instability of the compound to high temperatures, in particular given it is known to 
contain traces of palladium metal which may catalyse cycloisomerisation or other 
degradation pathways.  Therefore only repetitive chromatographic methods were an 
option to further purify 3.26.  Due to the difficulty of monitoring any improvement in 
purity of 3.26 by 1H NMR spectroscopy, it was decided instead to abandon this route and 
examine the second route shown in Scheme 3.35.    
 
The possibility of carrying out a double allylic oxidation on 3.26 was next examined.  
The rhodium-based allylic oxidation system was chosen since it had proven the most 
efficient catalyst in previous studies.  After 2 days no reaction was observed and starting 
material was recovered.  This disappointing result led to the examination of the allylic 
oxidation of a simple analogue of 3.26, protected diol 3.68, to see if it could be oxidised.   
   
The reduction of both ketones in 3.26 was readily achieved using sodium borohydride in 
methanol (Scheme 3.37).  This gave a mixture of cis- and trans- diastereoisomers in a 
ratio of 1.7:1 (isolated yields of 31% cis- and 52% trans- were obtained).  Due to the 
more simple NMR properties of the trans- diastereoisomer, it was decided to proceed 
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only with this stereoisomer to simplify analysis of later steps.  The trans-diol 3.67 was 
next protected with acetyl groups using classic conditions (acetic anhydride in pyridine) 
to give 3.68.  The allylic oxidation of 3.68 was carried out using the rhodium-based 
oxidant system.  After 3 days, significant quantities of starting material remained (as 
judged by 1H NMR spectroscopy), however some products had also been formed, so the 
reaction was stopped and the products isolated.    
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Scheme 3.37 – Preparation and allylic oxidation of trans-3.68 
 
Two products were isolated, however both were obtained in very small quantities and 
only one could be obtained in sufficient quantities (~0.3 mg, ~ 1%) to be fully 
characterised by 1H (Figure 3.17) and 2D NMR spectroscopy.  Analysis of 1H NMR data 
was hampered by residual trace impurities, however a number of key features could be 
assigned.  An “enone” was clearly present as evidenced by two doublet protons at δH 7.01 
and 5.78.  However these integrated in a ratio of 1:1 instead of 2:1 as would be 
anticipated in 3.69, suggesting an internal olefinic system.  Whilst HMBC correlations 
observed were minimal due to the small quantity obtained, two carbonyl correlations 
could be clearly observed.  One of these was the anticipated ester correlation of the two 
acetyl groups at δC 171.  The other was a correlation from the down-field “enone” proton 
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to a carbonyl at δC 165.  This suggested that instead of an enone, an α,β-unsaturated 
carboxylic acid had been formed.  The product was therefore tentatively assigned as 3.70.  
Strangely, this product did not ionise readily by electrospray ionisation techniques and 
the molecular weight of the product could therefore not be confirmed.  The second 
product obtained was not present in sufficient quantity or purity to be characterised by 2D 
NMR techniques.  However, high resolution mass spectrometry showed the mass of the 
pseudomolecular ion ([M-H]-) to be 295.1178 Dalton, indicating a molecular formula of 
C15H20O6.  This suggests that the product may be tentatively assigned as 3.71.  No 
attempt was made to repeat this reaction to obtain more material for further 
characterisation.   
 
Figure 3.17 – 1H NMR spectrum of 3.70 
 
The formation of 3.70 (and 3.71) under the conditions of the allylic oxidation can be 
explained by examination of the mechanism for this oxidant system, proposed by Catino 
et al. (Scheme 3.38).87  The authors propose that the oxidation occurs via an allylic 
radical of type 3.74, generated from a tbutyl hydroperoxide radical; itself generated via a 
redox process with the rhodium catalyst.  The allyl radical then reacts with a dirhodium 
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tbutyl peroxyether complex to generate the mixed peroxide, 3.73, which decomposes in 
the presence of base to give the final enone (or enedione).  The intermediacy of an allylic 
radical opens up the possibility of alkene migration in the final product, since the radical 
is necessarily located over two carbons.  Of the eleven examples given by Catino and co-
workers, only one was given in which the final product formed via migration of the olefin, 
however this was probably due to the choice of substrates employed in the published 
work.   
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Scheme 3.38 – Proposed mechanism for the allylic oxidation system of Catino et al. 
 
In the oxidation of trans-3.68, it is probable that once an allyl radical is formed the 
dirhodium tbutyl peroxyether complex is only able to interact with the carbon furthest 
away from the spiro- centre, due to steric hindrance.  This would lead to the generation of 
a terminal, mixed peroxide which would decompose to an aldehyde.  Under the oxidative 
conditions, the aldehyde is presumably then further oxidised to generate an α,β-
unsaturated carboxylic acid (as in 3.71).  If this process were repeated with the second 
allyl group, a second α,β-unsaturated carboxylic acid would be generated to give the 
product 3.70.  This is the proposed mechanism for the formation of 3.70 and 3.71 in the 
allylic oxidation of trans-3.68.   
 
This experiment showed that this route was not an immediately amenable pathway to 
spiro-mamakone A and was abandoned.  The products 3.70 and 3.71, and the proposed 
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mechanism for their formation showed that the rhodium-based oxidant system was 
readily capable of causing double-bond migration during oxidation of these spiro- 
compounds.  This led to a reassessment of previous oxidations discussed in Section 3.2.4.   
 
 
3.2.6 Reassessment of allylic oxidation reaction 
Investigations of the allylic oxidation of acyclic allyl groups drew attention to the 
possibility of generating oxidised olefins with migration.  This led to a reassessment of 
the structures assigned in Section 3.2.4 (3.57 to 3.60).   
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In assigning these structures, the possibility of alkene migration was overlooked due to 
the minimal number of examples in literature studies of the oxidant systems employed.  
However the allylic oxidation of acyclic olefin 3.68 had shown that in these spiro- 
systems oxygen may be introduced at the less sterically encumbered carbon of the 
intermediate allyl radical.  Two sites, C6 and C8, exist for reaction of this radical with a 
dirhodium tbutyl peroxyether complex  (Scheme 3.39), yielding, after base-catalysed 
decomposition of the mixed peroxides, the enones of type 3.75 and 3.76 respectively.  Of 
these two sites, C6 is much more sterically hindered, due to the spiro- centre α to it and 
therefore C8 is the more likely site of reaction.   
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Scheme 3.39 – Two possible oxidation pathways 
 
Reaction at C8 of the allyl radicals of 3.34, 3.35 and 3.56 would lead to the products 3.77, 
3.78, 3.79 and 3.80. 
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The tentative reassignment of these products allowed a number of both chemical and 
spectroscopic features to be explained.  The difficulty in carrying out further allylic 
oxidation steps can be readily explained by the lack of an allylic hydrogen in these 
structures, which makes it impossible to generate an allyl radical for further oxidation of 
the enone to an enedione.  In addition, the lack of even a weak COSY correlation 
between the down-field enone protons and the methylene groups provided further 
evidence.  However, NMR spectroscopy did not provide proof of these reassignments, 
since no 2D correlations were observed which could distinguish between the two possible 
sets of products.  Further evidence was therefore sought.   
 
Luche reduction of the enone generated would provide a means to differentiate enones of 
type 3.75 and type 3.76.  In type 3.75, the allylic alcohol proton would only couple to an 
olefinic proton, whereas in type 3.76, it would couple to both an olefinic proton and two 
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methylene protons.  For this experiment, 3.79 was chosen as the precursor enone.  This 
was as the other enones contained a second ketone, which would be expected to be 
reduced simultaneously and would lead to mixtures of products.  Enone 3.79 contained 
no other reducible groups and had been obtained in diastereomerically pure form, which 
would simplify analysis of the reduction product.   
 
The Luche reduction of 3.79 led to one main product, where the reduction of the enone is 
presumed to have occurred from the face opposite the naphthalene moiety (NOESY 
correlations to confirm this assumption were not observed).  Whilst small amounts of 
another stereoisomer were observed by 1H NMR spectroscopy of the crude material, this 
product was not isolated in sufficient purity for full characterisation.  The main product 
was fully characterised by 1H (Figure 3.18) and 2D NMR spectroscopy as well as high 
resolution mass spectrometry.  Mass spectrometry showed the mass of the 
pseudomolecular ion to be 333.1120 Dalton ([M-OH]+), which corresponds to the 
molecular formula C21H18O5.  The observation of the dehydrated ion is explained by the 
ease of dehydration of allylic alcohols to generate dienes.  Examination of COSY 2D 
NMR data showed that the allylic alcohol (δH 4.81) had a correlation to both an olefinic 
proton (δH 6.08) and two methylenic protons (δH 2.50 and 2.25).  This clearly proved that 
the enone from which the allylic alcohol was derived was of type 3.76.  All other 2D 
NMR data supported the structure of the reduction to be 3.81 (mixture of enantiomers).   
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Figure 3.18 – 1H NMR spectrum of 3.81 
 
This result confirmed that the products of the allylic oxidation of 3.34, 3.35 and 3.56 are 
of type 3.76 (3.77, 3.78, 3.79 and 3.80), where oxidation occurs with concomitant 
migration of the olefin.  It is clear that these enones cannot be converted to the desired 
enedione in the natural product by allylic oxidation.   
 
 
3.2.7 Cyclopentadiene as an enedione precursor  
 
With the allylic oxidation of olefinic spiro-mamakone precursors proving troublesome, 
alternative strategies for introduction of enedione functional groups were sought. 
An alternative method for introduction of an enedione, via singlet oxygen addition to a 
cyclopentadiene analogue of spiro-mamakone A, was examined.   
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Singlet oxygen is the lowest-energy excited state of molecular oxygen and is commonly 
generated in a photosensitised reaction via energy transfer from a dye such as Rose 
Bengal.  Its chemistry has been studied for around 50 years and synthetic chemistry has 
taken advantage of its 3 principal reaction types (Scheme 3.40).96,97  
 
1O2 OOH ene reaction
O O1O2
1O2 O
O
[4+2] cycloaddition
[2+2] cycloaddition
 
Scheme 3.40 – The chemistry of singlet oxygen97  
  
The main two reactions that singlet oxygen undergoes are the ene reaction and the [4+2] 
cycloaddition reactions.  The ene reaction involves addition to alkenes to generate allylic 
hydroperoxides with migration of the alkene, which can then be decomposed to 
synthetically useful allylic alcohols.  The [4+2] cycloaddition reaction of singlet oxygen 
to diene systems generates an endoperoxide which can then be decomposed to an enediol 
by reduction.  The [2+2] cycloaddition reaction of singlet oxygen to form dioxetanes is a 
more recent addition to singlet oxygen’s known chemistry.  These have generally been 
observed in 1,3 dienes where the cis- arrangement required for [4+2] cycloaddition is not 
readily available or those bearing electron-rich substituents.97   
 
The formation of a 1,4-enediol by [4+2] cycloaddition of singlet oxygen to a diene would, 
in the case of a spiro-disubstituted cyclopentadiene, be expected to be completely 
regiospecific, introducing oxygen at the two carbons α to the spiro- centre.  The 
regiospecific introduction of a 1,4-enediol would generate an excellent precursor to the 
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1,4-enedione required by spiro-mamakone A, by oxidation of the allylic alcohols.  This 
method clearly offered a promising alternative to allylic oxidation for introduction of an 
enedione, and the generation of a cyclopentadiene derivative of the core spiro-mamakone 
unit was undertaken.   
 
Two approaches were considered for access to a cyclopentadiene derivative of spiro-
mamakone A.  The first approach undertaken was via a bromination, dehydrobromination 
route (described in Section 3.2.8).  This method, however, was plagued by problems with 
regioselectivity.  A second, alternative route, took advantage of enones 3.79 and 3.80 via 
a reduction, elimination method, and allowed access to the key cyclopentadiene 
derivative (Section 3.2.9).     
 
 
3.2.8 Cyclopentadiene as an enedione precursor – via dehydrobromination  
A number of strategies are known for the generation of cyclic dienes which take 
advantage of dehydrobromination.  Classic methods for synthesising 1,3-cyclohexadiene 
include dehydrobromination of either 3-bromocyclohexene or 1,2-dibromocyclohexane, 
both of which occur under basic conditions.98,99  The former is accessed by allylic 
bromination, and the latter by bromination, of cyclohexene.  These strategies could be 
applied to the synthesis of spiro-mamakone by bromination or allylic bromination of the 
olefin, followed by dehydrobromination (Scheme 3.41).   
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Scheme 3.41 – Alternative strategy based on the oxidation of cyclopentadiene 
 
The allylic bromination of 3.34 was first attempted as a model system (Scheme 3.42), 
using N-bromosuccinimide (NBS) and azobisisobutylonitrile (AIBN) as radical initiator.  
The reaction gave a complex mixture of brominated products, with none of the desired 
product formed.  Three products (1H NMR spectra, Figure 3.19) could be isolated by 
purification on an analytical reverse phase (C18) column.  Products 3.83 (an impurity 
remained) and 3.84 were fully characterised by 1H and 2D NMR spectroscopy 
(insufficient material collected for 13C NMR spectroscopy) as well as high resolution 
mass spectrometry.  However, the third product was obtained in insufficient quantities for 
full characterisation.    
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Scheme 3.42 – Allylic bromination of olefin 3.34 
 
The pseudomolecular ion ([M+H]+) of both 3.83 (369.0115 Dalton) and 3.84 (369.0131 
Dalton) corresponded to the molecular formula C19H1379BrO3, showing that a single 
bromine substitution had occurred.  1H NMR data showed that the distinctive naphthalene 
proton system (1,2,3-trisubstituted) was not present in both 3.83 and 3.84, with one of the 
rings showing only two doublets, suggesting a 1,2,3,4-tetrasubstituted system, and 
therefore that bromination had occurred on the naphthalene moiety.  The low-field 
aromatic protons (H11/17) were still present in both products, indicating that the bromine 
substitution had occurred at position H13.  Both products showed the expected pair of 
enone doublets, showing that this central ring was unchanged.  1H NMR data showed that 
the difference between 3.83 and 3.84 was in the cyclopentene moiety.  Olefin 3.83 
showed the same distinctive coupling pattern in 1H NMR spectroscopy as had been seen 
in previous examples where migration of the olefin had occurred (vide supra), whereas 
olefin 3.84 showed the same pattern as that for the starting material.  Other 2D NMR data 
confirmed the assigned structures of 3.83 and 3.84 for these two products.   
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Figure 3.19 – 1H NMR spectra of the two products of allylic bromination of 3.34 
 
Whilst the allylic bromination of 3.34 had been unsuccessful, the bromination of 3.35 
using molecular bromine was also examined (Scheme 3.43).  Olefin 3.35 was reacted 
with Br2 (2.2 equivalents) in carbon tetrachloride.  This reaction proceeded more cleanly 
with some starting material recovered, but only one reaction product obtained.  1H NMR 
data of this product had the same aromatic pattern as the bromine-substituted naphthalene 
moiety observed in products 3.83 and 3.84, suggesting that bromine substitution of H13 
had occurred.  It also showed that the nonadiene moiety had been unaffected, and the 
product was tentatively assigned as 3.85.  This compound did not ionise using 
electrospray ionisation so that no confirmation of the molecular formula could be 
obtained.   
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Scheme 3.43 – Bromination of 3.35  
 
Under the reaction conditions used above, the electron rich naphthalene moiety was 
found to dominate the reactivity of the spiro-mamakone precursors.  The possibility of 
generating a cyclopentadiene derivative of an earlier intermediate, prior to introduction of 
the naphthalene moiety was therefore examined.   
 
The bromination of nonadione 3.27 was first examined (Scheme 3.44).  Bromine (1.2 
equivalents) was added to 3.27 in carbon tetrachloride and stirred for 5 hours at room 
temperature.  Despite the rapid decolourisation of the solution, 1H NMR spectroscopy of 
the crude mixture showed that starting material was largely the only compound present.  
A further 4.5 equivalents of bromine were added and the mixture stirred for a further 30 
minutes, after which time 1H NMR spectroscopy showed that no starting material 
remained and a mixture of products were present.  Purification by chromatography on 
silica allowed two products to be isolated, each in 38% yield, which were both 
characterised by 1H and 13C NMR spectroscopy and high resolution mass spectrometry.     
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Scheme 3.44 – Bromination of nonadione 3.27 
  
The mass of the pseudomolecular ion ([M-H]-) for the first product was 398.7882 Dalton, 
corresponding to a molecular formula of C9H779Br3O3, showing that over-bromination 
had occurred.  1H NMR data showed three proton environments, integrating equally, at δH 
4.26, 2.65 and 2.34.  If the protons at δH 4.26 are taken to correspond to 2 protons, then 
only a further 4 protons were observed where a further 8 protons would be expected in 
the desired product.  Heavy splitting of the observed protons showed that they were in the 
same system, suggesting that the olefin had been dibrominated and that the missing 
protons were those α to the ketones in the left-hand ring.  13C NMR data showed the 
presence of two carbons at δC 194 and 149, suggesting the presence of a substituted 
enedione moiety.  The additional oxygen and bromine given by the molecular formula 
allowed the product to be assigned as 3.87.   
 
The psuedomolecular ion ([M-H]-) for the second product was 320.8775 Dalton, 
corresponding to a molecular formula of C9H879Br2O3.  1H NMR data of this product 
were very similar to that of the first product, 3.87, except for an additional singlet at δH 
7.54 which integrated for 1 proton.  This evidence, plus 13C NMR data and the molecular 
formula led to the assignment of this product as 3.88.  Products 3.87 and 3.88 are 
postulated to arise from the overbromination of nonadione 3.27.  The one-pot 
bromination-dehydrobromination of ketones by Br2 to give enones has been previously 
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described and is presumed to occur in this case.100  How the substitution of this enone 
occurs to yield 3.87 and 3.88 is less clear, however.   
 
The bromination of nonadione 3.27 showed that the reactivity of the α-keto methylenes 
towards bromine caused side-reactions to occur.  In an attempt to resolve this problem the 
reduction of both ketones in 3.27 was carried out using sodium borohydride in methanol 
to give the diol 3.89 in approximately quantitative yield (Scheme 3.45).  Diol 3.89 was 
obtained as a mixture of stereoisomers, but since after bromination the ketones would be 
reformed, no attempt was made to separate these isomers.  The bromination of diol 3.89 
using bromine now proceeded cleanly to give the dibrominated nonadiol 3.90, in 
approximately quantitative yield.  Reoxidation of the alcohols could be carried out using 
6 equivalents of pyridinium dichromate to give dibrominated nonadione 3.86 in 50% 
yield.   
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Scheme 3.45 – Alternative route to dibrominated nonadione 3.86 
 
In order to prevent base-catalysed side-reactions during dehydrobromination, protection 
of the ketones of nonadione 3.86 was undertaken (Scheme 3.46).  Refluxing 3.86 under 
Dean-Stark conditions with an excess of ethylene glycol readily yielded the doubly 
protected ketal derivative 3.91 in approximately quantitative yield.   
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Scheme 3.46 – Attempted dehydrobromination of protected nonadione 3.91 
 
This was then submitted to base-catalysed dehydrobromination, with DBU.  After heating 
the reaction in acetonitrile at 70ºC for 4 days or in DMF for 2 days, only starting material 
was recovered.  These conditions, using a mild, hindered base, promote an E1 elimination 
mechanism and are standard for dehydrobromination.  The lack of reaction showed that 
an E1 elimination was not favoured in this system.  The use of a strong unhindered base, 
which might be expected to favour an E2 mechanism, was briefly examined to see if it 
promoted dehydrobromination.  Dibromide 3.91 was reacted with an excess of potassium 
tbutoxide.  This caused mono-dehydrobromination to occur, however because the most 
accessible proton was removed leading to product 3.93, the desired cyclopentadiene 
could not be formed.  Product 3.93 was fully characterised by 1H, 2D and 13C NMR 
spectroscopy and high resolution mass spectrometry.      
 
The possibility of attempting an allylic bromination of 3.89 to generate a 3-bromoalkene 
derivative of 3.27 could have been next attempted.  However, the generation of enones 
3.79 and 3.80 (vide supra) opened up the opportunity to generate a cyclopentadiene 
derivative of the spiro-mamakone core structure by a different method and this route was 
successfully examined instead (Section 3.2.8).   
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3.2.9 Cyclopentadiene as an enedione precursor – via allylic alcohol elimination  
 
A route to a cyclopentadiene from enones 3.79/3.80 generated during earlier studies 
(Section 3.2.6) can be envisioned (Scheme 3.47) via reduction to an allyl alcohol and 
dehydration.  Indeed the first of these steps had already been achieved (vide supra) and 
the dehydration of the alcohol previously observed by mass spectrometry.  This route was 
therefore examined.   
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Scheme 3.47 – Preparation of cyclopentadiene 3.95 from enones 3.79/3.80 
 
Whilst the Luche reduction of enone 3.79 had been achieved previously using a 
diastereomerically pure sample of 3.79, all stereochemical entities of 3.94 would be 
resolved on dehydration to give a single enantiomeric pair of 3.95.  This allowed a 
mixture of enones 3.79 and 3.80 to be employed in this route.  Luche reduction gave a 
complex mixture of stereoisomers of allyl alcohol 3.94 (including 3.81), as anticipated.    
 
The dehydration of the allyl alcohol 3.94 was next undertaken.  A variety of dehydrating 
conditions are known to effect the dehydration of cyclic allylic alcohols to generate 
dienes.  The most common involve the addition of catalytic quantities of acid to promote 
the loss of water.  The possible sensitivity of the spiroketal moiety to such conditions 
make these unattractive, and non-acidic conditions were sought.  Multi-step methods 
involving activation of the alcohol as a sulfonate ester and followed by elimination with 
base offered an alternative route.  However, a promising reagent which has been used to 
yield cyclopentadienes from cyclic allylic alcohols101 was the inner salt of 
(carboxysulfamoyl)triethylammonium hydroxide methyl ester, 3.96, also known as 
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Burgess reagent.102,103  It effectively combines the activation of the alcohol as a sulfonate 
ester and base-catalysed elimination in one step, as the direct result of being an inner salt.  
The accepted mechanism is described in Scheme 3.48.  It is a mild, non-acidic and 
efficient dehydrating agent.  Despite being an inner salt, it is readily soluble in most 
organic solvents and effects pyrolytic dehydration at relatively low temperatures 
(generally less then 100ºC).  
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Scheme 3.48 – Mechanism of Burgess reagent mediated alcohol dehydration  
 
The preparation of Burgess reagent was carried out in two steps from readily available 
chlorosulfonyl isocyanate (Scheme 3.49).104  The first step proceeded in 81% yield, and 
the second in 63% yield.  Both products were obtained as white solids whose melting 
points were in good agreement with literature values.   
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Scheme 3.49 – Preparation of Burgess reagent (3.96) 
 
The dehydration of 3.94 was successfully carried out by warming (50ºC) with 2 to 3 
equivalents of Burgess reagent in benzene overnight.  Whilst crude 1H NMR data 
suggested high conversion, relatively low isolated yields of around 30% were obtained.  
The product was fully characterised by 1H (Figure 3.20) 2D and 13C NMR spectroscopy 
as well as high resolution mass spectrometry.  All data confirmed the formation of 
cyclopentadiene derivative 3.95.   
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Figure 3.20 – 1H NMR spectrum of cyclopentadiene derivative 3.95 
 
 
3.2.10  Singlet oxygen addition to a cyclopentadiene derivative 
 
With cyclopentadiene derivative 3.95 in hand, singlet oxygen oxidation to generate a 1,4-
enediol was attempted.  Examination of the literature for singlet oxygen addition to 
similar precursors allowed the choice of Rose Bengal as photosensitiser, with methanol or 
methanol/DCM mixtures as solvent using a tungsten lamp as the source of visible 
light.105,106,107  Where the desired product was an enediol several groups included thiourea 
as a reducing agent to reduce in situ the initially formed endoperoxide.  This avoids the 
need to isolate the sensitive endoperoxide before reduction.  These conditions were 
employed in the oxidation of cyclopentadiene 3.95.  The reaction was placed under a 
balloon of oxygen with vigorous stirring to ensure good availability of oxygen in the 
solution.  The reaction was initially carried out in an ice-bath, however HPLC analysis of 
the crude reaction mixture after 2 hours showed no reaction was occurring, so it was 
warmed to room temperature and the reaction continued overnight.  HPLC analysis 
(Figure 3.21) now showed that almost all starting material had been consumed and two 
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new major products had been formed.  These two products were both significantly more 
polar than the starting material and eluted very closely, with a minor product eluting 
between them.  Since the reaction had been carried out on a very small scale, the products 
were purified by chromatography on HPLC using an analytical C18 column.  Whilst the 
two major and a minor impurities were not well resolved under the elution conditions 
used above for analysis, an initial purification was carried out using these conditions with 
both major products collected together.  1H NMR spectroscopy of this mixture showed 
the presence of two related compounds, but further purification was undertaken before 
full characterisation.  The mixture was purified again by HPLC on an analytical C18 
column using different elution conditions to give the two products as amorphous white 
solids.   
 
Figure 3.21 – HPLC analysis of singlet oxygen oxidation of cyclopentadiene 3.95 
 
The major of the two products (the second eluted) was characterised by 1H (Figure 3.22) 
and 2D NMR spectroscopy (COSY and HSQC, and partial HMBC data were obtained).  
1H NMR spectroscopy showed that the naphthalene moiety and the acetyl protected 
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allylic alcohol were both present and broadly unchanged.  Four other protons were 
observed at δH 6.16, 5.88, 5.48 and 3.86.  HSQC NMR data showed that the two down-
field protons were attached to carbons at δC 132.2 and 133.6 respectively.  The two 
upfield protons were attached to carbons at δC 86.0 and 65.0.  COSY correlations could 
be seen between the two down-field protons and the two up-field protons, but no 
correlation was observed between the two pairs (see Figure 3.23).   
 
Figure 3.22 – 1H NMR spectrum of the major product of singlet oxygen addition to 3.95 
 
These data suggested that the anticipated 1,4-enediol had not been formed.  This product 
would be anticipated to have two allylic alcohol protons and two olefinic protons with a 
high degree of symmetry.  Apart from the lack of correlation between the two pairs of 
protons, the data suggested that the product formed could be a 1,2-enediol of type 3.97.  
The lack of an observable COSY correlation between the two pairs is likely to be due to a 
dihedral angle of around 90º, which leads to very small coupling constants, making 
COSY correlations weak.  Due to a lack of material, no useful HMBC data could be 
obtained to confirm this proposed connectivity.   
 
 
Chapter 3: The spiro-Mamakones  207 
Whilst two olefinic protons and one allylic alcohol proton (δH 5.48) were present, the 
chemical shift of the proton at δH 3.86 was more indicative of an aliphatic alcohol.  The 
chemical shifts (δH 5.48, δC 86.0) of the allylic alcohol were somewhat higher than might 
be expected.  The product did not ionise under ESIMS or CIMS conditions, however 
under high resolution EIMS the pseudomolecular ion observed was 364.0935 Dalton, 
corresponding to a molecular formula of C21H16O6.  This molecular formula has two less 
protons than enediol 3.97, and suggests that reduction has not occurred, and that the 
product of the reaction may instead be 3.98.  This assignment is supported by the 
observation of two low resolution EIMS fragmentation products observed; m/z = 332 
(loss of O2) and m/z = 290 (loss of O2 and COCH2).  In addition, this proposed structure 
may account for the unusually high chemical shifts of the allylic alcohol.  Whilst 2D 
NOESY NMR data were obtained, no correlations were observed which could help 
establish the stereochemistry of the product.       
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Figure 3.23 – observed COSY correlations for 3.98 
 
The minor product (first eluted) of the singlet oxygen oxidation of 3.95 was obtained in 
smaller quantities which were insufficient to fully characterise this compound.  1H 
(Figure 3.24), COSY and partial HSQC NMR data were obtained, however, and 
indicated that this product was very similar to the major product.  1H NMR data showed a 
similar pattern to the major product with small differences in chemical shift (one proton 
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was obscured by the residual solvent peak, but was observed in a COSY NMR 
experiment).  Two possible structures can be readily postulated, either this product may 
be a diastereoisomer of the major product, or it is the reduced form of the product, 3.97.  
However, the similarity in the retention time (and therefore polarity) of these two 
products would suggest that it is not the diol 3.97, since this would be expected to be 
markedly more polar than 3.98.  It is therefore postulated that this product represents a 
diastereoisomer of the major product, although no data were obtained to determine either 
products’ relative or absolute stereochemistry.  The difference in stereochemistry 
between the two products might arise either from addition of oxygen from the top or 
bottom face of the cyclopentadiene (relative to the naphthalene moiety) or from its 
addition on the same or opposite side to the protected allyl alcohol on the central ring.  
This compound did not ionise in ESIMS, so the proposal that it is a stereoisomer of 3.98 
could not be confirmed by comparison of the molecular weight.      
 
Figure 3.24 – 1H NMR spectrum of the minor product of singlet oxygen addition to 3.95 
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The proposed products of the reaction of singlet oxygen with 3.95 are highly unexpected.  
The cycloaddition of singlet oxygen to dienes should reliably proceed regiospecifically at 
the 1,4- position to generate a 1,4-enediol.  The generation of a 1,2-enediol might, at first 
sight, seem to have arisen from a [2+2]-cycloaddition.  However, as mentioned above, 
those literature examples of [2+2]-cycloaddition to dienes occurs where the cis- position 
is inaccessible or where electron-rich substituents are present on the diene.  Neither of 
these scenarios are true in the present case, indeed 3.95 seems an ideal substrate for a 
[4+2]-cycloaddition.  Re-examination of the literature brought to light the possibility that 
[4+2]-cycloaddition was occurring, but that rearrangement of the endoperoxide to a 
dioxetane may then occur.108,109,110  This is therefore proposed as the most likely 
mechanism by which the diastereoisomeric products of 3.98 arise from the singlet oxygen 
oxidation of 3.95.   
 
In order to generate the desired 1,4-enediol precursor to spiro-mamakone A, the 
rearrangement of the endoperoxide to a dioxetane would need to be suppressed such that 
the reduction of the endoperoxide can occur.  The rearrangement of an endoperoxide is 
considered to be a thermal rearrangement, such that at low temperatures the endoperoxide 
is more stable.110  The singlet oxygen oxidation of 3.95 was therefore attempted at -78ºC 
and monitored by HPLC.  After 8 hours only the starting diene was present and no 
photooxidation products were in evidence.  The reaction was therefore reattempted at -
45ºC and, again, monitored by HPLC.  After 16 hours, largely starting material remained, 
however two new peaks were observed by HPLC, with the characteristic naphthalenediol 
UV spectrum.  These two peaks were purified by chromatography on the C18 analytical 
column.  Unfortunately both samples were shown to be mixtures of compounds, and were 
present in too small quantities for further purification and characterisation of the products.  
It was clear that whilst at low temperature photooxidation of 3.95 would proceed, it did 
not proceed at an appreciable rate and led to complex mixtures of products. 
 
Since 3.95 was a very advanced intermediate, only minimal quantities were available.  
The formation of the acetal was the principal ‘bottleneck’ in this synthetic route, with 
yields generally of only around 10 to 15%.  None of the subsequent synthetic steps 
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reliably proceeded at quantitative yields, such that further mass was lost at each stage.  
The total quantity of 3.95 that was obtained was only around 3-4 mg.  This severely 
limited the possibility of variation of the reaction parameters of the singlet oxygen 
addition to improve the reaction outcome.  The preparation of a model compound which 
could be prepared on a moderately large scale to test the parameters of the singlet oxygen 
oxidation was therefore undertaken.  An ideal model approximates the final system 
closely whilst being readily available on a reasonably large scale.  Cyclopentadiene 3.102 
seemed an appropriate model and its synthesis was undertaken (Scheme 3.50).  This 
protected diol cyclopentadiene was chosen over a dione cyclopentadiene since attempts to 
achieve the allylic oxidation of 3.27 yielded only starting material, similarly to the allylic 
oxidation of acyclic olefin 3.26 discussed earlier (Section 3.2.5).  Since reduction and 
protection of the ketones had allowed successful allylic oxidation in that case, it was also 
applied here, successfully.    
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Scheme 3.50 – Preparation of a model cyclopentadiene system 
 
 
Chapter 3: The spiro-Mamakones  211 
The double reduction of dione 3.27 (200 mg) was readily achieved using an excess of 
sodium borohydride in methanol to give the separable cis- and trans- diastereoisomers of 
diol 3.89 with an isolated yield of 43% for the trans- isomer.  For ease of analysis of 1H 
NMR spectroscopy at later stages in the synthesis only the trans- diastereoisomer was 
carried through the synthesis.  The diol was protected as an acetate under standard 
conditions (acetic anhydride and pyridine) to give 3.99 in 75% yield.  Allylic oxidation of 
protected diol 3.99 gave enone 3.100 in 79% yield.  Reduction of the enone to an allylic 
alcohol was achieved under Luche reduction conditions, as previously, to give the 
product as a mixture of stereoisomers in 88% isolated yield.  The allylic alcohol, 3.101, 
was subjected to dehydration conditions using Burgess reagent (50ºC, 7 hours).  Whilst 
the cyclopentadiene product, 3.102, was obtained from this reaction, it was only 
recovered in an approximate yield of 11% and was still contaminated by impurities.  A 
second fraction also obtained from this reaction had a complicated 1H NMR spectrum.  
This product was postulated to be a mixture of Diels-Alder products (3.103) arising from 
the dimerisation of the cyclopentadiene 3.102.  This postulate was supported by mass 
spectral analysis, which showed the pseudomolecular ion of the cyclopentadiene 
monomer, 3.102.  The observance of the pseudomolecular ion of a monomer is common 
in the mass spectral analysis of Diels-Alder derived dimers due to retro-Diels-Alder 
processes under the harsh ionisation conditions employed.  This product was therefore 
subjected to conditions aimed at achieving a retro-Diels-Alder reaction – refluxing in a 
highly dilute solution of benzene for 3 days.  After this time, 1H NMR spectroscopic 
analysis of the crude mixture showed the presence of the monomer and no dimer 
remained.  Disappointingly, however, only a further 6% of the monomer was isolated, 
although this sample was pure.   
 
The disappointing yields of the dehydration step during the synthesis of this 
cyclopentadiene model system resulted in an overall yield of only 4 mg of the pure final 
cyclopentadiene, 3.102, from 88 mg of starting trans-diol 3.89 (or 200 mg dione 3.27).  
As a result this model system would not allow an extensive examination of the reaction 
conditions of singlet oxygen oxidation to these spiro-cyclopentadiene systems.  
Nevertheless, the oxidation was attempted under the same conditions as employed for the 
 
212   Chapter 3: The spiro-Mamakones 
oxidation of 3.95, above, on around one quarter of the mass of 3.102.  The 1H NMR 
spectrum of the crude sample showed that a complex mixture of products had been 
formed.  On this scale, the analysis of a complex mixture of products would have been 
untenable, so the remaining 3.102 was also submitted to the same conditions employed 
for oxidation of 3.95.  Again a complex mixture was obtained, although a major product 
was the enone 3.100.  A plausible mechanism for the regeneration of enone 3.100 is via a 
1,2-diol.  The initial generation of a dioxetane, as seen in previous examples, may be 
reduced in situ to a 1,2-diol, which can then eliminate water to generate an enol, which 
would tautomerise to enone 3.100.  The recovery of this product therefore suggests, 
indirectly, that the dioxetane intermediate was generated from the endo-peroxide.  No 
other products could be isolated in sufficient quantity to allow characterisation or 
structure elucidation.   
 
The model system had therefore not generated any useful information on how to alter the 
conditions of the singlet oxygen cycloaddition of 3.95.  The insufficiency of material of 
3.95 and time constraints imposed on this project forced a reluctant abandonment of 
further synthetic attempts towards spiro-mamakone A.      
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3.3 Biological activity of spiro-mamakone synthetic analogues 
and analysis of structure-activity relationships 
 
A number of intermediates were obtained during the course of the above synthetic efforts 
to prepare spiro-mamakone A.  Many of these closely resemble in structure the natural 
product, which is known to be potently bioactive in a P388 leukaemia assay (IC50 of 0.33 
μM).  The other natural products obtained in the spiro-mamakone series also displayed 
cytotoxicity (IC50 values of 1.39 μM, 0.95 μM and 3.76 μM respectively for spiro-
mamakone B, C and D).  It was therefore valuable to examine the bioactivity of the 
intermediates generated in this synthetic work, in order to allow a structure-activity 
profile to be developed.  In addition to cytotoxic activity (as evidenced by the P388 
leukaemia assay), the natural products also displayed antimicrobial activity, however 
only the cytotoxicity of the synthetic analogues was tested (Figure 3.25).    
 
In an effort to expand the range of analogues tested, a small number of simple reactions 
were carried out on some of the intermediate analogues described above (Scheme 3.51).  
Alcohol 3.55 was protected as an acetate, to give 3.104, a close analogue of 3.56.  Like 
3.56, 3.104 was also subjected to allylic oxidation to give two diastereomeric enones 
(racemic mixture of enantiomers), 3.105 and 3.106.  Protected alcohol 3.104 and enones 
3.105 and 3.106 were fully characterised by 1H, 2D and 13C NMR spectroscopy and high 
resolution mass spectrometry.  A correlation between the acetate proton (H4) and one the 
methylene protons adjacent to the enone in a 2D NOESY experiment of 3.106 (not 
present in compound 3.105) allowed these two enones to be distinguished.  The Luche 
double reduction of 3.77 gave 3.107 as a mixture of stereoisomers which could not be 
separated.  The diols of 3.107 were protected as acetates using classic conditions to give 
3.108 as a mixture of stereoisomers. Because of the complex stereochemical mixtures of 
3.107 and 3.108, only 1H and high resolution mass spectral data were used to elucidate 
their structures.     
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Scheme 3.51 – Preparation of additional analogues of spiro-mamakone A for biological 
testing 
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Figure 3.25 – Results of biological testing (P388 murine leukaemia cell line assay) on 
spiro-mamakone analogues. (IC50 values shown) 
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More than half of the analogues tested did not show any activity in the concentration 
range tested, ie they did not show any cytotoxicity below concentrations of around 30-40 
μM.  No further tests were carried out at higher concentrations to determine the 
concentration at which they would show cytotoxicity.  All of these analogues have the 
same basic carbon skeleton as the natural spiro-mamakone series, although they vary 
quite widely in the range and placement of functional groups on the skeleton.  Amongst 
these, 3.107 is interesting in that it contains the same central ring allylic alcohol motif, 
but has a second allylic alcohol in the right-hand ring rather than an enedione.  This 
clearly demonstrates the importance of the enedione motif in the cytotoxic effect of the 
natural products.  The very weak activity of 3.54 also supports this conclusion.   
 
A small number of the analogues tested displayed potent cytotoxicity, in particular 3.34 
and 3.77.  These show activities comparable to the natural product series (spiro-
mamakone A displayed an IC50 of 0.33 μM).  In addition, several compounds displayed 
moderate cytotoxicity of between 8.9 and 43 μM.  These compounds also span a range of 
functionality making general conclusions difficult to draw.  Many of the compounds 
which display strong to moderate cytotoxicity include one or more enone moieties at 
various positions.  Enones are strongly electrophilic, readily undergoing 1,4-additions 
with nucleophiles.  It may be this reactivity which is dominating the cytotoxic effect by 
interacting with nucleophiles such as cysteine residues in proteins.  The absence of an 
enone means that this sort of reactivity is not possible in the natural product series.  The 
enedione moiety present in the natural series is a significantly less polarised functional 
group and is therefore much less prone to undergo 1,4-additions with nucleophiles.  This 
suggests that the cytotoxicity observed with the enone-containing analogues may derive 
their cytotoxicity via a different mechanism to the natural series.  However, a number 
(3.80 and 3.106) of biologically inactive analogues also contain enone moieties, so the 
assumption that enone containing analogues are acting via 1,4-additions to nucleophiles 
may be an over-simplification.   
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Some stereochemical dependence can be observed in the biological activities of the 
synthetic analogues.  For example in the case of stereoisomeric enones 3.79 and 3.80, one 
shows moderate bioactivity whilst the other is inactive.   
 
Overall, these results demonstrate that the spiro-mamakone series represent highly 
refined entities with respect to their biological activity.  Many quite closely related 
analogues were synthesised which showed no activity, or greatly reduced activity 
compared to the natural products.  A small number of synthetic analogues did display 
biological activity analogous to the natural products.  These all contained the reactive 
enone motif, which may impart biological activity by different mechanisms to the natural 
product.  
 
These results provide useful information on the structure-activity relationship profile of 
the spiro-mamakone series.  Further work which could expand upon the above results 
would be testing of both the natural products and synthetic analogues against more 
specific biological assays, to elucidate the mechanism of action of these compounds.   
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3.4 Future Work 
 
The work presented in this thesis towards the synthesis of spiro-mamakone natural 
products provides a solid basis for further synthetic investigations, with the obvious end-
point of completing the total synthesis of these natural products.  It may be possible, with 
further experimentation, to alter the regioselectivity of the singlet oxygen addition to give 
the crucial enedione moiety required of the natural products.  Improving the overall yield 
of the synthetic route to the cyclopentadiene precursor of this oxidation would greatly 
facilitate this goal.  Alternatively, entirely different synthetic routes may be required to 
access the spiro-mamakones.   
 
Synthetic routes which allow access to all of the spiro-mamakones would be beneficial.  
Diastereoisomers spiro-mamakones B and C are closely related to spiro-mamakone A; 
the only difference being the reduction of one ketone of the enedione moiety to an 
alcohol.  Preparation of spiro-mamakones B and C is therefore likely to be readily 
achievable by classic reductive methods (eg the Luche reduction) from spiro-mamakone 
A, although regio- and stereochemical control is likely to be limited.  spiro-Mamakones 
D and E are not so closely related and include additional oxygenation of the right-hand 
ring.  The dioxetane formation observed during singlet oxygen addition in this thesis may 
offer opportunities to access the spiro-mamakone D and E oxygenation pattern.   
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Finally, further analogues of the spiro-mamakone natural products could be targeted for 
synthesis.  This would provide further information on the structure-activity relationship 
of the natural metabolites, and could generate analogues with improved biological 
characteristics.   
 
A deeper understanding of the mechanisms by which the spiro-mamakones exert their 
biological activity would be crucial before any clinical applications for these metabolites 
could be considered.  It would also allow more rational analysis of the structure-activity 
relationship of synthetic analogues, by excluding those which act via different 
mechanisms.  With accurate structure-activity relationship data and the biological target 
of the spiro-mamakones pin-pointed, rational drug design could also be undertaken.  
Only with this information could the true viability of these natural products as 
pharmaceuticals be explored.    
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3.5 Conclusion 
 
The synthesis of spiro-mamakone A was attempted in this project, a task which was, 
ultimately unsuccessful.  However, a number of different synthetic strategies were 
examined and the limits of these various approaches to the synthetic target were explored.   
Significant progress was made towards the natural product and the reactivity of these 
systems better understood.   
 
Beyond the valuable synthetic information gleaned, a substantial number of analogues of 
the natural product were successfully synthesised.  These were all subjected to biological 
analysis which allowed the structure-activity relationship profile of the natural products 
to be examined.  This analysis confirmed that these natural products are finely-tuned 
biological entities, with many close analogues displaying no activity under the assay 
conditions.  The importance of the enedione motif, in particular, was brought to light by 
these results.    
 
In conclusion, whilst the synthesis of the final target natural product was not completed, 
significant progress was achieved and useful information regarding the natural product’s 
biological activity was obtained as a result of these studies.   
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Conclusions 
 
The primary aim of this thesis was to use synthetic chemistry as a tool to examine various 
aspects of the natural products discovered by the University of Canterbury natural 
products research group.  Two projects were undertaken.  The first involved the use of 
synthesis in order to establish the stereochemistry of the pteratides, a series of potently 
cytotoxic depsipeptides, discovered by Miss Chen.  The second project involved an 
attempt to carry out the total synthesis of spiro-mamakone A, another potently cytotoxic 
fungal natural product, whose structure was already known.  The generation of a library 
of analogues was also undertaken, and an examination of the biological activities of this 
library was used to probe the structure-activity relationship.   
 
The stereochemical assignment of the pteratides involved the synthesis of a number of 
unusual amino acids for use as reference materials.  The four diastereoisomers of N-
methylthreonine and 4-methylproline, as well as N-methyl-L-valine were all prepared by 
either following literature preparations, or by modifications thereof.  Modifications made 
to the literature synthesis of the 4-methylproline diastereoisomers led to a more concise 
synthesis, which gave good stereoselectivity for both enantiomeric pairs, and therefore 
provided an improved method, compared to literature procedures.  These reference 
materials, as well as commercial amino acids and natural product hydrolysates, were 
derivatised and analysed by HPLC chromatography to establish the full stereochemistry 
of each of the depsipeptides in the pteratide series.  This work allowed the publication of 
the pteratides in the peer-reviewed literature.  
 
The total synthesis of spiro-mamakone A could not be achieved in the time-frame of this 
thesis.  However, very advanced intermediates were synthesised, and only the generation 
of a key enedione motif eluded the synthesis of the target natural product.  A large 
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number of analogues which shared the spiro-mamakone carbon skeleton, but varied in 
their degree of oxidation, were generated.  The biological activity of this library of 
analogues was examined, with several analogues showing appreciable cytotoxicity.  As 
well as establishing a viable route to the spiro-mamakone skeleton, this project has 
therefore also given valuable insight into the structure-activity relationship of the spiro-
mamakone series.    
 
The aims of this thesis were, therefore, largely successfully completed.   
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Experimental 
 
5.1 General Methods 
 
Nuclear Magnetic Resonance 
The 1H, COSY, NOESY, HSQC and HMBC NMR spectra were recorded on a Varian 
INOVA 500 NMR spectrometer, at 23 ºC, operating at 500 MHz.  The INOVA was 
equipped with a variable temperature and indirect broadband PFG (pulsed field gradient) 
5 mm probe.  The 13C NMR spectra were recorded on a Varian UNITY 300 NMR 
spectrometer, at 23 ºC, operating at 75 MHz.  The UNITY was equipped with a variable 
temperature direct broadband 5 mm probe.  Chemical shifts are expressed in parts per 
million (ppm) on the δ scale, and were referenced to the appropriate solvent peaks: 
CDCl3 referenced to CHCl3 at δH 7.26 (1H) and CDCl3 at δC 77.0 (13C), CD3OD 
referenced to CH3OD at δH 3.3 (1H) and CH3OD at δC 49.3 (13C) and D2O referenced to 
HOD at δH 4.7 (1H) and (CH3)3COH (added tBuOH) δC 30.3 (13C).   
 
Mass Spectrometry  
Samples were analysed on a micromass LCT mass spectrometer equipped with an 
electrospray ionisation (ESI) probe.  A probe voltage of 3200 V at 150 ºC with a 
nebuliser gas flow of 160 L/hr and desolvation gas flow of 520 L/hr with the source 
temperature at 80 ºC.  The cone voltage was typically 20 V.  The solvent flow from a 
syringe pump in direct injection ESIMS mode was 20 μL/min.   
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High Pressure Liquid Chromatography 
Analytical High Pressure Liquid Chromatography (HPLC) was carried out on two HPLC 
instruments.  The bulk of the work was carried out on a Dionex HPLC instrument using 
reverse phase chromatography on a Prodigy C18 column (250 x 4.6 mm, 5 μm).  The 
column was maintained at a constant temperature (stated in each case) by a Dionex TCC-
100 thermostatted column compartment.  The samples were eluted at a flow rate of 1 
mL/min.  A photodiode array (PDA, Dionex UVD340) and Evaporative Light Scattering 
Detector (ELSD, Dionex ELSD800) were used for detection.  Some of the work on the 
stereochemical assignment of pteratide I (Section 2.4, stated in the text) was carried out 
on a Shimadzu LC-10AD VP liquid chromatograph, using a Phenomenex Prodigy C18 
column (5μ, 250 x 4.6 mm).  The samples were eluted at a flow rate of 1 mL/min and an 
SPD-M10A VP photodiode array detector was used for detection.     
 
The solvents used were either mixtures of MeCN (Scharlau/LEDA MeCN, 
HPLC/spectroscopy grade) or MeOH (Merck LiChrosolv) with H2O (purified using a 
MilliQ deionising system).  The aqueous phase was acidified with 0.05% TFA (Scharlau, 
synthesis grade) where possible.  Elution conditions (eg column temperature, solvents 
proportions) and retention times are given throughout this chapter.  
 
Column chromatography 
All column chromatography was performed as ‘flash’ chromatography under oxygen-free 
N2 gas pressure (~ 1.5 bar) in glass columns.  Solvents of commercial grade were used, 
distilled once in glass distillation apparatus except MeOH which was distilled twice.   
 
Silica flash chromatography was performed on Merck silica gel 60 (230-400 mesh).  
Reverse phase C18 chromatography was performed on Bakerbond® C18 (40 μm 
preparative LC packing).  Normal phase diol chromatography was performed on 
Bakerbond® Diol 40 μm Prep LC packing.   
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Thin Layer Chromatography 
All analytical thin layer chromatography (TLC) was performed on Merck silica gel 60 
F254 plastic backed sheets (250 μm thickness).  The solvent(s) used for development are 
indicated in each case.  Visualisation was performed first visually under normal light 
followed by short wavelength UV (254 nm).  Staining was carried out using either 
phosphomolybdic acid spray (PMA, 10% w/v phosphomolybdic acid in ethanol) or 
ninhydrin dip (1 g in 500 mL MeOH).   
 
IR spectroscopy 
IR measurements were taken on either a Shimadzu FTIR-8201PC Spectrophotometer or a 
Perkin Elmer Spectrum One FTIR Spectrophotometer.  Solid samples were measured by 
diffuse reflectance in KBr, and liquid samples were measured on KBr disks, with a 
background measured first in all instances.   
 
Optical Rotation 
Rotation values were obtained on a Perkin Elmer 341 polarimeter at 20 ºC at a 
wavelength of 589 nm.  The optical rotations were then calculated using the following 
equation: 
 
[α]20D = α / LC 
 
where L is the cell path length (dm) and C is the concentration (g/mL) 
 
Biological Assays 
Compounds were assayed for cytotoxicity, where applicable, using the P388 MTT 
antitumour assay.  It consists of a 2-fold dilution series of the sample of interest followed 
by incubation for 72 hours with P388 (murine leukaemia) cells.  The concentration of the 
sample required to reduce the P388 cell growth by 50% (compared to control cells) is 
determined using the absorbance values obtained when the yellow MTT tetrazolium is 
reduced by healthy cells to produce the purple colour MTT formazan.  The result is 
expressed as the IC50 (ng/mL) 
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Pteratide hydrolyses and Marfey’s derivatisation 
The peptides (0.5 mg each) were hydrolyzed by heating (110°C for 24 h) in HCl (6 M; 1 
mL).  After cooling, the solutions were evaporated to dryness and redissolved in H2O 
(100 μL).  A 1% (w/v) solution (100 μL) of FDAA (Marfey's reagent, N -(2,4-dinitro-5-
fluorophenyl)-L-alaninamide) in acetone was added to an aliquot (50 μL) of a 50 mM 
solution of each amino acid or natural product hydrolysate. After addition of NaHCO3 
solution (1 M; 20 μL), the mixture was incubated (1 hour at 40 ºC). The reaction was 
stopped by addition of HCl (2 M, 10 μL), the solvents were evaporated to dryness, and 
the residue was redissolved in MeOH-H2O (1:1; 1 mL). An aliquot of each of these 
solutions (10-50 μL) was analyzed by HPLC.   
 
Solvents 
All technical grade solvents were distilled prior to use and MeOH was distilled twice.  
Dry solvents were obtained using the following standard methods.  Toluene, benzene and 
pyridine were refluxed over calcium hydride and distilled immediately prior to use.  THF 
was refluxed over sodium metal and benzophenone before distillation directly prior to use.  
DMF was treated twice overnight with activated 4Å molecular sieves, followed by 
storage over 4Å molecular sieves.   MeOH was refluxed over magnesium metal activated 
with iodine before distillation immediately prior to use. Chloroform was refluxed over 
P2O5 and distilled immediately prior to use.   
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5.2 Work described in Chapter 2 
 
Section 2.2.2  
Fmoc-L-valine, 2.41 
L-Valine (200 mg, 1.71 mmol) was dissolved in dioxane (2 mL) and H2O (2 mL), 
NaHCO3 (290 mg, 3.42 mmol, 2 eq) was added and the mixture was cooled to 0 ºC.  
FmocCl (490 mg, 1.89 mmol, 1.1 eq) was then added and the reaction stirred at 0 ºC for 1 
hour before being warmed to room temperature and stirred overnight.  The reaction was 
acidified by addition of 1 M HCl(aq) and extracted with ethyl acetate (3 x 5 mL).  The 
combined organic phases were dried over MgSO4, filtered and the solvent removed in 
vacuo.  The crude product was then purified by chromatography on silica using a 
stepwise gradient of 50 to 100% ethyl acetate in petroleum ether to give the product (2.4, 
382 mg, 1.13 mmol, 66%) as a white solid.   
Rf 0.41 (silica, 1:1 petroleum ether:ethyl acetate, visualization UV/PMA);  1H NMR 
(CDCl3, 500 MHz) δ 7.77 (2H, d, 7.2 Hz), 7.60 (2H, m), 7.40 (2H, t, 7.0 Hz), 7.32 (2H, t, 
7.0 Hz), 5.26 (1H, br d, 8.7 Hz), 4.43 (2H, d, 6.9 Hz), 4.36 (1H, dd, 9.2 Hz, 4.7 Hz), 4.24 
(1H, t, 6.9 Hz), 2.25 (1H, m), 1.02 (3H, d, 6.7 Hz), 0.96 (3H, d, 6.7 Hz).   
 
Fmoc-L-valine-oxazolidinone, 2.51 
Fmoc-L-valine (2.4, 1.03 g, 3.04 mmol) was dissolved in toluene (62 mL) and pTSA (62 
mg, 0.33 mmol, 0.1 eq) and paraformaldehyde (618 mg, ~21 mmol, ~35 eq) were added.  
The mixture was refluxed with a Dean-Stark condenser for 1 hour.  After cooling to room 
temperature, the solvent was removed in vacuo and the crude product purified by 
chromatography on silica using a stepwise gradient of 5% to 20% ethyl acetate in 
petroleum ether.  This gave the product (2.5, 1.0 g, 2.85 mmol, 94%) as a colourless oil.    
Rf 0.40 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) 
νmax 1801, 1716, 1418, 1240 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.77 (2H, d, 7.5 Hz), 
7.54 (2H, d, 7.5 Hz), 7.42 (2H, dt, 7.5 Hz, 3.3 Hz), 7.33 (2H, dd, 7.5 Hz, 2.4 Hz, 1.0 Hz), 
5.45 (1/2H, br), 5.25 (1/2H, br), 5.02 (1H, d, 4.7 Hz), 4.70 (2H, br), 4.23 (1H, br), 4.16 
(1/2 H, br), 3.60 (1/2H, br), 2.36 (1/2H, br), 1.72 (1/2H, br), 1.1-0.6 (6H, br); 13C NMR 
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(CDCl3, 75 MHz) δ 171.3, 143.3, 141.4, 128.0, 127.2, 124.5, 124.2, 120.1, 59.9, 47.2, 
30.9, 17.7, Fmoc C=O not observed. 
 
Fmoc-N-methyl-L-valine, 2.61 
Fmoc-L-valine-oxazolidinone (2.5, 110 mg, 0.31 mmol) was dissolved in chloroform (1.6 
mL) and TFA (1.6 mL), and triethylsilane (160 μL, 1.00 mmol, 3.2 eq) was added.  The 
reaction was stirred at room temperature for 30 hours.  The solvents were removed in 
vacuo and the crude product purified by chromatography on silica using a stepwise 
gradient from 20% ethyl acetate in petroleum ether to ethyl acetate.  This gave the 
product (2.6, 84 mg, 0.24 mmol, 77%) as a white solid.  
Rf 0.18 (silica, 2:1 petroleum ether:ethyl acetate, visualization UV/PMA); 1H NMR 
(CDCl3, 500 MHz) δ 7.77 (2H, d, 7.5 Hz), 7.59 (2H, m), 7.41 (2H, t, 7.5 Hz), 7.32 (2H, t, 
7.5 Hz), 4.50 (2H, m), 4.28 – 4.10 (2H, m), 2.91 (2H, s), 2.89 (1H, s), 2.30 (2/3H, br), 
2.08 (1/3H, br), 1.04 (2H, d, 6.8 Hz), 0.94 (1H, d, 6.8 Hz), 0.90 (2H, d, 6.8 Hz), 0.76 (1H, 
d, 6.8 Hz); 13C NMR (CDCl3, 75 MHz) δ 175.5, 175.2, 157.7, 156.5, 143.7, 143.6, 141.4, 
127.8, 127.1, 124.9, 124.8, 120.0, 68.1, 67.9. 65.3, 47.2, 47.1, 31.6, 30.5, 27.4, 19.6, 19.0, 
18.8; HRESIMS m/z = 354.1698 [M+H]+ 2.0 ppm (354.1705 calcd for C21H24NO4). 
 
N-Methyl-L-valine, 2.71 
Fmoc-N-methyl-L-valine (2.6, 52 mg, 0.15 mmol) was dissolved in MeOH (4 mL) and 
piperidine (1 mL) and stirred at room temperature for 2 hours.  The solvents were 
removed in vacuo, then the product was suspended in H2O (4 mL) and extracted with 
chloroform (2 x 3 mL).  The aqueous phase was dried down in vacuo to give the product 
(2.6, 19 mg, 0.15 mmol, 100%) as a white solid. 
[α]20D = +27 (c 0.5, 6M HCl(aq); lit c 1.0, 6M HCl(aq) + 33.7º);2 1H NMR (D20, 500 MHz) 
δ 3.30 (1H, d, 4.8 Hz), 2.60 (3H, s), 2.11 (1H, m), 0.94 (3H, d ,7.2 Hz), 0.91 (3H, d, 7.2 
Hz);3 HRESIMS m/z = 132.1018 [M+H]+ 5 ppm (132.1025 calcd for C6H14NO2). 
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Section 2.2.3  
N-Benzyl-L-threonine methyl ester, 2.84 
L-Threonine methyl ester hydrochloride (1 g, 5.90 mmol) was dissolved in MeOH (10 
mL), TEA (825 μL, 5.90 mmol, 1 eq) and benzaldehyde (730 μL, 7.10 mmol, 1.2 eq) 
were added and the reaction was stirred at room temperature for 1 hour.  It was then 
cooled to 0 ºC and NaBH4 (225 mg, 5.90 mmol, 1 eq) was added.  The reaction was 
stirred for a further 15 minutes at 0 ºC, acidified slowly with 6M HCl(aq), then solvents 
were removed in vacuo.  H2O (10 mL) was added, the mixture basified using 5M 
NaOH(aq) and extracted with ethyl acetate (3 x 10 mL).  The combined organic phases 
were dried over MgSO4, filtered and the solvent removed in vacuo.  The crude material 
was then purified by chromatography on silica using a stepwise gradient of DCM to 5% 
MeOH in DCM to give the product (2.8, 1.22 g, 5.46 mmol, 93%) as a yellow oil.   
Rf 0.67 (silica, 19:1 DCM:MeOH, visualization UV/PMA); [α]20D = -49 (c 1.0, CHCl3; lit. 
c 1.0, MeOH, -34.5º);4 1H NMR (CDCl3, 500 MHz) δ 7.35-7.25 (5H, m, Bn), 3.84 (1H, d, 
13.0 Hz, Bn), 3.71 (3H, s, OCH3), 3.69-3.66 (2H, m, H3 and Bn), 3.04 (1H, d, 7.5 Hz, 
H2), 1.20 (3H, d, 6.2 Hz, H4); HRESIMS m/z = 224.1292 [M+H]+ 2.2 ppm (224.1287 
calcd for C12H18NO3). 
 
N-Benzyl-D-threonine methyl ester, ent-2.84 
Slightly yellow oil obtained (ent-2.8, 78 % yield). 
[α]20D = +49 (c 1.0, CHCl3); HRESIMS m/z = 224.1296 [M+H]+ 4.0 ppm (224.1287 calcd 
for C12H18NO3). 
 
N-Benzyl-N-methyl-L-threonine methyl ester, 2.94 
N-Benzyl-L-threonine methyl ester (2.8, 1.0 g, 4.43 mmol) was dissolved in MeCN (17 
mL), formaldehyde (37%, 1.58 mL, 18.8 mmol, 4.24 eq), NaBH3CN (304 mg, 4.43 mmol, 
1.0 eq) and acetic acid (347 mL, 5.99 mmol, 1.35 eq) sequentially and the reaction was 
stirred at room temperature for 1 hour.  H2O (20 mL) was added and the mixture basified 
using 5 M NaOH(aq), then extracted with ethyl acetate (3 x 20 mL).  The combined 
organic phases were dried over MgSO4, filtered and the solvent removed in vacuo.  The 
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crude product was then purified by chromatography on silica using 20% ethyl acetate in 
petroleum ether to give the product (2.9, 838 mg, 3.53 mmol, 80%) as a colourless oil.  
Rf 0.61 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/PMA); 
[α]20D = -98 (c 1.0, MeOH; lit. c 1.0, MeOH, -111.7º);4 1H NMR (CDCl3, 500 MHz) δ 
7.35-7.26 (5H, m, Bn), 3.98 (1H, m, H3), 3.82 (1H, d, 13.2 Hz, Bn), 3.78 (3H, s, OCH3), 
3.72 (~1H, br s, OH), 3.58 (1H, d, 13.2 Hz, Bn), 3.04 (1H, d, 9.9 Hz, H2), 2.28 (3H, s, 
NCH3), 1.17 (3H, d, 6.0 Hz, H4); 13C NMR (CDCl3, from HSQC on 500 MHz) δ 129.0 
(CH, Bn), 128.5 (CH, Bn), 127.5 (CH, Bn), 71.9 (CH, C2), 63.0 (CH, C3), 59.5 (CH2, 
Bn), 51.2 (CH3, OCH3), 37.8 (CH3, NCH3), 19.3 (CH3, C4); HRESIMS m/z = 238.1432 
[M+H]+ 4.6 ppm (238.1443 calcd for C13H20NO3). 
 
N-Benzyl-N-methyl-D-threonine methyl ester, ent-2.94 
Colourless oil obtained (ent-2.9, 77 %). 
[α]20D = +96 (c 1.0, MeOH); HRESIMS m/z = 238.1443 [M+H]+ 0 ppm (238.1443 calcd 
for C13H20NO3). 
 
N-Methyl-L-threonine methyl ester, 2.104 
N-Benzyl-N-methyl-L-threonine methyl ester (2.9, 55 mg, 0.20 mmol) was dissolved in 
MeOH (2 mL) and Pd/C (5 mg) was added.  The reaction was placed under a H2(g) 
atmosphere (using a balloon) and the reaction was stirred at room temperature for 20 
hours.  The catalyst was removed by filtration of the mixture though a short celite pad 
using DCM (50 mL) and the solvents were removed in vacuo to give the product (2.10, 
16 mg, 0.11 mmol, 55%) as a colourless oil.   
[α]20D = -19 (c 1.0, MeOH; lit. c 1.0, MeOH, -18.7º);4 1H NMR (CDCl3, 500 MHz) δ 3.77 
(3H, s, OCH3), 3.66 (1H, m, H3), 2.91 (3H, d, 7.7 Hz, H2), 2.42 (3H, s, NCH3), 1.21 (3H, 
d, 6.2 Hz, H4); HRESIMS m/z = 148.0973 [M+H]+ 0.7 ppm (148.0974 calcd for 
C6H14NO3). 
 
 
 
 
 
Chapter 5: Experimental 237
N-Methyl-D-threonine methyl ester, ent-2.104 
Colourless oil obtained (ent-2.10, 97 % yield).   
[α]20D = +17 (0.9, MeOH); HRESIMS m/z = 148.0980 [M+H]+ 4.1 ppm (148.0974 calcd 
for C6H14NO3). 
 
N-Methyl-L-threonine, 2.114 
N-Methyl-L-threonine methyl ester (2.10, 130 mg, 0.88 mmol) was dissolved in THF (10 
mL) and 0.1 M LiOH(aq) (8.8 mL, 0.88 mmol, 1 eq) and stirred at room temperature 
overnight.  The solvents were removed in vacuo to give the product as a white amorphous 
solid (2.11, ~ 100%).     
[α]20D = -2 (c 1.0, H2O); 1H NMR (D2O, 500 MHz) δ 3.68 (1H, m, H3)  2.72 (1H, d, 6.7 
Hz, H2), 2.15 (3H, s, NCH3), 1.05 (3H, 6.5 Hz, H4);5 HRESIMS m/z = 134.0821 [M+H]+ 
3.0 ppm (134.0817 calcd for C5H12NO3). 
 
N-Methyl-D-threonine, ent-2.114 
White amorphous solid (~100%). 
[α]20D = +10 (c 1.0, H2O) 
 
 
Section 2.2.4 
CBz-N-methyl-L-threonine, 2.12 
N-Methyl-L-threonine methyl ester (2.10, 62 mg, 0.34 mmol) was dissolved in dioxane (1 
mL), cooled in an ice-bath and NaHCO3(aq) (1M, 335 μL, 0.34 mmol, 1 eq) was added.  
CBzCl (76 μL, 0.54 mmol, 1.6 eq) was added slowly, with simultaneous addition of 
NaHCO3(aq) (1M, 335 μL, 0.34 mmol, 1 eq).  The reaction was allowed to warm to room 
temperature and stirred for 16 hours.  After removal of most of the solvent in vacuo, the 
mixture was partitioned between ethyl acetate and H2O.  The organic phase was then 
dried over MgSO4, filtered and the solvent removed in vacuo.  The crude material was 
purified by chromatography on silica using a step-wise gradient from 5 to 50% ethyl 
acetate in petroleum ether, to give the correct product (2.12, 66 mg, 0.25 mmol, 74%) as 
a colourless oil. 
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Rf 0.36 (silica, 1:1 petroleum ether:ethyl acetate, visualization UV/PMA); 1H NMR 
(CDCl3, 500 MHz) δ 7.38-7.31 (5H, m, CBz), 5.18 (2H, br s, CBz), 4.61 (1H, d, 4.8 Hz, 
H2), 4.45 (1H, m, H3), 3.77 (3H, s, OCH3), 3.03 (3H, s, N CH3), 1.25 (3H, d, 6.5 Hz, 
H4); 13C NMR (CDCl3, 75 MHz) δ 170.6 (C, C=O), 157.6 (C, CBz), 136.4 (C, CBz), 
128.5 (CH, CBz), 128.0 (CH, CBz), 127.7 (CH, CBz), 67.7 (CH2, CBz), 67.2 (CH, C3), 
64.5 (CH, C2), 52.4 (CH3, OCH3), 34.0 (CH3, N CH3), 19.5 (CH3, C4); HRESIMS m/z = 
282.1339 [M+H]+ 0.7 ppm (282.1341 calcd for C14H20NO5). 
 
Dehydration of CBz-N-methyl-L-threonine methyl ester, 2.11, to give 2.13 
CBz-N-methyl-L-threonine methyl ester (2.11, 30 mg, 0.11 mmol) was dissolved in dry 
pyridine (1 mL), cooled in an ice-bath and tosic anhydride (81 mg, 0.22 mmol, 2 eq) was 
added.  The reaction was allowed to warm slowly to room temperature and stirred for 16 
hours.  After removal of the solvent in vacuo, the crude residue was purified by 
chromatography on silica using a step-wise gradient of 10 to 40% ethyl acetate in 
petroleum ether.  Starting material (9.3 mg, 0.033 mmol, 30%) and the dehydration 
product (2.13, 9.3 mg, 0.035 mmol, 32%, colourless oil) were obtained.   
Rf 0.75 (silica, 1:1 petroleum ether:ethyl acetate, visualization UV/PMA); 1H NMR 
(CDCl3, 500 MHz) δ 7.41-7.25 (5H, m, CBz), 6.92 (1/4H, q, 7.1 Hz, H3), 6.83 (3/4H, q, 
7.1 Hz, H3), 5.19 (1/2H, br s, CBz), 5.10 (3/2H, br s, CBz), 3.76 (3/4H, s, OCH3), 3.64 
(9/4H, s, OCH3), 3.05 (3/4H, s, NCH3), 3.04 (9/4H, s, NCH3), 1.80 (3/4H, d, 7.1 Hz, H4), 
1.76 (9/4H, d, 7.1 Hz, H4); HRESIMS m/z = 264.1231 [M+H]+ 1.9 ppm (264.1236 calcd 
for C14H18NO4). 
 
N-Benzyl-N-methyl-O-acetyl-L-threonine methyl ester, 2.15 
N-Benzyl-N-methyl-L-threonine methyl ester (2.9, 25 mg, 0.11 mmol) was dissolved in 
anhydrous THF, DEAD (71 μL, 0.45 mmol, 4.1 eq), dry acetic acid (100 μL, 1.75 mmol, 
16 eq) and PPh3 (118 mg, 0.45 mmol, 4.1 eq) were added and the reaction was stirred at 
room temperature for 16 hours. After removal of solvents in vacuo, the crude residue was 
purified by chromatography on silica using a step-wise gradient of 1 to 20% ethyl acetate 
in petroleum ether. Starting material (2.9, 12.6 mg, 0.053 mmol, 48%) and product (2.15, 
15.6 mg, 0.056 mmol, 51%, colourless oil) were obtained.   
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 Rf 0.43 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/PMA); 1H NMR 
(CDCl3, 500 MHz) δ 7.31-7.22 (5H, m, Bn), 5.40 (1H, m, H3), 3.83 (1H, d, 13.6 Hz, Bn), 
3.75 (3H, s, OCH3), 3.64 (1H, d, 13.6 Hz, Bn), 3.36 (1H, d, 8.5 Hz, H2), 2.31 (3H, s, 
NCH3), 2.08 (3H, s, COCH3), 1.24 (3H, d, 6.3 Hz, H4); 13C NMR (CDCl3, 75 MHz) δ 
170.2 (C=O x 2), 128.6(Bn), 128.2 (Bn), 127.1 (Bn), 69.4 (C2 or C3), 67.7 (C2 or C3), 
59.5 (Bn), 51.2 (OCH3), 38.5 (NCH3), 21.3 (COCH3), 17.6 (C4), quartenary benzyl C not 
observed; HRESIMS m/z = 280.1557 [M+H]+ 2.9 ppm (280.1549 calcd for C15H22NO4). 
 
N-Methyl-O-acetyl-L-threonine methyl ester, 2.16 
N-Benzyl-N-methyl-O-acetyl-L-threonine methyl ester (2.15, 44 mg, 0.16 mmol) was 
dissolved in MeOH (2 mL) and palladium on carbon (10% w/w, 4 mg) was added.  The 
reaction was then placed under an atmosphere of H2(g) and stirred at room temperature for 
20 hours.  The reaction was filtered through a pad of celite using DCM (20 mL) and the 
solvents were removed in vacuo.  1H NMR spectrum of the crude product suggested the 
correct product had been formed, but impurities were present.  The crude material was 
taken up in HCl(aq) (1 M, 2 mL) and extracted with ethyl acetate (2 x 2 mL).  The aqueous 
phase was basified with NaHCO3(aq) (1 M) and extracted with ethyl acetate (3 x 2 mL), 
the combined organic phases were dried over MgSO4, filtered and the solvents removed 
in vacuo.  1H NMR spectrum showed the product was still very impure.   
1H NMR (CDCl3, 500 MHz) δ 5.03 (1 H, d, 4.4 Hz, H2), 4.48 (1H, m, H3), 3.77 (3H, s, 
OCH3), 3.12 (3H, s, NCH3), 2.18 (3H, s, COCH3), 1.21 (3H, d, 6.7 Hz, H4) 
 
N-Benzyl-N-methyl-O-acetyl-L-threonine, 2.17 
N-Benzyl-N-methyl-O-acetyl-L-threonine methyl ester (2.15, 15 mg, 0.054 mmol) was 
dissolved in THF (1.6 mL) and LiOH(aq) (0.1M, 1.6 mL, 0.16 mmol, 3 eq), and stirred at 
room temperature for 16 hours. The solvents were then removed in vacuo to give the 
product (2.17, 17.2 mg obtained – contains salt impurities).   
1H NMR (D2O, 500 MHz) δ 7.31-7.22 (5H, m, Bn), 3.87 (1H, m, H3), 3.73 (1H, d, 13.0 
Hz, Bn), 3.43 (1H, d, 13.0 Hz, Bn), 2.82 (1H, d, 9.9 Hz, H2), 2.14 (3H, s, NCH3), 1.80 
(3H, s, COCH3), 1.05 (3H, d, 6.2 Hz, H4); 13C NMR (CD3OD, 75 MHz) δ 182.7 (C, 
C=O), 178.2 (C, C=O), 140.2 (C, Bn), 130.9 (CH, Bn), 129.7 (CH, Bn), 128.6 (CH, Bn), 
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76.6 (CH, C2), 65.7 (CH, C3), 59.6 (CH2, Bn), 39.1 (CH3, NCH3), 24.5 (CH3, COCH3), 
20.3 (CH3, C4).  
 
N-Benzyl-N-methyl-O-benzoyl-L-threonine methyl ester, 2.18 
Colourless oil obtained (2.18, 84 %).  Full analytical data given for ent-2.18 (see below). 
[α]20D = -78 (c 1.0, CHCl3). 
 
N-Benzyl-N-methyl-O-benzoyl-D-threonine methyl ester, ent-2.18 
N-Benzyl-N-methyl-D-threonine methyl ester (2.9, 50 mg, 0.22 mmol) was dissolved in 
anhydrous THF, DEAD (142 μL, 0.90 mmol, 4.1 eq), benzoic acid (516 mg, 4.22 mmol, 
19 eq) and PPh3 (236 mg, 0.90 mmol, 4.1 eq) were added and the reaction was stirred at 
room temperature for 60 hours. After removal of solvents in vacuo, the crude residue was 
purified by chromatography on silica using a step-wise gradient of 2 to 20% ethyl acetate 
in petroleum ether to give the product (ent-2.18, 71 mg, 0.21, 9%) as a colourless oil. 
Rf 0.38 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/PMA); [α]20D = +75 (c 
1.0, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 8.03 (2H, d, 7.8 Hz, Bz), 7.58 (1H, t, 7.7 Hz, 
Bz), 7.46 (2H, t, 7.8 Hz, Bz), 7.26-7.19 (5H, m, Bn), 5.66 (1H, m, H3), 3.85 (1H, d, 13.6 
Hz, Bn), 3.75 (3H, s, OCH3), 3.70 (1H, d, 13.6 Hz, Bn), 3.49 (1H, d, 8.3 Hz, H2), 2.40 
(3H, s, NCH3), 1.37 (3H, d, 6.3 Hz, H4); 13C NMR (CDCl3, 75 MHz) δ 170.2 (C, C=O), 
165.7 (C, C=O), 139.1 (C, Bn), 132.9 (CH, Bz), 129.7 (CH, Bz), 128.7 (CH, Bn), 128.3 
(CH, Bz), 128.1 (CH, Bn), 127.0 (CH, Bn), 69.2 (CH, C2), 68.5 (CH, C3), 59.7 (CH2, 
Bn), 51.2 (CH3, OCH3), 38.4 (CH3, NCH3), 17.6 (CH3, C4); HRESIMS m/z = 342.1718 
[M+H]+ 3.8 ppm (342.1705 calcd for C20H24NO4). 
 
N-Methyl-O-benzoyl-L-threonine methyl ester, 2.19 
Colourless oil obtained (2.19, 84 %).  Full analytical data given for ent-2.19 (see below). 
[α]20D = -20 (c 1.0, CHCl3).   
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N-Methyl-O-benzoyl-D-threonine methyl ester, ent-2.19 
N-Benzyl-N-methyl-O-benzoyl-D-threonine methyl ester (ent-2.18, 10 mg, 0.029 mmol) 
was dissolved in ethyl acetate (1 mL), Pd/C (2 mg) was added and the reaction placed 
under an H2 atmosphere by use of a balloon.  The reaction was stirred at room 
temperature for 16 hours, then filtered through a short celite pad with DCM (~ 20 mL).  
After removal of the solvents in vacuo the product (ent-2.19, 5.5 mg, 0.022 mmol, 76%) 
was obtained as a colourless oil.  
Rf 0.16 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/ninhydrin); [α]20D = 
+16 (c 1.0, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 8.01 (2H, d, 7.9 Hz, Bz), 7.55 (1H, t, 
7.5 Hz, Bz), 7.43 (2H, t, 7.7 Hz, Bz), 5.57 (1H, m, H3), 3.71 (3H, s, OCH3), 3.38 (1H, d, 
7.9 Hz, H2), 2.41 (3H, s, NCH3), 1.38 (3H, d, 6.4 Hz, H4); 13C NMR (CDCl3, 75 MHz) δ 
173.1 (C, C=O), 165.7 (C, C=O), 133.0 (CH, Bz), 130.1 (C, Bz), 129.6 (CH, Bz), 128.4 
(CH, Bz), 71.4 (CH, C3), 66.5 (CH, C2), 52.0 (CH3, OCH3), 35.5 (CH3, NCH3), 16.8 
(CH3, C4); HRESIMS m/z = 252.1237 [M+H]+ 0.4 ppm (252.1236 calcd for C13H18NO4). 
 
N-Methyl-L-threonine, 2.20 
White amorphous solid obtained (contains salt impurites).  Further analytical data given 
for ent-2.20 (see below). 
 
N-Methyl-D-threonine, ent-2.20 
N-Methyl-O-benzoyl-D-threonine methyl ester (ent-2.19, 7 mg, 0.028 mmol) was 
dissolved in ethanol (200 μL) and 0.5M NaOH(aq) (220 μL, 0.11 mmol, 4 eq).  The 
reaction was stirred at room temperature for 16 hours.  The solvents were partially 
removed in vacuo, then the mixture was washed with ethyl acetate (2 x 1 mL), acidified 
with 1M HCl(aq) and washed again with ethyl acetate (2 x 1 mL) then the solvents were  
removed in vacuo to give the product as a white amorphous solid (ent-2.20, contains salt 
impurities).   
1H NMR (D2O, 500 MHz) δ 4.11 (1H, m, H3), 3.58 (1H, d, 6.6 Hz, H2), 2.73 (3H, s, 
NCH3), 1.30 (3H, d, 6.5 Hz, H4); 13C NMR (CDCl3, from HSQC at 500 MHz) δ 68.6 
(CH, C2), 66.0 (CH, C3), 32.6 (CH3, NCH3), 19.4 (CH3, C4); HRESIMS m/z = 134.0816 
[M+H]+ 0.7 ppm (134.0817 calcd for C5H12NO3). 
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Section 2.2.6 
L-allo-Threonine methyl ester, 2.26 
L-allo-Threonine (50 mg, 0.42 eq) was suspended in MeOH (2 mL) and thionyl chloride 
(200 μL, 2.74 mmol, 6.5 eq) was added dropwise.  The reaction was then refluxed for 5 
hours.  After cooling, the solvent and residual thionyl chloride were removed in vacuo to 
give the product (2.26, 70 mg, 0.42 mmol, ~100%) as a colourless oil.   
1H NMR (D2O, 75 MHz) δ 4.07 (1H, m, H3), 3.89 (1H, d, 3.4 Hz, OH), 3.68 (3H, s, O 
CH3), 3.13 (1H, m, H2), 1.08 (3H, d, 6.6 Hz, H4).  
 
D-allo-Threonine methyl ester, ent-2.26 
Prepared as 2.26, using D-allo-threonine as starting material.  Product obtained as 
colourless oil (~ 100%). 
 
N-Benzyl-L-allo-threonine methyl ester, 2.27 
Prepared as 2.8, using 2.26 as starting material.  White crystalline solid obtained (2.27, 
60% yield).  
Rf 0.31 (silica, 19:1 DCM: MeOH, visualization UV/PMA); mp 91-93 ºC; [α]20D = -56 (c 
0.4, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.35-7.27 (5H, m, Bn), 4.05 (1H, m, H3), 
3.92 (1H, d, 12.8 Hz, Bn), 3.76 (3H, s, OCH3), 3.69 (1H, d, 12.8 Hz, Bn), 3.42 (1H, d, 
4.7 Hz, H2), 1.10 (3H, d, 6.5 Hz, H4); 13C NMR (CDCl3, 75 MHz) δ 173.3 (C=O), 139.0 
(Bn), 128.5 (Bn), 128.4 (Bn), 127.4 (Bn), 67.1 (C2 or C3), 65.3 (C2 or C3), 52.7 (Bn or 
OCH3), 52.0 (Bn or OCH3), 18.8 (C4); HRESIMS m/z = 224.1288 [M+H]+ 0.4 ppm 
(224.1287 calcd for C12H18NO3). 
 
N-Benzyl-D-allo-threonine methyl ester, ent-2.27 
Prepared as 2.8, using ent-2.26 as starting material.  White crystalline solid obtained (ent-
2.27, 62 % yield).  
 [α]20D = +50 (c 0.4, CHCl3). 
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N-Benzyl-N-methyl-L-allo-threonine methyl ester, 2.28 
Prepared as 2.9, using 2.27 as starting material.  Colourless oil obtained (2.28, 88% yield). 
Rf 0.17 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/PMA); [α]20D = -128 (c 
1.0, CHCl3); IR (thin film) νmax 3500-3300, 1732, 1454, 1196, 1173 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ 7.32-7.24 (5H, m, Bn), 4.17 (1H, m, H3), 3.81 (3H, s, OCH3), 3.75 
(1H, d, 13.6 Hz, Bn), 3.62 (1H, d, 13.6 Hz, Bn), 3.09 (1H, d, 8.7 Hz, H2), 2.24 (3H, s, 
NCH3), 1.30 (3H, d, 6.4 Hz, H4); 13C NMR (CDCl3, 75 MHz) δ 172.7 (C=O), 138.7 (Bn), 
128.8 (Bn), 128.3 (Bn), 127.2 (Bn), 71.5 (C2 or C3), 66.1 (C2 or C3), 60.0 (Bn), 51.2 
(OCH3), 38.5 (NCH3), 20.0 (C4); HRESIMS m/z = 238.1439 [M+H]+ 1.7 ppm (238.1443 
calcd for C13H20NO3). 
 
N-Benzyl-N-methyl-D-allo-threonine methyl ester, ent-2.28 
Prepared as 2.9, using ent-2.27 as starting material.  Colourless oil obtained (ent-2.28, 
95% yield). 
[α]20D = +129 (c 1.0, CHCl3). 
 
N-Methyl-L-allo-threonine methyl ester, 2.29 
Prepared as 2.10, using ent-2.28 as starting material.  Colourless oil obtained (2.29, 80% 
yield). 
[α]20D = -4 (c 1.0, MeOH); IR (thin film) νmax 3400-3200, 1736, 1435, 1173 cm-1; 1H 
NMR (CDCl3, 500 MHz) δ 4.04 (1H, m, H3), 3.77 (3H, s, OCH3), 3.26 (1H, d, 4.7 Hz, 
H2), 2.44 (3H, s, NCH3), 1.10 (3H, d, 6.5 Hz, H4); 13C NMR (CDCl3, 75 MHz) δ 173.4  
(C=O), 68.0 (C2 or C3), 67.1 (C2 or C3), 51.9 (OCH3), 35.4 (NCH3), 18.8 (C4); 
HRESIMS m/z = 148.0982 [M+H]+ 5.4 ppm (148.0974 calcd for C6H14NO3). 
 
N-Methyl-D-allo-threonine methyl ester, ent-2.29 
Prepared as 2.10, using ent-2.28 as starting material.  Colourless oil obtained (ent-2.29, 
56% yield). 
[α]20D = +4 (c 0.08, MeOH) 
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N-Methyl-L-allo-threonine, 2.30 
N-Methyl-L-allo-threonine methyl ester, (2.29, 5 mg, 0.04 mmol) was dissolved in 6M 
HCl(aq) (1 mL) and the reaction heated to 50 ºC for 16 hours.  After cooling to room 
temperature, the solvent was removed in vacuo.  White solid obtained (2.30, 6 mg, 0.04 
mmol, ~ 100%). 
[α]20D = +6 (c 0.4, H2O); 1H NMR (D2O, 500 MHz) δ 4.30 (1H, m, H3), 3.86 (1H, d, 3.4 
Hz, H2), 2.68 (3H, s, NCH3), 1.19 (3H, d, 6.8 Hz, H4); 13C NMR (D2O, 75 MHz) δ 169.4 
(C=O), 65.4 (C2 and C3), 33.0 (NCH3), 18.2 (C4); HRESIMS m/z = 134.0823 [M+H]+ 
4.5 ppm (134.0817 calcd for C5H12NO3). 
 
N-Methyl-D-allo-threonine, ent-2.30 
Prepared as 2.30, using ent-2.29 as starting material.  White solid obtained (ent-2.30, ~ 
100%). 
 
 
Section 2.3.2 
N-Benzyl-L-trans-4-hydroxyproline ethyl ester, 2.34 
First esterification was carried out by a literature method to give L-trans-4-
hydroxyproline ethyl ester hydrochloride as follows:6 
L-trans-4-hydroxyproline (1 g, 7.63 mmol) was suspended in ethanol (10 mL) and thionyl 
chloride (620 μL, 8.55 mmol, 1.1 eq) was added dropwise with stirring. The reaction was 
then refluxed for 4 hours, during which time the hydroxyproline dissolved.  After cooling 
to room temperature, the mixture was poured into diethyl ether (100 mL), causing the 
precipitation of the product.  After further cooling to 4 ºC for 30 minutes the precipitate 
was filtered, washed with diethyl ether (2 x 20 mL) and the remaining solvents were 
removed in vacuo to give the product as a white amorphous solid HCl salt (1.42 g, 7.30 
mmol, 96%). 
1H NMR (CD3OD, 500 MHz) δ 4.57 (2H, m), 4.31 (2H, q, 7.0 Hz), 3.40 (1H, dd, 12.2 Hz, 
3.4 Hz), 3.31 (obscured by CD3OH), 2.42 (1H, dd, 13.7 Hz, 8.3 Hz), 2.17 (1H, ddd, 13.7 
Hz, 10.6 Hz, 4.3 Hz), 1.32 (3H, t, 7.0 Hz). 
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L-trans-4-hydroxyproline ethyl ester hydrochloride (1.28 g, 6.54 mmol) was then 
suspended in chloroform (25 mL), TEA (2.13 mL, 15.3 mmol, 2.3 eq) and benzyl 
bromide (830 μL, 7.0 mmol, 1.05 eq) were added and the reaction was refluxed for 6 
hours.  After cooling the reaction to room temperature, NaOH(aq) (1M,15 mL) was added, 
the phases separated, the aqueous phase extracted with DCM (2 x 20 mL) and the 
combined organic phases dried over MgSO4, filtered and the solvent removed in vacuo. 
The crude product was then purified by chromatography on silica using 30% petroleum 
ether in ethyl acetate to give the product (1.41 g, 5.64 mmol, 86%) as a slightly yellow oil.  
Rf 0.46 (silica, 3:7 petroleum ether:ethyl acetate, visualization UV/PMA); 
1H NMR (CDCl3, 500 MHz) δ 7.33-7.24 (5H, m, Bn), 4.46 (1H, m, H4), 4.13 (2H, q, 7.1 
Hz, Et), 3.93 (1H, d, 12.9 Hz, Bn), 3.67 (1H, d, 12.9 Hz, Bn), 3.60 (1H, t, 7.8 Hz, H2), 
3.32 (1H, dd, 10.2 Hz, 5.6 Hz, H5a), 2.48 (1H, dd, 10.2 Hz, 3.8 Hz, H5b), 2.26 (1H, dt, 
13.4 Hz, 7.1 Hz, H3a), 2.08 (1H, ddd, 13.4 Hz, 8.2 Hz, 3.4 Hz, H3b), 1.25 (3H, t, 7.2 Hz, 
Et); 13C NMR (CDCl3, 75 MHz) δ 173.5 (C, C=O), 138.1 (C, Bn), 129.0 (CH, Bn), 128.3 
(CH, Bn), 127.2 (CH, Bn), 70.4 (CH, C4), 63.6 (CH, C2), 61.1 (CH2, C5), 60.6 (CH2, Et), 
58.0 (CH2, Bn), 39.6 (CH2, C3), 14.2 (CH3, Et); HRESIMS m/z = 250.1445 [M+H]+ 0.8 
ppm (250.1443 calcd for C14H20NO3). 
 
N-Benzyl-O-tosyl-L-trans-4-hydroxyproline ethyl ester, 2.356 
N-Benzyl-L-trans-4-hydroxyproline ethyl ester (2.34, 150 mg, 0.60 mmol) was dissolved 
in dry pyridine (3 mL) and cooled in an ice-bath.  pTSACl (138 mg, 0.72 mmol, 1.2 eq) 
was then added, the reaction was allowed to warm to room temperature and stirred for 40 
hours.  Citric acid (5% w/v, 5 mL) was added and the reaction extracted using diethyl 
ether (4 x 5 mL).  The combined organic phases were dried over MgSO4, filtered and the 
solvent removed in vacuo.  The crude product was purified by chromatography on silica 
using a step-wise gradient of 0 to 20% ethyl acetate in petroleum ether to give the product 
(2.35, 139 mg, 0.34 mmol, 57%) as a yellow oil.   
OR 
N-Benzyl-L-trans-4-hydroxyproline ethyl ester (2.34, 500 mg, 2.01 mmol) was dissolved 
in dry pyridine (10 mL), cooled in an ice-bath and tosic anhydride (1.09 g, 3.01 mmol, 
1.5 eq) was added.  The reaction was allowed to warm to room temperature and stirred 
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for 40 hours, then worked up as above to give the product (2.35, 382 mg, 0.95 mmol, 
48%).  
Rf 0.30 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/PMA); 1H NMR 
(CDCl3, 500 MHz) δ 7.75 (2H, d, 8.3 Hz, Ts), 7.33-7.24 (7H, m, Bn and Ts), 4.98 (1H, m, 
H4), 4.11 (2H, q, 7.1 Hz, Et), 3.88 (1H, d, 12.9 Hz, Bn), 3.60 (1H, d, 12.9 Hz, Bn), 3.55 
(1H, t, 7.8 Hz, H2), 3.26 (1H, dd, 11.2 Hz, 6.2 Hz, H5a), 2.64 (1H, dd, 11.2 Hz, 3.9 Hz, 
H5b), 2.44 (3H, s, Ts), 2.27 (2H, m, H3), 1.23 (3H, t, 7.2 Hz, Et); 13C NMR (CDCl3, 75 
MHz) δ 172.4 (C, C=O), 144.9 (C, Bn or Ts), 137.4 (C, Bn or Ts), 133.5 (C, Bn or Ts), 
129.9 (CH, Bn or Ts), 128.9 (CH, Bn or Ts), 128.3 (CH, Bn or Ts), 127.8 (CH, Bn or Ts), 
127.3(CH, Bn or Ts), 79.4 (CH, C4), 63.5 (CH, C2), 60.9 (CH2, Et), 57.9 (CH2, C5), 57.8 
(CH2, Bn), 36.5 (CH2, C3), 21.6 (CH3, Ts), 14.2 (CH3, Et); HRESIMS m/z = 404.1514 
[M+H]+ 4.5 ppm (404.1532 calcd for C21H26NO5S). 
 
N-Benzyl-O-tosyl-L-cis-4-hydroxyproline ethyl ester, 2.36 
N-Benzyl-L-trans-4-hydroxyproline ethyl ester (2.34, 150 mg, 0.60 mmol) was dissolved 
in dry benzene (12 mL), triphenylphosphine (825 mg, 3.2 mmol, 5.3 eq), zinc tosylate 
(162 mg, 0.40 mmol, 0.7 eq) and DEAD (500 μL, 3.2 mmol, 5.3 eq) were added and the 
reaction (protected from light) was stirred at room temperature for 3 hours.  After 
removal of the solvent, the crude product was purified by chromatography using a step-
wise gradient of 0 to 50% ethyl acetate in petroleum ether to give the product (2.36, 126 
mg, 0.31 mmol, 52%) as a colourless oil.   
Rf 0.69 (silica, 1:1 petroleum ether:ethyl acetate, visualization UV/PMA); 1H NMR 
(CDCl3, 500 MHz) δ 7.74 (2H, d, 8.2 Hz, Ts), 7.31-7.23 (7H, m, Bn and Ts), 4.98 (1H, m, 
H4), 4.30 (1H, m, H2), 4.15 (2H, q, 7.2 Hz, Et), 3.98 (1 H, d, 13.2 Hz, Bn), 3.51 (1H, d, 
13.2 Hz, Bn), 3.25 (1H, dd, 8.4 Hz, 6.9 Hz, H2), 3.07 (1H, dd, 11.1 Hz, 2.2 Hz, H5), 2.61 
(1H, m, H5), 2.48 (1H, dt, 14.5 Hz, 8.1 Hz, H3a), 2.42 (2H, s, Ts), 2.20 (1H, m, H3b), 
1.26 (3H, t, 7.2 Hz, Et); 13C NMR (CDCl3, 75 MHz) δ 172.2 (C, C=O), 144.7 (C, Ts or 
Bn), 137.3 (C, Ts or Bn), 133.9 (C, Ts or Bn), 129.8 (CH, Ts or Bn), 129.7 (CH, Ts or 
Bn), 128.9 (CH, Ts or Bn), 128.3 (CH, Ts or Bn), 127.7 (CH, Ts or Bn), 127.2 (CH, Ts or 
Bn), 78.7 (CH, C4), 63.3 (CH, C2), 60.9 (CH2, Et), 57.8 (CH2, C5), 57.1 (CH2, Bn), 36.5 
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(CH2, C3), 21.6 (CH3, Ts), 14.2 (CH3, Et); HRESIMS m/z = 404.1533 [M+H]+ 0.2 ppm 
(404.1532 calcd for C21H26NO5S). 
 
N-Benzyl-L-cis-4-methylproline ethyl ester, 2.37 
Copper (I) iodide (148 mg, 0.77 mmol, 7 eq) was suspended in dry diethyl ether (1 mL) 
and cooled to 0 ºC in an ice bath.  Methyl lithium (1.6 M in diethyl ether, 960 μL, 1.58 
mmol, 14 eq) was added dropwise, and the reaction was stirred at 0 ºC for 2 hours.  A 
solution of N-benzyl-O-tosyl-L-trans-4-hydroxyproline ethyl ester (2.35, 45 mg, 0.11 
mmol) in dry diethyl ether (1 mL) was then added dropwise and stirred at 0 ºC for 8 hours.  
A saturated solution of Na2CO3(aq) (3 mL) was added and the aqueous phase was 
extracted with diethyl ether (3 x 3 mL).  The combined organic phases were dried over 
MgSO4, filtered and the solvent removed in vacuo.  The crude residue was purified by 
chromatography on silica using a stepwise gradient of 0 to 50% ethyl acetate in 
petroleum ether to give the product (2.37, 1.4 mg, 0.006 mmol, 5%) as a colourless oil.   
Rf 0.48 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/PMA); 1H NMR 
(CDCl3, 500 MHz) δ 7.35-7.23 (5H, m, Bn), 4.14 (2H, dq, 7.3 Hz, 2.5 Hz), 3.92 (1H, d, 
12.9 Hz, Bn), 3.55 (1H, d, 13.0 Hz, Bn), 3.36 (1H, t, 7.9 Hz, H2), 2.68 (1H, m, H5a), 2.63 
(1H, br t, 8.0 Hz, H5b), 2.32 (1H, dt, 12.3 Hz, 8.0 Hz, H3a), 2.24 (1H, m, H4), 1.58 (1H, 
12.4 Hz, 7.4 Hz, H3b), 1.25 (3H, t, 7.2 Hz, Et), 1.05 (3H, d, 6.7 Hz, H6); 13C NMR 
(CDCl3, taken from 2D data at 500 MHz) δ 129.0 (CH, Bn), 128.2 (CH, Bn), 127.1 (CH, 
Bn), 65.9 (CH, C2), 60.4 (CH2, Et), 59.9 (CH2, C5), 58.2 (CH2, Bn), 31.3 (CH, C4), 20.1 
(CH3, C6), 14.3 (CH3, Et); LRESIMS m/z = 248.2 [M+H]+ (248.2 calcd for C15H22NO2). 
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N-Benzyl-L-trans-4-methylproline ethyl ester, 2.38 
Copper (I) iodide (114 mg, 0.60 mmol, 7.5 eq) was suspended in dry diethyl ether (500 
μL) and cooled to –8 ºC in an MeOH /H2O/dry ice bath.  Methyl lithium (1.6 M in diethyl 
ether, 700 μL, 1.12 mmol, 14 eq) was added dropwise, and the reaction was stirred at –8 
ºC for 120 minutes.  A solution of N-benzyl-O-tosyl-L-cis-4-hydroxyproline ethyl ester 
(2.36, 32 mg, 0.08 mmol) in dry diethyl ether (1 mL) was then added dropwise and then 
stirred at –8 ºC for 8 hours.  A saturated solution of Na2CO3(aq) (3 mL) was added and 
after warming the mixture to room temperature, it was extracted with diethyl ether (3 x 3 
mL).  The combined organic phases were dried over MgSO4, filtered and the solvent 
removed in vacuo.    The crude residue was purified by chromatography on silica using a 
stepwise gradient of 0 to 50% ethyl acetate in petroleum ether.  The product (2.38, 15 mg, 
0.06 mmol, 75%) was obtained as a colourless oil.   
Rf 0.24 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/PMA); 1H NMR 
(CDCl3, 500 MHz) δ 7.34-7.23 (5H, m, Bn), 4.11 (2H, m, Et), 3.91 (1H, d, 12.7 Hz, Bn), 
3.53 (1H, d, 12.7 Hz, Bn), 3.29 (1H, dd, 9.5 Hz, 5.8 Hz, H2), 3.13 (1H, dd, 8.7 Hz, 6.9 
Hz, H5a), 2.34 (1H, m, H4), 2.15 (1H, m, H3a), 1.99 (1H, t, 8.8 Hz, H5b), 1.69 (1H, m, 
H3b), 1.24 (3H, t, 7.1 Hz, Et), 0.98 (3H, d, 6.8 Hz, H6); 13C NMR (CDCl3, taken from 2D 
data at 500 MHz) δ 129.2 (CH, Bn), 128.3 (CH, Bn), 65.4 (CH, C2), 61.6 (CH2, C5), 60.6 
(CH2, Et), 59.2 (CH2, Bn), 37.8 (CH2, C3), 31.4 (CH, C4), 18.9 (CH3, C6), 14.4 (CH3, 
Et); LRESIMS m/z = 248.1 [M+H]+ (248.2 calcd for C15H22NO2). 
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Section 2.3.3 
N-CBz-4-hydroxy-L-trans-proline ethyl ester, 2.497 
4-Hydroxy-L-trans-proline ethyl ester hydrochloride (1 g, 5.11 mmol) was dissolved in 
anhydrous MeOH (20 mL) and cooled to 0 ºC. TEA (2.15 mL, 15.4 mmol, 3.0 eq) was 
added followed by the dropwise addition of CBzCl (950 μL, 6.75 mmol, 1.3 eq). The 
reaction was warmed to room temperature and stirred for 16 hours. The solvent was 
removed in vacuo, ethyl acetate (30 mL) was added and then the mixture was washed 
with citric acid(aq) (5% w/v, 3 x 30 mL) and H2O (2 x 20 mL). The organic phase was 
dried over MgSO4, filtered and the solvent removed in vacuo. The crude product was 
purified on silica using a stepwise gradient of 5 to 50% ethyl acetate in petroleum ether to 
give N-CBz-4-hydroxy-L-trans-proline ethyl ester (2.49, 1.46 g, 4.98 mmol, 98%) as a 
colourless oil (an inseparable ~1:1 mixture of cis- and trans-isomers around the 
carbamate was obtained).  
Rf 0.27 (silica, 1:1 petroleum ether:ethyl acetate, visualization UV/PMA); [α]D20 –55 (c 
1.00, CHCl3); IR (thin film) νmax 1743, 1707, 1421, 1358, 1196 cm-1; 1H NMR (CDCl3, 
500 MHz) δ 7.40-7.29 (5H, m, CBz), 5.16-5.03 (2H, m, CBz), 5.05 (1H, d, 12.7 Hz, OH), 
4.51-4.46 (2H, m, H-4 and H-2), 4.21 (1H, q, 7.2 Hz, Et), 4.02 (1H, m, Et), 3.69-3.54 (2H, 
m, H-5), 2.31 (1H, m, H-3a), 2.10 (1H, m, H-3b), 1.27 (3/2H, t, 7.1 Hz, Et), 1.11 (3/2H, t, 
7.1 Hz, Et); 13C NMR (CDCl3, 75 MHz) δ 173.1 (C, ester C=O), 172.9 (C, ester C=O), 
155.4 (C, CBz C=O), 155.0 (C, CBz C=O), 136.9 (C, CBz), 136.7 (C, CBz), 128.9 (CH, 
CBz), 128.8 (CH, CBz), 128.4 (CH, CBz), 128.3 (CH, CBz), 128.2 (CH, CBz), 70.6 (CH, 
C-4), 69.9 (CH, C-4), 67.7 (CH2, CBz), 67.6 (CH2, CBz), 61.7 (CH2, Et), 61.6 (CH2, Et), 
58.4 (CH, C-2), 58.2 (CH, C-2), 55.6 (CH2, C-5), 55.0 (CH2, C-5), 39.6 (CH2, C-3), 38.9 
(CH2, C-3), 14.5 (CH3, Et), 14.4 (CH3, Et); HRESIMS m/z = 294.1344 [M+H]+ 1.0 ppm 
(294.1341 calcd for C15H20NO5).  
 
N-CBz-4-hydroxy-D-cis-proline ethyl ester, 2.50 
Preparation as 2.49, using 4-hydroxy-D-cis-proline ethyl ester hydrochloride as starting 
material.  Product obtained as a colourless oil in approximately quantitative yield (an 
inseparable ~1:1 mixture of cis- and trans-isomers around the carbamate was obtained).  
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Rf 0.24 (silica, 1:1 petroleum ether:ethyl acetate, visualization UV/PMA); [α]D20 +20 (c 
0.10, CHCl3); IR (thin film) νmax 1748, 1705, 1418, 1351, 1201 cm-1; 1H NMR (CDCl3, 
500 MHz) δ 7.38-7.30 (5H, m, CBz), 5.14 (2H, m, CBz), 4.43 (1H, d, 10.0 Hz, H-2), 4.38 
(1H, m, H-4), 4.26 (1H, q, 7.0 Hz, Et), 4.08 (1H, m, Et), 3.78 (1/2H, d, 11.7 Hz, H-5a), 
3.73 (1/2H, d, 11.7 Hz, H-5a), 3.64 (1/2H, dd, 12.2 Hz, 4.6 Hz, H-5b), 3.60 (1/2H, dd, 
11.8 Hz, 4.5 Hz, H-5b), 2.34 (1H, m, H-3a), 2.12 (1H, m, H-3b), 1.31 (3/2H, t, 7.3 Hz, 
Et), 1.15 (3/2H, t, 7.2 Hz, Et); 13C NMR (CDCl3, 75 MHz) δ 174.7 (C, ester C=O), 174.5 
(C, ester C=O), 154.9 (C, CBz C=O), 154.2 (C, CBz C=O), 136.3 (C, CBz), 136.2 (C, 
CBz), 128.5 (CH, CBz), 128.4 (CH, CBz), 128.1 (CH, CBz), 127.9 (CH, CBz), 127.8 
(CH, CBz), 71.3 (CH, C-4), 70.3 (CH, C-4), 67.3 (CH2, CBz), 62.0 (CH2, Et), 61.9 (CH2, 
Et), 58.3 (CH, C-2), 57.9 (CH, C-2), 56.2 (CH2, C-5), 55.9 (CH2, C-5), 38.6 (CH2, C-3), 
37.7 (CH2, C-3), 13.9 (CH3, Et); HRESIMS m/z = 294.1329 [M+H]+ 4.1 ppm (294.1341 
calcd for C15H20NO5). 
 
N-CBz-4-keto-L-proline ethyl ester, 2.51  
CrO3 (6.30 g, 63.0 mmol, 13 eq) was dissolved in a mixture of pyridine (10.2 mL) and 
DCM (50 mL) and stirred at room temperature for 15 minutes. After this time N-CBz-
trans-4-hydroxy-L-proline ethyl ester (2.49, 1.4 g, 4.77 mmol) dissolved in DCM (20 
mL) was added to the mixture. The reaction was stirred at room temperature for 16 hours, 
then filtered through a silica pad using 50% ethyl acetate in petroleum ether (200 mL). 
After removal of the solvents in vacuo, the product (1.18 g, 4.05 mmol, 85%) was 
obtained as a colourless oil (an inseparable ~1:1 mixture of cis- and trans-isomers around 
the carbamate was obtained).  
Rf 0.43 (silica, 2:1 petroleum ether:ethyl acetate, visualization UV/PMA); [α]D20 –4 (c 
1.00, CHCl3); IR (thin film) νmax 1767, 1743, 1713, 1416, 1192, 1158 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ 7.38-7.32 (5H, m, CBz), 5.20 (2H, m, CBz), 4.85 (1/2H, d, 10.8 Hz, 
H-2), 4.81 (1/2H, d, 10.8 Hz, H-2) 4.22 (1H, q, 7.2 Hz, Et), 4.09 (1H, m, Et), 3.96 (2H, 
m, H-5), 2.95 (1H, m, H-3a), 2.60 (1H, dd, 18.8 Hz, 2.6 Hz, H-3b), 1.27 (3/2H, t, 7.2 Hz, 
Et), 1.16 (3/2H, t, 7.2 Hz, Et); 13C NMR (CDCl3, 75 MHz) δ 207.8 (C, C-4), 207.1 (C, C-
4), 171.3 (C, ester C=O), 154.9 (C, CBz C=O), 154.1 (C, CBz C=O), 135.9 (C, CBz), 
129.0 (CH, CBz), 128.5 (CH, CBz), 128.3 (CH, CBz), 128.0 (CH, CBz), 67.7 (CH2, 
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CBz), 61.8 (CH2, Et), 56.0 (CH, C-2), 52.6 (CH2, C-5), 52.4 (CH2, C-5), 41.1 (CH2, C-3), 
40.6 (CH2, C-3), 14.0 (CH3, Et); HRESIMS m/z = 292.1191 [M+H]+ 2.1 ppm (292.1185 
calcd for C15H18NO5). 
OR 
N-CBz-L-trans-4-hydroxyproline ethyl ester (2.49, 1 g, 3.41 mmol) and IBX (2.88 g, 10.2 
mmol, 3.0 eq) were dissolved in DMSO (24 mL) at 70 ºC and stirred for 40 hours.  After 
cooling the mixture to room temperature ethyl acetate (50 mL) was added and the 
mixture extracted with NaHCO3 (aq) (1 M, 2 x 40 mL) and H2O (1 x 40 mL).  The organic 
phase was dried over MgSO4, filtered and the solvent removed in vacuo.  The crude 
product was purified on silica using a stepwise gradient of 5 to 15% ethyl acetate in 
petroleum ether.  The product (2.51, 360 mg, 1.24 mmol, 36%) was obtained as a 
colourless oil.   
 
N-CBz-4-keto-D-proline ethyl ester, ent-2.51  
Preparation as 2.51 (CrO3 method), using N-CBz-4-hydroxy-D-cis-proline ethyl ester, 
2.50. Product obtained as a colourless oil (ent-2.51, 87 %).  
[α]D20 +4 (c 1.00, CHCl3).  
 
N-CBz-L-4-exomethyleneproline ethyl ester, 2.52 
Wittig reaction (tBuOK(s))  
tBuOK (73 mg, 0.65 mmol, 3 eq), was dissolved in anhydrous THF (3 mL) and MePPh3I 
(260 mg, 0.65 mmol, 3 eq) was added in one portion.  The reaction was stirred for 15 
minutes at room temperature.  N-CBz-L-4-ketoproline ethyl ester (2.51, 62 mg, 0.21 
mmol), dissolved in anhydrous THF (3 mL) was then added dropwise to the solution and 
the reaction was stirred for a further 20 hours at room temperature.  After diluting the 
reaction with ethyl acetate (10 mL) the mixture was extracted with citric acid(aq) (5% w/v, 
2 x 10 mL) and NaHCO3(aq) (1M, 2 x 10 mL).  The organic phase was dried over MgSO4, 
filtered and the solvent removed in vacuo.  The crude product was purified on silica using 
a stepwise gradient of 4 to 16% ethyl acetate in petroleum ether to give the product (2.52, 
16 mg, 0.054 mmol, 26%) as a colourless oil.   
[α]D20 0 (c 1.00, CHCl3).  
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Wittig reaction (tBuOK, 1M THF)  
MePPh3I (390 mg, 0.97 mmol, 1.41 eq) was added in several portions over 5 minutes to a 
solution of tBuOK (960 μL of a 1M THF solution, 0.96 mmol, 1.39 eq, diluted in 
anhydrous THF, 2.5 mL) at room temperature and the mixture was then stirred for a 
further 15 minutes.  N-CBz-L-4-ketoproline ethyl ester (2.51, 200 mg, 0.69 mmol) 
dissolved in anhydrous THF (1.3 mL) was then added dropwise to the mixture.  The 
reaction was then stirred at room temperature for 2 hours.  After diluting the reaction with 
ethyl acetate (10 mL) the mixture was extracted with citric acid(aq) (5% w/v, 2 x 10 mL) 
and NaHCO3(aq) (1M, 2 x 10 mL).  The organic phase was dried over MgSO4, filtered and 
the solvent removed in vacuo.  The crude product was purified on silica using a stepwise 
gradient of 4 to 12% ethyl acetate in petroleum ether to give the product (2.52, 22 mg, 
0.076 mmol, 11%) as a colourless oil.   
Petasis reaction 
To N-CBz-4-keto-L-proline ethyl ester (2.51, 100 mg, 0.34 mmol), dissolved in 
anhydrous toluene (1 mL), was added a toluene solution of dimethyltitanocene8 (2.64, see 
below, ~ 0.88 mmol in ~ 1 mL, 2.6 eq) and the reaction was heated to 90 ºC for 3 hours. 
After cooling to room temperature the mixture was added dropwise to stirred petroleum 
ether (50 mL), whereupon a yellow precipitate formed, and was stirred for a further 30 
minutes. The precipitate was removed by filtration through a bed of celite and the 
solvents were removed in vacuo. The crude residue was purified by chromatography on 
silica using a stepwise gradient of 2 to 10% diethyl ether in petroleum ether to give the 
product (2.52, 54 mg, 0.19 mmol, 56%) as a colourless oil (an inseparable ~1:1 mixture 
of cis- and trans- isomers around the carbamate was obtained).  
Rf 0.57 (silica, 2:1 petroleum ether:ethyl acetate, visualization UV/PMA); [α]D20 –16 (c 
1.00, CHCl3); IR (thin film) νmax 1747, 1714, 1417, 1360, 1196, 896 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ 7.38-7.29 (5H, m, CBz), 5.14 (2H, m, H-6), 5.02 (2H, m, CBz), 
4.55 (1/2H, dd, 9.6 Hz, 2.9 Hz, H-2), 4.50 (1/2H, dd, 9.6 Hz, 2.9 Hz, H-2), 4.17 (3H, m, 
H-5, Et), 4.07 (1H, m, Et), 2.98 (1H, m, H-3a), 2.64 (1H, br d, 16.1 Hz, H-3b), 1.26 
(3/2H, t, 7.2 Hz, Et), 1.14 (3/2 H, t, 7.2 Hz, Et); 13C NMR (CDCl3, 75 MHz) δ 172.1 (C, 
ester C=O), 172.0 (C, ester C=O), 154.9 (C, CBz C=O), 154.3 (C, CBz C=O), 142.9 (C, 
C-4), 142.0 (C, C-4), 136.5 (C, CBz), 136.4 (C, CBz), 128.8 (CH, CBz), 128.6 (CH, 
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CBz), 128.5 (CH, CBz), 128.4 (CH, CBz), 128.01 (CH, CBz), 127.97 (CH, CBz), 127.9 
(CH, CBz), 127.8 (CH, CBz), 108.3 (CH2, C-6), 108.2 (CH2, C-6), 67.13 (CH2, CBz), 
67.07 (CH2, CBz), 61.3 (CH2, Et), 61.2 (CH2, Et), 59.0 (CH, C-2), 58.9 (CH, C-2), 51.0 
(CH2, C-5), 50.5 (CH2, C-5), 36.8 (CH2, C-3), 36.0 (CH2, C-3), 14.1 (CH3, Et), 14.0 
(CH3, Et); HRESIMS m/z = 290.1404 [M+H]+ 4.1 ppm (290.1392 calcd for C16H20NO4). 
 
N-CBz-4-exomethylene-D-proline ethyl ester, ent-2.52  
Prepared by the Wittig reaction (tBuOK(s)), using N-CBz-4-keto-D-proline ethyl ester, 
ent-2.51. Product obtained as a colourless oil (ent-2.52, 30%). 
[α]D20 0 (c 1.00, CHCl3).  
Prepared by the Petasis reaction.  Colourless oil obtained in 42% yield.  
[α]D20 +15 (c 1.00, CHCl3).  
 
N-CBz-4-methyl-L-trans-proline ethyl ester, 2.53 and intermediate olefin 
isomerisation product, 2.58 
N-CBz-4-exomethylene-L-proline ethyl ester (2.52, 30 mg, 0.104 mmol) was dissolved in 
chloroform (1 mL) and Ir(cod)pyr(PCy3)]PF6 (Crabtree’s catalyst, 2.43, 3 mg, 0.004 
mmol, 4 mol%) was added. The reaction was placed under an atmosphere of H2(g) by 
means of a balloon and stirred at room temperature for 5 days. The crude product was 
purified on silica using a stepwise gradient of 2 to 6% diethyl ether in petroleum ether to 
give the product (2.53, 25 mg, 0.087 mmol, 84%) as a colourless oil, plus isomerisation 
product (2.58, 3 mg, 0.010 mmol, 10%) as a colourless oil. Inseparable ~1:1 mixtures of 
cis- and trans-isomers around the carbamate were obtained for both products.  
2.58  Rf 0.29 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/PMA); [α]D20 -87 
(c 0.30, CHCl3); IR (thin film) νmax 1751, 1709, 1427, 1203, 1183 cm-1; 1H NMR (CDCl3, 
500 MHz) δ 7.38-7.30 (5H, m, CBz), 6.40 (1/2H, br s, H-5), 6.32 (1/2H, br s, H-5), 5.15 
(2H, m, CBz), 4.70 (1/2H, dd, 12.0 Hz, 5.0 Hz, H-2), 4.64 (1/2H, dd, 12.0 Hz, 5.0 Hz, H-
2), 4.23 (1H, q, 7.0 Hz, Et), 4.08 (1H, q, 7.1 Hz, Et), 2.99 (1H, m, H-3a), 2.53 (1H, m, H-
3b), 1.70 (3/2H, br s, H-6), 1.68 (3/2H, br s, H-6), 1.28 (3/2H, t, 7.1 Hz, Et), 1.15 (3/2H, 
t, 7.1 Hz, Et); 13C NMR (CDCl3, 75 MHz) δ 128.5 (CH, CBz), 128.0 (CH, CBz), 127.9 
(CH, CBz), 124.3 (CH, C-5), 123.7 (CH, C-5), 67.3 (CH2, CBz), 67.1 (CH2, CBz), 61.4 
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(CH2, Et), 58.7 (CH, C-2), 58.6 (CH, C-2), 39.6 (CH2, C-3), 14.1 (CH3, Et), 13.2 (CH3, 
C-6), quaternary carbons not observed; HRESIMS m/z = 290.1404 [M+H]+ 4.1 ppm 
(290.1392 calcd for C16H20NO4). 
2.53  Rf 0.24 (silica, 4:1 petroleum ether:ethyl acetate, visualization UV/PMA); [α]D20 –
43 (c 1.00, CHCl3) (cis:trans, ~1:15); IR (thin film) νmax 1747, 1710, 1417, 1357, 1194 
cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.38-7.28 (5H, m, CBz), 5.18-5.04 (2H, m, CBz), 
4.41 (1/2H, dd, 9.0 Hz, 2.6 Hz, H-2), 4.36 (1/2H, dd, 9.0 Hz, 2.6 Hz, H-2), 4.19 (1H, q, 
7.4 Hz, Et), 4.05 (1H, m, Et), 3.78 (1H, m, H-5a), 3.05 (1/2H, dd, 10.1 Hz, 8.5 Hz, H-5b), 
2.99 (1/2H, dd, 10.1 Hz, 8.8 Hz, H-5b), 2.41 (1H, m, H-4), 2.09 (1H, m, H-3a), 1.84 (1H, 
m, H-3b), 1.26 (3/2H, t, 7.2 Hz, Et), 1.14 (3/2H, t, 7.2 Hz, Et), 1.05 (3/2H, d, 6.7 Hz, H-
6), 1.03 (3/2H, d, 6.7 Hz, H-6); 13C NMR (CDCl3, 75 MHz) δ 172.8 (C, ester C=O), 
172.6 (C, ester C=O), 154.2 (C, CBz C=O), 136.7 (C, CBz), 128.4 (CH, CBz), 128.3 
(CH, CBz), 127.91 (CH, CBz), 127.85 (CH, CBz), 127.8 (CH, CBz), 127.7 (CH, CBz), 
66.94 (CH2, CBz), 66.88 (CH2, CBz), 61.1 (CH2, Et), 61.0 (CH2, Et), 59.5 (CH, C-2), 
59.1 (CH, C-2), 53.6 (CH2, C-5), 53.3 (CH2, C-5), 38.5 (CH2, C-3), 37.6 (CH2, C-3), 32.0 
(CH, C-4), 31.1 (CH, C-4), 17.33 (CH3, C-6), 17.29 (CH3, C-6), 14.14 (CH3, Et), 14.05 
(CH3, Et); HRESIMS m/z = 292.1545 [M+H]+ 1.4 ppm (292.1549 calcd for C16H22NO4). 
 
N-CBz-4-Methyl-D-trans-proline ethyl ester, ent-2.53:  
Prepared as 2.53, using N-CBz-4-exomethylene-D-proline ethyl ester, ent-2.52. Product 
obtained as a colourless oil (ent-2.53, 80%). 
[α]D20 +41 (c 0.31, CHCl3) (cis:trans, ~1:15). 
 
4-Methyl-L-cis-proline ethyl ester, 2.54 
N-CBz-4-Exomethylene-L-proline ethyl ester (2.52, 15 mg, 0.052 mmol) was dissolved in 
DCM (1 mL) and Pd/C (10%, 1.5 mg) added. The reaction was placed under an 
atmosphere of H2(g) by means of a balloon and stirred at room temperature for 16 hours. 
The catalyst was removed by filtration through a pad of celite using DCM (15 mL) and 
the solvent removed in vacuo to give the product (2.54, 5.5 mg, 0.035 mmol, 67%) as a 
colourless oil. [α]D20 –36 (c 0.31, CHCl3) (cis:trans, ~7:1); IR (thin film) νmax 3418, 1743, 
1263, 1230 cm-1; 1H NMR (CDCl3, 500 MHz) δ 4.47 (1H, t, 8.8 Hz, H-2), 4.30 (2H, q, 
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7.1 Hz, Et), 3.68 (1H, m, H-5a), 2.98 (1H, br t, 10.5 Hz, H-5b), 2.63-2.56 (2H, m, H-3a 
and H-4), 1.66 (1H, m, H-3b), 1.32 (3H, t, 7.1 Hz, Et), 1.13 (3H, d, 6.4 Hz, H-6); 13C 
NMR (CDCl3, 75 MHz) δ 169.1 (C, ester C=O), 62.9 (CH2, Et), 59.0 (CH, C-2), 52.3 
(CH2, C-5), 36.8 (CH2, C-3), 33.2 (CH, C-4), 16.4 (CH3, C-6), 14.0 (CH3, Et); HRESIMS 
m/z = 158.1183 [M+H]+ 1.3 ppm (158.1181 calcd for C8H16NO2). 
 
4-Methyl-D-cis-proline ethyl ester, ent-2.54 
Prepared as 2.54, using N-CBz-4-exomethylene-D-proline ethyl ester, ent-2.52. Product 
obtained as a colourless oil (ent-2.54, ~100%). 
[α]D20 +39 (c 0.30, CHCl3) (cis:trans, ~7:1). 
 
4-Methyl-L-trans-proline ethyl ester, 2.55 
N-CBz-4-Methyl-L-trans-proline ethyl ester (2.53, ~2 mg, ~0.007 mmol) was dissolved 
in DCM (1 mL) and Pd/C was added (10 %, ~0.1 mg).  The reaction was placed under 
H2(g) at atmospheric pressure by means of a balloon and stirred at room temperature for 
16 hours.  The catalyst was removed by filtration through a pad of celite using DCM (3 
mL) and the solvent removed in vacuo to give the product as a colourless oil (2.55, ~ 
100%).   
1H NMR (CD3OD, 500 MHz) δ 4.52 (1H, dd, 9.1 Hz, 5.1 Hz, H1), 4.31 (2H, q, 7.1 Hz, 
Et), 3.55 (1H, dd, 11.3 Hz, 7.5 Hz, H5a), 2.90 (1H, m, H5b), 2.46-2.32 (2H, m, H3a and 
H4), 2.02 (1H, m, H3b), 1.32 (3H, t, 7.1 Hz, Et), 1.14 (3H, d, 6.4 Hz, H6). 
 
4-Methyl-D-trans-proline ethyl ester, ent-2.55 
Prepared as 2.55, using N-CBz-4-Methyl-D-trans-proline ethyl ester, ent-2.53. Product 
obtained as a colourless oil (ent-2.55, ~ 100%).   
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4-Methyl-L-trans-proline hydrochloride, 2.56 
N-CBz-4-Methyl-L-trans-proline ethyl ester (2.53, 4 mg, 0.014 mmol) was dissolved in 
HCl(aq) (6 M, 300 μL), sealed in a thick-walled glass tube and heated to 70 ºC for 6 hours. 
After cooling to room temperature, the reaction was extracted with ethyl acetate (2 x 300 
μL) and the HCl(aq) removed by evaporation under a stream of N2(g) to give the product 
(2.3 mg, 0.014 mmol, ~100%) as an white amorphous solid. 
[α]D20 –33 (c 0.21, H2O) (cis:trans, ~1:15) (lit. free amine –56.6º, c 1.03, H2O; –23.9º, c 
1.54, 3N HCl);9 IR (diffuse reflectance) νmax 1736, 1456, 1358, 1265, 1211 cm-1; 1H 
NMR (D2O, 500 MHz) δ 4.38 (1H, dd, 9.6 Hz, 5.1 Hz, H-2), 3.49 (1H, dd, 11.6 Hz, 7.2 
Hz, H-5a), 2.83 (1H, dd, 11.5 Hz, 8.6 Hz, H-5b), 2.38-2.25 (2H, m, H-3a and H-4), 1.94 
(1H, dt, 13.2 Hz, 9.0 Hz, H-3b), 0.99 (3H, d, 6.6 Hz, H-6); 13C NMR (D2O, 75 MHz) δ 
172.8 (C, C=O), 59.9 (CH, C-2), 52.9 (CH2, C-5), 36.4 (CH2, C-3), 32.3 (CH, C-4), 16.6 
(CH3, C-6); HRESIMS m/z = 130.0862 [M+H]+ 4.6 ppm (130.0868 calcd for C6H12NO2). 
 
4-Methyl-D-trans-proline hydrochloride, ent-2.56 
As described above, using 4-methyl-D- trans-proline ethyl ester (ent-2.53). Amorphous 
white solid obtained in 80% yield.  
[α]D20 +31 (c 0.04, H2O) (cis:trans, ~1:15). 
 
4-Methyl-L-cis-proline hydrochloride, 2.57  
As described above, using 4-methyl-L-cis-proline ethyl ester (2.54). Amorphous white 
solid obtained in approximately quantitative yield.  
[α]D20 –41 (c 0.07, H2O) (cis:trans, ~7:1); IR (diffuse reflectance) νmax 3100-2900, 1738, 
1455, 1405, 1213 cm-1; 1H NMR (D2O, 500 MHz) δ 4.30 (1H, dd, 8.2 Hz, 9.8 Hz, H-2), 
3.43 (1H, dd, 11.4 Hz, 7.4 Hz, H-5a), 2.87 (1H, br t, 10.6 Hz, H-5b), 2.52 (1H, dt, 13.1 
Hz, 7.6 Hz, H-3a), 2.38 (1H, m, H-4), 1.64 (1H, dt, 13.1 Hz, 9.8 Hz, H-3b), 0.99 (3H, d, 
6.7 Hz, H-6); 13C NMR (D2O, 75 MHz) δ 173.0 (C, C=O), 60.7 (CH, C-2), 52.7 (CH2, C-
5), 36.9 (CH2, C-3), 33.7 (CH, C-4), 16.4 (CH3, C-6); HRESIMS m/z = 130.0862 [M+H]+ 
4.6 ppm (130.0868 calcd for C6H12NO2).  
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4-Methyl-D-cis-proline hydrochloride, ent-2.57 
As described above, using 4-methyl-D-cis-proline ethyl ester. Amorphous white solid 
obtained in 87% yield.  
[α]D20 +31 (c 0.12, H2O) (cis:trans, ~7:1) (lit. free amine +85.2º, c 1.68, H2O; +47.9º, c 
1.28, 3N HCl).9 
 
Dimethyltitanocene (Petasis reagent), 2.64 8  
Titanocene dichloride (Cp2TiCl2, 220 mg, 0.88 mmol) was dissolved in dry toluene (2 
mL) and cooled in an ice-bath.  MeLi (1.6 M in diethyl ether, 1.27 mL, 2.03 mmol, 2.3 
eq) was added dropwise and the reaction stirred for 1 hour.  The mixture was poured 
slowly into a cooled solution of NH4Cl (6% w/v, 2 mL), the organic phase separated, 
washed with further NH4Cl solution (2 mL), dried over MgSO4, filtered and the solvent 
reduced (~ 1 mL) in vacuo to give an orange solution of product.   
 
Epimerisation of 4-hydroxy-L-trans-proline to give 4-hydroxy-D-cis-proline 10 
Acetic anhydride (400 μL, 4.2 mmol, 5.5 eq) and glacial acetic acid (1.27 mL, 22 mmol, 
29 eq) were warmed to 50 ºC and 4-hydroxy-L-trans-proline (100 mg, 0.76 mmol) was 
added.  The reaction was then heated to reflux for 5.5 hours.  The reaction was cooled to 
room temperature and the solvents removed in vacuo. The crude residue was taken up in 
2M HCl(aq) (1.38 mL) and refluxed for a further 3 hours.  A spatula of activated carbon 
was added to the mixture whilst hot, and after cooling to room temperature the solution 
was filtered though a bed of celite (washed though with extra 2 mL of deionised H2O).  
The solvent was removed in vacuo to give the product as a white amorphous solid.    
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Marfey’s derivatisation general procedure 11 
A 1% (w/v) solution (100 μL) of FDAA (Marfey's reagent, Nα-(2,4-dinitro-5-
fluorophenyl)-L-alaninamide) in acetone was added to an aliquot (50 μL) of a 50 mM 
solution of each amino acid. After addition of NaHCO3 solution (1 M; 20 μL), the 
mixture was incubated (1 hour at 40 ºC). The reaction was stopped by addition of HCl (2 
M, 10 μL), the solvents were evaporated to dryness, and the residue was redissolved in 
MeOH-H2O (1:1; 1 mL). An aliquot of each of these solutions (10 μL) was analyzed by 
HPLC (see below).   
 
HPLC analysis of Marfey’s derivatives 
All Marfey’s derivatives were analysed on a Prodigy C18, 250 × 4.6 mm, 5 μm column.    
The elution conditions used are described below. 
4-Methylprolines 2.56, ent-2.56, 2.57 and ent-2.57: 
solvents: A: H2O + 0.05% TFA, B: MeOH; 0 min 45% B, 30 min 65% B; 25 ºC; 1 
mL.min-1; detection at 330 nm. Rt: 2.56, 18.26 min; ent-2.56, 19.25 min; 2.57, 16.62 min; 
ent-2.57, 18.48 min. 
4-Methyl-L-cis-proline ethyl ester, 2.54:   
solvents: A: H2O + 0.05% TFA, B: MeCN; linear gradient: 0 min 35% B, 30 min 45% B; 
25 ºC; 1 mL min-1; detection at 330 nm.  Rt: L-trans, 23.87 min; L -cis, 26.36 min. 
4-Hydroxy-L-trans-proline epimerisation product and commercial 4-hydroxyproline 
diastereoisomers: 
solvents: A: H2O + 0.05% TFA, B: MeCN; linear gradient: 0 min 20% B, 30 min 35% B, 
31 min 100% B; 25 ºC; 1 mL min-1 detection at 330 nm.  Rt: L-trans, 12.20 min; L-cis, 
13.29 min; D-trans, 10.77 min; D-cis, 12.55 min. 
solvents: A: H2O + 0.05% TFA, B: MeCN; isocatic: 30 min 18% B, 31 min 100% B; 25 
ºC; 1 mL min-1; detection at 330 nm.  Rt: L-trans, 19.57 min; D-cis, 21.93 min. 
 
Elution conditions and retention times of all other amino acids (except those analysed on 
a Shimadzu HPLC system) are given in Table 2.3.   
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Eluent A corresponds to the following elution system: solvents: A: H2O + 0.05 % TFA, 
B: MeCN; linear gradient: 0 min 35 % B, 30 min 45 % B; 25 º C; 1 mL min-1; detection 
at 330 nm.   
Eluent B corresponds to the following elution system: solvents: A: H2O + 0.05 % TFA, 
B: MeOH; linear gradient: 0 min 45 % B, 30 min 65 % B; 24 º C; 1 mL min-1; detection 
at 330 nm.   
Elution conditions for those amino acids analysed on a Shimadzu HPLC are below: 
Shimadzu eluent - solvents: A: H2O + 0.05% TFA, B: MeCN; 0 min 20% B, linear 
gradient: 2 min 20% B, 32 min 45% B, 35 min 100% B; 40 ºC; 1 mL min-1; detection at 
330 nm.   
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5.3 Work described in Chapter 3 
 
Unless otherwise stated, all HPLC analysis of reactions described below was carried out 
using on a Prodigy C18, 250 × 4.6 mm, 5 μm column.  The elution conditions used were 
as follows; solvents: A: H2O + 0.05% TFA, B: MeCN; 0 min10%, linear gradient: 2 min 
10% B, 14 min 75% B, linear gradient: 24 min 75 % B, 26 min 100% B; 40 ºC; 1 mL 
min-1.   
 
The carbon skeleton of all synthetic analogues of spiro-mamakone A, as well as those 
derivatives corresponding to the carbon skeleton of the northern hemisphere of spiro-
mamakone A, are numbered here in accordance with that reported for spiro-mamakone 
A:12 
OO
OH
O
O
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18 19
 
The numbering of all other carbon skeleton systems are described below, as appropriate.   
 
Section 3.2.1 
1,8-Dihydroxynaphthalene (DHN)13  
1,8-Naphthalenesultone (6 g, 29.1 mmol) and potassium hydroxide (24.4 g, 438 mmol, 15 
eq) were fused at 220 ºC until they formed a tarry black oil.  Heating was continued for 
around 5 minutes after which time the reaction was allowed to cool to room temperature.  
Aqueous HCl (4M) was added until the reaction had been acidified and the mixture was 
extracted with ethyl acetate (5 x 100 mL).  The combined organic phase was dried over 
MgSO4, filtered and the solvent was removed in vacuo.  The crude product was purified 
by silica chromatography using a step-wise gradient of 7 to 15% diethyl ether in 
petroleum ether.  This gave 3.44 g (21.5 mmol, 74%) of product as a white solid;  
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mp 139-141 ºC (recrystallised from petroleum ether,  lit 141-142 ºC);13 Rf 0.32 (silica, 
4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (diffuse reflectance) νmax 
3300-3100, 1612, 1466, 1412, 1280, 1234, 1034 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
7.59 (2H, s, OH), 7.36 (2H, d, 8.2 Hz, H4/6), 7.29 (2H, dd, 8.2, 7.5 Hz, H3/7), 6.78 (2H, 
d, 7.5 Hz, H2/8); 13C NMR (CDCl3, 75 MHz) δ 152.7, 137.0, 126.7, 120.5, 109.3, C9 not 
observed; HRESIMS m/z = 159.0440 [M-H]- 3.8 ppm (159.0446 calcd for C10H7O2). 
 
 
4-Ethoxy-10-hydroxy-2H-benzo[h]chromen-2-one, 3.32 
DHN (60 mg, 0.38 mmol) was dissolved in ethyl-3,3-ethoxyacrylate (3.28, 210 μL, 1.14 
mmol, 3 eq) and pTSA (2 mg, 0.01mmol, 3 mole%) was added.  The reaction was heated 
to 85 ºC with stirring for 3 hours, then cooled to room temperature.  The crude product 
was purified by silica chromatography using a step-wise gradient of 0 to 20% ethyl 
acetate in petroleum ether.  This gave the product (3.32, 31 mg, 0.12 mmol, 32%) as a tan 
solid. 
OH O
O
O
19 11
13
15
14
12
2
3
4
5
6
7
8
10
 
mp 191-193 ºC (recrystallised from petroleum ether); Rf 0.20 (silica, 4:1 petroleum 
ether:ethyl acetate, visualization UV/PMA); IR (diffuse reflectance) νmax 3300-3000, 
1680, 1626, 1611, 1490, 1343 1269, 1224 cm-1; 1H NMR (CDCl3, 500 MHz) δ 8.84 (1H, 
br s, OH), 7.76 (1H, d, 9.2 Hz, H3 or H4), 7.64 (1H, d, 9.1 Hz, H3 or H4), 7.54 (1H, t, 8.3 
Hz, H7), 7.40 (1H, d, 8.0 Hz, H6), 7.10 (1H, d, 7.8 Hz, H8), 5.72 (1H, s, H12), 4.26 (2H, 
q, 7.0 Hz, H14), 1.59 (3H, t, 7.0 Hz, H15); 13C NMR (CDCl3, 75 MHz) δ 166.7 (C, C11 
or C13), 160.7 (C, C11 or C13), 154.5 (C, C9), 152.0 (C, C1), 137.2 (C, C5), 130.3 (CH, 
C7), 124.7 (CH, C3 or C4), 119.4 (CH, C6), 118.7 (CH, C3 or C4), 113.1 (C, C8), 112.2 
(C, C2 or C10), 110.2 (C, C2 or C10), 88.5 (CH, C12), 65.5 (CH2, C14), 14.1 (CH3, 
C15); LREIMS [M] +. 256, 228, 186. 
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Section 3.2.2 
2,2-Diallylcyclopentane-1,3-dione, 3.26 14 
1,3-Cyclopentadione (1 g, 10.2 mmol) was suspended in benzene (20 mL), allyl alcohol 
(1.4 mL, 20.5 mmol, 2.01 eq), Pd2(dba)3 (230 mg, 0.25 mmol, 0.025 eq) and 
triphenylphosphite (530 μL, 2.02 mmol, 0.20 eq) were added and the reaction was 
refluxed for 3 hours.  The formation of H2O was observed during the reaction.  Upon 
cooling, the solvent was removed in vacuo.  This crude material could then be used for 
ring-closing metathesis.  Purification was possible by silica chromatography using a step-
wise gradient of 2 to 8% diethyl ether in petroleum ether.  This gave the product (3.26) as 
a volatile colourless oil in around 85%;  
Rf 0.35 (silica, 4:1 petroleum ether:ethyl acetate, visualisation PMA); IR (thin film) νmax 
1728, 1420, 1196 cm-1; 1H NMR (CDCl3, 500 MHz) δ 5.56 (2H, m), 5.07 (2H, br d, 4.4 
Hz), 5.05 (2H, br s), 2.62 (4H, s), 2.37 (4H, d, 7.6 Hz); 13C NMR (CDCl3, 75 MHz) δ 
216.4, 131.3, 120.0, 61.3, 39.4, 36.4; HREIMS m/z = 178.0994 [M]+ 0.1 ppm (178.0994 
calcd for C11H14O2). 
 
spiro-Nona-7-ene-1,4-dione, 3.27 15 
Crude 2,2-diallylcyclopentane-1,3-dione (3.26, approx. 1.8 g) was dissolved in anhydrous 
DCM (30 mL) under an inert atmosphere.  Grubbs’ 2nd generation catalyst was added 
(350 mg, 0.41 mmol, approx. 4 mol%) and the reaction was stirred under an equilibrating 
inert atmosphere for 18 hours.  Purification was carried out by silica chromatography 
using a step-wise gradient of 20 to 30% diethyl ether in petroleum ether.  This gave 1.48 
g (3.27, 9.88 mmol, 97% over two steps) of a slightly yellow solid;  
mp 91-93 ºC (recrystallised from diethyl ether, lit. 89-90 ºC);15 Rf 0.18 (silica, 4:1 
petroleum ether:ethyl acetate, visualization PMA); IR (diffuse reflectance) νmax 1751, 
1713, 1443, 1273, 1227, 1111 cm-1; 1H NMR (CDCl3, 500 MHz) δ 5.62 (2H, br s), 2.83 
(4H, s), 2.67 (4H, br s); 13C NMR (CDCl3, 75 MHz) δ 214.4, 127.4, 61.3, 41.1, 34.9; 
HRCIMS m/z = 150.0684 [M]+ 2.2 ppm (150.0681 calcd for C9H10O2). 
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Thermal degradation of 3.27 to spiro-nona-6-ene-1,4-dione, 3.36 
Ketone 3.26 was heated to 80 ºC at atmospheric pressure in a glass finger containing a 
cooling tube (H2O).  Sublimation was observed and the crystalline solid collected.  1H 
NMR spectroscopy showed considerable quantities of the thermal degradation product 
3.36 as well as 3.27 (ratio of ~3:1).   
3.36 1H NMR (CDCl3, 500 MHz) δ 6.12 (1H, dt, 5.6 Hz, 2.3 Hz, H6 or H7), 5.38 (1H, dt, 
5.6 Hz, 2.3 Hz, H6 or H7), 2.95-2.76 (4H, m, H2 and H3), 2.61 (2H, m, H8), 2.18 (2H, t, 
7.4 Hz, H9); 13C NMR (CDCl3, HSQC data at 500 MHz) δ 127.0 (CH, C6 or C7), 33.0 
(CH2, C8), 30.6 (CH2, C9), no other carbons observed. 
 
spiro-Nona-6-ene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal, 3.37 
DHN (430 mg, 2.68 mmol, 2.0 eq) and 3.27 (200 mg, 1.33 mmol) were dissolved in 
anhydrous toluene and triflic acid (30 μl, 0.34 mmol, 0.25 eq) was added.  The reaction 
was heated under Dean-Stark refluxing conditions at 125 ºC for 16 hours.  The reaction 
was cooled to room temperature, extracted with NaHCO3(aq) (1M, 3 x 4 mL), dried over 
MgSO4, filtered and the solvent removed in vacuo.  The crude residue was purified by 
chromatography on Florisil using 0 to 1% diethyl ether in petroleum ether to give a 
mixture of 3.35 (for full characterisation, vide infra) and 3.37 in approximately 1:1 ratio 
(82 mg, 0.28 mmol, 21%).   
 Rf 0.45 (silica, 4:1 petroleum ether:ethyl acetate, visualization PMA); 1H NMR (CDCl3, 
500 MHz) δ 7.48 (2H, d, 8.2 Hz), 7.41 (2H, dd, 8.1 Hz, 7.5 Hz), 6.90 (2H, 7.5 Hz), 6.13 
(1H, dt, 5.7 Hz, 2.4 Hz), 5.64 (1H, dt, 5.7 Hz, 2.2 Hz), 2.58-2.43 (4H, m), 2.30-2.09 (4H, 
m); 13C NMR (CDCl3, 2D NMR data, 500 MHz) δ 215.2 (C, C4), 147.8 (C, C10 and 
C19), 137.6 (CH, C6 or C7), 134.3 (C, C14), 127.5 (CH, C12 and C16), 126.9 (CH, C6 
or C7), 120.8 (CH, C13 and C15), 114.2 (C, C19), 109.6 (CH, C11 and C17), 108.2 (C, 
C1), 71.8 (C, C5), 34.7 (CH2, C2, C3, C8 or C9), 32.6 (CH2, C2, C3, C8 or C9), 29.3 
(CH2, C2, C3, C8 or C9), 28.6 (CH2, C2, C3, C8 or C9). 
 
 
 
 
 
 Chapter 5: Experimental 
 
264 
Cyclopentanone-1,1-dimethoxyacetal, 3.40 
Cyclopentanone (1 mL, 12.5 mmol) was dissolved in dimethoxypropane (15 mL) and 
pTSA (60 mg, 0.32 mmol, 0.026 eq) was added.  The reaction was refluxed for 16 hours, 
then cooled.  Diethyl ether (20 mL) was added, the mixture washed with NaHCO3 (aq) (1M, 
3 x 20 mL), dried over MgSO4, filtered and the solvents were removed in vacuo.  This 
gave the product as a colourless oil which was used without further purification.   
1H NMR (CDCl3, 500 MHz) δ 3.03 (6H, s, OCH3), 1.56 (4H, br dd, 7.3Hz, H2/5), 1.46 
(4H, br dd, 7.3 Hz, H3/4); 13C NMR (CDCl3, from HSQC data at 500 MHz) δ 49.5 (CH3, 
OCH3), 34.4 (CH2, C2/5), 23.3 (CH2, C3/4). 
 
Cyclopentanone-1,1-[1,8-dihydroxynaphthalene]-acetal, 3.41 
Cyclopentanone-1,1-dimethoxyacetal (3.40, 20 mg, 0.13 mmol) and 1,8-
dihydroxynaphthalene (20 mg, 0.15 mmol, 1.2 eq) were dissolved in dried, degassed 
toluene (0.5 mL) and triflic acid (3 μL, 0.011 mmol, 0.08 eq) was added, whereupon the 
mixture became dark.  The reaction was stirred at room temperature for 20 hours, then 
diethyl ether (1 mL) was added and the reaction was washed with NaHCO3 (aq) (1M, 3 x 1 
mL), dried over MgSO4, filtered and the solvents were removed in vacuo.  The crude 
product was purified by chromatography on silica using petroleum ether to elute the 
product (16 mg) as a colourless oil which contained 3.41 contaminated with acetonide 
3.39 in a ratio of ~1:1 (3.41 ~8 mg, 0.035 mmol, 28%). 
Rf 0.76 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
1605, 1412, 1381, 1273 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.43 (2H, dd, 8.3 Hz, 0.8 Hz, 
H9/H11), 7.37 (2H, dd, 7.4 Hz, 8.3 Hz, H8/12), 6.86 (2H, dd, 7.4 Hz, 0.8 Hz, H7/13), 
2.05 (4 H, m, H2/5), 1.85 (4H, m, H3/4); 13C NMR (CDCl3, 75 MHz) δ 148.9 (C, C6/14), 
134.4 (C, C10), 127.1 (CH, C8/12), 120.1 (CH, C9/11), 114.3 (C, C15), 112.7 (C, C1), 
109.0 (CH, C7/13), 37.0 (CH2, C2/5), 23.8 (CH2, C3/4); HREIMS m/z = 226.0992 [M]+. 
0.8 ppm (226.0994 calcd for C15H14O2). 
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spiro-Nona-7-ene-1,4-dione-1,1-dimethoxyacetal, 3.38 
spiro-Nona-7-ene-1,4-dione (3.26, 100 mg, 0.51 mmol) was dissolved in 
dimethoxypropane (2 mL) and pTSA (4 mg, 0.02 mmol) was added.  The reaction was 
refluxed for 16 hours, then cooled to room temperature.  Diethyl ether (3 mL) was added 
and the mixture was washed with NaHCO3 (aq) (1M, 2 x 2 mL).  The organic phase was 
dried over MgSO4, filtered and the solvents removed in vacuo.  The crude product which 
was obtained as a yellow oil (approximately quantitative yield as judged by NMR 
spectroscopy) was used in subsequent steps without further purification.   
1H NMR (CDCl3, 500 MHz) δ 5.62 (2H, br s, H7/8), 3.25 (6H, s, OCH3), 2.32 (2H, t, 8 
Hz, H3), 2.06 (2H, t, 8 Hz, H2); 13C NMR (CDCl3, 75 MHz) δ 217.3 (C1), 128.3 (C7/8), 
107.5 (C4), 61.5 (C5), 49.4 (OCH3), 38.0 (C6/9), 33.4 (C3), 26.7 (C2). 
 
Preparation of spiro-nona-7-ene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal 
(or 4-keto-2,3-dihydro-6,9-deoxy-spiro-mamakone A), 3.35, via transacetalisation of 
DHN and 3.38 
DHN (50 mg, 0.31 mmol) and spiro-nona-7-ene-1,4-dione-1,1-dimethoxyacetal (3.38, ~ 
0.33 mmol, 1 eq) were dissolved in anhydrous toluene (1 mL) and triflic acid (12 μL, 
0.14 mmol, 0.45 eq) was added.  The reaction mixture became a dark brown upon 
addition of the acid and was stirred at 45 ºC for 16 hours.  The reaction mixture was then 
diluted with diethyl ether (2 mL) and washed with NaHCO3 (aq) (1M, 2 x 1 mL).  The 
organic phase was dried over MgSO4, filtered and the solvent removed in vacuo.  The 
crude residue was purified on silica using a stepwise gradient of petroleum ether to 20% 
diethyl ether in petroleum ether.  This gave the product as an off-white solid (3.35, 22 mg, 
0.075 mmol, 24%);  
mp 150-151 ºC (recrystallised from diethyl ether); Rf 0.46 (silica, 4:1 petroleum 
ether:ethyl acetate, visualization UV/PMA); IR (diffuse reflectance) νmax 1744, 1611, 
1414, 1275, 1248 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.49 (2H, dd, 8.4 Hz, 0.7 Hz, 
H13/15), 7.41 (2H, dd, 8.3 Hz, 7.5 Hz, H12/16), 6.91 (2H, dd, 7.5 Hz, 0.7 Hz, H11/17), 
5.70 (2H, br m, H7/8), 3.05 (2H, br d, 14 Hz, H6/9), 2.61 (2H, br d, 14 Hz, H6/9), 2.53 
(2H, dd, 8.2 Hz, 7.7 Hz, H2 or H3), 2.17 (2H, dd, 8.2 Hz, 7.7 Hz, H2 or H3); 13C NMR 
(CDCl3, 75 MHz) δ 214.3 (C, C4), 147.5 (C, C10/18), 134.2 (C, C14), 128.1 (CH, C7/8), 
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127.3 (CH, C12/16), 120.6 (CH, C13/15), 113.9 (C, C19), 109.3 (CH, C11/17), 108.1 (C, 
C1), 62.0 (C, C5), 36.4 (CH2, C6/9), 33.7 (CH2, C2 or C3), 28.1 (CH2, C2 or C3); 
HRESIMS m/z = 293.1187 [M+H]+ 3 ppm (293.1178 calcd for C19H17O3). 
 
1,8-Dihydroxynaphthalene acetonide, 3.39 
1,8-Dihydroxynaphthalene (640 mg, 4.0 mmol) was dissolved in dimethoxypropane (10 
mL) and pTSA (10 mg, 0.06 mmol) was added.  The reaction was refluxed for 16 hours, 
then cooled to room temperature.  Diethyl ether (10 mL) was added and the mixture was 
washed with NaHCO3 (aq) (1M, 2 x 10 mL).  The organic phase was dried over MgSO4 
and filtered.  The crude residue was passed through a short silica column with petroleum 
ether then the solvent was removed in vacuo to give a yellow solid/oil.  Removal of the 
yellow oily impurity could be achieved by passing the residue through a short C18 reverse 
phase pad with a solution of 60% MeCN in H2O.   Removal of MeCN in vacuo yielded 
an aqueous suspension which was extracted exhaustively using diethyl ether.  The 
combined organic phases were dried over MgSO4, filtered and the solvent removed in 
vacuo to yield the product (3.39, 590 mg, 2.95 mmol, 74%) as a white crystalline solid.  
mp 61-64 ºC (recrystallised from petroleum ether); Rf 0.75 (silica, 4:1 petroleum 
ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 1608, 1411, 1385, 1375, 
1281, 1265 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.4 (4H, m, H3/4/6/7), 6.86 (2H, dd, 6.8 
Hz, 1.4 Hz, H2/8), 1.66 (6H, s, H12/13); 13C NMR (CDCl3, 75 MHz) δ 148.0 (C1/9), 
134.2 (C5), 127.3 (C3/7), 120.0 (C4/6), 113.5 (C10), 108.7 (C2/8), 101.7 (C11), 25.2 
(C12/13); HREIMS m/z = 200.0835 [M]+. 1.0 ppm (200.0837 calcd for C13H12O2).  
 
Preparation of spiro-nona-7-ene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal 
(or 4-keto-2,3-dihydro-6,9-deoxy-spiro-mamakone A), 3.35, via transacetalisation of 
3.39 and 3.27 
1,8-Dihydroxynaphthalene acetonide (3.39, 900 mg, 4.50 mmol, 1.7 eq) and spiro-nona-
7-ene-1,4-dione (3.27, 400 mg, 2.66 mmol) were dissolved in chloroform (6 mL) and 
triflic acid (40 μL, 0.45 mmol, 0.17 eq) was added.  The reaction mixture became a dark 
brown upon addition of the acid and was stirred at 45 ºC for 48 hours.  The reaction 
mixture was then diluted with diethyl ether (2 mL) and washed with NaHCO3 (aq) (1M, 2 x 
 
Chapter 5: Experimental 267
1 mL).  The organic phase was dried over MgSO4, filtered and the solvent removed in 
vacuo.  The crude residue was purified on Florisil solid phase using a stepwise gradient 
of 0 to 20% diethyl ether in petroleum ether.  This gave the product as an off-white solid 
(3.35, 120 mg, 0.41 mmol, 15%). 
 
 
Section 3.2.3 
spiro-Nona-2,7-diene-1,4-dione, 3.44 
spiro-Nona-7-ene-1,4-dione (3.27, 200 mg, 1.33 mmol) was dissolved in MeOH (20 mL) 
and CuBr2 (630 mg, 2.82 mmol, 2.1 eq) was added.  The reaction was refluxed for 2 
hours, then cooled to room temperature.  After removal of solvent in vacuo, the crude 
residue was purified on silica using a stepwise gradient of 5% to 20% diethyl ether in 
petroleum ether.  This gave the product as a faintly yellow crystalline solid (3.44, 190 mg, 
1.28 mmol, 96%).   
mp 33-35 ºC; Rf  0.20 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR 
(diffuse reflectance) νmax 1705, 1327, 1265 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.30 (2H, 
s, H2/3), 5.69 (2H, br s, H7/8), 2.64 (4H, br s, H6/9); 13C NMR (CDCl3, 75 MHz) δ 207.0 
(C1/4), 149.3 (C2/3), 128.5 (C7/8), 54.3 (C5), 41.0 (C6/9); HREIMS m/z = 148.0521 
[M]+. 2.5 ppm (148.0524 calcd for C9H8O2). 
 
Mono-reduction of 3.44 to give 4-hydroxy-spiro-nona-2,7-diene-1-one, 3.45 and 4-
hydroxy-spiro-nona-7-ene-1-dione, 3.46 
spiro-Nona-2,7-diene-1,4-dione (3.44, 230 mg, 1.6 mmol, 2 eq) was dissolved in 
anhydrous MeOH (3 mL) and cooled to – 78 ºC using an acetone/dry ice bath.  NaBH4 
(30 mg, 0.8 mmol) was added and the reaction stirred at – 78 ºC for 1 hour. Citric acid(aq) 
(5 % w/v, 6 mL) was added and after warming to room temperature, the reaction was 
extracted with diethyl ether (10 mL).  The organic phase was then washed with 
NaHCO3(aq) (1M, 5 mL), dried over MgSO4, filtered and the solvent removed in vacuo. 
The crude material was purified by chromatography on silica using a stepwise gradient of 
15 to 25% diethyl ether in petroleum ether.  This gave the product (3.45, 50 mg, 0.33 
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mmol, 42%) as a colourless oil, with 4-hydroxy-spiro-nona-7-ene-1-dione (3.46, 36 mg, 
0.24 mmol, 30%) and starting material (3.44, 22 mg, 0.15 mmol, 19%) also recovered.    
3.45: Rf 0.22 (2:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) 
νmax 3419, 1699, 1338, 1272, 1107 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.51 (1H, dd, 5.9 
Hz, 2.3 Hz, H3), 6.29 (1H, dd, 5.9 Hz, 1.3 Hz, H2), 5.70 (2H, m, H7/8), 4.68 (1H, br s, 
H4), 2.79 (2H, m, H6 or H9), 2.46 (1H, m, H6 or H9), 2.32 (1H, m, H6 or H9); 13C NMR 
(CDCl3, 75 MHz) δ 210.9 (C, C1), 161.7 (CH, C3), 133.7 (CH, C2), 129.1 (CH, C7 or 
C8), 128.3 (CH, C7 or C8), 80.0 (CH, C4), 58.1 (C, C5), 43.0 (CH, C6 or C9), 37.4 (CH, 
C6 or C9); HRCIMS m/z = 150.0681 [M]+ 0.2 ppm (150.0681 calcd C9H10O2). 
3.46: Rf 0.31 (1:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) 
νmax 3440, 1728, 1334, 1164 cm-1; 1H NMR (CDCl3, 500 MHz) δ 5.71 (1H, m, H7 or H8), 
5.56 (1H, m, H7 or H8), 4.16 (1H, t, 4.2 Hz, H4), 2.62 (1H, m, H6 or H9), 2.54-2.44 (3H, 
m, H6/9/2), 2.33 (1H, ddd, 19.2 Hz, 9.3 Hz, 4.5 Hz, H2), 2.27 (1H, m, H6 or H9), 2.16 
(1H, m, H3), 1.99 (1H, ddd, 13.6 Hz, 9.4 Hz, 4.2 Hz, H3); 13C NMR (CDCl3, 75 MHz) δ 
219.4 (C1), 129.6 (C7 or C8), 127.0 (C7 or C8), 77.5 (C4), 60.2 (C5), 41.2 (C6 or C9), 
35.1 (C6 or C9), 33.3 (C2), 28.2 (C3); HRCIMS m/z = 153.0912 [M+H]+ 2.5 ppm 
(153.0916 calcd for C9H13O2). 
 
O-tButyldimethylsilyl-4-hydroxy-spiro-nona-2,7-diene-1-one, 3.47 
4-Hydroxy-spiro-nona-2,7-diene-1-one (3.45, 50 mg, 0.33 mmol) was dissolved in 
anhydrous DMF (400 μL), tBDMSCl (75 mg, 0.50 mmol, 1.5 eq) and imidazole (57 mg, 
0.83 mmol, 2.5 eq) were added and the reaction stirred at room temperature for 16 hours.  
H2O (2 mL) was added and the mixture was extracted with diethyl ether (3 x 2 mL).  The 
combined organic phases were dried over MgSO4, filtered and the solvent removed in 
vacuo.  The crude product was purified by chromatography on silica using a stepwise 
gradient of petroleum ether to 4% diethyl ether in petroleum ether, to give the product 
(3.47, 4 mg, 0.015 mmol, 5%) as a very volatile, colourless oil.   
Rf 0.52 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) 
νmax1718, 1254, 1128, 872, 837 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.35 (1H, dd, 5.9 Hz, 
2.2 Hz, H3), 6.22 (1H, dd, 5.9 Hz, 1.2 Hz, H2), 5.63 (2H, br s, H7/8), 4.59 (1H, br s, H4), 
2.86 (1H, m, H6 or H9), 2.80 (1H, m, H6 or H9), 2.35 (1H, m, H6 or H9), 2.28 (1H, m, 
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H6 or H9), 0.90 (9H, s, H13), 0.12 (3H, s, H10), 0.07 (3H, s, H11); 13C NMR (CDCl3, 75 
MHz) δ 210.7 (C1), 162.2 (C3), 133.1 (C2), 129.3 (C7 or C8), 128.0 (C7 or C8), 80.7 
(C4), 58.3 (C5), 42.9 (C6 or C9), 38.1 (C6 or C9), 25.7 (C13), -4.8 (C10), -4.9 (C11), 
C12 not observed; HRESIMS m/z = 265.1634 [M+H]+ 3.7 ppm (265.1624 calcd for 
C15H25SiO2). 
 
O-Acetyl-4-hydroxy-spiro-nona-2,7-diene-1-one, 3.48 
4-Hydroxy-spiro-nona-2,7-diene-1-one (3.45, 50 mg, 0.33 mmol) was dissolved in 
anhydrous pyridine (1 mL) and acetic anhydride (200 μL, 2.12 mmol, 6.4 eq) was added.  
The reaction was stirred at room temperature for 16 hours.  Diethyl ether (6 mL) was 
added, the organic phase was washed with citric acid(aq) (5% w/v, 4 x 5 mL), dried over 
MgSO4, filtered and the solvent removed in vacuo.  This gave the product (3.48, 59 mg, 
0.31 mmol, 94%) as a colourless oil. 
IR (thin film) νmax1736, 1717, 1373, 1232, 1028 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.48 
(1H, dd, 5.9 Hz, 2.3 Hz, H3), 6.37 (1H, dd, 5.9 Hz, 1.1 Hz, H2), 5.70 (1H, br s, H4), 5.64 
(2H, m, H7/8), 2.77 (1H, m, H6 or H9), 2.60 (1H, br d, 17.2 Hz, H6 or H9), 2.52-2.47 
(2H, m, H6 or H9), 2.11 (3H, s, H11); 13C NMR (CDCl3, 75 MHz) δ 209.1 (C, C1), 170.1 
(C, C10), 157.7 (CH, C3), 135.3 (CH, C2), 128.4 (CH, C7 or C8), 128.3 (CH, C7 or C8), 
80.3 (CH, C4), 56.5 (C, C5), 43.2 (CH2, C6 or C9), 38.0 (CH2, C6 or C9), 20.8 (CH3, 
C11); HRCIMS m/z = 193.0862 [M+H]+ 1.4 ppm (193.0865 calcd for C11H13O3). 
 
1,8-Dihydroxy-3-[O-acetyl-4-hydroxy-spiro-nona-7-ene-1-one]-naphthalene-
acetonide, 3.49 
O-Acetyl-4-hydroxy-spiro-nona-2,7-diene-1-one (3.48, 20 mg, 0.10 mmol), 1,8-
dihydroxynaphthalene acetonide (3.39, 30 mg, 0.15 mmol, 1.5 eq) and DHN (1 mg, 0.006 
mmol, 6 mol%) were dissolved in anhydrous, degassed chloroform (2 mL) and triflic acid 
(3 μL, 0.034 mmol, 34 mol%) was added.  The reaction was stirred at 45 ºC for 16 hours, 
then cooled to room temperature.  NaHCO3(aq) (1 M, 3 mL) was added to the mixture and 
the phases separated.  The aqueous phase was further extracted with diethyl ether (3 x 3 
mL) and the combined organic phases were dried over MgSO4, filtered and the solvent 
removed in vacuo.  The crude product was purified using chromatography on Florisil 
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using a stepwise gradient of petroleum ether to 10% diethyl ether in petroleum ether to 
give the product (3.49, ~0.5 mg, ~0.001 mmol, ~1%) as an amorphous solid. 
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Rf 0.41 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); 1H NMR (CDCl3, 
500 MHz) δ 7.43 (1H, d, 8.5 Hz, H15), 7.42-7.36 (2H, m, H16/H12 or H13), 7.32 (1H, d, 
8.5 Hz, H12 or H13), 6.86 (1H, dd, 7.2 Hz, 1.2 Hz, H17), 5.80 (1H, d, 9.8 Hz, H4) 5.65 
(1H, m, H7 or H8), 5.55 (1H, m, H7 or H8), 3.79 (1H, dd, 10.9 Hz, 9.5 Hz, H3), 2.99 (1H, 
dd, 19.2 Hz, 9.5 Hz, H2), 2.92 (1H, m, H6 or H9), 2.64 (1H, dd, 19.2 Hz, 10.9 Hz, H2), 
2.55 (1H, m, H6 or H9), 2.40 (1H, m, H6 or H9), 1.92 (3H, s, H21), 1.68 (3H, s, H23 or 
H24), 1.67 (3H, s, H23 or H24); 13C NMR (CDCl3, from HSQC data at 500 MHz) δ 
129.7 (CH, C7 or C8), 126.8 (CH, C12 or C16), 126.7 (CH, C7 or C8), 126.6 (CH, C12 
or C16), 120.4 (CH, C13/15), 109.5 (CH, C17), 81.1 (CH, C4) 42.5 (CH2, C2) 41.3 (CH2, 
C6 or C9), 39.0 (CH, C3) 38.1 (CH2, C6 or C9), 25.6 (CH3, C23/24), 21.1 (CH3, C21). 
 
 
Section 3.2.4 
o-Iodoxybenzoic acid, 3.50 16 
o-Iodobenzene (10 g, 40.3 mmol) was added to a solution of oxone (74 g, 120.4 mmol, 3 
eq) in deionised H2O (400 mL) and stirred at 70 ºC for 90 minutes.  The reaction was 
then cooled in an ice-bath and the precipitate formed was filtered, washed with H2O (4 x 
10 mL) and acetone (2 x 10 mL), and residual solvents were removed in vacuo.  This 
gave the product (3.50, 8.06 g, 28.8 mmol, 71%) as a white solid.   
mp 224-228 ºC (decomposition observed at this temperature; lit. 233 ºC);16 IR (diffuse 
reflectance) νmax 3300-3000, 1645, 1332, 1300 cm-1; 1H NMR (DMSO-d6, 500 MHz) δ 
8.24 (1H, d, 7.9 Hz), 8.13 (1H, d, 7.4 Hz), 8.10 (1H, t, 7.9 Hz), 7.94 (1H, t, 7.4 Hz); 13C 
NMR (CDCl3, 75 MHz) δ 167.7, 146.7, 133.6, 133.2, 131.6, 130.3, 125.2. 
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spiro-Nona-2,7-diene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal (or 4-keto-
6,9-deoxy-spiro-mamakone A), 3.34 
spiro-Nona-7-ene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal (3.35, 95 mg, 0.33 
mmol), IBX (3.50, 380 mg, 1.36 mmol, 4.1 eq) and N-methoxypyridine-N-oxide hydrate 
(170 mg, 1.36 mmol, 4.1 eq) were dissolved in DMSO (1.4 mL) over around 15 minutes 
to form a clear reddish solution.  The reaction was then stirred at 70°C for 20 hours 
during which time a white precipitate formed.  NaHCO3 (aq) was slowly added (1M, 
approximately 2 mL, effervescence observed and white IBX derivatives precipitate out of 
solution) and the resulting mixture was extracted with diethyl ether (4 x 3 mL).  The 
combined organic phases were dried over MgSO4 and filtered.  The crude product was 
then purified by chromatography on deacidified silica using a stepwise gradient of 
petroleum ether and diethyl ether (0 to 2% diethyl ether).  The product was eluted first 
with 0.5 % ether and any remaining starting material eluted after with 1%.  The product 
was obtained as a white solid (3.34, isolated yield 40 mg, 42%).  
mp 142-144 ºC (recrystallised from diethyl ether); Rf 0.56 (4:1 petroleum ether:ethyl 
acetate, visualization UV/PMA); IR (diffuse reflectance) νmax 1725, 1611, 1411, 1278, 
1262, 1250 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.51 (2H, dd, 8.4 Hz, 0.7 Hz, H13/15), 
7.43 (2H, dd, 8.4 Hz, 7.5 Hz, H12/16), 7.38 (1H, d, 6.1 Hz, H2 or H3), 6.93 (2H, dd, 7.5 
Hz, 0.7 Hz, H11/17), 6.39 (1H, d, 6.1 Hz, H2 or H3), 5.65 (2H, br s, H7/8), 3.22 (2H, br d, 
16 Hz, H6/9), 2.64 (2H, br d, 16 Hz, H6/9); 13C NMR (CDCl3, 75 MHz) δ 206.6 (C, C4), 
153.3 (CH, C2), 147.6 (C, C10/18), 135.2 (CH, C3), 134.2 (C, C14), 128.0 (CH, C7/8), 
127.5 (CH, C12/C16), 120.9 (CH, C13/C15), 113.7 (C, C19), 109.3 (CH, C11/C17), 
105.8 (C, C1), 61.2 (C, C5), 38.0 (CH2, C6/C9); HRESIMS m/z = 291.1030 ± 2.0 ppm 
[M+H]+ (291.1021 calcd for C19H15O3). 
 
Dehydrogenation with concomitant olefin rearrangement to give spiro-nona-2,6-
diene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal, 3.53 
spiro-Nona-7-ene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal (3.35, 72 mg, 0.25 
mmol), IBX (3.50, 240 mg, 0.86 mmol, 3.4 eq) and N-methoxypyridine-N-oxide hydrate 
(106 mg, 0.86 mmol, 3.4 eq) were dissolved in DMSO (1.4 mL) over around 15 minutes 
to form a clear reddish solution.  The reaction was then stirred at 55°C for 16 hours 
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during which time a white precipitate formed.  NaHCO3 (aq) was slowly added (1M, 
approximately 2 mL, effervescence observed and white IBX derivatives precipitate out of 
solution) and the resulting mixture was extracted with diethyl ether (4 x 3 mL).  The 
combined organic phases were dried over MgSO4 and filtered.  The crude product was 
then purified by chromatography on deacidified silica using a stepwise gradient of 
petroleum ether and diethyl ether (0 to 2% diethyl ether) to give a mixture of 3.34 and 
3.53 (14mg, 0.05 mmol).  A portion of the mixture (~ 4 mg) was separated by 
chromatography on an analytical C18 HPLC column using the following elution system; 
solvents: A: H2O, B: MeCN; isocratic: 0 min 55% B, linear gradient: 2 min 55% B, 23 
min 65% B; 25 ºC; 1 mL min-1.  3.53: Rt 19.42 min, 1.0 mg; 3.34: Rt 20.76 min, 2.5 mg. 
3.53: IR (diffuse reflectance) νmax 1725, 1612, 1412, 1276 cm-1; 1H NMR (CDCl3, 500 
MHz) δ 7.50 (2H, m, H13/15), 7.47 (1H, d, 6.1 Hz, H2), 7.44-7.40 (2H, m, H12/16), 6.93 
(1H, dd, 7.5 Hz, 0.8 Hz, H11 or H17), 6.90 (1H, dd, 7.6 Hz, 0.7 Hz, H11 or H17), 6.45 
(1H, d, 6.2 Hz, H3), 6.01 (1H, dt, 5.8 Hz, 2.3 Hz, H6 or H7), 5.63 (1H, dt, 5.7 Hz, 2.1 Hz, 
H6 or H7), 2.58-2.48 (2H, m), 2.24-2.13 (2H, m); 13C NMR (CDCl3, 75 MHz) δ 206.7 (C, 
C4), 154.0 (CH, C2), 147.5 (C, C10/18), 136.5 (CH, C6 or C7), 135.6 (CH, C3), 134.2 (C, 
C14), 128.8 (CH, C6 or C7), 127.5 (CH, C12 or C16), 127.4 (CH, C12 or C16), 120.8 
(CH, C13 or C15), 120.75 (CH, C13 or C15), 113.6 (C, C19), 109.4 (CH, C11 or C17), 
109.1 (CH, C11 or C17), 106.2 (C, C1), 69.6 (C, C5), 32.3 (CH2, C8 or C9), 29.1(CH2, 
C8 or C9); HRESIMS m/z = 291.1022 ± 0.3 ppm [M+H]+ (291.1021 calcd for C19H15O3). 
 
4-Hydroxy-spiro-nona-7-ene-1-one-1,1-[1,8-dihydroxynaphthalene]-acetal (or 6,8-
deoxy-2,3-dihydro-spiro-mamakone A), 3.55 
spiro-Nona-7-ene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal (3.35, 10 mg, 0.034 
mmol), was dissolved in MeOH (1 mL) and NaBH4 (7.5 mg, 0.20 mmol, 5.9 eq) was 
added.  The reaction was stirred at room temperature for 16 hours, then NaHCO3 (aq) (1M, 
2 mL) was added and the reaction extracted with ethyl acetate (3 x 2 mL).  After drying 
over MgSO4, filtration and evaporation of solvent, the crude product was purified on 
silica (deacidified) using a stepwise gradient of petroleum ether to 10% diethyl ether in 
petroleum ether, to give the product as a colourless oil (3.55, 4.8 mg, 0.016 mmol, 47%).   
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Rf  0.26 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
3406, 2926, 1609, 1411, 1381, 1275 cm-1; 1H NMR (CDCl3, 300 MHz) δ 7.47 (1H, dd, 
8.3 Hz, 0.9 Hz, H13 or H15), 7.46 (1H, dd, 8.4 Hz, 0.9 Hz, H13 or H15), 7.40 (1H, dd, 
8.3 Hz, 7.5 Hz, H12 or H16), 7.395 (1H, dd, 8.4 Hz, 7.4 Hz, H12 or H16), 6.89 (1H, dd, 
7.5 Hz, 1.0 Hz, H11 or H17), 6.88 (1H, dd, 7.4 Hz, 0.9 Hz, H11 or H17), 5.77 (1H, m, H7 
or H8), 5.69 (1H, m, H7 or H8), 4.08 (1H, m, H4), 3.05 (1H, m, H6 or H9), 2.86 (1H, m, 
H6 or H9), 2.76 (1H, m, H6 or H9), 2.48 (1H, d, 9.34 Hz, OH), 2.31 (1H, m, H3), 2.15 
(1H, m, H6 or H9), 2.06 (1H, m, H2), 1.80 (2H, m, H2/3); 13C NMR (CDCl3, 75 MHz) δ 
148.4 (C, C10 or C18), 147.6 (C, C10 or C18), 134.4 (C, C14), 129.9 (CH, C7 or C8), 
127.8 (CH, C7 or C8), 127.3 (CH, C12 or C16), 127.2 (CH, C12 or C16), 120.6 (CH, 
C13 or C15), 120.4 (CH, C13 or C15), 114.0 (C, C19), 112.0 (C, C1), 109.3 (CH, C11 or 
C17), 109.2 (CH, C11 or C17), 77.8 (CH, C4), 58.9 (C, C5), 39.2 (CH2, C6 or C9), 32.7 
(CH2, C6 or C9), 30.7 (CH2, C2), 29.7 (CH2, C3); HRESIMS m/z 295.1339 [M+H]+ 1.7 
ppm (295.1334 calcd for C19H19O3). 
 
4-Hydroxy-spiro-nona-2,7-diene-1-one-1,1-[1,8-dihydroxynaphthalene]-acetal (or 
6,9-deoxy-spiro-mamakone A), 3.54 
spiro-Nona-2,7-diene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal (3.34, 10 mg, 
0.034 mmol) and CeCl3 (anhydrous, 9 mg, 0.036 mmol, 1.1 eq) were dissolved in MeOH 
(500 μL) and cooled to 0 ºC.  NaBH4 (1.3 mg, 0.034 mmol, 1 eq) was added and the 
reaction stirred at 0 ºC for 1 hour.  NaHCO3 (aq) (1 M, 1 mL) was added and the reaction 
extracted with diethyl ether (4 x 1 mL).  The combined organic phases were dried over 
MgSO4, filtered and the solvent was removed in vacuo.  The crude product was purified 
by chromatography on deacidified silica using a stepwise gradient of petroleum ether to 
12% diethyl ether in petroleum ether, to give the product as a colourless oil (3.54, 10 mg, 
0.034 mmol, ~100%).   
Rf 0.31 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
1607, 1413, 1382, 1277, 1100 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.47 (1H, dd, 5.1 Hz, 
0.8 Hz, H13 or H15), 7.45 (1H, dd, 5.3 Hz, 0.7 Hz, H13 or H15), 7.40 (1H, t, 7.9 Hz, H12 
or H16), 7.38 (1H, t, 7.9 Hz, H12 or H16), 6.91 (1H, dd, 7.5 Hz, 0.8 Hz, H11 or H17), 
6.83 (1H, dd, 7.5 Hz, 0.8 Hz, H11 or H17), 6.35 (1H, dd, 6.0 Hz, 2.7 Hz, H3), 6.02 (1H, d, 
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6.0 Hz, H2), 5.76 (1H, m, H7 or H8), 5.69 (1H, m, H7 or H8), 4.39 (1H, d, 2.7 Hz, H4), 
3.19 (1H, ddd, 16.9 Hz, 2.6 Hz, 2.4 Hz, H6 or H9), 2.85 (2H, m, H6/H9), 2.09 (1H, 16.9 
Hz, 1.9 Hz, 1.6 Hz, H6 or H9); 13C NMR (CDCl3, 75 MHz) δ 148.6 (C, C10 or C18), 
148.3 (C, C10 or C18), 140.3 (CH, C3), 134.3 (C, C14), 132.9 (CH, C2), 129.5 (CH, C7 
or C8), 128.2 (CH, C7 or C8), 127.3 (CH, C12/C16), 120.5 (CH, C13 or C15), 120.4 (CH, 
C13 or C15), 114.1 (C, C19), 111.0 (C, C1), 109.2 (CH, C11 or 17), 108.8 (CH, C11 or 
C17), 81.1 (CH, C4), 59.9 (C, C5), 40.3 (CH2, C6/C9); HRESIMS m/z = 293.1186 
[M+H]+ 3 ppm (293.1178 calcd for C19H17O3). 
 
O-Acetyl-4-hydroxy-spiro-nona-2,7-diene-1-one-1,1-[1,8-dihydroxynaphthalene]-
acetal (or O-Acetyl-6,9-deoxy-spiro-mamakone A), 3.56  
4-Hydroxy-spiro-nona-2,7-diene-1-one-1,1-[1,8-dihydroxynaphthalene]-acetal (3.54, 5 
mg, 0.017 mmol) was dissolved in pyridine (500 μL) and acetic anhydride was added 
(200 μL).  The reaction was stirred at room temperature for 20 hours, then diethyl ether 
was added (2 mL) and the mixture extracted with NaHCO3 (aq) (1M, 3 x 2 mL).  After 
drying over MgSO4, filtration and evaporation of solvent, the crude product was purified 
on silica (deacidified) using a stepwise gradient of 0 to 12% diethyl ether in petroleum 
ether, to give the product (3.56, 5.5 mg, ~ 100%) as a colourless oil.    
Rf 0.69 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
1738, 1607, 1412, 1381, 1279, 1219 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.46 (1H, dd, 
8.4 Hz, 0.9 Hz, H13 or H15), 7.45 (1H, dd, 8.4 Hz, 0.9 Hz, H13 or H15), 7.40 (1H, dd, 
7.5 Hz, 8.4 Hz, H12 or H16), 7.39 (1H, dd, 8.3 Hz, 7.5 Hz, H12 or H16), 6.91 (1H, dd, 
7.5 Hz, 0.9 Hz, H11 or H17), 6.86 (1H, dd, 7.4 Hz, 0.9 Hz, H11 or H17), 6.17 (1H, dd, 
6.1 Hz, 2.2 Hz, H3), 6.05 (1H, dd, 6.0 Hz, 1.2 Hz, H2), 5.74 (1H, dd, 2.1 Hz, 1.2 Hz, H4), 
5.68 (2H, m, H7/8), 3.18 (1H, m, H6 or H9), 2.97 (1H, m, H6 or H9), 2.60 (1H, m, H6 or 
H9), 2.45 (1H, m, H6 or H9), 2.11 (3H, s, H21); 13C NMR (CDCl3, 75 MHz) δ 170.8 (C, 
C20), 148.8 (C, C10 or C18), 148.5 (C, C10 or C18), 136.8 (CH, C3), 134.3 (C, C14), 
133.2 (CH, C2), 128.7 (CH, C7 or C8),128.4 (CH, C7 or C8), 127.32 (CH, C12 or C16), 
127.28 (CH, C12 or C18), 120.4 (CH, C13 or C15), 120.3 (CH, C13 or C15), 114.1 (C, 
C19), 109.9 (C, C1), 108.9 (CH, C11/C17), 82.1 (CH, C4), 60.5 (C, C5), 38.9 (CH2, C6 
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or C9), 34.3 (CH2, C6 or C9), 21.1 (CH3, C21); HRESIMS m/z = 335.1293 [M+H]+ 3 
ppm (335.1283 calcd for C21H19O4). 
 
Dimethylpyrazole (DMP)17  
Acetylacetone (8 mL, 78 mmol) was added slowly to hydrazine hydrate (20 mL, 640 
mmol, 8.2 eq) with vigorous stirring and a white precipitate was formed.  The reaction 
was stirred for 15 minutes, then the precipitate was filtered, washed with hexane (3 x 20 
mL) and all solvents removed in vacuo to give the product (3.36 g, 28.6 mmol, 37%) as a 
white solid. 
mp 105-108 ºC (lit – 107-108 ºC);18  1H NMR (CDCl3, 500 MHz) δ 7.25 (1H, br s, NH), 
5.85 (1H, s), 2.27 (6H, s).19 
 
Pearlman’s catalyst (Pd(OH)2/C)20 
PdCl2 (300 mg, 1.7 mmol) and activated charcoal (720 mg) in deionised H2O (6 mL) 
were heated to 80 ºC and LiOH.H2O (150 mg, 3.6 mmol, 2.1 eq) was added in one 
portion.  Heating was stopped and the reaction was stirred at room temperature for 16 
hours.  The product was filtered and washed with 0.5 % acetic acid(aq) (w/v) and residual 
solvent removed in vacuo at 70 ºC for 4 hours.   
 
spiro-Nona-6-ene-1,4,8-trione-1,1-[1,8-dihydroxynaphthalene]-acetal, 3.78 
(erroneously assigned as 3.57) 
spiro-Nona-7-ene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal (3.35, 12 mg, 0.041 
mmol), dirhodium(II)tetrakis(caprolactam) (0.3 mg, 0.45 μmol, 1 mol%) and NaHCO3 
(1.5 mg, 0.018 mmol, 0.4 eq) were suspended in anhydrous DCM (1 mL).  tButyl 
hydroperoxide 5M in decanes (40 μL, 0.20 mmol, 5 eq) was added.  The reaction was 
stirred at room temperature for 16 hours, then filtered through a silica (deacidified) pad 
using DCM.  The crude product was further purified on silica (deacidified) using a 
stepwise gradient of petroleum ether to 24% diethyl ether in petroleum ether, to give 
product (3.78, 5.5 mg, 0.018 mmol, 44%) as a colourless oil and recovered starting 
material (3.35, 3 mg, 0.010 mmol, 24%).  
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Rf  0.23 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
1750, 1718, 1609, 1270 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.55 (1H, d, 5.7 Hz, H8), 
7.523 (1H, dd, 8.3 Hz, 0.7 Hz, H13 or H15), 7.518 (1H, dd, 8.4 Hz, 0.8 Hz, H13 or H15), 
7.44 (1H, dd, 8.3 Hz, 7.6 Hz, H12 or H16), 7.43 (1H, dd, 8.3 Hz, 7.6 Hz, H12 or H16), 
6.93 (1H, dd, 6.6 Hz, 0.8 Hz, H11 or H17), 6.92 (1H, dd, 6.6 Hz, 0.8 Hz, H11 or H17), 
6.36 (1H, d, 5.7 Hz, H7), 2.94 (1H, d, 18.3 Hz, H9),  2.69 (2H, m, H2 or H3), 2.50 (1H, d, 
18.3 Hz, H9), 2.46 (1H, ddd, 14.0 Hz, 9.4 Hz, 6.0 Hz, H2 or H3), 2.33 (1H, ddd, 14.0 Hz, 
9.4 Hz, 7.4 Hz, H2 or H3); 13C NMR (CDCl3, 75 MHz) δ 210.4 (C, C4), 205.9 (C, C6), 
157.6 (CH, C8), 146.8 (C, C10 or C18), 146.6 (C, C10 or C18), 136.6 (CH, C7), 134.2 (C, 
C14), 127.5 (CH, C12 or C16), 127.4 (CH, C12 or C16), 121.2 (CH, C13/C15), 113.5 (C, 
C19), 109.6 (CH, C11 or C17), 109.4 (CH, C11 or C17),107.1 (C, C1), 66.8 (C, C5), 38.3 
(CH2, C9), 35.1 (CH2, C2 or C3), 29.1 (CH2, C2 or C3); HRESIMS m/z = 307.0979 
[M+H]+ 3.0 ppm (307.0970 calcd for C19H15O4). 
 
spiro-Nona-2,6-diene-1,4,8-trione-1,1-[1,8-dihydroxynaphthalene]-acetal, 3.77 
(erroneously assigned as 3.58) 
spiro-Nona-2,7-diene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal (3.34, 10 mg, 
0.034 mmol), dirhodium(II)tetrakis(caprolactam) (0.2 mg, 0.3 μmol,1 mol%) and 
NaHCO3 (1.4 mg, 0.017 mmol, 0.5 eq) were suspended in anhydrous DCM (1 mL).  
tButyl hydroperoxide 5M in decanes (35 μL, 0.17 mmol, 5 eq) was added and an 
immediate colour change from light purple to deep pink was observed.  The reaction was 
stirred at room temperature for 20 hours, then filtered through a silica (deacidified with 
TEA) pad using DCM.  The crude product was further purified on silica (deacidified) 
using a stepwise gradient of petroleum ether to 16% diethyl ether in petroleum ether, to 
give the product (3.77, 3.4 mg, 34%) as a colourless oil.   
Rf 0.20 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (think film) νmax 
1732, 1725, 1609, 1581, 1411, 1378, 1270 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.59 (1H, 
d, 6.0 Hz, H2), 7.56 (1H, d, 5.6 Hz, H8), 7.55 (2H, m, H13/15), 7.454 (1H, dd, 8.4 Hz, 
7.6 Hz, H12 or H16), 7.448 (1H, dd, 8.4 Hz, 7.6 Hz, H12 or H16), 6.97 (1H, dd, 7.5 Hz, 
0.8 Hz, H11 or H17), 6.95 (1H, dd, 7.5 Hz, 0.8 Hz, H11 or H17), 6.52 (1H, d, 6.0 Hz, 
H3), 6.33 (1 H, d, 5.6 Hz, H7), 3.09 (1H, d, 18.7 Hz, H9), 2.62 (1H, d, 18.7 Hz, H9); 13C 
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NMR (CDCl3, 75 MHz) δ 206.5 (C, C6), 201.5 (C, C4), 159.1 (CH, C8), 154.3 (CH, C2), 
146.6 (C, C10/18), 135.4 (CH, C7), 135.1 (CH, C3), 134.2 (C, C14), 127.6 (CH, C12 or 
C16), 127.5 (CH, C12 or C16), 121.52 (CH, C13 or C15), 121.49 (CH, C13 or C15), 
109.6 (CH, C11/17), 105.3 (C, C1), 65.0 (C, C5), 39.0 (CH2, C9), C19 not observed; 
HRESIMS m/z = 305.0821 [M+H]+ 1 ppm (305.0814 calcd for C19H13O4). 
 
O-Acetyl-4-hydroxy-spiro-nona-2,6-diene-1,8-dione-1,1-[1,8-dihydroxynaphthalene]-
acetal, 3.79 ([4R,5R] and [4S,5S]) and 3.80 ([4R,5S] and [4S,5R]). (erroneously 
assigned as 3.59 and 3.60) 
O-Acetyl-4-hydroxy-spiro-nona-2,7-diene-1-one-1,1-[1,8-dihydroxynaphthalene]-acetal 
(3.56, 5 mg, 0.015 mmol), dirhodium(II)tetrakis(caprolactam) (0.1 mg, 0.15 μmol, 1 
mol%) and NaHCO3 (0.7 mg, 0.008 mmol, 0.5 eq) were suspended in anhydrous DCM (1 
mL).  tButyl hydroperoxide 5M in decanes (20 μL, 0.08 mmol, 5 eq) was added and an 
immediate colour change from light purple to deep pink was observed.  The reaction was 
stirred at room temperature for 16 hours, then filtered through a silica (deacidified with 
TEA) pad using DCM.  The crude product was further purified on silica (deacidified) 
using a stepwise gradient of 8 to 16% diethyl ether in petroleum ether, to give 3.79 (2.1 
mg, 0.0060 mmol, 40 %) and 3.80 (0.8 mg, 0.0023 mmol, 15%) as colourless oils. 
3.79: Rf  0.18 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) 
νmax 1742, 1723, 1607, 1412, 1225 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.80 (1H, d, 5.7 
Hz, H8), 7.49 (1H, dd, 8.4 Hz, 0.9 Hz, H13 or H15), 7.48 (1H, dd, 8.4 Hz, 0.9 Hz, H13 or 
H15) 7.41 (2H, t, 8.2 Hz, H12/16), 6.93 (1H, dd, 7.5 Hz, 0.9 Hz, H11 or H17), 6.89 (1H, 
dd, 7.5 Hz, 0.9 Hz, H11 or H17), 6.24 (1H, dd, 6.1 Hz, 1.7 Hz, H3), 6.21 (1H, d, 5.7 Hz, 
H7), 6.11 (1H, dd, 6.0 Hz, 1.9 Hz, H2), 6.05 (1H, t, 1.8 Hz, H4), 3.06 (1H, d, 18.8 Hz, 
H9), 2.63 (1H, d, 18.8 Hz, H9), 2.11 (3H, s, H21); 13C NMR (CDCl3, from 2D spectra at 
500 MHz) δ 207.6 (C, C6), 170.5 (C, C20), 162.2 (CH, C8), 148.3 (C, C10 or C18), 
147.6 (C, C10 or C18), 137.1 (CH, C3), 136.0 (CH, C7), 134.4 (C, C14), 132.5 (CH, C2), 
127.5 (CH, C12/16), 121.1 (CH, C13/15), 113.8 (C, C19), 109.5 (C/CH, C11/C17/C1), 
78.0 (CH, C4), 63.5 (C, C5), 37.3 (CH2, C9), 20.9 (CH3, C21); HRESIMS m/z = 
349.1081 [M+H]+ 1.4 ppm (349.1076 calcd for C21H17O5). 
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3.80: Rf  0.16 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) 
νmax 1740, 1722, 1608, 1412, 1221 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.58 (1H, d, 5.8 
Hz, H7), 7.50 (1H, dd, 8.3 Hz, 0.7 HzH13 or H15), 7.48 (1H, dd, 8.3 Hz, 0.8 Hz, H13 or 
H15), 7.41 (1H, dd, 8.3 Hz, 7.6 Hz, H12 or H16), 7.40 (1H, dd, 8.3 Hz, 7.5 Hz, H12 or 
H16), 6.89 (1H, dd, 7.6 Hz, 0.9 Hz, H11 or H17), 6.87 (1H, dd, 7.6 Hz, 0.8 Hz, H11 or 
H17), 6.28 (1H, d, 5.8 Hz, H8), 6.24 (1H, dd, 6.1 Hz, 1.8 Hz, H2 or H3), 6.13 (1H, dd, 
6.1 Hz, 1.6 Hz, H2 or H3), 5.95 (1H, t, 1.6 Hz, H4), 3.2 (1H, d, 19.0 Hz, H6), 2.74 (1H, d, 
19.0 Hz, H6), 2.07 (3H, s, H21); 13C NMR (CDCl3, from 2D spectra at 500 MHz) δ 207.8 
(C, C9), 170.4 (C, C20), 161.8 (CH, C7), 147.8 (C, C10/18), 136.6 (CH, C2 or C3), 135.1 
(CH, C8), 134.5 (C, C14), 132.3 (CH, C2 or C3), 127.6 (CH, C12/16), 121.0 (CH, 
C13/15), 113.9 (C, C19), 109.5 (CH, C11/17), 109.3 (C, C1), 81.6 (CH, C4), 63.4 (C, C5), 
40.3 (CH2, C6), 21.0 (CH3, C21); HRESIMS m/z = 349.1082 [M+H]+ 1.7 ppm (349.1076 
calcd for C21H17O5). 
 
 
Section 3.2.5 
7,8-Dimethyl-spiro-nona-7-ene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal, 
3.63 
2,2-Diallylcyclopentane-1,3-dione (3.26, 100 mg, 0.56 mmol), 1,8-dihydroxynaphthalene 
acetonide (3.39, 170 mg, 0.84 mmol, 1.5 eq) and DHN (5 mg, 0.03 mmol, 5 mol%) were 
dissolved in anhydrous, degassed chloroform (1 mL) and triflic acid (20 μL, 0.22 mmol, 
0.4 eq) was added.  The reaction was stirred at 40 ºC for 40 hours, then cooled to room 
temperature.  NaHCO3(aq) (1 M, 3 mL) was added to the mixture and the phases separated.  
The aqueous phase was further extracted with diethyl ether (3 x 3 mL) and the combined 
organic phases were dried over MgSO4, filtered and the solvent removed in vacuo.  The 
crude product was purified using chromatography on Florisil using a stepwise gradient of 
0 to 12% diethyl ether in petroleum ether to give the product (3.61, 3.5 mg, 0.011 mmol, 
2%) as a white amorphous solid.    
Rf 0.54 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (diffuse 
reflectance) νmax 1750, 1609, 1411, 1380, 1271, 1146 cm-1; 1H NMR (CDCl3, 500 MHz) 
δ 7.48 (2H, dd, 8.3 Hz, 0.7 Hz, H13/15), 7.41 (2H, dd, 8.3 Hz, 7.5 Hz, H12/16), 6.90 (2H, 
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dd, 7.5 Hz, 0.7 Hz, H11/17), 2.97 (2H, br d, 15.5 Hz, H6/9), 2.51 (2H, t, 7.9 Hz, H2 or 
H3), 2.48 (2H, br d, 15.5 Hz, H6/9), 2.15 (2H, t, 7.9 Hz, H2 or H3), 1.66 (6H, br s, 
H6Me/H7Me); 13C NMR (CDCl3, 75 MHz) δ 214.5 (C, C4), 147.6 (C, C10/18), 134.3 (C, 
C14), 128.4 (C, C7/8), 127.3 (CH, C12/16), 120.6 (CH, C13/15), 113.9 (C, C19), 109.3 
(CH, C11/17), 108.2 (C, C1), 60.3 (C, C5), 41.4 (CH2, C6/9), 33.7 (CH2, C2 or C3), 28.0 
(CH2, C2 or C3), 13.6 (CH3, C6Me/C7Me); HRESIMS m/z = 321.1489 [M+H]+ 0.6 ppm 
(321.1491 calcd for C21H21O3). 
 
1,3-Dihydroxy-2,2-diallylcyclopentane, 3.67 
2,2-Diallylcyclopentane-1,3-dione (3.26, 45 mg, 0.25 mmol) was dissolved in anhydrous 
MeOH (2 mL) and the mixture was cooled in an ice bath.  NaBH4 (30 mg, 0.94 mmol, 3.8 
eq) was added and the reaction allowed to warm to room temperature with stirring.  After 
2 hours deionised H2O (3 mL) was added and the mixture extracted with diethyl ether (4 
x 3 mL).  The combined organic phases were dried over MgSO4, filtered and reduced in 
vacuo.  The crude residue was purified using chromatography on silica using a step-wise 
gradient of 5 to 40% diethyl ether in petroleum ether.  cis-1,3-Dihydroxy-2,2-
diallylcyclopentane (cis-3.67, 14.3 mg, 0.078 mmol, 31%) and trans-1,3-dihydroxy-2,2-
diallylcyclopentane (trans-3.67, 23.7 mg, 0.13 mmol, 52%) were obtained as a colourless 
oils.   
cis-3.67: Rf 0.35 (2:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin 
film) νmax 3500-3200, 2958, 1456, 1043 cm-1; 1H NMR (CDCl3, 500 MHz) δ 6.03-5.89 
(1H, m, H7 or H10), 5.84-5.73 (1H, m, H7 or H10), 5.21-5.00 (4H, m, H8 and H11), 3.88 
(2H, br s, H1 and H4), 2.48 (2H, br t, 7.2Hz, H6 and H9), 2.17-2.07 (4H, m, H2 and H3), 
1.91-1.83 (2H, m, H6 and H9); 13C NMR (CDCl3, 75 MHz) δ 136.0 (CH, C7/10), 135.8 
(CH, C7/C10), 117.5 (CH2, C8/C11), 117.0 (CH2, C8/C11), 79.0 (CH, C1/C4), 78.7 (CH, 
C1/C4), 53.1 (C, C5), 53.0 (C, C5), 37.2 (CH2, C6/C9), 35.2 (CH2, C6/C9), 31.8 (CH2, 
C2/C3), 31.6 (CH2, C2/C3). 
trans-3.67: Rf 0.19 (2:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin 
film) νmax 3500-3200, 2958, 1441, 1024 cm-1; 1H NMR (CDCl3, 500 MHz) δ 6.00 (2H, m, 
H7 and H10), 5.14 (4H, m, H8 and H11), 4.12 (2H, m, H1 and H4), 2.34 (2H, m, H6 and 
H9), 2.16 (4H, m, H6, H9, H2 and H3), 1.52 (2H, m, H2 and H3); 13C NMR (CDCl3, 75 
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MHz) δ 135.6 (CH, C7/C10), 117.7 (CH2, C8/C11), 78.9 (CH, C1/C4), 35.6 (CH2, 
C6/C9), 29.7 (CH2, C2/C3); HRCIMS m/z = 183.1384 [M+H]+ 0.7 ppm (183.1385 calcd 
for C11H19O2). 
 
O,O-Diacetyl-trans-1,3-dihydroxy-2,2-diallylcyclopentane, trans-3.68 
trans-1,3-Dihydroxy-2,2-diallylcyclopentane (trans-3.67, 23 mg, 0.13 mmol) was 
dissolved in anhydrous pyridine (500 μL) and acetic anhydride was added (200 μL, 2.1 
mmol, 16 eq).  The reaction was stirred at room temperature for 16 hours.  Diethyl ether 
(4 mL) was added and the mixture was extracted with citric acid(aq) (5% w/v, 3 x 4 mL).  
The organic phase was dried over MgSO4, filtered and reduced in vacuo to give the 
product (trans-3.68, 21 mg, 0.079 mmol, 61%) as a colourless oil.   
IR (thin film) νmax 1739, 1238, 1208 cm-1; 1H NMR (CDCl3, 500 MHz) δ 5.82 (2H, m, 
H7 and H10), 5.10-5.03 (4H, m, H8 and H11), 2.34 (2H, m, H6 and H9), 2.26 (2H, m, H2 
and H3), 2.12 (2H, m, H6 and H9), 2.04 (6H, s, H13 and H15), 1.58 (2H, m, H2 and H3); 
13C NMR (CDCl3, 75 MHz) δ 170.5 (C12/C14), 134.0 (C7/C10), 117.9 (C8/C11), 79.5 
(C1/C4), 49.6 (C5), 36.0 (C6/C9), 27.7 (C2/C3), 21.2 (C13/C15); HRCIMS m/z = 
267.1594 [M+H]+ 0.8 ppm (267.1596 calcd for C15H23O4). 
 
O,O-Diacetyl-trans-1,3-dihydroxy-2,2-di(allylcarboxylic acid) cyclopentane, 3.70 and 
O,O-diacetyl-trans-1,3-dihydroxy-2-allyl-2-(allylcarboxylic acid) cyclopentane, 3.71 
O,O-Diacetyl-trans-1,3-dihydroxy-2,2-diallylcyclopentane (18 mg, 0.068 mmol) was 
dissolved in DCM (1 mL) and dirhodium(II)tetrakis(caprolactam) (0.5 mg, 0.68 μmol, 1 
mol%) and NaHCO3 (3 mg, 0.034 mmol, 0.5 eq) were added.  tButyl hydroperoxide (5M 
in decanes, 0.5 mL, 2.5 mmol, 37 eq) was added and the reaction stirred at room 
temperature for 16 hours.  The solvents were removed in vacuo, and the crude residue 
was purified chromatography on silica using a step-wise gradient of 0 to 40% diethyl 
ether in petroleum ether.  Two products were isolated, the first of which, 3.70, required 
further purification by chromatography on silica using 10 to 30% diethyl ether in 
petroleum ether.  This gave the product (3.70, ~ 0.1 mg, 0.3 μmol, 0.4%) as a colourless 
oil.  A second product, 3.71, was not obtained in sufficient quantity to attempt further 
purification, however was tentatively assigned as 3.71.   
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3.70; Rf 0.36 (2:1 petroleum ether:ethyl acetate, visualization PMA); 1H NMR (CDCl3, 
500 MHz) δ 7.01 (2H, d, 16.6 Hz, H6 and H9), 5.78 (2H, d, 16.5 Hz, H7 and H10), 5.19 
(2H, dd, 6.5 Hz, 3.3 Hz, H1 or H4), 5.08 (2H, t, 6.5 Hz, H1 or H4), 2.21 (2H, m, H2/3), 
2.01 (3H, s, H13 or H15), 2.00 (3H, s, H13 or H15), 1.62-1.53 (2H, m, H2/3); 13C NMR 
(CDCl3, from HSQC and HMBC data at 500 MHz) δ 170.8 (C, C12 or C14), 170.6 (C, 
C12 or C14), 164.5 (C, C8 and C11), 149.6 (CH, C6 and C9), 117.4 (CH, C 7 and C10), 
79.2 (CH, C1 or C4), 76.7 (CH, C1 or C4), 27.8 (CH2, C2 and C3), 27.5 (CH2, C2 and 
C3), 21.4 (CH3, C13/15), C5 not observed. 
3.71: Rf 0.18 (2:1 petroleum ether:ethyl acetate, visualization PMA); HRESIMS m/z = 
295.1178 ± 1.4 ppm [M-H]- (295.1182 calcd for C15H19O6). 
 
 
Section 3.2.6 
O-Acetyl-4,8-dihydroxy-spiro-nona-2,6-diene-1-one-1,1-[1,8-dihydroxynaphthalene]-
acetal, 3.81 
O-Acetyl-4-hydroxy-spiro-nona-2,6-diene-1,8-dione-1,1-[1,8-dihydroxynaphthalene]-
acetal (3.79, 2 mg, 0.006 mmol) was dissolved in anhydrous MeOH (1 mL) with cerium 
trichloride (3 mg, 0.012 mmol, 2 eq).  The mixture was cooled in an ice-bath and NaBH4 
(0.3 mg, 0.008 mmol, 1.3 eq) was added.  The mixture was stirred at 0 ºC for 1 hour, then 
NaHCO3(aq) (1M, 2 mL) was added.  The mixture was extracted with diethyl ether (4 x 2 
mL) and the combined phases dried over MgSO4, filtered and the solvent was removed in 
vacuo.  The residue was purified on deacidified silica using a step-wise gradient of 10 to 
24% diethyl ether in petroleum ether.  The product (3.81, 0.9 mg, 0.003 mmol, 42%) was 
obtained as a colourless oil.   
Rf 0.21 (2:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
1738, 1606, 1413, 1381, 1226 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.50 (1H, d, 8.3 Hz, 
H13 or H15), 7.47 (1H, d, 8.3 Hz, H13 or H15), 7.41 (1H, t, 7.2 Hz, H12 or H16), 7.40 
(1H, t, 7.2 Hz, H12 or H16), 6.96 (1H, d, 7.6 Hz, H11 or H17), 6.87 (1H, d, 7.6 Hz, H11 
or H17), 6.20 (1H, dd, 6.1 Hz, 1.8 Hz, H2 or H3), 6.12 (1H, d, 5.7 Hz, H6), 6.08 (1H, dd, 
5.7 Hz, 2.3 Hz, H7), 6.05 (1H, dd, 6.1 Hz, 1.8 Hz, H2 or H3), 5.92 (1H, t, 1.8 Hz, H4), 
4.81 (1H, dt, 7.0 Hz, 2.2 Hz, H8), 2.50 (1H, dd, 14.7 Hz, 7.2 Hz, H9), 2.25 (1H, 14.6 Hz, 
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2.6 Hz, H9), 2.14 (3H, s, H21); 13C NMR (CDCl3, 75 MHz) δ 170.4 (C20), 148.3 (C, C10 
or C18), 147.8 (C, C10 or C18), 137.7 (CH, C6 or C7), 137.4 (CH, C2 or C3), 134.3 (CH, 
C6 or C7), 134.1 (C, C14), 131.9 (CH, C2 or C3), 127.5 (CH, C12 or C16), 127.2 (CH, 
C12 or C16), 121.0 (CH, C13 or C15), 120.6 (CH, C13 or C15), 114.0 (C, C19), 109.20 
(CH, C11 or C17), 109.17 (CH, C11 or C17), 109.0 (C, C1), 78.9 (C, C4), 75.9 (C, C8), 
67.0 (C, C5), 35.5 (CH2, C9), 21.1 (CH3, C21); HRESIMS m/z = 333.1120 ± 1.4 ppm 
[M+H]+ (333.1127 calcd for C21H16O4). 
 
 
Section 3.2.8 
spiro-Nona-2,6-diene-1,4-dione-1,1-[1,8-dihydroxy-4-bromo-naphthalene]-acetal, 
3.83 and spiro-nona-2,7-diene-1,4-dione-1,1-[1,8-dihydroxy-4-bromonaphthalene]-
acetal, 3.84  
spiro-Nona-2,7-diene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal (3.34, 5 mg, 17 
μmol) was dissolved in CCl4 (500 μL), N-bromosuccinimde (3.3 mg, 0.019 mmol, 1.1 eq) 
and AIBN (trace) were added and the reaction was stirred at room temperature for 20 
hours.  Additional N-bromosuccinimide (1.1 eq) was then added and the reaction stirred 
for a further 24 hours.  After removal of the solvent in vacuo, the crude mixture was 
partially purified on deacidified silica using a stepwise gradient of petroleum ether to 6% 
diethyl ether in petroleum ether, giving a mixture of three brominated products.  3.83 (Rt 
16.96 min, 0.6 mg, 1.6 μmol, 9%) was purified by separation on an analytical C18 HPLC 
column using 70% MeCN in H2O (isocratic), then 3.84 (Rt 17.29 min, 0.9 mg, 2.4 μmol, 
14%) and a minor product were separated on an analytical C18 HPLC column using 80% 
MeOH in H2O (isocratic). 
Mixture - Rf 0.54-0.63 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA) 
3.83: IR (thin film) νmax 1729, 1609, 1413, 1365, 1269 cm-1; 1H NMR (CDCl3, 500 MHz) 
δ 7.80 (1H, dd, 8.6 Hz, 0.7 Hz, H15), 7.69 (1H, d, 8.1 Hz, H12), 7.56 (1H, dd, 8.6 Hz, 7.6 
Hz, H16), 7.45 (1H, d, 6.1 Hz, H2), 7.01 (1H, dd, 7.6 Hz, 0.7 Hz, H17), 6.80 (1H, d, 8.1 
Hz, H11), 6.47 (1H, d, 6.1 Hz, H3), 6.01 (1H, m, H7 or H8), 5.60 (1H, m, H7 or H8), 
2.51 (2H, m, H6/9), 2.17 (2H, m, H6/9); 13C NMR (CDCl3, from 2D spectra at 500 MHz) 
δ 206.5 (C, C4), 153.7 (CH, C2), 147.8 (C, C18), 147.4 (C, C10), 137.0 (CH, C7 or C8), 
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136.2 (CH, C3), 133.0 (C, C14), 131.2 (CH, C12), 129.0 (CH, C16), 128.7 (CH, C7 or 
C8), 120.9 (CH, C15), 114.5 (C, C19), 110.6 (CH, C17), 110.5 (CH, C11), 69.9 (C, C5), 
32.5 (CH2, C6 or C9), 29.4 (CH2, C6 or C9), C1/C13 not observed; HRESIMS m/z = 
369.0115 [M+H]+ 3.0 ppm (369.0126 calcd for C19H1479BrO3). 
3.84: IR (thin film) νmax 1732, 1609, 1413, 1365, 1268 cm-1; 1H NMR (CDCl3, 500 MHz) 
δ 7.81 (1H, dd, 8.6 Hz, 0.7 Hz, H15), 7.70 (1H, d, 8.1 Hz, H12), 7.56 (1H, dd, 8.5 Hz, 7.7 
Hz, H16), 7.35 (1H, d, 6.1 Hz, H2), 7.01 (1H, dd, 7.7 Hz, 0.7 Hz, H17), 6.83 (1H, d, 8.1 
Hz, H11), 6.41 (1H, d, 6.1 Hz, H3), 5.65 (2H, br s, H7/H8), 3.18 (2H, m, H6/H9), 2.63 
(2H, m, H6’/H9’); 13C NMR (CDCl3, from 2D spectra at 500 MHz) δ 206.5 (C, C4), 
152.9 (CH, C2), 147.6 (C, C18), 147.3 (C, C10), 135.9 (CH, C3), 132.8 (C, C14), 131.1 
(CH, C12), 129.1 (CH, C16), 128.2 (CH, C7/C8), 121.0 (CH, C15), 114.3 (C, C19), 
114.0 (C, C13), 110.8 (CH, C17), 110.5 (CH, C11), 106.4 (C, C1), 61.4 (C, C5), 38.3 
(CH2, C6/C9); HRESIMS m/z = 369.0131 [M+H]+ 1.4 ppm (369.0126 calcd for 
C19H1479BrO3). 
 
spiro-Nona-7-ene-1,4-dione-1,1-[1,8-dihydroxy-4-bromonaphthalene]-acetal, 3.85 
spiro-Nona-7-ene-1,4-dione-1,1-[1,8-dihydroxynaphthalene]-acetal (3.35, 4 mg, 0.014 
mmol) was dissolved in CCl4 (500 μL) and 1 M Br2 solution (in CCl4, 30 μL, 0.030, 2.2 
eq) was added.  The reaction was stirred for 30 minutes and partial decolourisation of the 
solution was observed.  After removal of the solvent in vacuo, the crude product was 
purified on deacidified silica using a stepwise gradient from 0 to 3% diethyl ether in 
petroleum ether.  This gave the product (3.85, 1.5 mg, 0.004 mmol, 29%) as a colourless 
oil. In addition, some starting material was recovered.   
Rf 0.38 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
1750, 1608, 1412, 1365, 1269 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.78 (1H, dd, 8.5 Hz, 
0.7 Hz, H15), 7.69 (1H, d, 8.1 Hz, H12), 7.54 (1H, dd, 8.5 Hz, 7.6 Hz, H16), 6.99 (1H, dd, 
7.6 Hz, 0.7 Hz, H17), 6.80 (1H, d, 8.1 Hz, H11), 5.70 (2H, br s, H7/8), 3.01 (2H, m), 2.60 
(2H, m), 2.54 (2H, t, 7.8 Hz), 2.17 (2H, t, 7.8 Hz); 13C NMR (CDCl3, 75 MHz) δ 213.7 
(C4), 147.6 (C10 or C18), 147.5 (C10 or C18), 132.6 (C14), 130.8 (C7, C8, C12 or C16), 
128.7  (C7, C8, C12 or C16), 128.1 (C7, C8, C12 or C16), 128.0  (C7, C8, C12 or C16), 
120.5 (C15), 114.6 (C19 or C13), 113.8 (C19 or C13), 110.5 (C11 or C17), 110.3 (C11 or 
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C17), 108.4 (C1), 61.9 (C5), 36.50 (C6 or C9), 36.47 (C6 or C9), 33.7 (C2 or C3), 28.1 
(C2 or C3).  
 
3,7,8-Tribromo-2-hydroxy-spiro-nona-2,7-diene-1,4-dione, 3.87 and 7,8-dibromo-2-
hydroxy-spiro-nona-2,7-diene-1,4-dione, 3.88 
spiro-Nona-7-ene-1,4-dione (3.27, 20 mg, 0.13 mmol) was dissolved in CCl4 (500 μL) 
and a solution of bromine (1M, 150 μL, 0.15 mmol, 1.2 eq) was added.  The solution 
decolourised rapidly and was stirred at room temperature for 5 hours.  TLC/1H NMR 
spectroscopy of the crude mixture at both 1 hour and 5 hours showed that largely starting 
material remained.  Bromine (30 μL, 0.58 mmol, 4.5 eq) was added and stirred for 30 
minutes, after which time TLC/1H NMR spectroscopy of the crude mixture showed no 
starting material remained and a mixture of products had been formed.  The solvent and 
residual bromine were removed in vacuo and the crude residue purified by 
chromatography on silica using 1 to 6% ether in petroleum ether to give 3,7,8-tribromo-2-
hydroxy-spiro-nona-2,7-diene-1,4-dione (3.87, 21 mg, 0.05 mmol, 38%) as a slightly 
yellow crystalline solid and 7,8-dibromo-2-hydroxy-spiro-nona-2,7-diene-1,4-dione (3.88, 
17 mg, 0.05 mmol, 38%) as a slightly yellow crystalline solid.   
3.87: Rf 0.52 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); mp 163-164 ºC 
(recrystallised from diethyl ether); IR (diffuse reflectance) νmax 2952, 1759, 1716, 1707, 
1550, 1268, 1235, 1162 cm-1; 1H NMR (CDCl3, 300 MHz) δ 4.36 (2H, m, H7/8), 2.65 
(2H, m, H6/9), 2.34 (2H, m, H6/9); 13C NMR (CDCl3, 75 MHz) δ 194.2 (C2), 148.6 (C3), 
56.7 (C5), 52.0 (C7/8), 42.0 (C6/9), C1/4 not observed; HRESIMS m/z = 398.7882 ± 3.8 
ppm [M-H]- (398.7867 calcd for C9H679Br3O3). 
3.88: Rf 0.38 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); mp 136-138 ºC 
(recrystallised from diethyl ether); IR (diffuse reflectance) νmax 3059, 1758, 1707, 1560, 
1275 cm-1; 1H NMR (CDCl3, 300 MHz) δ 7.54 (1H, br s, H3), 4.35 (2H, m, H7/8), 2.58 
(2H, m, H6/9), 2.29 (2H, m, H6/9); 13C NMR (CDCl3, 75 MHz) δ 200.0 (C4), 197.1 (C1), 
148.4 (C3), 55.3 (C5), 52.0 (C7 or C8), 51.9 (C7 or C8), 41.6 (C6 or C9), 41.3 (C6 or C9) 
C2 not observed; HRESIMS m/z = 320.8775 ± 4.1 ppm [M-H]- (320.8762 calcd for 
C9H779Br2O3). 
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1,4-Hydroxy-spiro-nona-7-ene, 3.89 (stereoisomeric mixture) 
spiro-Nona-7-ene-1,4-dione (3.27, 50 mg, 0.33 mmol) was dissolved in anhydrous 
MeOH (2 mL), NaBH4 (33 mg, 0.84 mmol, 2.5 eq) was added and the reaction was 
stirred at room temperature for 2 hours.  Citric acid (5 % w/v, 4 mL) was added and the 
reaction was extracted with ethyl acetate (3 x 4 mL).  The combined organic phases were 
dried over MgSO4, filtered and the solvents were removed in vacuo.  This crude product 
(3.89, ~ 50 mg, ~ 100%), which was isolated as a colourless oil, was used directly in the 
next step.  Analytical data for each diastereoisomer given below (Section 3.2.8). 
IR (thin film) 3400-3200, 1417, 1344, 1095, 1053 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
5.74-5.58 (2H, m, H7/8), 4.40-3.75 (2H, m, H1/4), 2.68-2.56 (2H, m, H6 or H9), 2.10-
1.93 (6H, m, H2/3/6/9). 
 
1,4-Hydroxy-7,8-bromo-spiro-nonane, 3.90 (stereoisomeric mixture) 
1,4-Hydroxy-spiro-nona-7-ene (3.89, ~50 mg, ~0.33 mmol) was dissolved in DCM (1 
mL) and bromine (30 μL, 0.59 mmol, 1.8 eq) was added and the reaction stirred at room 
temperature for 2 hours.  The solvent and excess bromine was removed in vacuo and this 
crude product (3.90, 100 mg, 0.32 mmol, ~ 100%), which was isolated as a yellowish oil, 
was used directly in the next step.   
IR (thin film) 3400-3200, 1435, 1169, 1041 cm-1; 1H NMR (CDCl3, 500 MHz) δ 4.67-
4.10 (4H, m, H1/4/7/8), 3.10-1.20 (8H, m, H2/3/6/9); HRFABMS m/z = 312.9417 
[M+H]+ 7.1 ppm (312.9439 calcd for C9H1579Br2O2). 
 
7,8-Dibromo-spiro-nona-1,4-dione, 3.86 
1,4-Hydroxy-7,8-bromo-spiro-nonane (3.90, 100 mg, 0.32 mmol) was dissolved in DCM 
(3 mL), PDC (730 mg, 1.94 mmol, 6.1 eq) was added and the reaction was stirred at room 
temperature for 2 days.  It was then filtered through a short silica pad using DCM and the 
solvent was removed in vacuo to give the product as an amorphous white solid (3.86, 50 
mg, 0.16 mmol, 50%).   
mp 127-132 ºC (recrystallised from diethyl ether); IR (diffuse reflectance) νmax 1718, 
1415, 1281, 1176 cm-1; 1H NMR (CDCl3, 500 MHz) δ 4.27 (2H, m, H7/8), 2.85 (4H, m, 
H2/3), 2.58 (2H, m, H6/9), 2.23 (2H, m, H6/9); 13C NMR (CDCl3, 75 MHz) δ 212.6 
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(C1/4), 61.1 (C5), 52.6 (C7/8), 41.9  (C2/3), 35.2 (C6/9); HRESIMS m/z = 306.8972 ± 
0.7 ppm [M+H]+ (306.8970 calcd for C9H979Br2O2). 
 
7,8-Dibromo-spiro-nona-1,4-dione-1,1,4,4-di[ethane-1,2-diol]-acetal, 3.91 
7,8-Dibromo-spiro-nona-1,4-dione (3.86, 20 mg, 0.065 mmol) was dissolved in benzene 
(3 mL), ethylene glycol (400 μL, 7.2 mmol, 111 eq) and pTSA (1 mg, 0.005 mmol, 8 
mol%) were added and the reaction was refluxed for 16 hours with a Dean-Stark 
apparatus for H2O removal.  Additional ethylene glycol (200 μL, 3.6 mmol, 55 eq) was 
added to the reaction and refluxing was continued for a further 5 hours, then the reaction 
was cooled to room temperature.  Diethyl ether (10 mL) was added and the reaction was 
washed with NaHCO3(aq) (1M, 4 x 5 mL).  The organic phase was dried over MgSO4, 
filtered and the solvents removed in vacuo to give the product (3.91, 26 mg, 0.065 mmol, 
~ 100%) as a colourless oil.  
 Rf 0.13 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
1443, 1322, 1168, 1141, 1053 cm-1; 1H NMR (CDCl3, 500 MHz) δ 4.12 (2H, m, H7/8), 
4.02-3.94 (8H, m, H10/11/12/13), 2.49 (2H, dd, 14.0 Hz, 6.7 Hz, H6/9), 2.17 (2H, m, 
H6/9), 1.93-1.86 (4H, m, H2/3); 13C NMR (CDCl3, 75 MHz) δ 115.7 (C, C1/4), 65.0 
(CH2, C10/11/12/13), 57.7 (C, C5), 54.6 (CH, C7/8), 38.1 (CH2, C6/9), 32.1 (CH2, C2 or 
C3), 31.9 (CH2, C2 or C3); HRESIMS m/z = 396.9658 ± 2.0 ppm [M+H]+ (396.9650 
calcd for C13H1979Br2O4). 
 
7-Bromo-spiro-nona-7-ene-1,4-dione-1,1,4,4-di[ethane-1,2-diol]-acetal, 3.93 
Dibrominated 3.91 (15 mg, 0.038 mmol) was dissolved in a solution of tBuOK in 
anhydrous THF (1 mL, 1 mmol, 26 eq) and the reaction was stirred at room temperature 
for 16 hours.  After removal of the solvent in vacuo, the crude residue was repeatedly 
partitioned between diethyl ether (3 x 2 mL) and H2O (2 mL).  The organic phase was 
dried over MgSO4, filtered and the solvent removed in vacuo.  The crude residue was 
purified by chromatography on silica using 0 to 20% ether in petroleum ether.   
Rf 0.18 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
1321, 1147, 1045 cm-1; 1H NMR (CDCl3, 500 MHz) δ 5.73 (1H, quintet, 2.2 Hz, H8), 
4.01-3.92 (8H, m, OCH2CH2O), 2.76 (2H, q, 2.2 Hz, H6 or H9), 2.52 (2H, q, 2.3 Hz, H6 
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or H9), 1.93 (4H, s, H2/3); 13C NMR (CDCl3, 75 MHz) δ 129.2 (CH, C8), 118.0 (C, 
C1/4), 116.4 (C, C7), 65.2 (CH2, OCH2CH2O), 65.1 (CH2, OCH2CH2O), 59.1 (C, C5), 
42.4 (CH2, C6 or C9), 36.3 (CH2, C6 or C9), 32.3 (CH2, C2 and C3); HRESIMS m/z = 
317.0377 ± 3.5 ppm [M+H]+ (317.0388 calcd for C13H1879BrO4). 
 
 
Section 3.2.9 
O-Acetyl-4,8-dihydroxy-spiro-nona-2,6-diene-1-one-1,1-[1,8-dihydroxynaphthalene]-
acetal, 3.94 (stereoisomeric mixture) 
A mixture of O-acetyl-4-hydroxy-spiro-nona-2,6-diene-1,8-dione-1,1-[1,8-
dihydroxynaphthalene]-acetal and O-acetyl-4-hydroxy-spiro-nona-2,8-diene-1,6-dione-
1,1-[1,8-dihydroxynaphthalene]-acetal (3.79 and 3.80, 12 mg, 0.034 mmol) were 
dissolved in anhydrous MeOH (1 mL) with cerium trichloride (10 mg, 0.041 mmol, 1.2 
eq).  The mixture was cooled in an ice-bath and sodium borohydride (1.3 mg, 0.034 
mmol, 1 eq) was added.  The mixture was stirred at 0 ºC for 1 hour, then NaHCO3(aq) (1M, 
3 mL) was added.  The mixture was extracted with diethyl ether (4 x 3 mL) and the 
combined phases dried over MgSO4, filtered and the solvent removed in vacuo.  The 
residue was purified on deacidified silica using a step-wise gradient of 10 to 24% diethyl 
ether in petroleum ether.  The product (3.94, 11 mg, 0.031 mmol, 91%) was obtained as a 
mixture of stereoisomers as a colourless oil.   
IR (thin film) νmax 3400-3100, 2916, 1729, 1719, 1607, 1412, 1379 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ 7.51-7.36 (4H, m, H12, H13, H15 and H16), 6.98-6.82 (2H, m, H11 
and H17), 6.22-5.75 (5H, m, H2, H3, H4, H6 and H7), 4.84-4.79 (1H, m, H8), 3.52-1.77 
(2H, m, H9), 2.14 (~2H, s, H21), 2.10 (~1H, s, H21); HRESIMS m/z = 333.1124 ± 0.9 
ppm [M-OH]+ (333.1127 calcd for C21H16O4). 
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Burgess reagent - methyl (carboxysulfamoyl)triethylammonium hydroxide, 3.96 21 
Step 1, methyl (chlorosulfonyl)carbamate  
Freshly distilled chlorosulfonyl isocyanate (2 mL, 26.6 mmol, 1.16 eq) was dissolved in 
anhydrous benzene (7 mL) and placed in a H2O bath.  Anhydrous MeOH (930 μL, 23.0 
mmol), was added over 30 minutes.  Petroleum ether (6 mL) was added and the mixture 
placed in an ice-bath for 30 minutes.  The white precipitate formed was filtered and 
washed with petroleum ether (2 x 10 mL) and then dried in vacuo.  The product was 
obtained as white amorphous solid (3.23 g, 18.6 mmol, 81%). 
mp 71-74 ºC (lit. 72-74 ºC).21 
Step 2, methyl (carboxysulfamoyl)triethylammonium hydroxide, 3.96  
Anhydrous TEA (3.6 mL, 25.8 mmol, 2.2 eq) was dissolved in anhydrous benzene (10 
mL) and placed in a H2O bath.  Methyl (chlorosulfonyl)carbamate (2 g, 11.5 mmol) was 
dissolved in anhydrous benzene (25 mL) and this mixture was added to the TEA solution 
over 30 minutes.  The mixture was stirred at room temperature for a further hour.  The 
white precipitate formed was filtered and the filtrate reduced in vacuo.  Anhydrous THF 
(18 mL) was added to the residue and the solution cooled to -20 ºC.  After 1 hour, 
crystallisation was observed and after 16 hours, the product (3.96, white crystals, 1.73 g, 
7.25 mmol, 63%) was collected by filtration and dried in vacuo.   
mp 72-75 ºC (lit. 70-72 ºC)21 
 
O-Acetyl-4-hydroxy-spiro-nona-2,6,8-triene-1,1-[1,8-dihydroxynaphthalene]-acetal, 
3.95 
Allyl alcohol 3.94 (mixture of isomers, 11 mg, 0.031 mmol) was dissolved in anhydrous 
benzene (2 mL) and Burgess reagent (3.96, 15 mg, 0.063 mmol, 2 eq) was added.  The 
reaction was stirred at 50 ºC for 16 hours, then cooled to room temperature.  Diethyl ether 
(3 mL) was added and the mixture was extracted with NaHCO3(aq) (1M, 2 x 3 mL).  The 
organic phase was dried over MgSO4, filtered and the solvent removed in vacuo.  The 
crude residue was purified by chromatography on deacidified silica using a step-wise 
gradient of 0 to 6% diethyl ether in petroleum ether, which gave the product (3.95, 3mg, 
0.009 mmol, 29%) as a colourless oil. 
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Rf 0.41 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
1739, 1607, 1412, 1380, 1274, 1233, 1222, 1025 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
7.42 (1H, d, 8.4 Hz, H13 or H15), 7.41 (1H, d, 8.4 Hz, H13 or H15), 7.37-7.33 (2H, m, 
H12 and H16), 6.85 (1H, dd, 7.6 Hz, 0.9 Hz, C11 or C17), 6.80 (1H, dd, 7.6 Hz, 0.9 Hz, 
H11 or C17), 6.38 (1H, dd, 5.9 Hz, 2.2 Hz, H3), 6.31 (1H, ddd, 5.3 Hz, 2.2 Hz, 1.5 Hz, 
H6, H7, H8 or H9), 6.29-6.26 (2H, m, H2 and H6, H7 H8 or H9), 6.18-6.14 (2H, m, H6, 
H7 H8 or H9), 6.00 (1H, dd, 2.2 Hz, 1.1 Hz, H4), 2.03 (3H, s, H21); 13C NMR (CDCl3, 
75 MHz) δ 170.3 (C, C20), 148.3 (C, C10 or C19), 148.1 (C, C10 or C19), 136.4 (CH, 
C3), 135.9 (CH, C6, C7, C8 or C9), 134.4 (CH, C2, C6, C7, C8 or C9), 134.3 (CH, C2, 
C6, C7, C8 or C9), 132.6 (CH, C6, C7, C8 or C9), 132.2 (CH, C6, C7, C8 or C9), 127.1 
(CH, C12 and C16), 120.4 (CH, C13 or C15), 120.3 (C13 or C15), 113.9 (C, C19), 111.6 
(C, C1), 108.8 (CH, C11 or C18), 108.7 (CH, C11 or C18), 78.3 (CH, C4), 72.8 (C, C5), 
21.0 (CH3, C21); HRESIMS m/z = 333.1117 ± 3.0 ppm [M+H]+ (333.1127 calcd for 
C21H16O4). 
 
 
Section 3.2.9 
O-Acetyl-4-hydroxy-spiro-nona-2,6-diene-8,9-dioxetane-1,1-[1,8-
dihydroxynaphthalene]-acetal, 3.98 
O-Acetyl-4-hydroxy-spiro-nona-2,6,8-triene-1,1-[1,8-dihydroxynaphthalene]-acetal (1 
mg, 0.003 mmol) was dissolved in DCM (0.5 mL) and MeOH (0.5 mL) and thiourea (0.2 
mg, ~0.003 mmol, ~1 eq) and Rose Bengal (trace) were added.  The mixture was placed 
under an atmosphere of oxygen at atmospheric pressure and cooled in an ice-bath.  A 150 
W tungsten lamp was used as the light source.  The reaction was vigorously stirred in an 
ice-bath for 2 hours, then warmed to room temperature for 16 hours.  Ethyl acetate (4 
mL) was added and the organic phase was extracted with NaHCO3(aq) (1M, 3 x 3 mL).  
The organic phase was dried over MgSO4, filtered and the solvent removed in vacuo.  
The residue was purified by chromatography by passing it through an analytical HPLC 
C18 column in 5 aliquots using the following elution conditions [solvents: A: H2O + 
0.05% TFA, B: MeCN; isocratic: 0 min 10%, linear gradient: 2 min 10% B, 14 min 75% 
B, isocratic 24 min 75%, linear gradient: 35 min 100% B; 40 ºC; 1 mL min-1, detection at 
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330 nm].  This gave a partially purified mixture of two products (Rt 13.0 mins and 13.8 
mins) which could be separated by passing the mixture through an analytical HPLC C18 
column in 5 aliquots using the following elution conditions [solvents: A: H2O + 0.05% 
TFA, B: MeOH; isocratic: 0 min 10%, linear gradient: 2 min 10% B, 14 min 75% B, 
isocratic 24 min 75%, linear gradient: 35 min 100% B; 40 ºC; 1 mL min-1, detection at 
330 nm].   The first product (Rt 16.8 mins) could not be obtained in sufficient quantity for 
full elucidation of its structure, however it was clearly related to the second product (3.98, 
Rt 18,2 mins, ~0.3 mg, ~0.0008 mmol, ~27%), which was obtained as an amorphous 
solid and was assigned as O-acetyl-4,8,9-hydroxy-spiro-nona-2,6-diene-1,1-[1,8-
dihydroxynaphthalene]-acetal.   
1H NMR (CDCl3, 500 MHz) δ 7.55 (2H, d, 8.4 Hz, H13 and H15), 7.46 (1H, t, 8.2 Hz, 
H12 or H16), 7.45 (1H, t, 8.2 Hz, H12 or H16), 6.97 (2H, d, 7.7 Hz, H11 or H17),  6.29 
(1H, dd, 6.2 Hz, 1.8 Hz, H3), 6.26 (1H, t, 1.8 Hz, H4), 6.16 (1H, dd, 6.3 Hz, 1.7 Hz, H6 
or H7), 6.10 (1H, dd, 6.2 Hz, 1.8 Hz, H2), 5.88 (1H, dd, 6.3 Hz, 1.4 Hz, H6 or H7), 5.48 
(1H, dt, 7.2 Hz, 1.6 Hz, H8), 3.86 (1H, d, 7.2 Hz, C9), 2.07 (3H, s, H21); 13C NMR 
(CDCl3, 500 MHz, observed by 2D NMR) δ 171.6 (C, C20), 136.8 (CH, C3), 133.6 (CH, 
C6 or C7), 132.2 (CH, C6 or C7), 130.0 (CH, C2), 127.4 (CH, C12 and C16), 121.0 (CH, 
C13 and C15), 109.3 (CH, C11 and C18), 86.0 (CH, C8), 78.0 (CH, C4), 65.0 (CH, C9), 
19.4 (CH3, C21); HREIMS m/z = 364.0935 [M]+ 3.3 ppm (364.0947 calcd for C21H16O6). 
 
trans-1,4-Dihydroxy-spiro-nona-7-ene, trans-3.89 
A crude mixture of cis- and trans-3.89 was prepared as above (Section 3.2.7) from 3.27 
(200 mg, 1.33 mmol).  The mixture was then purified by chromatography on silica using 
a stepwise gradient of 10 – 50% diethyl ether in petroleum ether.  cis-1,4-Dihydroxy-
spiro-nona-7-ene (cis-3.89, 103 mg, 0.68 mmol, 51%) and trans-1,4-dihydroxy-spiro-
nona-7-ene (trans-3.89, 87 mg, 0.57 mmol, 43%) were obtained as colourless oils.   
cis-3.89:  Rf 0.35 (1:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin 
film) νmax 3500-3100, 1456-1420, 1173, 1053, 1038 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
5.76-5.72 (1H, m, H7 or H8), 5.58 (1H, m, H7 or H8), 3.88 (2H, br s, H1/4), 2.66 (2H, m, 
H6/9), 2.05 (2H, m, H2/3), 1.94 (4H, m, H2/3/6/9); 13C NMR (CDCl3, 75 MHz) δ 130.4 
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(CH, C7 or C8), 127.8 (CH, C7 or C8), 80.4 (CH, C1/4), 41.7 (CH2, C6 or C9), 33.6 
(CH2, C6 or 9), 31.8 (CH2, C2/3). 
trans-3.89:  Rf 0.16 (1:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin 
film) νmax 3500-3100, 1622, 1455-1420, 1173, 1053, 1037 cm-1; 1H NMR (CDCl3, 500 
MHz) δ 5.68 (2H, br s, H7/8), 4.07 (2H, m, H1/4), 2.64 (2H, br d, 14.8 Hz, H6/9), 2.13 
(2H, m, H2/3), 2.04 (2H, br d, 14.8 Hz, H6/9), 1.54 (2H, m, H2/3); 13C NMR (CDCl3, 75 
MHz) δ 129.4 (CH, C7/8), 78.2 (CH, C1/4), 56.9 (C, C5), 36.5 (CH2, C6/9), 29.6 (CH2, 
C2/3); HRCIMS m/z = 172.1336 [M+NH4]+ 0.7 ppm (172.1338 calcd for C9H18NO2). 
 
O,O-Diacetyl-trans-1,4-dihydroxy-spiro-nona-7-ene, 3.99 
trans-1,4-Dihydroxy-spiro-nona-7-ene (trans-3.89, 87 mg, 0.56 mmol) was dissolved in 
anhydrous pyridine (4 mL) and acetic anhydride (1.5 mL, 15.9 mmol, 28 eq) and the 
mixture was stirred at room temperature for 16 hours.  Citric acidaq (5%, 10 mL) was 
added and the mixture extracted with diethyl ether (3 x 10 mL).  The combined organic 
phases were dried over anhydrous MgSO4, filtered and reduced in vacuo to give the 
product as a colourless oil (3.99, 100 mg, 0.42 mmol, 75%).  
IR (thin film) νmax 1739, 1374, 1240, 1028 cm-1; 1H NMR (CDCl3, 500 MHz) δ 5.58 (2H, 
br s, H7/H8), 5.04 (2H, m, H1/H4), 2.55 (2H, br d, 14.9 Hz, H6 and H9), 2.25-2.17 (2H, 
m, H2 and H3), 2.11 (2H, br d, 14.9 Hz, H6 and H9), 2.03 (6H, s, H11 and H13), 1.61-
1.54 (2H, m, H2 and H3); 13C NMR (CDCl3, 75 MHz) δ 171.2 (C, C10/12), 129.0 (CH, 
C7/8), 79.6 (CH, C1/4), 55.1 (C, C5), 37.2 (CH2, C6/9), 27.6 (CH2, C2/3), 21.5 (CH3, 
C11/13); HRDCIMS m/z = 239.1279 [M+H]+ 1.8 ppm (239.1283 calcd for C13H9O4). 
 
O,O-Diacetyl-trans-1,4-dihydroxy-spiro-nona-6-ene-8-one, 3.100 
O,O-Diacetyl-trans-1,4-dihydroxy-spiro-nona-7-ene (3.99, 100 mg, 0.42 mmol) was 
dissolved in anhydrous DCM, and NaHCO3 (17 mg, 0.21 mmol, 0.5 eq) and 
dirhodium(II)tetrakis(caprolactam) (2.6 mg, 0.003 mmol, 1 mol%) were added. tButyl 
hydroperoxide 5M in decanes (2 mL, 10 mmol, 24 eq) was added and an immediate 
colour change from light purple to deep pink was observed.  The reaction was stirred at 
room temperature for 16 hours, then purified on silica (deacidified) using a stepwise 
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gradient of 10 to 40% diethyl ether in petroleum ether to give the product as a colourless 
oil (3.100, 84 mg, 0.33 mmol, 79%). 
Rf 0.35 (1:1 petroleum ether:ethyl acetate, visualization PMA); IR (thin film) νmax 1742, 
1717, 1375, 1236, 1030 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.50 (1H, d, 5.8 Hz, H6), 
6.23 (1H, d, 5.8 Hz, H7), 5.39 (1H, t, 7.7 Hz, H1 or H4), 5.04 (1H, dd, 6.1 Hz, 2.2 Hz, H1 
or H4), 2.63 (1H, d, 18.2 Hz, H9), 2.39 (1H, m, H2 or H3), 2.33-2.24 (1H, m, H2 or H3), 
2.09 (3H, s, H11 or H13), 2.05 (1H, d, 18.4 Hz, H9), 2.01 (3H, s, H11 or H13), H 1.81 
(1H, m, H2 or H3), 1.74-1.62 (1H, m, H2 or H3); 13C NMR (CDCl3, 75 MHz) δ 206.6, 
170.0, 163.4, 135.7, 80.6, (79.0), (76.2), 58.1, 39.8, 28.3, 27.6, 21.0, 20.9; HRESIMS m/z 
= 253.1073 ± 1.2 ppm [M+H]+ (253. 1076 calcd for C13H17O5). 
 
O,O-Diacetyl-trans-1,4,8-trihydroxy-spiro-nona-6-ene, 3.101 
O,O-Diacetyl-trans-1,4-dihydroxy-spiro-nona-6-ene-8-one (3.100, 84 mg, 0.33 mmol) 
was dissolved in anhydrous MeOH (1 mL), cerium trichloride (anhydrous, 99 mg, 0.40 
mmol, 1.2 eq) was added and the mixture was cooled in an ice-bath.  Sodium borohydride 
(13 mg, 0.33 mmol, 1 eq) was added and the reaction was stirred at 0 ºC for 1 hour.  
Deionised H2O (3 mL) was added and the reaction extracted with diethyl ether (4 x 3 mL).  
The combined organic phases were dried over MgSO4, filtered and the solvent removed 
in vacuo.  The crude product was purified by chromatography on deacidified silica using 
a stepwise gradient of petroleum ether 20 to 50% diethyl ether in petroleum ether, to give 
the product (3.101, mixture of isomers, 74 mg, 0.29 mmol, 88%) as a colourless oil. 
Rf 0.33 (1:1 petroleum ether:ethyl acetate, visualization PMA); IR (thin film) νmax 3400-
3200, 1740, 1375, 1238, 1028 cm-1; 1H NMR (CDCl3, 500 MHz) δ 5.99 (1/2H, dd, 5.6 Hz, 
2.3 Hz, H7), 5.95 (1/2H, dd, 5.6 Hz, 2.2 Hz, H7), 5.75 (1/2H, d, 5.7 Hz, H6), 5.73 (1/2H, 
dd, 5.7 Hz, 1.0 Hz, H6), 5.14 (1/2H, t, 7.6 Hz, H1 or H4), 5.10 (1/2H, t, 6.4 Hz, H1 or 
H4), 5.04 (1/2H, m, H1 or H4), 4.88 (1/2H, m, H1 or H4), 4.82-4.74 (1H, m, H8), 2.47-
2.17 (3H, m, H2, H3 and H9), 2.08 (3/2H, s), 2.06 (3/2H, s), 2.04 (3/2H, s), 2.03 (3/2H, s), 
1.97-1.51 (3H, m, H2, H3 and H9); 13C NMR (CDCl3, 75 MHz) δ 170.9 (C, C10 or C12), 
170.6 (C, C10 or C12), 170.4 (C, C10 or C12), 170.2 (C, C10 or C12), 136.7 (CH, 
C7),136.6 (CH, C7), 134.7 (CH, C6), 134.6 (CH, C6), 81.3 (CH, C1 or C4), 81.1 (CH, 
C1 or C4), 78.1 (CH, C1 or C4), 77.5 (CH, C1 or C4), 76.5 (CH, C1 or C4), 61.8 (C, C5), 
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61.5 (C, C5), 39.6 (CH2, C2, C3 or C9), 38.9 (CH2, C2, C3 or C9), 28.04 (CH2, C2, C3 or 
C9), 28.01 (CH2, C2, C3 or C9), 27.9 (CH2, C2, C3 or C9), 27.3 (CH2, C2, C3 or C9), 
21.1 (CH3, C11/13); HRESIMS m/z = 237.1118 ± 3.8 ppm [M-OH]+ (237.1127 calcd for 
C13H17O4). 
 
O,O-Diacetyl-trans-1,4,-dihydroxy-spiro-nona-6,8-diene, 3.102 
O,O-Diacetyl-trans-1,4,8-trihydroxy-spiro-nona-6-ene (3.101, 74 mg, 0.29 mmol) was 
dissolved in anhydrous benzene (3 mL) and Burgess reagent (3.96, 21 mg, 0.87 mmol, 3 
eq) was added.  The reaction was warmed to 50 ºC for 7 hours, then cooled to room 
temperature.  Deionised H2O (3 mL) was added and the mixture was extracted with 
diethyl ether (4 x 2 mL).  The combined organic phases were dried over MgSO4, filtered 
and the solvent removed in vacuo.  The crude product was purified by chromatography 
on deacidified silica using a stepwise gradient of 0 to 12% diethyl ether in petroleum 
ether, to give the product as a colourless oil (3.102, ~8 mg, ~0.034 mmol, ~ 12%).  A 
complex mixture of the isomers of 3.103 was obtained on elution with diethyl ether.  
Rf 0.38 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); IR (thin film) νmax 
1738, 1373, 1232, 1026 cm-1; 1H NMR (CDCl3, 500 MHz) δ 6.38 (2H, m, H7/H8), 6.25 
(2H, m, H6/H9), 5.36 (2H, m, H1/H4), 2.47 (2H, m, H2 and H3), 1.99 (6H, s, H11/H13), 
1.87 (2H, m, H2 and H3); 13C NMR (CDCl3, 75 MHz) δ 170.4, 135.4, 133.0, 69.5, 29.8, 
21.1; HRESIMS m/z = 237.1136 ± 3.8 ppm [M+H]+ (237.1127 calcd for C13H17O4). 
 
Retro Diels-Alder reaction of 3.103, giving 3.102 
The stereoisomeric mixture of 3.102 dimers, 3.103 (~ 50 mg, ~ 0.11 mmol), was 
dissolved in anhydrous benzene (30 mL) and the reaction refluxed for 3 days.  After this 
time 1H NMR spectroscopy of the crude mixture showed no more dimer was present and 
the monomer, 3.102, had been formed.  After cooling to room temperature and removal 
of the solvent in vacuo, the crude residue was purified by chromatography on deacidified 
silica as above.  The monomer 3.103 was obtained (4 mg, 0.02 mmol, ~18%).   
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Section 3.3 
O-Acetyl-4-hydroxy-spiro-nona-7-ene-1-one-1,1-[1,8-dihydroxynaphthalene]-acetal 
(or O-acetyl-2,3-dihydro-6,9-deoxy-spiro-mamakone A), 3.104 
4-Hydroxy-spiro-nona-7-ene-1-one-1,1-[1,8-dihydroxynaphthalene]-acetal (20 mg, 0.068 
mmol) was dissolved in anhydrous pyridine (500 μL) and acetic anhydride was added 
(200 μL, 2.1 mmol, 31 eq).  The reaction was stirred at room temperature for 16 hours.  
Deionised H2O (3 mL) was added and the mixture extracted with diethyl ether (4 x 3 mL).  
The combined organic phases were dried over MgSO4, filtered and reduced in vacuo.  No 
further purification was required.  The product (3.104, 19 mg, 0.056 mmol, 82 %) was 
obtained as a colourless oil. 
IR (thin film) νmax 1738, 1609, 1412, 1381, 1243 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
7.45-7.36 (4H, m, H12/H13/H15/H16), 6.90 (1H, d, 7.5 Hz, H11 or H17), 6.88 (1H, d, 
7.5 Hz, H11 or H17), 5.71-5.65 (2H, m, H7 and H8), 5.41 (1H, dd, 8.2 Hz, 6.7 Hz, H4), 
3.05 (1H, m, H6 or H9), 2.85 (1H, m, H6 or H9), 2.68 (1H, m, H6 or H9), 2.42 (1H, m, 
H6 or H9), 2.28 (1H, m, H3), 2.09 (3H, s, H21), 1.93 (2H, m, H2), 1.72 (1H, m, H3); 13C 
NMR (CDCl3, 75 MHz) δ 171.3 (C, C20), 148.5 (C, C10 or C18), 148.4 (C, C10 or C18), 
134.5 (C, C14), 129.01 (CH, C7 or C8), 128.97 (CH, C7 or C8), 127.6 (CH, C12 or C16), 
127.5 (CH, C12 or C16), 120.6 (CH, C13 or C15), 120.5 (CH, C13 or C15), 114.4 (C, 
C19), 110.0 (C, C1), 109.7 (CH, C11 or C18), 109.4 (CH, C11 or C18), 79.3 (CH, C4), 
57.8 (C, C5), 38.2 (CH2, C6 or C9), 34.4 (CH2, C6 or C9), 30.9 (CH2, C2), 26.3 (CH2, 
C3), 21.5 (C21); HRESMS m/z = 336.1366 [M]+. 1.2 ppm (336.1362 calcd for C21H20O4). 
 
O-Acetyl-4-hydroxy-spiro-nona-6-ene-1,8-dione-1,1-[1,8-dihydroxynaphthalene]-
acetal, 3.105 ([4R,5R] and [4S,5S]) and 3.106 ([4R,5S] and [4S,5R]) 
O-Acetyl-4-hydroxy-spiro-nona-7-ene-1-one-1,1-[1,8-dihydroxynaphthalene]-acetal 
(3.104, 19 mg, 0.056 mmol) was dissolved in DCM (1 mL) and 
dirhodium(II)tetrakis(caprolactam) (0.4 mg, 0.56 μmol, 1 mol%) and NaHCO3 (2.3 mg, 
0.028 mmol, 0.5 eq) were added.  tButyl hydroperoxide (5M in decanes, 0.5 mL, 2.5 
mmol, 45 eq) was added and the reaction stirred at room temperature for 16 hours.  The 
solvents were removed in vacuo, and the crude residue purified chromatography on silica 
(deacidified) using a step-wise gradient of 0 to 20% diethyl ether in petroleum ether.  The 
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isomeric products O-acetyl-4-hydroxy-spiro-nona-6-ene-1,8-dione-1,1-[1,8-
dihydroxynaphthalene]-acetal (3.105, 8.7 mg, 0.025 mmol, 45%) and O-acetyl-4-
hydroxy-spiro-nona-8-ene-1,7-dione-1,1-[1,8-dihydroxynaphthalene]-acetal (3.106, 4.1 
mg, 0.012 mmol, 21%) were obtained as colourless oils.  
3.105:  Rf 0.19 (4:1 petroleum ether:ethyl acetate, visualization PMA); IR (thin film) νmax 
1741, 1721, 1610, 1411, 1380, 1276, 1236, 1053 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
7.67 (1H, d, 5.8 Hz, H6), 7.49-7.36 (4H, m, H12, H13, H15 and H16), 6.97 (1H, d, 7.4 
Hz, H11 or H17), 6.86 (1H, d, 7.4 Hz, H11 or H17), 6.18 (1H, d, 5.8 Hz, H7), 5.72 (1H, t, 
8.5 Hz, H4), 2.86 (1H, d, 18.1 Hz, H9), 2.66 (1H, d, 18.1 Hz, H9), 2.43 (1H, m, H3), 2.16 
(1H, m, H2), 2.05 (1H, m, H2), 2.04 (3H, s, H21), 1.82 (1H, m, H3); 13C NMR (CDCl3, 
75 MHz) δ 207.4 (C, C8), 170.7 (C, C20), 162.6 (CH, C6), 147.6 (C, C10 or C18), 147.4 
(C, C10 or C18), 136.5 (C, C14), 134.5 (CH, C7), 127.7 (CH, C12 or C16), 127.6 (CH, 
C12 or C16), 121.2 (CH, C13 or C15), 121.1 (CH, C13 or C15), 114.0 (C, C19), 109.8 
(CH, C11 or C17), 109.6 (CH, C11 or C17), 108.9 (C, C1), 74.9 (CH, C4), 61.7 (C, C5), 
36.8 (CH2, C9), 32.1 (CH2, C2), 26.8 (CH2, C3), 21.2 (CH3, C21); HRESIMS m/z = 
351.1235 ± 0.9 ppm [M+H]+ (351.1232 calcd for C21H19O5). 
3.106:  Rf 0.14 (4:1 petroleum ether:ethyl acetate, visualization PMA); IR (thin film) νmax 
1738, 1721, 1609, 1412, 1379, 1276, 1236, 1054 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
7.65 (1H, d, 5.9 Hz, H9), 7.48 (2H, d, 8.1 Hz, H13 and H15), 7.41 (1H, t, 7.4 Hz, H12 or 
H16), 7.39 (1H, t, 7.4 Hz, H12 or H16), 6.91 (1H, d, 7.5 Hz, H11 or H17), 6.87 (1H, d, 
7.5 Hz, H11 or H17), 6.31 (1H, d, 5.8 Hz, H8), 5.46 (1H, dd, 8.1 Hz, 6.3 Hz, H4), 3.06 
(1H, d, 18.9 Hz, H6), 2.45 (1H, mH3), 2.43 (1H, d, 18.8 Hz, H6), 2.21 (1H, m, H2), 2.10 
(1H, m, H2),. 2.09 (3H, s, H21), 1.95 (1H, m, H3); 13C NMR (CDCl3, 75 MHz) δ 207.5 
(C, C6), 170.7 (C, C20), 160.6 (CH, C9), 147.8 (C, C10 or C18), 147.5 (C, C10 or C18), 
136.2 (C, C14), 134.5 (C, C8), 127.7 (CH, C12 or C16), 127.6 (CH, C12 or C16), 121.2 
(CH, C13 or C15), 121.1 (CH, C13 or C15), 114.0 (C, C19), 109.9 (CH, C11 or C17), 
109.6 (CH, C11 or C17), 108.9 (C, C1), 78.8 (CH, C4), 61.7 (C, C5), 40.7 (CH2, C9), 
31.9 (CH2, C2), 27.3 (CH2, C3), 21.2 (CH3, C21); HRESIMS m/z = 351.1242 ± 2.8 ppm 
[M+H]+ (351.1232 calcd for C21H19O5). 
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4,8-Dihydroxy-spiro-nona-2,6-diene-1-one-1,1-[1,8-dihydroxynaphthalene]-acetal, 
3.107 (mixture of diastereoisomers) 
spiro-Nona-2,7-diene-1,4,6-trione-1,1-[1,8-dihydroxynaphthalene]-acetal (3.77, 3.2 mg, 
0.010 mmol) and CeCl3 (anhydrous, 5.4 mg, 0.022 mmol, 2.1 eq) were dissolved in 
MeOH (500 μL) and cooled to 0 ºC.  NaBH4 (0.8 mg, 0.022 mmol, 2.1 eq) was added and 
the reaction stirred at 0 ºC for 1 hour.  NaHCO3 (aq) 1 M (1 mL) was added and the 
reaction extracted with diethyl ether (4 x 1 mL).  The combined organic phases were 
dried over MgSO4, filtered and the solvent removed in vacuo.  The crude product, 
obtained as a colourless oil (3.107, mixture of isomers, 3.2 mg, 0.010 mmol, 98%), was 
used directly in the next step.   
1H NMR (CDCl3, 300 MHz) δ 7.55-7.34 (4H, H12/13/15/16), 7.0-6.82 (2H, H11/17), 
6.38-5.94 (4H, H2/3/7/8), 4.98-4.62 (2H, H4/6), 2.91-2.63 (1H, H9), 2.32-1.96 (1H, H9); 
HRESIMS m/z = 331.0961 [M+Na]+ 4.5 ppm (331.0946 calcd for C19H16O4Na). 
 
O,O-Diacetyl-4,8-dihydroxy-spiro-nona-2,6-diene-1-one-1,1-[1,8-
dihydroxynaphthalene]-acetal, 3.108 
4,8-Dihydroxy-spiro-nona-2,6-diene-1-one-1,1-[1,8-dihydroxynaphthalene]-acetal (3.107, 
3.2 mg, 0.010 mmol) was dissolved in pyridine (500 μL) and acetic anhydride was added 
(200 μL).  The reaction was stirred at room temperature for 16 hours, then diethyl ether 
was added (2 mL) and the mixture extracted with NaHCO3 (aq) (1M, 3 x 2 mL).  After 
drying over MgSO4, filtration and evaporation of solvent, the crude product was purified 
on silica (deacidified) using a stepwise gradient of 0 to 12% diethyl ether in petroleum 
ether, to give the product (mixture of isomers, 3.1 mg, 79%) as a colourless oil.    
Rf  0.35 (4:1 petroleum ether:ethyl acetate, visualization UV/PMA); 
1H NMR (CDCl3, 300 MHz) δ 7.49-7.35 (4H, H12/13/15/16), 6.95-6.82 (2H, H11/17), 
6.22-5.72 (6H, H2/3/4/6/7/8), 3.15-2.41 (2H, H9), 2.17-2.04 (6H, H21/23); HRESIMS 
m/z = 415.1167 [M+Na]+ 2.2 ppm (415.1158 calcd for C23H20O6Na). 
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Four new cyclodepsipeptides, pteratides I-IV (1-4), have been isolated from the extract of a Pterula
species collected from a Malaysian tropical forest. Homonuclear and heteronuclear 2D NMR techniques
as well as MS fragmentation experiments, in combination with methanolysis, determined the gross
structures of the peptides and showed that pteratides I and II each contained the nonproteinogenic amino
acid 4-methylproline. The absolute configurations of the amino acids in pteratides I-IV were established
using Marfey’s method. Pteratides I and II are each potently cytotoxic against the P388 murine leukemia
cell line (IC50 values of 41 and 40 nM, respectively). Pteratides III and IV show weaker, but still notable,
activity with IC50 values of 7.4 and 2.9 íM, respectively.
Introduction
Many natural cyclodepsipeptides exhibit potent biological
activities, for example, the cytotoxic and antiviral sansalvamide,1
the fusaricidins,2,3 which are antimicrobial against Gram-positive
bacteria, and the antitumor agent kahalalide F,4 which is
currently in clinical trials against prostate cancer. We now report
the isolation of a new group of highly cytotoxic cyclodepsipep-
tides, the pteratides, from the fruiting bodies of the coral-shaped
Malaysian basidiomycete, identified as a Pterula species.
Despite the wide geographical distribution, the secondary
metabolites of this genus have not been extensively studied.
The Pterula sp. most studied to date has been a cultivated strain,
Pterula sp. 82168, which was found to produce the five
previously unknown bioactive natural products hydroxystrobi-
lurin A,5 pterulones A and B,6,7 pterulinic acid,6 and noroude-
mansin A.8 The Pterula sp. described here has also been the
source of the pterulamides, six highly N-methylated linear
peptides with unusual N- and C-end groups.9
* To whom correspondence should be addressed. Tel: +64-3-3642434.
Fax: +64-3-3642429.
† Department of Chemistry, University of Canterbury.
‡ School of Biological Sciences, University of Canterbury.
§ School of Chemical Sciences and Food Technology, Universiti Kebangsaan
Malaysia.
(1) Hwang, Y.; Rowley, D.; Rhodes, D.; Gertsch, J.; Fenical, W.;
Bushman, F. Mol. Pharm. 1999, 55, 1049-1053.
(2) Kajimura, Y.; Kaneda, M. J. Antibiot. 1996, 49, 129-135.
(3) Kajimura, Y.; Kaneda, M. J. Antibiot. 1997, 50, 220-228.
(4) Hamann, M. T.; Scheuer, P. J. J. Am. Chem. Soc. 1993, 115, 5825-
5826.
(5) Engler, M.; Anke, T.; Sterner, O. J. Antibiot. 1995, 48, 884-885.
(6) Engler, M.; Anke, T.; Sterner, O. J. Antibiot. 1997, 50, 330-333.
(7) Engler, M.; Anke, T.; Sterner, O. Z. Naturforsch. C 1998, 53, 318-
324.
(8) Engler-Lohr, M.; Anke, T.; Hellwig, V.; Steglich, W. Z. Naturforsch.
C 1999, 54, 163-168.
10.1021/jo060843u CCC: $33.50 © 2006 American Chemical Society
J. Org. Chem. 2006, 71, 7947-7951 7947Published on Web 09/20/2006
Results and Discussion
The MeOH extracts of three separate Pterula fruiting bodies
(A-C) each exhibited potent cytotoxicity against P388 murine
leukaemia cells (IC50 < 1 íg/mL). Despite morphological
similarity, the extracts from the three fruiting bodies differed
in their chemical profile as assessed by HPLC-UV-MS.10
Bioactivity-guided isolation of the cytotoxic principles yielded
four new cyclodepsipeptides: pteratides I (1; from A and C),
II and III (2 and 3; from B), and IV (4; from C), along with the
less cytotoxic linear pterulamides.9 None of the previously
described Pterula metabolites were found in these extracts. 5-8
HRESIMS on pteratide I (1) established the mass of the
pseudomolecular ion [M + H]+ as 987.5918 Da, which
corresponded to a molecular formula for 1 of C53H78N8O10. The
1H NMR spectrum of 1 clearly revealed its peptidic nature; two
amide resonances (ä 9.31 and ä 7.24), signals for eight
R-protons in the range between 4.6 and 5.5 ppm, and five
N-methyl groups between 2.5 and 3.2 ppm were observed.
TOCSY, HSQC, and HMBC spectra were used to identify the
constituent amino acids in 1. Two valine, two alanine, one
leucine, one phenylalanine, and one threonine unit could be
readily identified. The signals of an additional aromatic group
were attributed to a benzoyl residue.
The amino acid with the R-proton at äH 4.90 did not belong
to the set of standard proteinogenic amino acids. In addition to
this R-proton, there were also signals for two sets of diaste-
reotopic methylene groups (äH 1.79 and 2.06, 2.93 and 3.89), a
methine proton (äH 2.75), and a methyl group (äH 1.03). COSY,
HMBC correlations and chemical shift arguments established
the relationships between these groups leading to the identifica-
tion of the amino acid as 4-methylproline (4-MePro). A ROESY
correlation between the H-2 and the 4-methyl group and the
absence of such a correlation between the H-2 and H-4
established a trans-relationship, i.e., (2S*,4R*)-configuration.
The locations of the five N-methyl groups were determined using
HMBC correlations to the R-carbons of the amino acid residues.
By this approach the two valine, the two alanine, and the leucine
residues were each found to be N-methylated. Long-range H,C-
couplings from the amide proton at äH 7.24 were observed to
the carbonyl carbons of the benzoyl group and to the threonine
residue indicating N-benzoylation of this amino acid. HMBC
correlations between the N-methyl groups, or the amide protons
to the carbonyl carbon of the next respective amino acid,
provided the necessary information for establishing the amino
acid sequence of 1. Two partial sequences were identified: NBz-
Thr-NMe-Leu-NMe-Ala1 and 4-MePro-NMe-Ala2-NH-Phe-
NMe-Val1-NMe-Val2 (Figure 1). An ester linkage between the
â-hydroxyl group of the threonine residue and Val2 was evident
from the long-range coupling of the threonine â-proton (äH 5.12)
to the carbonyl carbon of Val2 (äC 168.7) and was supported
by the low-field chemical shift of this â-proton. The remaining
ring-closing connection between Ala1 and the 4-methylproline
was confirmed by NOESY correlations between the R-proton
of Ala1 and H-5a as well as H-5b of 4-MePro (Figure 1).
To confirm this sequence, pteratide I (1) was ring-opened
by methanolysis, and the resultant methyl ester was analyzed
by ESI MS/MS. The fragmentation of the sodiated molecular
ion of the methyl ester of 1 (m/z 1041.7) gave y5, y6 and y7
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FIGURE 1. HMBC (single arrows) and NOESY (double arrows)
correlations establishing the amino acid sequence of 1.
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fragment ions due to sequential losses of NBz-Thr, NMe-Leu,
and NMe-Ala, respectively (see the Supporting Information).
The a6 and b6 fragment ions were also observed in the MS/MS
spectrum of 1 methyl ester confirming the presence of the
fragment NBz-Thr-NMe-Leu-NMe-Ala-MePro-NMe-Ala-Phe.
The HRESIMS of pteratide II (2) showed the pseudomo-
lecular ion [M + Na]+ at m/z 1023.5902, indicating a molecular
formula of C54H80N8O10 for this compound. The structural
similarity to pteratide I (1) was immediately apparent from the
1H NMR spectrum. Detailed analysis of the 2D NMR spectra
revealed that the constituent amino acids were one valine, two
alanine, one leucine, one isoleucine, one phenylalanine, and one
N-benzoylated threonine. In addition to these amino acids, a
trans-4-methylproline unit was again identified. Using the
correlation data from the HMBC NMR experiment, it was found
that the five N-methyl groups observable in the 1H NMR
spectrum were associated with the two alanine, valine, leucine,
and the isoleucine residue. The sequence was established using
HMBC correlations as NBz-Thr-NMe-Leu-NMe-Ala1-4-MePro-
NMe-Ala2-NH-Phe-NMe-Ile-NMe-Val. As in 1, the ring-closing
ester bond was evident from the long-range coupling between
the â-proton of threonine (äH 5.20) and the carbonyl carbon of
the C-terminal valine (äC 168.8). Pteratide II (2) therefore is a
homologue of pteratide I (1), with a valine substituted by
isoleucine. The suggested sequence was again confirmed by ESI
MS/MS analysis of the ring-opened methanolysis product of 2.
Pteratide III (3), isolated from the same extract as 2, had a
pseudomolecular ion [M + H]+ at m/z 819.5000, corresponding
to a molecular formula for 3 of C45H66N6O8. The 1H NMR
spectrum again suggested a peptidic nature for this compound.
As for the spectra of 1 and 2, signals for amide protons, aromatic
protons, R-protons of amino acids, N-methyl groups, and several
overlapping methyl signals were observed. Analysis of the
separate spin systems revealed that 3 contained six amino acid
residues: three valine units, one leucine, one phenylalanine, and
one threonine. The phenylalanine accounted for only half of
the aromatic protons observed. The other aromatic protons
belonged to a benzoyl group that was found to be attached to
the amino group of threonine, as shown by a HMBC correlation
of the R-proton of threonine (äH 5.74) to the carbonyl carbon
of the benzoyl group (äC 174.4). The four N-methyl groups were
attached to valine-3, leucine, phenylalanine, and threonine,
which was thus both N-benzoylated and N-methylated. The
sequence of the amino acids (HMBC correlation data) was
NBz-NMe-Thr-NMe-Phe-NH-Val1-NH-Val2-NMe-Leu-NMe-
Val3. Again, a long-range H,C-coupling from the â-proton of
threonine (äH 5.68) to the carbonyl carbon of the C-terminal
valine unit (äC 170.2) indicated the ring-closing ester bond
between these two amino acids.
The molecular formula of pteratide IV (4) was found to be
C52H78N8O10 by evaluation of HRESIMS and 13C NMR data.
Using TOCSY, HSQC, and HMBC data, this peptide was found
to contain eight amino acids, five of them N-methylated, and
also one benzoyl group. The sequence of these amino acids was
elucidated using long-range H,C-couplings detected with the
IMPRESS NMR technique, which provides higher resolution
in the F1 dimension.11 The sequence was determined as NBz-
NMe-Val1-NMe-Ile-NH-Thr-NMe-Phe-NH-Val2-NMe-Ala1-
NMe-Ala2-NH-Val3 with a ring-closing ester bond between
Val3 and Thr.
Using Marfey’s method,12 all amino acids in 1-4 were found
to be of (S)-configuration. By comparison against standards the
isoleucines found in 2 and 4, the threonines in 1, 2, and 4 and
the N-methylthreonine in 3 could be assigned as (2S,3S), (2S,3R),
and (2S,3R), respectively. The 4-methylproline13,14 in 1 and 2
was found in both cases to be (2S,4R).
Pteratides I (1) and II (2) exhibited potent cytotoxicity against
P388 murine leukaemia cells with IC50 values of 41 nM (0.039
íg/mL) and 40 nM (0.039 íg/mL), respectively. Pteratides III
(3) and IV (4) were 2 orders of magnitude less active than 1
and 2 with IC50 values of 7.4 íM (6.1 íg/mL) and 2.9 íM (2.9
íg/mL), respectively.
The pteratides have intriguing structures characterized by the
high degree of N-methylation and, in the case of pteratides I-III
(1-3), by N-benzoylation of the ring-closing threonine residues.
Additionally, the rare nonproteinogenic amino acid (2S,4R)-4-
methylproline is found in pteratides I and II (1, 2). The (2S,4S)
diastereoisomer of this unusual amino acid is known from the
peptides of cyanobacteria,15,16 while 4-methylproline from
cyclopeptides of the sponge Theonella sp.17 and an imperfect
fungus18 have undetermined stereochemistry. Beyond doubt, the
most remarkable feature of pteratides is their potent cytotox-
icity: the mechanism of action remains to be examined.
Experimental Section
Fungal Material. Fruiting bodies of an unidentified Pterula
species were collected in the Sungkai Wildlife Forest, Perak,
Malaysia (collections A and B) and at Krau, Pahang, Malaysia
(collection C). Voucher specimens have been deposited in the
collection at the School of Chemical Sciences and Food Technology,
Universiti Kebangsaan Malaysia (collection A, UKM-F3384A;
collection B, UKM-F3384B; collection C, UKM-F4794). Identifica-
tion of the fungal material was made by one of the authors
(A.L.J.C.) based on the characteristic ageotropic, multifid, brown
fruit bodies growing on dead sticks. Fungal thalli from the three
separate collections were cut into pieces and separately extracted
with MeOH.
Isolation of Pteratides I-IV (1-4). The compounds were
isolated by standard chromatographic methods (see the Supporting
Information).
Pteratide I (1): amorphous white solid; [R]20D -128 (c 0.1,
MeOH); for 1H and 13C NMR data see Table 1, for TOCSY,
HMBC, and NOESY data see the Supporting Information; HRES-
IMS m/z 987.5918 [M + H]+ (calcd for C53H79N8O10, 987.5919).
Pteratide II (2): amorphous white solid; [R]20D -40 (c 0.1,
MeOH); for 1H and 13C NMR data see Table 1, for TOCSY,
HMBC, and NOESY data see the Supporting Information; HRES-
IMS m/z 1023.5902 [M + Na]+ (calcd for C54H80N8O10Na,
1023.5895).
Pteratide III (3): amorphous white solid; [R]20D -47 (c 0.1,
MeOH); for 1H and 13C NMR data see Table 2, for TOCSY,
(11) Crouch, R.; Boyer, R. D.; Johnson, R.; Krishnamurthy, K. Magn.
Reson. Chem. 2004, 42, 301-307.
(12) Marfey, P. Carlsberg Res. Commun. 1984, 49, 591-596.
(13) Golakoti, T.; Yoshida, W. Y.; Chaganty S.; Moore, R. E. Tetrahe-
dron 2000, 56, 9093-9102.
(14) The four 4-MePro isomers were prepared by stereochemically
selective routes. A paper describing the synthesis and the physical data for
the stereoisomers and the Marfey derivatives is currently in preparation.
(15) Golakoti, T.; Yoshida, W. Y.; Chaganty, S.; Moore, R. E. J. Nat.
Prod. 2001, 64, 54-59.
(16) Fujii, K.; Sivonen, K.; Adachi, K.; Noguchi, K.; Sano, H.; Hirayama,
K.; Suzuki, M.; Harada, K. Tetrahedron Lett. 1997, 38, 5525-5528.
(17) Gulavita, N. K.; Pomponi, S. A.; Wright, A. E.; Yarwood, D.; Sills,
M. A. Tetrahedron Lett. 1994, 35, 6815-6818.
(18) Kawazu, K.; Murakami, T.; Ono, Y.; Kanzaki, H.; Kobayashi, A.;
Mikawa, T.; Yoshikawa, N. Biosci. Biotechnol. Biochem. 1993, 57, 98-
101.
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HMBC, and NOESY data see the Supporting Information; HRES-
IMS m/z 819.5000 [M + H]+ (calcd for C45H67N6O8, 819.5020).
Pteratide IV (4): amorphous white solid; [R]20D -85 (c 0.33,
MeOH); for 1H and 13C NMR data see Table 3, for TOCSY,
HMBC, and NOESY data see the Supporting Information; HRES-
IMS m/z 975.5940 [M + H]+ (calcd for C52H79N8O10, 975.5919).
Methanolysis of Pteratides I and II (1, 2). The peptides 1 and
2 (20 íg each) were dissolved in dry MeOH (100 íL), and NaOMe
solution (4%, 100 íL) was added. The mixtures were stirred for 3
h at 30 °C. After cooling, the solutions were evaporated to dryness
and redissolved in ice H2O-EtOAc (1:1) (1 mL). After solvent/
solvent partitioning, the EtOAc layer for each compound was
evaporated to dryness and analyzed by the ESI MS/MS.
Methyl Ester of 1: ESI MS/MS m/z 1041.7 (80) [MCOOMe +
Na]+, 997.8 (100) [1041.7 - C2H4O]+, 836.8 (40) [1041.7 - (NBz-
Thr)]+, 783.5 (6) [(NBz-Thr-NMe-Leu-NMe-Ala-MePro-NMe-Ala-
Phe) + Na]+, 755.7 (20) [783.5-CO]+, 709.7 (20) [836.8 - (NMe-
Leu)]+, 624.7 (10) [709.7 - (NMeAla)]+.
Methyl Ester of 2: ESI MS/MS m/z 1055.7 (64) [MCOOMe +
Na]+, 1011.7 (100) [1055.7 - C2H4O]+, 850.8 (12) [1055.7 -
TABLE 1. NMR Data for Pteratide I (1) and II (2)
1a 2b 1a 2b
position 13C 1H 13C 1H position 13C 1H 13C 1H
Thr NH 7.24 7.85 Ala2 NMe 29.0 2.50 28.2 2.32
1 168.9 169.5 1 170.7 171.8
2 52.2 5.33 53.0 5.22 2 56.2 4.63 55.9 4.91
3 73.0 5.12 72.5 5.20 3 15.0 2.50 13.5 1.22
4 18.1 1.39 16.9 1.34 Phe NH 9.31 9.31
Bz-1 167.7 169.4 1 172.3 172.8
Bz-2 133.8 132.0 2 54.5 4.60 54.7 4.53
Bz-3/7 127.5 7.85 127.1 7.77 3 35.0 3.05 34.0 3.00
Bz-4/6 132.5 7.50 128.6 7.43 3.37 3.29
Bz-5 129.1 7.58 132.1 7.51 4 139.0 138.5
Leu NMe 30.6 2.91 29.5 2.89 5/9 129.5 7.41 128.8 7.36
1 169.2 169.7 6/8 128.7 7.26 128.2 7.16
2 53.6 5.28 53.2 5.27 7 126.9 7.19 126.8 7.10
3 37.5 1.34 37.0 1.29 Val1 NMe 29.9 3.24
1.97 1.83 1 171.1
4 25.0 1.50 24.7 1.43 2 57.7 5.10
5 22.5 0.91 21.4 0.83 3 27.6 2.45
6 23.2 0.93 21.9 0.84 4 18.5 0.92
Ala1 NMe 29.3 2.58 29.0 2.54 5 20.2 0.88
1 168.6 168.4 Ile NMe 29.2 3.14
2 52.0 5.48 51.7 5.33 1 171.4
3 14.4 1.25 12.9 1.15 2 56.2 5.14
MePro 1 171.8 173.2 3 33.2 2.17
2 56.4 4.90 55.7 5.24 3-Me 18.8 0.77
3 36.0 1.79 35.3 1.81 4 23.9 0.93
2.06 1.88 1.43
4 33.5 2.75 33.2 2.53 5 15.0 0.78
5 54.0 2.93 53.5 2.95 Val2 NMe 29.7 2.71 29.0 2.65
3.89 3.72 1 168.7 168.8
4-Me 17.9 1.03 16.9 0.97 2 66.2 4.88 66.5 4.87
3 27.8 2.31 27.0 2.42
4 20.0 1.18 19.6 1.07
5 19.9 0.98 19.1 0.88
a Recorded in CDCl3 (500 MHz). b Recorded in MeOH-d4 (500 MHz).
TABLE 2. NMR Data for Pteratide III (3) in MeOH-d4
position 13Ca 1H position 13C 1H position 13Ca 1H
Thr NMe 36.5 3.27 Phe 5/9 130.0 7.35 Leu NMe 30.0 3.11
1 172.7 6/8 128.9 7.31 1 174.1
2 61.8 5.74 7 127.2 7.25 2 50.5 5.48
3 68.5 5.68 Val1 NH 7.66 3 37.1 1.34
4 16.1 0.58 1 173.7 2.02
Bz-1 174.4 2 54.1 4.51 4 25.1 1.59
Bz-2 135.2 3 29.7 1.53 5 22.5 1.03
Bz-3/7 128.3 7.47 4 16.1 0.16 6 21.3 1.07
Bz-4/6 128.4 7.50 5 18.1 0.63 Val3 NMe 29.5 2.98
Bz-5 131.2 7.50 Val2 NH 8.41 1 170.2
Phe NMe 30.7 3.04 1 174.2 2 65.4 4.39
1 170.6 2 64.1 3.74 3 30.1 2.45
2 63.3 5.05 3 29.5 2.29 4 19.7 1.05
3 35.1 3.13 4 18.5 1.00 5 19.4 1.13
3.68 5 19.4 1.09
4 137.8
a The 13C chemical shifts were determined from HSQC-DEPT and HMBC-CIGAR experiments.
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(NBz-Thr)]+, 783.5 (6) [NBz-Thr-NMe-Leu-NMe-Ala-MePro-
NMe-Ala-Phe + Na]+, 755.7 (20) [783.5 - CO]+, 723.7 (16) [850.8
- (NMeLeu)]+, 638.7 (10) [723.7 - (NMeAla)]+.
Stereochemical Analysis. The peptides 1-4 (0.5 mg each) were
each hydrolyzed by heating (110 °C for 24 h) in HCl (6 M; 1 mL).
After cooling, the solutions were evaporated to dryness and
redissolved in H2O (100 íL). A 1% (w/v) solution (100 íL) of
FDAA (Marfey’s reagent, NR-(2,4-dinitro-5-fluorophenyl)-L-alani-
namide)12 in acetone was added to an aliquot (50 íL) of each acid
hydrolysate solution (or to 50 íL of a 50 mM solution of the
respective amino acid). After addition of NaHCO3 solution (1 M;
20 íL), the mixture was incubated (1 h at 40 °C). The reaction
was stopped by addition of HCl (2 M; 10 íL), the solvents were
evaporated to dryness, and the residue was redissolved in MeOH-
H2O (1:1; 1 mL). An aliquot of each of these solutions (10 íL)
was analyzed by HPLC (Prodigy C18, 250  4.6, 5 ím; solvents:
A: water + 0.05% TFA, B: MeCN; linear gradient: 0 min 35%
B, 30 min 45% B; 25 °C; 1 mL min-1; detection at 330 nm). In all
HPLC analyses of the FDAA derivatives the same column and flow
rate were used and the compounds were detected at 330 nm. For
the separation of the Thr, NMe-Thr, NMe-Ala, and 4-MePro FDAA
derivatives, an alternative linear gradient was used (A: water +
0.05% TFA, B: MeOH; 0 min 45% B, 30 min 65% B). The FDAA
derivatives of 4-MePro were analyzed by a third linear gradient
(A: water + 0.05% HCOOH, B: MeOH; 0 min 45% B, 30 min
65% B). Retention times (min) of the FDAA amino acid derivatives
used as standards together with the data for the observed peaks in
the HPLC trace of the FDAA-derivatized hydrolysis products of
1-4 are included in the Supporting Information (Table T5).
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TABLE 3. NMR Data for Pteratide IV (4) in CDCl3
position 13C 1H position 13C 1H position 13C 1H
Val1 NMe 32.3 2.74 Thr NH 7.15 Val2 3 29.7 2.26
1 170.9 1 168.8 4 20.2 1.02
2 58.6 5.28 2 54.85 4.46 5 15.8 0.66
3 26.9 2.21 3 71.6 5.71 Ala1 NMe 31.3 3.27
4 19.5 0.77 4 16.0 0.93 1 173.4
5 17.5 0.95 Phe NMe 31.8 2.82 2 49.8 6.41
Bz-1 171.5 1 168.52 3 15.0 1.29
Bz-2 135.6 2 62.8 4.63 Ala2 NMe 28.7 2.72
Bz-3/7 126.3 7.27 3 34.0 2.85 1 169.2
Bz-4/6 128.5 7.42 3.62 2 54.9 5.52
Bz-5 129.9 7.33 4 136.9 3 14.7 1.36
Ile NMe 30.3 3.09 5/9 128.8 7.28 Val3 NH 7.52
1 169.6 6/8 128.7 7.30 1 168.46
2 60.4 4.45 7 127.1 7.30 2 58.2 4.57
3 30.9 2.20 Val2 NH 7.15 3 32.3 1.89
3-Me 16.1 0.70 1 172.6 4 18.1 0.77
4 24.1 1.32 2 54.3 4.88 5 19.4 0.91
5 9.8 0.84
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